

---

# **CANCER INCIDENCE IN MASSACHUSETTS 2009 – 2013:**

**CITY AND TOWN SUPPLEMENT**

---

---

Office of Data Management and Outcomes Assessment

Massachusetts Department of Public Health

*May 2017*



This page intentionally left blank.

---

---

# **CANCER INCIDENCE IN MASSACHUSETTS 2009 – 2013:**

## **CITY AND TOWN SUPPLEMENT**

---

---

Charlie Baker, Governor  
Karyn Polito, Lieutenant Governor  
Marylou Sudders, Secretary of Health and Human Services  
Monica Bharel, Commissioner of Public Health

Natalie Nguyen Durham, Interim Director, Office of Data Management and  
Outcomes Assessment  
Susan T. Gershman, Director, Massachusetts Cancer Registry  
Massachusetts Department of Public Health

*May 2017*

This page intentionally left blank.



## ACKNOWLEDGMENTS

This report was prepared by Susan T. Gershman, Director, Massachusetts Cancer Registry, and Massachusetts Cancer Registry staff and consultants. Special thanks are extended to the following: Richard Knowlton and Annie MacMillan for their diligent work in the preparation of this report, Steve Pankowicz formerly of the Mass CHIP Program for his time and his excellent work in creating a program for formatting the tables in the report, staff of the Massachusetts Cancer Registry for their editing and data processing efforts, and Gail Merriam and the staff of the Comprehensive Cancer Control Program for updating the section on Cancer Control Initiatives and Publications.

### **Massachusetts Cancer Registry Staff**

Susan T. Gershman, MS, MPH, PhD, CTR, <i>Director</i>	
Bruce Caldwell, <i>Research Analyst/Geocoder</i>	Jeremiah Nesser, <i>Technical Assistant to Non-Hospital Reporting</i>
Nancy Donovan, MA, CTR, <i>Cancer Registrar</i>	Jayne Nussdorfer, CTR, <i>Cancer Registrar</i>
Patricia J. Drew, CTR, <i>Cancer Registrar/Quality Assurance Coordinator</i>	Barbara J. Rhodes, CMA, CTR, <i>Cancer Registrar/Death Clearance Coordinator</i>
Loi Huynh, <i>Software Developer</i>	Pamela Shuttle, CTR, RHIT, <i>Cancer Registrar/Non-Hospital Reporting Coordinator</i>
Richard Knowlton, MS, <i>Epidemiologist</i>	Hung Tran, <i>Software Developer</i>
Ann MacMillan, MPH, <i>Epidemiologist</i>	
Mary Mroszczyk, CTR, <i>Geocoding/ Special Projects Coordinator</i>	

### **Massachusetts Cancer Registry Advisory Committee**

Lindsay Frazier, MD, ScM ( <i>Chair</i> )	
Anita Christie, RN, MHA, CPHQ	Gail Merriam, MSW, MPH
Jan Sullivan, MS	J. David Naparstek, ScM, CHO
Deborah Dillon, MD	Larissa Nekhlyudov, MD, MPH
Joanna Haas, MD	Al Ozonoff, MA, PhD
Joseph Jacobson, MD	Paul C. Shroy, MD, MPH
Nancy Keating, MD, MPH	Ingrid Stendhal, CTR
Carol Lowenstein, CTR, MBA	Susan Sturgeon, DrPH, MPH
Reggie Mead	Michelle A. Williams, MS, SM, ScD

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please contact the following:

Massachusetts Cancer Registry.....	(617) 624-5642
Research and Epidemiology.....	(617) 624-5642
Occupational Health Surveillance.....	(617) 624-5632
Bureau of Environmental Health.....	(617) 624-5757
Cancer Prevention and Control Initiative.....	(617) 624-5484
Massachusetts Department of Public Health website.....	www.mass.gov/dph

We acknowledge the Centers for Disease Control and Prevention for its support of the staff and the printing and distribution of this report under cooperative agreement 5 U58 DP003920-05 awarded to the Massachusetts Cancer Registry at the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

This page intentionally left blank.

## CONTENTS

	<u>Page</u>
<b>INTRODUCTION AND METHODS</b>	
<b>Introduction</b> .....	1
Content .....	1
Comparison with Previous Reports .....	1
<b>Methods</b> .....	2
Data Sources .....	2
Presentation of Data .....	3
Observed and Expected Case Counts.....	3
Standardized Incidence Ratios .....	3
Statistical Significance and Interpretation of SIRs .....	4
Example of Calculation of an SIR and Its Significance.....	5
Notes about Data Interpretation.....	5
Data Limitations .....	6
Border Areas and Neighboring States.....	6
Cases Diagnosed in Non-Hospital Settings .....	6
City/Town Misassignment .....	7
Small Numbers of Cases .....	7
<b>TABLES</b>	
Observed and Expected Counts, with Standardized Incidence Ratios, by Sex, for 351 Cities and Towns, 2009 - 2013 .....	9
<b>APPENDICES</b>	
<b>APPENDIX I</b>	
International Classification of Diseases for Oncology (Third Edition) Codes Used for This Report .....	364
<b>APPENDIX II</b>	
Selected Resources for Information on Cancer .....	365
<b>APPENDIX III</b>	
Massachusetts Department of Public Health (MDPH) Cancer Prevention and Control Initiatives .....	366
<b>REFERENCES</b> .....	367

This page intentionally left blank.

## INTRODUCTION

### Content

The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and towns of Massachusetts for the five-year time period 2009 through 2013. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for all invasive cancer types combined. These ratios compare the cancer incidence experience of each city or town with the cancer experience of the state as a whole. The method involves comparing the number of cases that were observed for a city or town to the number of cases that would be expected if the city or town had the same cancer rates as the state as whole. The report is organized into the following sections:

**METHODS** provides a detailed explanation of the data collection, data processing, and statistical techniques employed in this report.

**TABLES** present data for selected types of cancer by city/town and sex.

**APPENDIX I** provides a listing of *International Classification of Diseases for Oncology* codes used in the preparation of this report.

**APPENDIX II** provides selected resources for information on cancer.

**APPENDIX III** describes the Massachusetts Department of Public Health's current cancer control initiatives, and provides links to bureaus within the department that address some aspect of cancer. Links to resources for publications are also provided.

### Comparison with Previous Reports

This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR). It is available on line at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry  
Office of Data Management and Outcomes Assessment  
Massachusetts Department of Public Health  
250 Washington Street, 6<sup>th</sup> floor  
Boston, MA 02108-4619  
telephone 617-624-5642; fax 617-624-5695

The preceding report, *Cancer Incidence in Massachusetts 2008-2012: City and Town Supplement*, included data for diagnosis years 2008 through 2012. This report contains data for the diagnosis years 2009 through 2013. There have been no changes in this report's format from the previous report.

## METHODS

### Data Sources

#### *Cancer Incidence*

The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners throughout Massachusetts. Facilities that reported the 2009-2013 diagnoses that comprise this report include 69 Massachusetts acute care hospitals, 18 independent laboratories, 10 surgical centers, 5 radiation/oncology centers, 5 medical practice associations, 4 endoscopy centers, and approximately 500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows participating states to exchange data on cases diagnosed or treated in other areas. Together with states participating in the agreement, and states with individual agreements, the MCR now has reciprocal reporting agreements with 43 states and with Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the MCR collects information on *in situ* and invasive cancers and benign tumors of the brain and associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of the skin.

The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information is available. Not all hospitals report this type of case, however, some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting these types of data makes the MCR's overall case ascertainment more complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, colon/rectum, and oral cancers.

In addition, the MCR identifies previously unreported cancer cases through review of death certificate data to further improve case completeness. This process is referred to as death clearance and identifies cancers mentioned on death certificates that were not previously reported to the MCR. In some instances, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. Thus these "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by review of clinical and pathological information. Such cases are included in this report, but they comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3), which was implemented in North America with cases diagnosed as of January 1, 2001. (1) Please see Appendix A for the classification of cancers by ICD-O3 codes.

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2009-2013, the MCR's annual case count was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the gold standard for this certification element as well as for six other certification elements for each case year since 1997.

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2009-2013 and reported to the MCR as of December 1, 2016. These data include some additional cases diagnosed in 2008-2012 that were not counted in the previous report, *Cancer Incidence in Massachusetts 2008-2012: City and Town Supplement*. The lag time between this report and the annual statewide report of 2009-2013 cancer cases is due to the fact that data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts.

The statewide report presented data at the state level and did not require such accuracy of city and town of residence. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities. Such changes might result in slight differences in numbers and rates in future reports of MCR data, reflecting the nature of population-based cancer registries that receive case reports on an ongoing basis.

Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2009-2013. The Massachusetts data presented include invasive cancers only (except cancer of the urinary bladder, where *in situ* cancers are also included). Invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body. *In situ* cancers are neoplasms diagnosed at the earliest stage, before they have spread, when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biologic significance, survival prognosis and types of treatment of the tumors. Cancer of the urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and treatment patterns.

### **Presentation of Data**

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main types of cancer and for all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and other malignant neoplasms. This category is meant to provide a summary of the total cancer experience in a community. As different cancers have different causes, this category does not reflect any specific risk factor that may be important for this community.

### ***Observed and Expected Case Counts***

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the actual number of newly diagnosed cases among residents of that city/town for a given time period.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer for this time period is a calculated number based on that city/town’s population distribution<sup>2</sup> (by sex and among eighteen age groups) for the time period 2009-2013, and the corresponding statewide average annual age-specific incidence rates. The source of the city and town population data for the 2009-2013 period was the US Census American Community Survey (ACS), an ongoing national survey that provides demographic estimates on a yearly basis.<sup>2</sup>

### ***Standardized Incidence Ratios***

A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that describes in numerical terms how a city/town’s cancer experience in a given time period compares with that of the state as a whole.

- An SIR of *exactly 100* indicates that a city/town’s incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town’s incidence of a certain type of cancer is *higher than expected* for that type of cancer based on statewide average annual age-specific

incidence rates. For example, an SIR of 105 indicates that a city/town's cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.

- An SIR of *less than 100* indicates that a city/town's incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, an SIR of 85 indicates that a city/town's cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

### ***Statistical Significance and Interpretation of SIRs***

The interpretation of the SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when there are small increases or decreases in the observed or expected number of cases. Two SIRs may have the same size but not the same stability. For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would change the SIR a great deal, whereas in the second instance, even if there were several fewer cases, the SIR would only change minimally. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5), to indicate if the observed number of cases is significantly different from the expected number, or if the difference is most likely due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases is significantly different from the expected number of cases. "Significantly different" means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100, there is no significant difference between the observed and expected numbers. Statistically, the width of the interval reflects the size of the population and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates that have wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would change the SIR a great deal.

#### **Examples:**

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than the expected number.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than the expected number.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference is likely due to chance. When the interval includes 100.0, then the true SIR may be 100.0.



### Example of Calculation of an SIR and Its Significance

$$\text{SIR} = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for the years 2007-2011:

<b>Age Group</b>	<b><u>Town X</u> Population</b>	<b><u>State</u> Age-Specific Incidence Rate</b>	<b><u>Town X</u> Expected Cases</b>	<b><u>Town X</u> Observed Cases</b>
	(A)	(B)	(C) = (A) x (B)	(D)
<b>00-04</b>	74,657	0.0001	7.47	11
<b>05-09</b>	134,957	0.0002	26.99	25
<b>10-14</b>	54,463	0.0005	27.23	30
<b>15-19</b>	25,136	0.0015	37.70	40
<b>20-24</b>	17,012	0.0018	30.62	30
<b>UP TO</b>				
<b>85+</b>	6,337	0.0010	6.34	8
<b>Total:</b>			<b>136.35</b>	<b>144</b>

$$\text{SIR} = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in Town X is 6% higher than the corresponding statewide average incidence for this cancer. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3. Also, since the range includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is expected.

Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances.

### Notes about Data Interpretation

The SIR is a useful indication of the disease categories that have relatively high or low rates for a given community. These statistics, however, should be used with care. Such statistics provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors unrelated to disease causation may contribute to an elevated SIR, including demographic factors, changes in diagnostic techniques, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to keep in mind that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average annual age-specific incidence rates. This means that *valid comparisons can only be made between a community and the state as a whole. SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.* (Comparisons between two communities would be valid only if there were no differences in the age and sex distributions of the two communities' populations.)

Another point to keep in mind when reviewing these data is the large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females and 2 types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender cancer categories). Note that gender/cancer categories with less than 5 observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly lower than 14,391. This is important for the reader because when multiple significance tests are performed, some will result in a significant finding due to chance alone. Based on the number of calculations in this report, we expect 720 significant findings to be due to chance alone. Half of these would be significant excesses (360) and half would be significant deficits (360). There are statistical techniques that can be used to reduce this number, however use of these techniques leads to the opposite problem – true significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some will be due to chance alone.

### **Data Limitations**

It should be emphasized that apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Four other limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.

### ***Border Areas and Neighboring States***

Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the MCR. The MCR has reciprocal reporting agreements with 29 states and with Puerto Rico.

### ***Cases Diagnosed in Non-Hospital Settings***

During the time period covered by this report, the MCR's primary information source for most newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting hospitals on cases diagnosed and treated in staff physician offices, when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices and a general laboratory. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer. The exact extent of this under-reporting has not been determined, but cases included in this report represent the great majority of cases statewide and provide an essential basis for evaluating statewide cancer incidence patterns.

### ***City/Town Misassignment***

In accordance with standard central cancer registry procedures, each case reported to the MCR ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the address provided by the reporting hospital. In practice, however, a patient may provide the hospital with his/her mailing address (e.g., a post office box located outside the patient's city/town of residence); a business address; a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). In addition, if a patient has moved since being diagnosed, the hospital may report the patient's current address. Because of the large number of cases reported to the MCR, and because data are reported to the MCR via electronic media, most city/town case assignments are performed by an automated computer process. This simplified matching process may misassign some cases based on the reported locality name. When MCR staff become aware of such misassignments, they manually correct the errors. Furthermore, in order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment are reviewed manually.

### ***Small Numbers of Cases***

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases for a specific category is less than five. In these instances, the observed and expected cases are presented in the tables *for qualitative comparison only*.

This page intentionally left blank.

# **TABLES**

This page intentionally left blank.

# **APPENDICES**

**APPENDIX I: INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD EDITION)  
CODES USED FOR THIS REPORT <sup>1</sup>**

<b><u>Cancer Site / Type</u></b>	<b><u>Primary Site Codes</u></b>	<b><u>Histologic Type Codes <sup>2</sup></u></b>
<b>Bladder, Urinary</b>	C67.0 - C67.9	all except 9590 - 9989
<b>Brain and Other Nervous System</b>	C70.0 - C72.9	all except 9590 - 9989
<b>Breast</b>	C50.0 - C50.9	all except 9590 - 9989
<b>Cervix Uteri</b>	C53.0 - C53.9	all except 9590 - 9989
<b>Colon / Rectum</b>	C18.0 - C18.9, C19.9, C20.9, C26.0	all except 9590 - 9989
<b>Esophagus</b>	C15.0 - C15.9	all except 9590 - 9989
<b>Hodgkin Lymphoma</b>	C00.0 - C80.9	9650 - 9667
<b>Kidney and Renal Pelvis <sup>3</sup></b>	C64.9, C65.9	all except 9590 - 9989
<b>Larynx</b>	C32.0 - C32.9	all except 9590 - 9989
<b>Leukemia</b>	C00.0 - C80.9 C42.0, C42.1, C42.4	9733, 9742, 9800 - 9820, 9826, 9831 - 9948, 9963, 9964 9823, 9827
<b>Liver and Intrahepatic Bile Ducts</b>	C22.0, C22.1	all except 9590 - 9989
<b>Lung and Bronchus</b>	C34.0 - C34.9	all except 9590 - 9989
<b>Melanoma of Skin</b>	C44.0 - C44.9	8720 - 8790
<b>Multiple Myeloma</b>	C00.0 - C80.9	9731, 9732, 9734
<b>Non-Hodgkin Lymphoma</b>	C00.0 - C80.9 all except C42.0, C42.1, C42.4	9590 - 9595, 9670 - 9729 9823, 9827
<b>Oral Cavity and Pharynx</b>	C00.0 - C14.8	all except 9590 - 9989
<b>Ovary</b>	C56.9	all except 9590 - 9989
<b>Pancreas</b>	C25.0 - C25.9	all except 9590 - 9989
<b>Prostate</b>	C61.9	all except 9590 - 9989
<b>Stomach</b>	C16.0 - C16.9	all except 9590 - 9989
<b>Testis</b>	C62.0 - C62.9	all except 9590 - 9989
<b>Thyroid</b>	C73.9	all except 9590 - 9989
<b>Uteri, Corpus and Uterus, NOS</b>	C54.0 - C54.9, C55.9	all except 9590 - 9989
<b>All Sites / Types</b>	C00.0 - C80.9	8000 - 9989

<sup>1</sup>includes codes added to the *International Classification of Diseases for Oncology, Third Edition* since its publication.

<sup>2</sup>Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which includes invasive and *in situ* behaviors. Non-invasive (*in situ*) cancers are not included.

<sup>3</sup>Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category that is not included in this cancer type.



## **APPENDIX II: SELECTED RESOURCES FOR INFORMATION ON CANCER**

This Appendix contains a listing of selected resources for additional information on cancer. Cancers are complex diseases, many of which have multiple factors that may contribute to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

**Massachusetts Department of Public Health:** <http://www.mass.gov/dph>

**American Cancer Society:** <http://www.cancer.org>

### **Centers for Disease Control and Prevention**

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):  
<http://www.fruitsandveggiesmorematters.org/>

### **National Cancer Institute**

Information: <http://www.cancer.gov>

Cancer Literature in PubMed:

[https://www.ncbi.nlm.nih.gov/pubmed?cmd\\_current=Limits&pmfilter\\_Subsets=Cancer](https://www.ncbi.nlm.nih.gov/pubmed?cmd=current=Limits&pmfilter_Subsets=Cancer)

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

**Your Cancer Risk** (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
<http://www.yourdiseaserisk.wustl.edu>

**OncoLink** (Abramson Cancer Center of the University of Pennsylvania):  
<http://www.oncolink.org>

**Cancerquest** (Emory University – Winship Cancer Institute): [www.cancerquest.org](http://www.cancerquest.org)

**National Coalition for Cancer Survivorship:** <http://www.canceradvocacy.org>

### **APPENDIX III: MDPH CANCER PREVENTION AND CONTROL INITIATIVES**

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers and nonprofit organizations collect information about cancer, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through healthy lifestyles, early diagnosis, and increased access to care. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health outcomes and unequal access to cancer care.

#### **MDPH Bureaus and Programs:**

Bureau of Environmental Health, [www.mass.gov/dph/environmental\\_health](http://www.mass.gov/dph/environmental_health)

Bureau of Substance Abuse Services, [www.mass.gov/dph/bsas](http://www.mass.gov/dph/bsas)

Comprehensive Cancer Prevention and Control Program, [www.mass.gov/compcancer](http://www.mass.gov/compcancer)

Men's Health/Women's Health/Care Coordination Program

Tobacco Cessation and Prevention Program, [www.mass.gov/dph/mtcp](http://www.mass.gov/dph/mtcp)

Occupational Health Surveillance Program, [www.mass.gov/dph/ohsp](http://www.mass.gov/dph/ohsp)

Office of Elder Affairs [www.mass.gov/elders/](http://www.mass.gov/elders/)

Oral Health Program, [www.mass.gov/dph/oralhealth](http://www.mass.gov/dph/oralhealth)

Division of Prevention and Wellness [www.mass.gov/dph/healthpromotion](http://www.mass.gov/dph/healthpromotion)

MDPH publications on cancer prevention and screening are available at the Massachusetts Health Promotion Clearinghouse, [www.maclearinghouse.com](http://www.maclearinghouse.com).

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry, telephone: 617-624-5642 and on the web at [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr).

## REFERENCES

1. Fritz A, Percy C, Jack A, et al. (eds). *International Classification of Diseases for Oncology*, 3rd Ed. Geneva: World Health Organization, 2000.
2. United States Census Bureau, American Community Survey, accessed February 17, 2017: <https://www.census.gov/library/publications/2009/acs/state-and-local.html>

# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	14.6	103.0	(57.6-169.9)	Male	12	9.9	121.3	(62.6-211.9)
Female	7	5.3	131.2	(52.6-270.3)	Female	9	8.3	108.9	(49.7-206.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.1	nc	(nc-nc)	Male	6	3.1	193.4	(70.6-420.9)
Female	4	2.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	4	8.9	nc	(nc-nc)
Female	62	63.6	97.4	(74.7-124.9)	Female	5	7.7	64.5	(20.8-150.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	6	7.5	79.5	(29.0-173.0)
<b><u>Colon / Rectum</u></b>					Female	4	3.3	nc	(nc-nc)
Male	19	16.4	116.0	(69.8-181.2)	<b><u>Ovary</u></b>				
Female	24	16.2	148.5	(95.1-221.0)	Female	7	5.6	124.4	(49.8-256.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.1	120.9	(39.0-282.2)	Male	8	5.3	151.1	(65.0-297.7)
Female	0	1.1	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	55	54.7	100.6	(75.8-130.9)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.5	nc	(nc-nc)
Male	14	8.9	158.1	(86.4-265.3)	Female	4	2.1	nc	(nc-nc)
Female	8	4.9	161.7	(69.6-318.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.4	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	6	0.7	812.9	(296.8-1769.3)	Male	5	4.2	117.9	(38.0-275.0)
<b><u>Leukemia</u></b>					Female	17	12.6	134.4	(78.3-215.2)
Male	1	6.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.7	170.4	(73.4-335.9)	Female	20	14.8	135.3	(82.6-208.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.5	91.3	(29.4-213.0)	Male	227	204.2	111.2	(97.2-126.6)
Female	2	1.8	nc	(nc-nc)	Female	250	211.4	118.3	(104.1-133.9)
<b><u>Lung and Bronchus</u></b>									
Male	41	26.6	154.0	(110.5-209.0)					
Female	36	28.2	127.7	(89.4-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	20.8	81.8	(47.6-131.0)	Male	14	14.3	97.9	(53.5-164.2)
Female	7	7.2	97.7	(39.1-201.3)	Female	18	11.3	159.9	(94.7-252.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.6	152.8	(61.2-314.9)	Male	4	4.5	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	5	3.3	149.4	(48.1-348.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	17	12.9	131.7	(76.7-210.9)
Female	96	91.5	104.9	(85.0-128.1)	Female	11	10.6	103.8	(51.8-185.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	12	11.1	108.1	(55.8-188.9)
<b><u>Colon / Rectum</u></b>					Female	4	4.6	nc	(nc-nc)
Male	16	24.3	65.9	(37.6-107.0)	<b><u>Ovary</u></b>				
Female	17	22.7	74.8	(43.5-119.7)	Female	15	7.9	189.9	(106.2-313.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.9	102.3	(37.3-222.6)	Male	7	7.6	92.2	(36.9-190.0)
Female	4	1.4	nc	(nc-nc)	Female	6	7.2	83.6	(30.5-182.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	73	76.0	96.1	(75.3-120.8)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	5.1	nc	(nc-nc)
Male	8	12.8	62.5	(26.9-123.2)	Female	2	2.9	nc	(nc-nc)
Female	7	6.9	101.7	(40.7-209.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.2	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	7	6.2	113.1	(45.3-233.0)
<b><u>Leukemia</u></b>					Female	15	17.5	85.5	(47.8-141.1)
Male	7	8.9	78.7	(31.5-162.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	6.1	195.6	(100.9-341.7)	Female	19	20.4	92.9	(55.9-145.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	8.1	nc	(nc-nc)	Male	242	292.2	82.8	(72.7-93.9)
Female	3	2.4	nc	(nc-nc)	Female	292	293.9	99.3	(88.3-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	20	37.8	52.9	(32.3-81.8)					
Female	24	38.6	62.2	(39.8-92.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	12.6	150.4	(90.5-234.8)	Male	8	7.9	100.9	(43.4-198.8)
Female	4	4.4	nc	(nc-nc)	Female	6	6.1	98.8	(36.1-215.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.1	140.2	(67.1-257.9)
Female	44	48.6	90.6	(65.8-121.6)	Female	7	6.1	115.6	(46.3-238.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	0	5.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.6	nc	(nc-nc)
Male	15	13.4	112.1	(62.7-184.9)	<b><u>Ovary</u></b>				
Female	12	12.9	92.7	(47.8-161.9)	Female	4	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	7	4.4	159.2	(63.8-328.1)
Female	0	0.9	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	51	39.8	128.1	(95.4-168.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.9	nc	(nc-nc)
Male	9	6.6	136.7	(62.4-259.6)	Female	1	1.6	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	8.5	105.3	(48.1-199.9)
Male	5	5.0	100.0	(32.2-233.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.4	176.5	(64.4-384.1)	Female	9	11.1	80.8	(36.9-153.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.1	nc	(nc-nc)	Male	182	160.3	113.5	(97.6-131.3)
Female	0	1.4	nc	(nc-nc)	Female	151	163.2	92.5	(78.3-108.5)
<b><u>Lung and Bronchus</u></b>									
Male	29	21.9	132.4	(88.6-190.1)					
Female	22	23.8	92.3	(57.8-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.6	83.1	(35.8-163.8)	Male	3	6.1	nc	(nc-nc)
Female	6	3.8	160.0	(58.4-348.2)	Female	4	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.5	91.0	(29.3-212.3)
Female	35	39.5	88.6	(61.7-123.3)	Female	8	5.1	157.2	(67.7-309.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.1	nc	(nc-nc)
Male	12	10.5	113.9	(58.8-199.0)	<b><u>Ovary</u></b>				
Female	14	11.4	122.8	(67.1-206.0)	Female	3	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.7	133.7	(43.1-311.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	38	33.2	114.3	(80.9-157.0)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.3	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.0	100.6	(40.3-207.2)
Male	3	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.0	nc	(nc-nc)	Female	6	8.7	69.3	(25.3-150.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	125	126.8	98.6	(82.1-117.5)
Female	0	1.1	nc	(nc-nc)	Female	145	135.6	107.0	(90.3-125.8)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.2	104.7	(62.0-165.5)					
Female	32	19.7	162.3	(111.0-229.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	32.4	111.2	(77.9-154.0)	Male	20	20.7	96.7	(59.0-149.3)
Female	11	13.6	81.1	(40.4-145.2)	Female	16	17.9	89.5	(51.1-145.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.1	81.8	(26.4-191.0)	Male	9	6.5	137.7	(62.8-261.3)
Female	3	5.5	nc	(nc-nc)	Female	5	6.0	83.1	(26.8-193.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	23	18.5	124.3	(78.8-186.5)
Female	153	139.6	109.6	(92.9-128.4)	Female	19	18.3	103.7	(62.4-162.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	4.5	201.1	(91.8-381.9)	Male	23	15.0	153.5	(97.2-230.3)
<b><u>Colon / Rectum</u></b>					Female	13	7.6	170.1	(90.5-290.9)
Male	43	34.8	123.4	(89.3-166.2)	<b><u>Ovary</u></b>				
Female	35	41.1	85.2	(59.3-118.5)	Female	12	12.6	95.1	(49.1-166.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	8.6	58.2	(18.8-135.9)	Male	11	11.4	96.6	(48.1-172.8)
Female	3	2.6	nc	(nc-nc)	Female	17	13.8	123.5	(71.9-197.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	92	108.6	84.7	(68.3-103.9)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	7.6	144.8	(72.2-259.2)
Male	23	17.6	130.7	(82.8-196.2)	Female	5	5.3	93.7	(30.2-218.6)
Female	7	11.2	62.5	(25.0-128.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.0	nc	(nc-nc)
Male	7	5.0	140.0	(56.1-288.5)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	7	7.9	88.8	(35.6-183.0)
<b><u>Leukemia</u></b>					Female	19	24.0	79.2	(47.6-123.6)
Male	13	12.9	101.0	(53.7-172.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	10.6	84.6	(38.6-160.6)	Female	28	31.7	88.3	(58.6-127.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	11.2	80.0	(36.5-151.9)	Male	448	423.2	105.9	(96.3-116.1)
Female	3	4.1	nc	(nc-nc)	Female	490	482.5	101.6	(92.8-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	82	57.6	142.3	(113.2-176.6)					
Female	84	68.3	122.9	(98.1-152.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	14.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	9	10.0	90.0	(41.1-170.9)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.1	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	13.6	169.7	(107.5-254.7)	Male	8	9.9	80.6	(34.7-158.8)
Female	10	6.0	167.8	(80.3-308.6)	Female	6	9.0	66.6	(24.3-145.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	6	2.8	218.0	(79.6-474.6)	Female	0	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.9	124.2	(61.9-222.2)
Female	77	70.3	109.5	(86.4-136.8)	Female	11	8.6	128.1	(63.9-229.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.5	nc	(nc-nc)	Male	12	7.9	151.2	(78.1-264.2)
<b><u>Colon / Rectum</u></b>					Female	5	3.7	136.9	(44.1-319.4)
Male	24	16.0	149.6	(95.8-222.6)	<b><u>Ovary</u></b>				
Female	25	18.6	134.2	(86.8-198.1)	Female	5	6.2	81.0	(26.1-189.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.1	nc	(nc-nc)	Male	9	5.1	175.1	(79.9-332.4)
Female	1	1.2	nc	(nc-nc)	Female	7	6.0	116.4	(46.6-239.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	61	54.8	111.4	(85.2-143.1)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.4	nc	(nc-nc)
Male	4	9.1	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	5	4.6	108.7	(35.0-253.6)
<b><u>Leukemia</u></b>					Female	16	13.7	116.9	(66.8-189.8)
Male	8	6.0	133.2	(57.4-262.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.0	140.1	(56.1-288.7)	Female	11	15.7	69.9	(34.8-125.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.7	nc	(nc-nc)	Male	237	202.7	116.9	(102.5-132.8)
Female	3	1.9	nc	(nc-nc)	Female	252	233.2	108.1	(95.1-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	31	25.7	120.7	(82.0-171.4)					
Female	40	31.3	127.9	(91.4-174.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amherst

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	18.6	86.0	(49.1-139.7)	Male	11	12.4	88.4	(44.1-158.2)
Female	3	7.1	nc	(nc-nc)	Female	13	12.0	108.7	(57.8-185.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.8	nc	(nc-nc)	Male	5	3.7	136.2	(43.9-317.9)
Female	1	4.4	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	6	12.0	49.9	(18.2-108.6)
Female	72	75.9	94.8	(74.2-119.4)	Female	15	10.5	142.3	(79.6-234.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.7	103.9	(47.4-197.2)
<b><u>Colon / Rectum</u></b>					Female	3	4.4	nc	(nc-nc)
Male	16	19.7	81.3	(46.4-132.0)	<b><u>Ovary</u></b>				
Female	25	21.5	116.2	(75.2-171.5)	Female	12	7.6	158.1	(81.6-276.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	9	6.5	138.9	(63.4-263.8)
Female	0	1.3	nc	(nc-nc)	Female	7	7.0	99.5	(39.9-205.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	3.8	nc	(nc-nc)	Male	47	62.6	75.1	(55.2-99.9)
Female	0	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	4.3	nc	(nc-nc)
Male	5	10.0	49.9	(16.1-116.4)	Female	1	2.9	nc	(nc-nc)
Female	5	6.2	80.2	(25.9-187.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	6.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	6	5.7	105.7	(38.6-230.0)
<b><u>Leukemia</u></b>					Female	4	19.7	nc	(nc-nc)
Male	10	9.2	109.2	(52.3-200.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.0	71.8	(23.1-167.6)	Female	12	17.6	68.1	(35.1-118.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.5	nc	(nc-nc)	Male	179	258.3	69.3	(59.5-80.2)
Female	2	2.4	nc	(nc-nc)	Female	225	277.8	81.0	(70.7-92.3)
<b><u>Lung and Bronchus</u></b>									
Male	15	33.3	45.0	(25.2-74.2)					
Female	20	37.0	54.1	(33.0-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	34.6	72.3	(46.8-106.8)	Male	23	22.5	102.4	(64.9-153.7)
Female	9	13.3	67.7	(30.9-128.6)	Female	27	19.0	141.9	(93.5-206.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.8	102.5	(41.1-211.3)	Male	9	7.2	125.3	(57.2-237.8)
Female	5	6.0	83.2	(26.8-194.1)	Female	9	6.0	148.8	(67.9-282.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	26	20.2	128.8	(84.1-188.7)
Female	159	153.8	103.4	(87.9-120.8)	Female	21	18.8	111.8	(69.2-171.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.1	nc	(nc-nc)	Male	17	16.8	101.3	(59.0-162.1)
<b><u>Colon / Rectum</u></b>					Female	4	8.0	nc	(nc-nc)
Male	30	38.1	78.8	(53.1-112.5)	<b><u>Ovary</u></b>				
Female	29	40.7	71.3	(47.7-102.4)	Female	14	13.5	103.9	(56.7-174.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.5	84.6	(36.4-166.7)	Male	11	12.3	89.3	(44.5-159.7)
Female	4	2.6	nc	(nc-nc)	Female	11	13.4	82.3	(41.0-147.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	113	122.1	92.6	(76.3-111.3)
Female	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.2	61.0	(19.7-142.4)
Male	18	19.6	91.6	(54.3-144.8)	Female	4	5.2	nc	(nc-nc)
Female	11	12.0	91.8	(45.8-164.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	4.2	166.9	(66.9-343.9)
Male	3	5.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	15	8.9	168.8	(94.4-278.5)
<b><u>Leukemia</u></b>					Female	37	27.6	134.2	(94.5-185.0)
Male	20	14.0	143.3	(87.5-221.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	10.9	91.5	(43.8-168.3)	Female	24	34.8	69.0	(44.2-102.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	12.5	64.1	(27.6-126.3)	Male	421	464.5	90.6	(82.2-99.7)
Female	3	4.3	nc	(nc-nc)	Female	454	509.6	89.1	(81.1-97.7)
<b><u>Lung and Bronchus</u></b>									
Male	38	62.4	60.9	(43.1-83.6)					
Female	38	70.6	53.8	(38.1-73.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	45.9	93.7	(67.8-126.2)	Male	25	29.8	83.9	(54.3-123.8)
Female	16	17.8	89.9	(51.3-145.9)	Female	26	25.4	102.3	(66.8-149.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	9.0	89.1	(38.4-175.7)	Male	10	9.3	107.8	(51.6-198.2)
Female	9	7.7	117.1	(53.4-222.3)	Female	4	8.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	19	26.7	71.2	(42.8-111.2)
Female	212	195.0	108.7	(94.6-124.4)	Female	33	24.9	132.4	(91.1-185.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	6.9	nc	(nc-nc)	Male	19	21.3	89.4	(53.8-139.6)
<b><u>Colon / Rectum</u></b>					Female	15	10.5	142.9	(79.9-235.8)
Male	43	50.2	85.7	(62.0-115.4)	<b><u>Ovary</u></b>				
Female	45	54.8	82.1	(59.9-109.9)	Female	16	17.4	91.8	(52.4-149.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	12.0	108.5	(57.7-185.5)	Male	18	16.1	111.8	(66.2-176.8)
Female	2	3.5	nc	(nc-nc)	Female	21	18.2	115.5	(71.5-176.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	149	149.8	99.5	(84.1-116.8)
Female	5	2.8	175.9	(56.7-410.5)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	10.9	82.9	(37.8-157.5)
Male	29	25.3	114.7	(76.8-164.8)	Female	5	7.1	70.4	(22.7-164.3)
Female	13	15.3	84.8	(45.1-145.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	6.6	120.8	(52.0-238.0)
Male	4	7.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	12	11.8	101.6	(52.5-177.6)
<b><u>Leukemia</u></b>					Female	35	36.9	94.7	(66.0-131.7)
Male	16	18.6	85.9	(49.1-139.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	14.5	75.6	(37.7-135.3)	Female	49	43.8	112.0	(82.8-148.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	15.7	108.0	(62.9-173.0)	Male	554	599.8	92.4	(84.8-100.4)
Female	2	5.6	nc	(nc-nc)	Female	670	663.6	101.0	(93.5-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	69	80.8	85.4	(66.4-108.1)					
Female	87	90.7	95.9	(76.8-118.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.4	110.6	(40.4-240.6)	Male	2	3.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	18	26.4	68.1	(40.3-107.6)	Female	3	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	4	6.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	6.1	81.6	(26.3-190.5)	Female	2	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	21	23.4	89.6	(55.5-137.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.0	nc	(nc-nc)
Male	5	2.4	209.5	(67.5-489.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	5	6.0	83.3	(26.9-194.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	69	82.7	83.5	(64.9-105.6)
Female	0	0.7	nc	(nc-nc)	Female	63	83.6	75.4	(57.9-96.4)
<b><u>Lung and Bronchus</u></b>									
Male	6	10.4	57.4	(21.0-125.0)					
Female	6	11.3	53.1	(19.4-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	5	2.2	229.9	(74.1-536.4)
Female	3	1.1	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	12	14.2	84.5	(43.6-147.6)	Female	0	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	11	11.8	93.5	(46.6-167.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.0	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	45	44.7	100.6	(73.4-134.6)
Female	2	0.4	nc	(nc-nc)	Female	45	46.1	97.6	(71.2-130.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.8	nc	(nc-nc)					
Female	4	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	9	9.8	91.9	(41.9-174.5)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	23.5	101.9	(65.3-151.7)
Female	0	0.3	nc	(nc-nc)	Female	24	32.4	74.1	(47.4-110.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.8	nc	(nc-nc)					
Female	1	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.7	95.4	(53.3-157.3)	Male	8	10.8	74.1	(31.9-146.1)
Female	2	6.5	nc	(nc-nc)	Female	4	9.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	5	3.3	149.7	(48.3-349.4)
Female	2	3.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.8	81.9	(35.3-161.4)
Female	67	77.6	86.4	(66.9-109.7)	Female	7	9.3	75.1	(30.1-154.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	4.0	124.0	(39.9-289.3)
Male	12	18.5	64.9	(33.5-113.4)	<b><u>Ovary</u></b>				
Female	22	19.9	110.6	(69.3-167.5)	Female	9	6.8	131.9	(60.2-250.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	4.4	203.7	(93.0-386.7)	Male	5	5.8	86.5	(27.9-201.8)
Female	2	1.3	nc	(nc-nc)	Female	5	6.5	76.9	(24.8-179.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	40	57.0	70.2	(50.1-95.5)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.9	154.7	(56.5-336.6)
Male	8	9.6	83.2	(35.8-163.9)	Female	4	2.5	nc	(nc-nc)
Female	2	6.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	21	14.3	146.7	(90.8-224.3)
Male	2	6.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.4	148.4	(63.9-292.3)	Female	17	18.1	94.0	(54.7-150.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.1	82.4	(26.5-192.2)	Male	178	220.0	80.9	(69.5-93.7)
Female	4	2.2	nc	(nc-nc)	Female	234	254.6	91.9	(80.5-104.5)
<b><u>Lung and Bronchus</u></b>									
Male	26	28.2	92.1	(60.2-135.0)					
Female	39	34.1	114.3	(81.2-156.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Athol

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	14.1	127.3	(75.4-201.2)	Male	4	9.2	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	8.0	62.1	(20.0-145.0)
Female	36	47.8	75.4	(52.8-104.4)	Female	3	6.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	8	6.6	121.6	(52.4-239.7)
<b><u>Colon / Rectum</u></b>					Female	4	2.6	nc	(nc-nc)
Male	18	14.9	120.6	(71.5-190.7)	<b><u>Ovary</u></b>				
Female	15	13.2	113.3	(63.4-186.9)	Female	5	4.3	116.4	(37.5-271.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.8	131.2	(42.3-306.3)	Male	4	5.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	29	48.6	59.7	(39.9-85.7)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.3	nc	(nc-nc)
Male	8	7.7	103.7	(44.6-204.3)	Female	0	1.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	8.7	138.4	(71.4-241.7)
Male	2	5.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.5	141.7	(45.7-330.6)	Female	23	11.1	207.4	(131.4-311.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	175	186.8	93.7	(80.3-108.6)
Female	3	1.4	nc	(nc-nc)	Female	162	162.9	99.5	(84.7-116.0)
<b><u>Lung and Bronchus</u></b>									
Male	37	26.0	142.6	(100.4-196.5)					
Female	25	22.9	109.2	(70.6-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	41.3	111.4	(81.6-148.6)	Male	30	27.9	107.4	(72.5-153.4)
Female	17	15.3	111.0	(64.6-177.7)	Female	21	23.0	91.4	(56.6-139.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.8	79.3	(31.8-163.4)	Male	5	8.7	57.6	(18.6-134.4)
Female	7	7.2	97.6	(39.1-201.0)	Female	6	7.0	86.1	(31.4-187.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	16	24.9	64.1	(36.6-104.2)
Female	173	178.3	97.0	(83.1-112.6)	Female	19	21.9	86.8	(52.2-135.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.3	95.2	(34.8-207.3)	Male	21	20.7	101.6	(62.8-155.3)
<b><u>Colon / Rectum</u></b>					Female	12	9.4	128.3	(66.2-224.2)
Male	56	46.3	120.9	(91.3-157.1)	<b><u>Ovary</u></b>				
Female	45	46.9	96.0	(70.0-128.4)	Female	24	15.8	151.9	(97.3-226.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	11.3	97.0	(48.4-173.7)	Male	17	14.8	114.7	(66.8-183.7)
Female	4	3.0	nc	(nc-nc)	Female	14	15.3	91.6	(50.0-153.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	3.6	247.7	(113.0-470.3)	Male	135	146.3	92.3	(77.3-109.2)
Female	2	2.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	9.9	50.4	(16.2-117.5)
Male	16	24.4	65.5	(37.4-106.4)	Female	8	6.0	133.9	(57.7-263.9)
Female	10	14.0	71.6	(34.3-131.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	6.9	115.2	(49.6-226.9)
Male	10	6.7	149.4	(71.5-274.7)	<b><u>Thyroid</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	12	11.8	101.9	(52.6-178.0)
<b><u>Leukemia</u></b>					Female	21	34.7	60.4	(37.4-92.4)
Male	14	17.4	80.5	(43.9-135.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	12.9	46.4	(16.9-100.9)	Female	47	40.2	117.0	(86.0-155.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	15.2	92.3	(50.4-154.9)	Male	570	567.2	100.5	(92.4-109.1)
Female	10	5.0	201.2	(96.3-370.1)	Female	589	595.7	98.9	(91.0-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	98	75.4	130.0	(105.6-158.5)					
Female	80	82.0	97.5	(77.3-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Auburn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	20.5	131.9	(86.9-191.9)	Male	11	12.5	87.7	(43.7-157.0)
Female	12	7.7	155.4	(80.2-271.5)	Female	8	10.1	79.1	(34.1-155.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	6	3.4	176.9	(64.6-385.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.2	80.3	(36.6-152.4)
Female	73	79.0	92.4	(72.4-116.2)	Female	11	10.5	105.1	(52.4-188.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	10	8.6	116.7	(55.9-214.6)
<b><u>Colon / Rectum</u></b>					Female	2	4.3	nc	(nc-nc)
Male	19	21.6	87.9	(52.9-137.3)	<b><u>Ovary</u></b>				
Female	18	23.5	76.5	(45.3-120.9)	Female	11	7.1	155.5	(77.5-278.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.1	137.7	(55.2-283.7)	Male	6	7.0	85.8	(31.3-186.7)
Female	2	1.5	nc	(nc-nc)	Female	5	7.9	63.3	(20.4-147.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	52	62.1	83.8	(62.5-109.8)
Female	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.7	nc	(nc-nc)
Male	13	10.3	126.3	(67.2-216.0)	Female	2	3.1	nc	(nc-nc)
Female	5	6.3	79.3	(25.5-185.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.2	nc	(nc-nc)
Male	7	2.9	237.9	(95.3-490.1)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	13.5	110.8	(62.0-182.7)
Male	8	7.8	102.5	(44.1-202.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.1	99.0	(36.1-215.5)	Female	21	17.5	120.0	(74.2-183.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	6.5	138.8	(63.3-263.5)	Male	237	253.2	93.6	(82.0-106.3)
Female	0	2.4	nc	(nc-nc)	Female	269	273.8	98.3	(86.9-110.7)
<b><u>Lung and Bronchus</u></b>									
Male	29	35.7	81.3	(54.4-116.7)					
Female	42	39.0	107.6	(77.5-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Avon

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.2	115.2	(42.1-250.8)	Male	6	3.4	177.6	(64.8-386.6)
Female	0	2.0	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.0	233.9	(93.7-482.0)
Female	25	21.9	114.3	(74.0-168.7)	Female	4	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.2	nc	(nc-nc)
Male	5	5.7	87.9	(28.3-205.2)	<b><u>Ovary</u></b>				
Female	5	5.9	85.2	(27.4-198.8)	Female	3	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	8	18.9	42.3	(18.2-83.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.2	nc	(nc-nc)
Male	5	3.0	169.5	(54.6-395.5)	Female	0	0.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.8	132.6	(42.7-309.5)
Male	4	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	78	70.3	111.0	(87.7-138.5)
Female	0	0.7	nc	(nc-nc)	Female	78	74.4	104.9	(82.9-130.9)
<b><u>Lung and Bronchus</u></b>									
Male	14	9.6	145.5	(79.5-244.1)					
Female	16	10.9	146.8	(83.8-238.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.5	93.5	(37.5-192.6)	Male	2	5.2	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.6	nc	(nc-nc)
Female	36	33.1	108.9	(76.2-150.7)	Female	4	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	7	8.4	82.8	(33.2-170.7)	<b><u>Ovary</u></b>				
Female	8	9.7	82.9	(35.7-163.3)	Female	3	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.0	293.1	(107.0-638.1)	Male	4	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	18	25.2	71.6	(42.4-113.1)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	6.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.5	nc	(nc-nc)	Female	11	6.9	160.3	(79.9-286.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	86	102.5	83.9	(67.1-103.6)
Female	1	0.9	nc	(nc-nc)	Female	113	113.9	99.2	(81.7-119.3)
<b><u>Lung and Bronchus</u></b>									
Male	17	13.9	122.5	(71.3-196.2)					
Female	16	16.3	98.2	(56.1-159.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	99	70.7	140.1	(113.8-170.5)	Male	54	42.6	126.7	(95.2-165.4)
Female	25	24.5	102.2	(66.2-150.9)	Female	46	30.6	150.5	(110.2-200.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	11.4	96.2	(48.0-172.2)	Male	12	13.7	87.9	(45.4-153.5)
Female	11	9.4	117.6	(58.6-210.4)	Female	17	10.9	156.5	(91.1-250.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	40	37.7	106.2	(75.9-144.7)
Female	304	247.9	122.6	(109.2-137.2)	Female	45	32.6	138.0	(100.6-184.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	7.3	123.0	(56.1-233.5)	Male	32	29.4	109.0	(74.5-153.9)
<b><u>Colon / Rectum</u></b>					Female	17	13.6	124.8	(72.7-199.9)
Male	59	71.9	82.0	(62.4-105.8)	<b><u>Ovary</u></b>				
Female	71	70.5	100.7	(78.6-127.0)	Female	24	22.2	108.1	(69.3-160.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	22	18.0	122.3	(76.6-185.1)	Male	31	24.4	127.3	(86.5-180.7)
Female	3	4.7	nc	(nc-nc)	Female	21	24.4	86.2	(53.3-131.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	267	226.6	117.8	(104.1-132.8)
Female	1	3.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	16.0	124.8	(76.2-192.8)
Male	40	35.0	114.3	(81.6-155.6)	Female	9	9.1	99.2	(45.3-188.3)
Female	17	20.3	83.6	(48.7-133.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	6.1	146.8	(67.0-278.7)
Male	8	10.4	77.2	(33.2-152.2)	<b><u>Thyroid</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	14	14.2	98.4	(53.7-165.1)
<b><u>Leukemia</u></b>					Female	27	38.5	70.1	(46.2-102.0)
Male	31	26.2	118.4	(80.4-168.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	29	18.4	157.9	(105.7-226.8)	Female	54	58.5	92.3	(69.3-120.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	28	22.6	123.8	(82.2-178.9)	Male	947	877.7	107.9	(101.1-115.0)
Female	7	7.6	91.9	(36.8-189.3)	Female	935	857.1	109.1	(102.2-116.3)
<b><u>Lung and Bronchus</u></b>									
Male	88	125.3	70.2	(56.3-86.5)					
Female	124	129.9	95.4	(79.4-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	15	23.2	64.5	(36.1-106.4)	Female	0	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	8	5.9	136.0	(58.6-268.0)	<b><u>Ovary</u></b>				
Female	3	6.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	18.1	104.9	(63.1-163.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.2	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.1	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	6	5.1	117.3	(42.8-255.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	67	70.3	95.3	(73.9-121.0)
Female	0	0.7	nc	(nc-nc)	Female	56	79.1	70.8	(53.5-92.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	9.0	122.8	(61.2-219.8)					
Female	5	10.9	46.0	(14.8-107.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	8	10.8	73.9	(31.8-145.6)	Female	2	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.1	66.1	(24.1-143.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	6	2.5	236.7	(86.4-515.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	30	37.4	80.3	(54.1-114.6)
Female	0	0.3	nc	(nc-nc)	Female	28	35.4	79.2	(52.6-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.6	nc	(nc-nc)					
Female	4	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	19.6	117.3	(74.3-176.0)	Male	17	11.5	148.1	(86.2-237.1)
Female	5	6.1	82.1	(26.5-191.6)	Female	2	8.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.3	125.9	(67.0-215.3)
Female	61	63.3	96.3	(73.7-123.7)	Female	6	8.2	72.9	(26.6-158.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	5	7.5	66.8	(21.5-155.9)
<b><u>Colon / Rectum</u></b>					Female	5	3.4	146.8	(47.3-342.5)
Male	20	20.3	98.4	(60.1-151.9)	<b><u>Ovary</u></b>				
Female	15	18.6	80.8	(45.2-133.2)	Female	0	5.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.6	nc	(nc-nc)	Male	7	6.5	107.1	(42.9-220.6)
Female	3	1.2	nc	(nc-nc)	Female	8	6.1	130.5	(56.2-257.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	53	51.5	102.9	(77.1-134.6)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.4	nc	(nc-nc)
Male	7	8.9	78.7	(31.5-162.2)	Female	3	2.4	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	10.9	91.7	(43.9-168.6)
Male	10	7.4	134.8	(64.5-247.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	4.8	146.0	(58.5-300.8)	Female	10	13.8	72.4	(34.7-133.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.7	nc	(nc-nc)	Male	217	227.3	95.4	(83.2-109.0)
Female	1	1.9	nc	(nc-nc)	Female	182	217.9	83.5	(71.8-96.6)
<b><u>Lung and Bronchus</u></b>									
Male	25	32.5	77.0	(49.8-113.7)					
Female	27	31.5	85.8	(56.5-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	15.4	65.1	(31.2-119.7)	Male	9	10.3	87.1	(39.8-165.4)
Female	4	4.3	nc	(nc-nc)	Female	6	7.5	80.5	(29.4-175.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.2	188.8	(68.9-410.9)	Male	3	3.3	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	9.2	119.7	(59.7-214.2)
Female	63	59.9	105.1	(80.8-134.5)	Female	14	6.7	208.6	(113.9-349.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	6	7.9	76.1	(27.8-165.6)
<b><u>Colon / Rectum</u></b>					Female	6	3.0	201.7	(73.7-439.1)
Male	18	17.1	105.5	(62.5-166.7)	<b><u>Ovary</u></b>				
Female	18	13.7	131.6	(77.9-208.0)	Female	5	5.2	96.9	(31.2-226.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	4.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	4.3	139.1	(50.8-302.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	48	58.0	82.7	(61.0-109.7)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	3.7	188.4	(75.5-388.1)
Male	7	9.2	76.4	(30.6-157.5)	Female	4	1.7	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	12.2	73.9	(33.7-140.4)
Male	5	6.3	79.4	(25.6-185.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	20	14.0	143.1	(87.4-221.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	169	214.5	78.8	(67.4-91.6)
Female	2	1.5	nc	(nc-nc)	Female	202	189.0	106.9	(92.7-122.7)
<b><u>Lung and Bronchus</u></b>									
Male	15	28.7	52.3	(29.3-86.3)					
Female	20	24.1	83.0	(50.7-128.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	15.2	78.9	(40.7-137.9)	Male	9	10.4	86.9	(39.6-165.0)
Female	3	5.6	nc	(nc-nc)	Female	10	8.8	113.7	(54.4-209.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.2	185.1	(67.6-402.9)	Male	2	3.2	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	17	9.3	183.0	(106.5-293.0)
Female	72	69.7	103.3	(80.8-130.0)	Female	11	8.2	134.8	(67.2-241.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.5	nc	(nc-nc)	Male	6	7.9	76.0	(27.8-165.5)
<b><u>Colon / Rectum</u></b>					Female	3	3.5	nc	(nc-nc)
Male	16	17.2	92.9	(53.1-150.9)	<b><u>Ovary</u></b>				
Female	17	16.7	102.0	(59.4-163.3)	Female	2	6.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.3	187.4	(80.7-369.3)	Male	6	5.5	108.7	(39.7-236.5)
Female	2	1.1	nc	(nc-nc)	Female	7	5.6	125.9	(50.5-259.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	72	55.6	129.4	(101.3-163.0)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.7	135.5	(43.7-316.1)
Male	8	9.1	87.5	(37.7-172.5)	Female	2	2.1	nc	(nc-nc)
Female	5	5.4	92.9	(29.9-216.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	13.7	101.9	(55.7-170.9)
Male	6	6.4	94.0	(34.3-204.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.8	104.0	(33.5-242.8)	Female	17	16.1	105.7	(61.6-169.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.8	86.8	(28.0-202.6)	Male	233	211.9	110.0	(96.3-125.0)
Female	0	1.9	nc	(nc-nc)	Female	212	227.0	93.4	(81.2-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	30	27.8	108.1	(72.9-154.3)					
Female	21	31.1	67.5	(41.8-103.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belmont

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	26.9	96.6	(63.1-141.6)	Male	16	16.9	94.6	(54.1-153.7)
Female	5	9.9	50.4	(16.3-117.7)	Female	8	14.1	56.7	(24.4-111.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.1	137.8	(55.2-284.0)	Male	6	5.3	113.7	(41.5-247.6)
Female	4	4.4	nc	(nc-nc)	Female	5	4.4	112.6	(36.3-262.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	16	15.2	105.3	(60.1-171.0)
Female	130	109.9	118.3	(98.8-140.5)	Female	10	13.9	72.2	(34.5-132.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.9	nc	(nc-nc)	Male	5	11.8	42.5	(13.7-99.1)
<b><u>Colon / Rectum</u></b>					Female	6	5.8	103.5	(37.8-225.3)
Male	21	28.8	73.0	(45.2-111.6)	<b><u>Ovary</u></b>				
Female	25	30.3	82.5	(53.4-121.8)	Female	10	9.6	103.7	(49.7-190.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.8	73.1	(23.6-170.6)	Male	10	9.3	107.3	(51.3-197.3)
Female	4	1.9	nc	(nc-nc)	Female	8	10.0	80.1	(34.5-157.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	84	85.2	98.6	(78.6-122.0)
Female	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.2	nc	(nc-nc)
Male	13	14.2	91.5	(48.7-156.5)	Female	5	3.9	128.2	(41.3-299.1)
Female	5	8.7	57.5	(18.5-134.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.4	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	7	6.3	110.4	(44.2-227.4)
<b><u>Leukemia</u></b>					Female	26	20.7	125.5	(81.9-183.8)
Male	4	10.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	8.2	61.1	(19.7-142.6)	Female	28	24.3	115.1	(76.5-166.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	8.6	nc	(nc-nc)	Male	293	342.3	85.6	(76.1-96.0)
Female	2	3.1	nc	(nc-nc)	Female	354	371.7	95.2	(85.6-105.7)
<b><u>Lung and Bronchus</u></b>									
Male	32	47.1	68.0	(46.5-95.9)					
Female	41	51.6	79.5	(57.0-107.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.3	nc	(nc-nc)	Male	5	4.3	117.5	(37.9-274.2)
Female	1	1.5	nc	(nc-nc)	Female	5	2.9	172.0	(55.4-401.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	30	23.7	126.5	(85.4-180.7)	Female	6	2.5	242.1	(88.4-526.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	9	7.0	128.2	(58.5-243.4)	<b><u>Ovary</u></b>				
Female	6	5.0	120.2	(43.9-261.6)	Female	0	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	19	22.5	84.3	(50.7-131.6)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.5	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	5	1.8	284.0	(91.5-662.8)
<b><u>Leukemia</u></b>					Female	4	5.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	1.5	nc	(nc-nc)	Female	7	5.3	133.1	(53.3-274.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	80	86.8	92.2	(73.1-114.7)
Female	0	0.6	nc	(nc-nc)	Female	90	72.6	124.1	(99.7-152.5)
<b><u>Lung and Bronchus</u></b>									
Male	11	11.7	94.1	(46.9-168.4)					
Female	10	9.1	110.0	(52.6-202.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.1	122.0	(39.3-284.7)	Male	7	2.6	271.8	(108.9-560.0)
Female	1	1.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	14	13.7	101.8	(55.6-170.9)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	12	13.5	88.6	(45.7-154.8)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.3	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	58	52.6	110.2	(83.7-142.5)
Female	0	0.4	nc	(nc-nc)	Female	40	44.9	89.0	(63.6-121.2)
<b><u>Lung and Bronchus</u></b>									
Male	10	7.3	136.4	(65.3-250.8)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	5	1.4	346.9	(111.8-809.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.0	256.0	(82.5-597.5)
Female	12	12.0	100.3	(51.7-175.1)	Female	3	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	16	11.6	137.8	(78.7-223.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	42	45.1	93.2	(67.1-125.9)
Female	1	0.4	nc	(nc-nc)	Female	39	40.3	96.7	(68.8-132.2)
<b><u>Lung and Bronchus</u></b>									
Male	4	6.3	nc	(nc-nc)					
Female	4	5.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	51	42.7	119.6	(89.0-157.2)	Male	37	27.2	136.2	(95.9-187.7)
Female	21	15.9	132.1	(81.8-202.0)	Female	33	22.6	146.0	(100.5-205.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	8.1	147.5	(76.1-257.7)	Male	12	8.5	141.0	(72.8-246.4)
Female	6	7.0	85.7	(31.3-186.5)	Female	5	7.1	70.2	(22.6-163.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	25	24.3	102.9	(66.5-151.8)
Female	176	172.3	102.2	(87.6-118.4)	Female	20	22.2	90.1	(55.0-139.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.9	nc	(nc-nc)	Male	25	19.4	128.9	(83.4-190.2)
<b><u>Colon / Rectum</u></b>					Female	14	9.3	149.7	(81.8-251.3)
Male	32	45.7	69.9	(47.8-98.8)	<b><u>Ovary</u></b>				
Female	48	48.3	99.4	(73.3-131.8)	Female	16	15.6	102.8	(58.7-167.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	11.2	116.5	(62.0-199.2)	Male	15	15.0	100.2	(56.0-165.3)
Female	5	3.1	161.5	(52.0-376.9)	Female	17	16.2	104.8	(61.0-167.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	161	139.9	115.1	(98.0-134.3)
Female	0	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	9.9	nc	(nc-nc)
Male	22	22.8	96.5	(60.5-146.2)	Female	4	6.3	nc	(nc-nc)
Female	18	13.6	132.3	(78.4-209.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	5.8	171.7	(82.2-315.8)
Male	6	6.4	93.7	(34.2-203.9)	<b><u>Thyroid</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	13	10.4	125.3	(66.6-214.2)
<b><u>Leukemia</u></b>					Female	35	32.6	107.2	(74.7-149.1)
Male	23	17.1	134.4	(85.2-201.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	13.0	107.5	(58.7-180.3)	Female	34	39.2	86.7	(60.1-121.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	14.5	103.2	(57.7-170.2)	Male	615	553.0	111.2	(102.6-120.4)
Female	12	5.0	239.6	(123.7-418.6)	Female	648	590.2	109.8	(101.5-118.6)
<b><u>Lung and Bronchus</u></b>									
Male	84	75.5	111.3	(88.8-137.8)					
Female	95	81.5	116.6	(94.3-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	38.5	135.1	(100.9-177.1)	Male	30	26.2	114.4	(77.2-163.3)
Female	17	13.5	125.7	(73.2-201.3)	Female	22	21.0	104.9	(65.7-158.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	8.3	108.1	(49.3-205.2)	Male	11	8.2	134.2	(66.9-240.1)
Female	4	6.6	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	23	23.6	97.5	(61.8-146.3)
Female	158	164.9	95.8	(81.4-112.0)	Female	19	19.7	96.5	(58.1-150.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.9	nc	(nc-nc)	Male	13	20.0	64.9	(34.5-111.1)
<b><u>Colon / Rectum</u></b>					Female	9	8.4	107.1	(48.9-203.3)
Male	33	43.9	75.2	(51.7-105.6)	<b><u>Ovary</u></b>				
Female	54	41.5	130.2	(97.8-169.9)	Female	15	14.4	104.2	(58.3-171.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	10.9	82.6	(37.7-156.7)	Male	14	14.0	100.0	(54.6-167.7)
Female	2	2.7	nc	(nc-nc)	Female	10	13.5	74.0	(35.4-136.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	140	143.4	97.7	(82.2-115.2)
Female	1	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.3	107.5	(51.4-197.6)
Male	32	23.4	136.8	(93.6-193.2)	Female	8	5.3	151.6	(65.3-298.6)
Female	9	12.7	70.6	(32.2-134.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	6.5	nc	(nc-nc)
Male	3	6.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.9	nc	(nc-nc)	Male	14	11.3	123.6	(67.5-207.3)
<b><u>Leukemia</u></b>					Female	29	32.5	89.3	(59.8-128.2)
Male	27	16.2	166.2	(109.5-241.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	11.5	165.0	(99.3-257.6)	Female	29	37.2	78.0	(52.2-112.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	14.5	69.0	(33.0-126.9)	Male	562	539.6	104.1	(95.7-113.1)
Female	3	4.4	nc	(nc-nc)	Female	559	541.3	103.3	(94.9-112.2)
<b><u>Lung and Bronchus</u></b>									
Male	74	69.9	105.8	(83.1-132.9)					
Female	104	73.5	141.5	(115.6-171.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.0	171.3	(88.4-299.2)	Male	6	5.0	119.6	(43.7-260.3)
Female	5	3.1	160.6	(51.7-374.7)	Female	5	4.9	102.0	(32.9-238.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	5	4.5	111.1	(35.8-259.2)
Female	31	39.0	79.5	(54.0-112.8)	Female	4	4.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.0	nc	(nc-nc)
Male	7	8.3	84.7	(33.9-174.6)	<b><u>Ovary</u></b>				
Female	5	9.7	51.5	(16.6-120.1)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	2.0	391.1	(168.4-770.6)	Male	0	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	27	26.6	101.6	(66.9-147.8)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.7	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.3	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	7.7	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	10	8.7	114.5	(54.8-210.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	125	101.9	122.6	(102.1-146.1)
Female	0	1.0	nc	(nc-nc)	Female	117	125.8	93.0	(76.9-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	20	13.2	152.0	(92.8-234.7)					
Female	13	16.2	80.1	(42.6-136.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.9	143.9	(57.7-296.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.0	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	17.1	111.3	(67.0-173.8)
Female	0	0.1	nc	(nc-nc)	Female	17	15.8	107.8	(62.8-172.7)
<b><u>Lung and Bronchus</u></b>									
Male	4	2.1	nc	(nc-nc)					
Female	2	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	22	19.5	113.0	(70.8-171.2)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.9	nc	(nc-nc)
Male	7	5.4	129.7	(52.0-267.3)	<b><u>Ovary</u></b>				
Female	2	3.9	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	24	17.8	134.9	(86.4-200.7)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.1	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	10	4.4	225.3	(107.9-414.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	63	65.9	95.6	(73.5-122.3)
Female	0	0.5	nc	(nc-nc)	Female	48	58.2	82.5	(60.9-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	4	8.5	nc	(nc-nc)					
Female	5	7.0	71.2	(22.9-166.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	344	466.1	73.8	(66.2-82.0)	Male	253	319.6	79.2	(69.7-89.6)
Female	140	179.4	78.1	(65.7-92.1)	Female	203	294.0	69.1	(59.9-79.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	72	107.4	67.0	(52.4-84.4)	Male	114	95.7	119.2	(98.3-143.2)
Female	71	91.8	77.3	(60.4-97.5)	Female	127	81.4	156.1	(130.1-185.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	15	16.0	93.7	(52.4-154.5)	Male	284	287.5	98.8	(87.6-111.0)
Female	1903	2058.3	92.5	(88.3-96.7)	Female	256	262.0	97.7	(86.1-110.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	96	81.4	117.9	(95.5-144.0)	Male	262	225.7	116.1	(102.4-131.0)
<b><u>Colon / Rectum</u></b>					Female	114	109.2	104.4	(86.1-125.4)
Male	561	515.8	108.8	(100.0-118.2)	<b><u>Ovary</u></b>				
Female	577	549.2	105.1	(96.7-114.0)	Female	188	187.1	100.5	(86.6-115.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	118	124.3	95.0	(78.6-113.7)	Male	157	164.7	95.3	(81.0-111.5)
Female	36	34.9	103.2	(72.3-142.9)	Female	179	179.6	99.7	(85.6-115.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	61	56.6	107.7	(82.4-138.4)	Male	1865	1570.7	118.7	(113.4-124.2)
Female	48	51.2	93.8	(69.2-124.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	164	110.9	147.9	(126.1-172.3)
Male	229	268.2	85.4	(74.7-97.2)	Female	104	70.7	147.0	(120.1-178.2)
Female	172	163.8	105.0	(89.9-121.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	98	118.9	82.5	(66.9-100.5)
Male	90	72.5	124.2	(99.9-152.7)	<b><u>Thyroid</u></b>				
Female	17	23.7	71.7	(41.7-114.8)	Male	153	141.3	108.3	(91.8-126.9)
<b><u>Leukemia</u></b>					Female	473	475.3	99.5	(90.7-108.9)
Male	156	204.6	76.2	(64.7-89.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	129	160.0	80.6	(67.3-95.8)	Female	438	460.0	95.2	(86.5-104.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	273	164.1	166.4	(147.2-187.3)	Male	6682	6365.2	105.0	(102.5-107.5)
Female	91	58.0	156.8	(126.2-192.5)	Female	6758	7078.4	95.5	(93.2-97.8)
<b><u>Lung and Bronchus</u></b>									
Male	911	831.9	109.5	(102.5-116.9)					
Female	850	948.4	89.6	(83.7-95.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	28.1	117.4	(80.8-164.9)	Male	23	17.0	135.2	(85.7-202.9)
Female	10	10.2	98.2	(47.0-180.5)	Female	14	12.5	112.1	(61.2-188.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.7	128.6	(47.0-280.0)	Male	8	5.5	145.1	(62.5-285.9)
Female	3	3.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	11	15.1	72.7	(36.2-130.0)
Female	83	98.3	84.4	(67.2-104.6)	Female	9	13.4	67.2	(30.7-127.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	17	11.5	147.5	(85.9-236.2)
<b><u>Colon / Rectum</u></b>					Female	5	5.5	90.6	(29.2-211.5)
Male	21	28.6	73.4	(45.4-112.1)	<b><u>Ovary</u></b>				
Female	27	30.0	90.0	(59.3-130.9)	Female	12	8.9	134.7	(69.5-235.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	7.1	169.7	(87.6-296.5)	Male	9	9.5	94.4	(43.1-179.1)
Female	3	1.9	nc	(nc-nc)	Female	10	10.3	97.4	(46.6-179.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	90	86.3	104.3	(83.9-128.2)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.4	94.2	(34.4-205.0)
Male	9	13.8	65.1	(29.7-123.6)	Female	5	3.9	128.1	(41.3-299.0)
Female	7	8.2	85.9	(34.4-176.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.8	nc	(nc-nc)
Male	10	4.1	244.6	(117.1-449.8)	<b><u>Thyroid</u></b>				
Female	3	1.2	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	15.7	120.8	(72.7-188.7)
Male	7	10.5	66.4	(26.6-136.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.8	64.3	(20.7-149.9)	Female	18	22.4	80.4	(47.6-127.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	9.0	77.6	(31.1-159.9)	Male	358	346.2	103.4	(93.0-114.7)
Female	1	3.1	nc	(nc-nc)	Female	324	347.7	93.2	(83.3-103.9)
<b><u>Lung and Bronchus</u></b>									
Male	55	49.5	111.2	(83.7-144.7)					
Female	62	52.1	119.1	(91.3-152.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	26	20.1	129.1	(84.3-189.1)	Female	3	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	5	5.6	88.9	(28.6-207.4)	<b><u>Ovary</u></b>				
Female	5	4.2	118.7	(38.2-276.9)	Female	0	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	19	20.3	93.8	(56.4-146.5)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.2	nc	(nc-nc)	Female	5	4.6	108.5	(35.0-253.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	61	71.8	85.0	(65.0-109.2)
Female	0	0.5	nc	(nc-nc)	Female	70	60.9	115.0	(89.7-145.3)
<b><u>Lung and Bronchus</u></b>									
Male	6	9.1	65.7	(24.0-143.1)					
Female	9	7.3	123.3	(56.3-234.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	10.1	59.1	(21.6-128.7)	Male	18	6.6	273.6	(162.0-432.4)
Female	1	2.9	nc	(nc-nc)	Female	9	4.4	205.2	(93.6-389.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	41	36.4	112.6	(80.8-152.8)	Female	3	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	3	11.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	8.7	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	46	36.7	125.3	(91.7-167.2)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.4	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	6.6	166.4	(83.0-297.8)
Male	5	4.0	126.3	(40.7-294.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.4	208.2	(67.1-485.9)	Female	5	8.6	58.2	(18.8-135.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.7	nc	(nc-nc)	Male	116	136.7	84.9	(70.1-101.8)
Female	0	1.0	nc	(nc-nc)	Female	115	116.8	98.5	(81.3-118.2)
<b><u>Lung and Bronchus</u></b>									
Male	9	18.5	48.5	(22.1-92.1)					
Female	9	15.9	56.5	(25.8-107.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.0	99.3	(32.0-231.8)	Male	3	3.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	8	2.3	348.3	(150.0-686.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	27	18.7	144.5	(95.2-210.3)	Female	0	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	4.7	171.1	(73.7-337.2)	Female	4	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	11	17.2	63.8	(31.8-114.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.5	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	53	67.1	79.0	(59.1-103.3)
Female	0	0.5	nc	(nc-nc)	Female	72	60.2	119.6	(93.6-150.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	9.0	nc	(nc-nc)					
Female	5	8.0	62.5	(20.2-146.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	40.0	129.8	(97.0-170.3)	Male	33	25.2	130.9	(90.1-183.9)
Female	24	16.5	145.5	(93.2-216.5)	Female	23	21.7	105.9	(67.1-158.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.4	94.0	(37.7-193.8)	Male	7	7.9	89.0	(35.6-183.3)
Female	5	6.7	75.1	(24.2-175.3)	Female	7	7.2	97.1	(38.9-200.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	25	22.5	111.0	(71.8-163.8)
Female	183	165.0	110.9	(95.4-128.2)	Female	21	22.1	95.0	(58.8-145.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	5.5	180.7	(86.5-332.3)	Male	21	17.6	119.5	(73.9-182.7)
<b><u>Colon / Rectum</u></b>					Female	10	9.1	109.7	(52.5-201.8)
Male	54	42.5	127.1	(95.5-165.8)	<b><u>Ovary</u></b>				
Female	67	50.1	133.7	(103.6-169.8)	Female	13	14.9	87.0	(46.3-148.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	10.2	146.9	(82.1-242.3)	Male	14	13.9	101.0	(55.2-169.4)
Female	3	3.1	nc	(nc-nc)	Female	18	16.7	107.8	(63.9-170.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	122	125.1	97.5	(81.0-116.4)
Female	4	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.3	107.8	(51.6-198.3)
Male	19	20.8	91.5	(55.1-142.9)	Female	7	6.5	107.3	(43.0-221.1)
Female	15	13.4	111.7	(62.5-184.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.1	98.0	(31.6-228.6)
Male	4	5.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	6	1.9	308.1	(112.5-670.6)	Male	8	9.3	85.9	(37.0-169.3)
<b><u>Leukemia</u></b>					Female	36	29.7	121.3	(84.9-167.9)
Male	10	15.9	62.7	(30.0-115.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	13.1	159.9	(99.0-244.5)	Female	36	36.4	98.9	(69.3-137.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	13.2	136.2	(80.7-215.3)	Male	528	507.5	104.0	(95.4-113.3)
Female	5	5.0	100.7	(32.5-235.0)	Female	648	579.4	111.8	(103.4-120.8)
<b><u>Lung and Bronchus</u></b>									
Male	61	70.0	87.1	(66.6-111.9)					
Female	88	82.5	106.7	(85.6-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	17.8	101.2	(59.9-159.9)	Male	15	10.3	145.1	(81.2-239.4)
Female	8	6.5	123.8	(53.3-243.9)	Female	13	7.5	173.6	(92.3-296.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	14	9.0	154.8	(84.5-259.7)
Female	84	60.7	138.4	(110.4-171.3)	Female	13	8.4	155.2	(82.5-265.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	7	6.7	105.0	(42.1-216.3)
<b><u>Colon / Rectum</u></b>					Female	3	3.5	nc	(nc-nc)
Male	12	17.4	69.0	(35.6-120.5)	<b><u>Ovary</u></b>				
Female	16	18.6	86.0	(49.1-139.7)	Female	4	5.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	6	5.9	101.5	(37.1-221.0)
Female	3	1.2	nc	(nc-nc)	Female	3	6.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	70	53.2	131.7	(102.7-166.4)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.9	nc	(nc-nc)
Male	6	8.2	73.1	(26.7-159.1)	Female	1	2.4	nc	(nc-nc)
Female	5	5.1	98.3	(31.7-229.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	8.7	80.8	(32.4-166.5)
Male	7	6.2	112.2	(45.0-231.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.7	126.8	(46.3-276.1)	Female	11	14.2	77.3	(38.6-138.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	213	211.4	100.7	(87.7-115.2)
Female	0	2.0	nc	(nc-nc)	Female	215	215.8	99.6	(86.8-113.9)
<b><u>Lung and Bronchus</u></b>									
Male	28	31.8	87.9	(58.4-127.1)					
Female	18	33.7	53.4	(31.7-84.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	23.7	80.1	(48.2-125.2)	Male	15	16.3	91.9	(51.4-151.6)
Female	13	7.3	177.4	(94.4-303.4)	Female	17	11.7	145.5	(84.7-233.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.3	112.7	(41.2-245.4)	Male	2	5.0	nc	(nc-nc)
Female	6	3.7	161.3	(58.9-351.0)	Female	3	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	10	14.8	67.5	(32.3-124.1)
Female	92	88.5	104.0	(83.8-127.5)	Female	12	10.8	111.5	(57.5-194.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	14	12.4	113.0	(61.7-189.6)
<b><u>Colon / Rectum</u></b>					Female	5	4.6	108.7	(35.0-253.6)
Male	23	27.1	84.8	(53.8-127.3)	<b><u>Ovary</u></b>				
Female	25	22.4	111.4	(72.1-164.4)	Female	11	7.9	139.3	(69.4-249.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.6	91.2	(33.3-198.6)	Male	13	8.6	151.0	(80.3-258.3)
Female	1	1.4	nc	(nc-nc)	Female	10	7.3	137.2	(65.7-252.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	81	84.4	96.0	(76.3-119.3)
Female	0	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.8	86.4	(27.8-201.6)
Male	8	14.4	55.6	(24.0-109.6)	Female	4	2.9	nc	(nc-nc)
Female	7	6.8	102.5	(41.1-211.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	4.5	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	11	7.2	152.4	(76.0-272.7)
<b><u>Leukemia</u></b>					Female	26	18.4	141.4	(92.3-207.2)
Male	5	10.3	48.3	(15.6-112.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.4	nc	(nc-nc)	Female	15	20.1	74.5	(41.7-122.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	8.8	158.6	(86.6-266.1)	Male	314	330.5	95.0	(84.8-106.1)
Female	3	2.4	nc	(nc-nc)	Female	304	293.9	103.4	(92.1-115.7)
<b><u>Lung and Bronchus</u></b>									
Male	51	42.4	120.2	(89.5-158.1)					
Female	29	39.1	74.1	(49.6-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	16	18.5	86.6	(49.5-140.7)	Female	4	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	4.5	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	10	14.1	70.7	(33.9-130.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	225.8	(72.8-526.9)	Female	2	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.2	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	50	50.0	100.1	(74.3-132.0)
Female	0	0.5	nc	(nc-nc)	Female	45	60.0	75.0	(54.7-100.4)
<b><u>Lung and Bronchus</u></b>									
Male	8	6.3	126.5	(54.5-249.3)					
Female	9	8.7	103.5	(47.2-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	81	82.4	98.3	(78.1-122.2)	Male	27	54.4	49.7	(32.7-72.2)
Female	34	31.4	108.3	(75.0-151.3)	Female	25	47.0	53.2	(34.4-78.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	17	17.6	96.4	(56.1-154.4)	Male	10	16.9	59.3	(28.4-109.0)
Female	18	15.0	119.8	(71.0-189.3)	Female	13	14.2	91.6	(48.7-156.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	47	49.1	95.7	(70.3-127.3)
Female	302	357.4	84.5	(75.2-94.6)	Female	37	44.8	82.6	(58.2-113.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	26	12.9	200.9	(131.2-294.4)	Male	41	39.5	103.7	(74.4-140.7)
<b><u>Colon / Rectum</u></b>					Female	20	18.9	105.9	(64.6-163.5)
Male	114	91.1	125.1	(103.2-150.3)	<b><u>Ovary</u></b>				
Female	108	96.5	111.9	(91.8-135.1)	Female	42	31.8	132.0	(95.1-178.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	20	22.0	91.0	(55.6-140.6)	Male	31	29.2	106.2	(72.2-150.8)
Female	8	6.1	131.2	(56.5-258.5)	Female	43	31.6	136.3	(98.6-183.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	7.3	68.1	(21.9-158.9)	Male	286	278.3	102.8	(91.2-115.4)
Female	5	6.3	79.3	(25.5-184.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	25	19.6	127.7	(82.6-188.5)
Male	57	46.6	122.2	(92.6-158.4)	Female	13	12.4	105.1	(55.9-179.7)
Female	27	28.3	95.4	(62.9-138.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	13.7	94.9	(50.5-162.2)
Male	19	12.8	148.0	(89.1-231.1)	<b><u>Thyroid</u></b>				
Female	4	4.2	nc	(nc-nc)	Male	32	22.2	144.1	(98.5-203.4)
<b><u>Leukemia</u></b>					Female	90	71.4	126.0	(101.3-154.8)
Male	27	35.0	77.0	(50.8-112.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	27.1	77.5	(47.9-118.4)	Female	79	79.7	99.2	(78.5-123.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	40	29.2	136.9	(97.8-186.4)	Male	1171	1104.2	106.0	(100.1-112.3)
Female	16	10.1	159.2	(90.9-258.5)	Female	1254	1209.5	103.7	(98.0-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	186	146.9	126.6	(109.1-146.2)					
Female	206	165.7	124.3	(107.9-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.1	121.5	(39.2-283.6)	Male	4	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	13	15.5	83.9	(44.6-143.5)	Female	3	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	4.3	140.2	(51.2-305.1)	Female	1	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	13	16.1	80.9	(43.0-138.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	41	57.2	71.7	(51.5-97.3)
Female	3	0.5	nc	(nc-nc)	Female	61	52.9	115.2	(88.1-148.0)
<b><u>Lung and Bronchus</u></b>									
Male	7	7.6	91.5	(36.7-188.6)					
Female	13	7.6	170.1	(90.5-290.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	51	53.0	96.3	(71.7-126.6)	Male	46	34.4	133.8	(98.0-178.5)
Female	14	22.7	61.6	(33.6-103.3)	Female	34	33.4	101.7	(70.4-142.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	10.5	114.2	(58.9-199.5)	Male	13	10.7	121.7	(64.7-208.0)
Female	12	10.4	115.5	(59.6-201.8)	Female	8	10.2	78.5	(33.8-154.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	39	30.5	127.8	(90.9-174.7)
Female	238	242.5	98.2	(86.1-111.5)	Female	38	31.9	119.2	(84.4-163.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	8.8	nc	(nc-nc)	Male	21	24.0	87.5	(54.2-133.8)
<b><u>Colon / Rectum</u></b>					Female	7	13.2	53.0	(21.2-109.1)
Male	38	55.9	68.0	(48.1-93.3)	<b><u>Ovary</u></b>				
Female	41	67.8	60.5	(43.4-82.0)	Female	33	22.1	149.0	(102.6-209.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	14.0	35.6	(11.5-83.2)	Male	17	18.5	91.9	(53.5-147.1)
Female	3	4.4	nc	(nc-nc)	Female	25	23.0	108.7	(70.4-160.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	175	180.8	96.8	(83.0-112.3)
Female	7	5.0	140.1	(56.1-288.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	12.3	64.8	(27.9-127.8)
Male	31	29.0	106.8	(72.6-151.7)	Female	9	8.8	102.4	(46.7-194.5)
Female	17	19.7	86.4	(50.3-138.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	14	9.0	156.3	(85.4-262.2)
Male	2	8.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	2.9	nc	(nc-nc)	Male	16	13.6	117.5	(67.1-190.9)
<b><u>Leukemia</u></b>					Female	50	49.6	100.8	(74.8-132.8)
Male	30	21.3	140.5	(94.8-200.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	26	19.1	136.4	(89.1-199.9)	Female	42	55.7	75.4	(54.4-102.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	17.9	39.1	(15.7-80.6)	Male	640	699.4	91.5	(84.6-98.9)
Female	5	7.2	69.8	(22.5-162.9)	Female	764	845.6	90.4	(84.1-97.0)
<b><u>Lung and Bronchus</u></b>									
Male	62	95.4	65.0	(49.8-83.3)					
Female	80	118.6	67.5	(53.5-84.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	11	11.9	92.8	(46.3-166.0)	Female	0	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	8.7	114.6	(54.9-210.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	30	34.0	88.2	(59.5-125.9)
Female	0	0.4	nc	(nc-nc)	Female	36	41.0	87.8	(61.5-121.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	4.6	nc	(nc-nc)					
Female	5	6.2	80.5	(25.9-187.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	30.7	87.8	(57.9-127.8)	Male	18	19.2	93.6	(55.4-147.9)
Female	5	10.8	46.3	(14.9-108.2)	Female	15	14.5	103.1	(57.7-170.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.5	162.8	(74.3-309.2)	Male	7	6.1	115.7	(46.3-238.3)
Female	4	4.5	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	21	17.0	123.7	(76.6-189.1)
Female	127	115.4	110.0	(91.7-130.9)	Female	14	14.7	95.0	(51.9-159.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.8	nc	(nc-nc)	Male	12	13.1	91.9	(47.4-160.5)
<b><u>Colon / Rectum</u></b>					Female	5	6.2	80.8	(26.0-188.5)
Male	31	32.0	96.9	(65.8-137.5)	<b><u>Ovary</u></b>				
Female	27	31.7	85.3	(56.2-124.1)	Female	7	10.2	68.4	(27.4-141.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	7.8	nc	(nc-nc)	Male	12	10.5	113.8	(58.7-198.8)
Female	0	2.0	nc	(nc-nc)	Female	10	10.6	94.5	(45.2-173.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	97	94.8	102.3	(83.0-124.8)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	7.0	nc	(nc-nc)
Male	20	15.6	128.0	(78.2-197.7)	Female	4	4.1	nc	(nc-nc)
Female	5	9.3	53.5	(17.2-124.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.9	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	12	6.9	172.9	(89.2-302.0)
<b><u>Leukemia</u></b>					Female	28	20.7	135.5	(90.0-195.8)
Male	17	11.9	142.6	(83.0-228.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	8.5	82.7	(33.1-170.4)	Female	31	25.9	119.6	(81.3-169.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	10.0	100.1	(47.9-184.1)	Male	394	385.3	102.2	(92.4-112.9)
Female	3	3.4	nc	(nc-nc)	Female	392	394.2	99.5	(89.8-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	40	54.5	73.4	(52.5-100.0)					
Female	63	58.3	108.1	(83.1-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	74.4	61.8	(45.3-82.5)	Male	56	51.6	108.5	(81.9-140.8)
Female	17	30.0	56.7	(33.0-90.9)	Female	44	49.7	88.5	(64.3-118.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	17.6	113.8	(69.5-175.7)	Male	18	15.0	119.7	(70.9-189.2)
Female	12	15.2	78.9	(40.7-137.8)	Female	7	13.6	51.5	(20.6-106.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	42	46.1	91.2	(65.7-123.2)
Female	299	338.6	88.3	(78.6-98.9)	Female	34	43.8	77.6	(53.7-108.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	13.7	65.5	(29.9-124.4)	Male	37	35.3	104.7	(73.7-144.4)
<b><u>Colon / Rectum</u></b>					Female	16	18.2	88.0	(50.3-142.9)
Male	71	80.9	87.7	(68.5-110.7)	<b><u>Ovary</u></b>				
Female	69	90.6	76.1	(59.2-96.3)	Female	21	31.2	67.3	(41.7-102.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	19.7	71.1	(38.9-119.4)	Male	32	26.1	122.5	(83.8-172.9)
Female	5	5.9	85.4	(27.5-199.3)	Female	26	30.1	86.5	(56.5-126.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	10.2	68.5	(27.4-141.1)	Male	247	250.3	98.7	(86.7-111.8)
Female	3	8.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	17.6	62.5	(31.2-111.9)
Male	33	42.4	77.8	(53.6-109.3)	Female	8	11.7	68.2	(29.4-134.4)
Female	14	27.1	51.6	(28.2-86.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	26	22.7	114.7	(74.9-168.1)
Male	4	11.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	4.0	nc	(nc-nc)	Male	27	23.3	115.7	(76.2-168.4)
<b><u>Leukemia</u></b>					Female	78	80.6	96.8	(76.5-120.8)
Male	26	32.8	79.2	(51.7-116.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	26.6	67.8	(40.1-107.1)	Female	67	76.7	87.3	(67.7-110.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	25.5	70.5	(41.7-111.4)	Male	901	1018.5	88.5	(82.8-94.4)
Female	13	9.7	133.8	(71.2-228.9)	Female	940	1176.9	79.9	(74.8-85.1)
<b><u>Lung and Bronchus</u></b>									
Male	106	132.7	79.9	(65.4-96.6)					
Female	103	158.1	65.1	(53.2-79.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	26.0	80.6	(49.9-123.2)	Male	18	16.2	111.2	(65.9-175.8)
Female	7	9.6	72.8	(29.2-150.1)	Female	16	13.0	123.0	(70.3-199.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.7	nc	(nc-nc)	Male	9	5.2	174.5	(79.6-331.2)
Female	6	4.0	148.3	(54.1-322.8)	Female	6	4.3	139.8	(51.0-304.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	10	14.5	69.0	(33.0-127.0)
Female	100	103.0	97.1	(79.0-118.1)	Female	16	13.2	121.6	(69.5-197.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	11	11.3	97.5	(48.6-174.4)
<b><u>Colon / Rectum</u></b>					Female	9	5.5	163.1	(74.4-309.7)
Male	28	27.4	102.1	(67.9-147.6)	<b><u>Ovary</u></b>				
Female	30	28.8	104.2	(70.3-148.8)	Female	6	9.1	65.6	(24.0-142.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	120.2	(51.8-236.9)	Male	9	9.0	100.3	(45.8-190.4)
Female	1	1.9	nc	(nc-nc)	Female	8	9.7	82.7	(35.6-163.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	83	81.9	101.4	(80.7-125.7)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.0	nc	(nc-nc)
Male	9	13.5	66.8	(30.5-126.7)	Female	2	3.7	nc	(nc-nc)
Female	4	8.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.9	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	10	5.9	169.5	(81.2-311.8)
<b><u>Leukemia</u></b>					Female	29	18.0	160.8	(107.7-230.9)
Male	17	10.1	167.6	(97.6-268.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.7	91.3	(36.6-188.1)	Female	30	23.3	128.8	(86.9-183.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	8.5	nc	(nc-nc)	Male	327	328.5	99.5	(89.0-110.9)
Female	0	3.0	nc	(nc-nc)	Female	371	351.1	105.7	(95.2-117.0)
<b><u>Lung and Bronchus</u></b>									
Male	46	45.7	100.6	(73.6-134.1)					
Female	54	50.5	106.9	(80.3-139.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carlisle

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.1	nc	(nc-nc)	Male	7	4.0	174.0	(69.7-358.5)
Female	1	2.1	nc	(nc-nc)	Female	5	2.9	170.2	(54.8-397.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	21	24.8	84.6	(52.4-129.4)	Female	5	2.9	170.8	(55.1-398.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	5	6.8	73.8	(23.8-172.3)	<b><u>Ovary</u></b>				
Female	4	6.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	27	23.4	115.6	(76.2-168.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.2	119.8	(38.6-279.6)
Male	3	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	7	5.6	124.4	(49.8-256.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	67	84.4	79.4	(61.5-100.8)
Female	1	0.7	nc	(nc-nc)	Female	71	80.3	88.4	(69.1-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	11.6	43.3	(13.9-101.0)					
Female	3	11.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	13.4	134.7	(79.8-212.9)	Male	9	8.5	105.3	(48.0-199.9)
Female	7	5.0	139.9	(56.0-288.3)	Female	12	6.9	174.0	(89.8-303.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	7.6	79.0	(28.8-171.9)
Female	41	56.7	72.3	(51.9-98.1)	Female	14	7.0	199.8	(109.2-335.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.8	nc	(nc-nc)	Male	8	6.2	129.6	(55.8-255.4)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	15	14.2	105.5	(59.0-174.1)	<b><u>Ovary</u></b>				
Female	10	14.8	67.4	(32.2-123.9)	Female	4	4.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.6	168.7	(61.6-367.1)	Male	4	4.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	46	45.5	101.1	(74.0-134.8)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.1	nc	(nc-nc)
Male	4	7.3	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	6	4.4	136.2	(49.7-296.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.6	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	9.7	61.9	(22.6-134.7)
Male	3	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.9	nc	(nc-nc)	Female	12	13.1	91.5	(47.2-159.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.6	nc	(nc-nc)	Male	175	175.0	100.0	(85.8-116.0)
Female	2	1.6	nc	(nc-nc)	Female	178	188.1	94.6	(81.2-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	31	24.0	129.3	(87.9-183.6)					
Female	36	26.5	135.6	(95.0-187.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	6.1	131.0	(56.4-258.2)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	21	25.4	82.6	(51.1-126.3)
Female	0	0.2	nc	(nc-nc)	Female	21	20.6	101.8	(63.0-155.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.7	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	14.2	98.8	(54.0-165.8)	Male	2	9.2	nc	(nc-nc)
Female	5	4.1	122.5	(39.5-285.8)	Female	6	6.6	90.6	(33.1-197.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	179.3	(57.8-418.5)	Male	2	2.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	5	1.9	259.9	(83.8-606.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	107.3	(49.0-203.8)
Female	54	52.7	102.4	(76.9-133.6)	Female	5	6.1	81.7	(26.3-190.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.7	nc	(nc-nc)
Male	11	16.1	68.2	(34.0-122.1)	<b><u>Ovary</u></b>				
Female	12	13.1	91.6	(47.3-160.0)	Female	1	4.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	6	5.1	118.2	(43.2-257.4)
Female	0	0.8	nc	(nc-nc)	Female	6	4.1	145.0	(53.0-315.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	27	48.6	55.6	(36.6-80.9)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.4	nc	(nc-nc)
Male	9	8.0	112.2	(51.2-213.0)	Female	0	1.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.6	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	10.4	124.9	(66.4-213.6)
Male	5	5.8	86.5	(27.9-201.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	11	12.0	91.7	(45.7-164.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	140	189.3	74.0	(62.2-87.3)
Female	0	1.4	nc	(nc-nc)	Female	179	169.4	105.7	(90.8-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	20	24.7	81.1	(49.5-125.3)					
Female	31	21.5	144.3	(98.0-204.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	14.4	118.2	(68.8-189.3)	Male	22	8.1	270.6	(169.5-409.7)
Female	10	5.1	196.6	(94.1-361.7)	Female	11	5.4	204.9	(102.2-366.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	5	2.2	229.0	(73.8-534.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.1	70.1	(22.6-163.5)
Female	49	44.4	110.3	(81.6-145.8)	Female	7	6.4	110.1	(44.1-226.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	8	5.3	152.3	(65.6-300.2)
<b><u>Colon / Rectum</u></b>					Female	1	2.6	nc	(nc-nc)
Male	19	13.9	137.2	(82.6-214.2)	<b><u>Ovary</u></b>				
Female	14	14.1	99.3	(54.2-166.5)	Female	3	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	7	4.8	146.7	(58.8-302.3)
Female	0	1.0	nc	(nc-nc)	Female	6	5.1	118.5	(43.3-257.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	48	42.5	112.9	(83.2-149.6)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.2	nc	(nc-nc)
Male	6	6.4	93.1	(34.0-202.7)	Female	1	1.8	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.5	nc	(nc-nc)
Male	8	4.9	161.7	(69.6-318.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.5	nc	(nc-nc)	Female	11	10.5	104.5	(52.1-187.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.2	nc	(nc-nc)	Male	192	167.9	114.4	(98.8-131.7)
Female	1	1.5	nc	(nc-nc)	Female	181	161.5	112.0	(96.3-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	22	25.4	86.7	(54.3-131.3)					
Female	27	26.7	101.0	(66.5-146.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	39.9	117.9	(86.6-156.7)	Male	22	25.5	86.3	(54.1-130.7)
Female	14	13.9	100.6	(55.0-168.9)	Female	25	19.6	127.7	(82.6-188.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	7.5	160.1	(82.6-279.6)	Male	13	8.1	160.9	(85.6-275.2)
Female	7	6.1	115.0	(46.1-236.9)	Female	9	6.3	143.5	(65.5-272.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	26	22.7	114.7	(74.9-168.1)
Female	173	156.5	110.6	(94.7-128.3)	Female	17	19.5	87.3	(50.8-139.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.2	114.6	(41.8-249.4)	Male	20	18.1	110.7	(67.6-171.0)
<b><u>Colon / Rectum</u></b>					Female	8	8.2	97.2	(41.8-191.5)
Male	39	43.0	90.7	(64.5-124.0)	<b><u>Ovary</u></b>				
Female	47	41.6	112.9	(83.0-150.2)	Female	21	13.7	152.8	(94.5-233.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	10.4	67.4	(27.0-138.9)	Male	17	13.9	122.2	(71.2-195.7)
Female	3	2.7	nc	(nc-nc)	Female	16	13.9	114.9	(65.6-186.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	117	128.7	90.9	(75.2-109.0)
Female	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	9.3	nc	(nc-nc)
Male	23	21.4	107.5	(68.1-161.3)	Female	5	5.3	93.7	(30.2-218.6)
Female	9	12.3	72.9	(33.3-138.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.0	100.2	(32.3-233.9)
Male	5	6.0	82.9	(26.7-193.4)	<b><u>Thyroid</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	12	9.6	124.4	(64.2-217.3)
<b><u>Leukemia</u></b>					Female	36	28.2	127.5	(89.3-176.6)
Male	17	15.8	107.8	(62.8-172.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	22	11.2	196.5	(123.1-297.6)	Female	49	35.4	138.3	(102.3-182.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	13.6	73.4	(35.1-134.9)	Male	513	514.5	99.7	(91.3-108.7)
Female	2	4.4	nc	(nc-nc)	Female	599	524.7	114.2	(105.2-123.7)
<b><u>Lung and Bronchus</u></b>									
Male	67	71.1	94.3	(73.1-119.7)					
Female	76	75.0	101.4	(79.9-126.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelsea

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	23.0	73.8	(43.0-118.2)	Male	8	16.7	47.8	(20.6-94.2)
Female	9	8.4	107.0	(48.8-203.1)	Female	8	14.3	56.0	(24.1-110.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.3	127.7	(55.0-251.6)	Male	3	4.8	nc	(nc-nc)
Female	6	4.8	126.2	(46.1-274.7)	Female	5	3.8	130.5	(42.1-304.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	15.2	118.6	(70.2-187.4)
Female	88	99.8	88.2	(70.7-108.6)	Female	14	12.6	111.5	(60.9-187.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.3	164.0	(65.7-337.9)	Male	6	12.0	50.0	(18.2-108.7)
<b><u>Colon / Rectum</u></b>					Female	9	5.2	171.5	(78.3-325.6)
Male	31	27.1	114.2	(77.6-162.1)	<b><u>Ovary</u></b>				
Female	16	26.5	60.3	(34.5-98.0)	Female	4	9.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.2	96.9	(35.4-210.8)	Male	8	8.3	96.6	(41.6-190.3)
Female	0	1.6	nc	(nc-nc)	Female	18	8.6	210.5	(124.7-332.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	59	78.2	75.5	(57.5-97.4)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	5.7	176.3	(84.4-324.2)
Male	5	14.5	34.5	(11.1-80.5)	Female	3	3.4	nc	(nc-nc)
Female	10	7.9	127.0	(60.8-233.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.8	nc	(nc-nc)
Male	6	3.6	165.5	(60.4-360.3)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	8	8.1	99.2	(42.7-195.5)
<b><u>Leukemia</u></b>					Female	41	24.1	170.4	(122.2-231.1)
Male	14	11.2	124.5	(68.0-208.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.1	123.5	(59.1-227.1)	Female	16	21.6	74.0	(42.3-120.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	8.4	178.9	(100.1-295.1)	Male	320	327.0	97.9	(87.4-109.2)
Female	7	2.7	258.4	(103.5-532.5)	Female	354	341.0	103.8	(93.3-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	56	40.7	137.7	(104.0-178.8)					
Female	58	43.6	133.0	(101.0-171.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.4	137.9	(50.4-300.1)	Male	5	2.7	187.9	(60.6-438.5)
Female	2	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	12	17.0	70.6	(36.4-123.3)	Female	1	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.9	nc	(nc-nc)
Male	6	4.6	129.4	(47.3-281.7)	<b><u>Ovary</u></b>				
Female	3	4.5	nc	(nc-nc)	Female	5	1.5	333.3	(107.4-777.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	19	14.8	128.2	(77.2-200.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.0	124.0	(40.0-289.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	68	55.9	121.7	(94.5-154.3)
Female	0	0.5	nc	(nc-nc)	Female	40	56.4	70.9	(50.7-96.6)
<b><u>Lung and Bronchus</u></b>									
Male	14	7.6	184.5	(100.8-309.6)					
Female	3	8.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	6	1.7	360.4	(131.6-784.4)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.8	102.6	(37.5-223.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	26	20.7	125.6	(82.0-184.1)
Female	0	0.2	nc	(nc-nc)	Female	14	18.5	75.7	(41.4-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.6	nc	(nc-nc)					
Female	4	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	5.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.3	94.6	(30.5-220.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	14	19.0	73.6	(40.2-123.4)
Female	0	0.2	nc	(nc-nc)	Female	10	18.1	55.1	(26.4-101.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.4	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	66	65.7	100.4	(77.7-127.7)	Male	22	40.9	53.8	(33.7-81.4)
Female	14	24.2	57.7	(31.5-96.9)	Female	20	32.4	61.6	(37.6-95.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.0	75.0	(34.2-142.4)	Male	14	12.9	108.2	(59.1-181.6)
Female	10	9.9	100.5	(48.1-184.9)	Female	7	10.8	65.1	(26.1-134.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	28	36.4	76.8	(51.0-111.0)
Female	246	249.0	98.8	(86.8-112.0)	Female	33	33.0	100.0	(68.8-140.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.2	97.8	(42.1-192.7)	Male	32	28.0	114.2	(78.1-161.2)
<b><u>Colon / Rectum</u></b>					Female	25	13.7	183.1	(118.5-270.3)
Male	93	68.4	136.0	(109.8-166.6)	<b><u>Ovary</u></b>				
Female	73	72.5	100.7	(78.9-126.6)	Female	31	22.4	138.1	(93.8-196.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	16.7	95.7	(54.7-155.5)	Male	20	22.6	88.5	(54.0-136.7)
Female	5	4.7	107.3	(34.6-250.4)	Female	26	24.4	106.4	(69.5-155.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	4.7	106.9	(34.4-249.4)	Male	141	206.8	68.2	(57.4-80.4)
Female	2	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	15.1	79.6	(41.1-139.0)
Male	40	33.6	118.9	(84.9-161.9)	Female	13	9.4	138.8	(73.8-237.3)
Female	27	20.3	133.3	(87.8-194.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	8.3	131.9	(65.8-236.1)
Male	9	9.7	93.0	(42.4-176.6)	<b><u>Thyroid</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	8	14.8	54.0	(23.3-106.4)
<b><u>Leukemia</u></b>					Female	31	44.4	69.9	(47.5-99.2)
Male	23	25.8	89.2	(56.5-133.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	19.2	62.7	(32.3-109.4)	Female	53	56.5	93.9	(70.3-122.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	21.4	60.9	(32.4-104.1)	Male	762	829.1	91.9	(85.5-98.7)
Female	4	7.5	nc	(nc-nc)	Female	855	867.0	98.6	(92.1-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	142	116.2	122.2	(103.0-144.1)					
Female	141	125.8	112.1	(94.3-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	5	5.2	95.4	(30.7-222.6)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.5	134.1	(49.0-291.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	21	16.4	128.3	(79.4-196.1)
Female	0	0.1	nc	(nc-nc)	Female	13	16.9	76.8	(40.8-131.3)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.3	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	5	8.0	62.2	(20.0-145.2)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	2.3	220.3	(71.0-514.0)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	8.2	85.2	(34.1-175.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	27	32.8	82.4	(54.3-119.9)
Female	0	0.2	nc	(nc-nc)	Female	25	27.6	90.7	(58.7-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.7	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	13.0	176.9	(112.1-265.4)	Male	4	8.7	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)	Female	8	8.1	99.0	(42.6-195.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.8	63.9	(20.6-149.1)
Female	58	62.4	92.9	(70.5-120.1)	Female	7	8.1	86.6	(34.7-178.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	7	6.5	107.5	(43.1-221.4)
<b><u>Colon / Rectum</u></b>					Female	2	3.4	nc	(nc-nc)
Male	16	14.5	110.7	(63.2-179.8)	<b><u>Ovary</u></b>				
Female	14	17.8	78.8	(43.0-132.2)	Female	3	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	5	5.9	84.4	(27.2-196.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	48	47.0	102.1	(75.3-135.4)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.1	nc	(nc-nc)
Male	5	7.6	65.5	(21.1-153.0)	Female	1	2.3	nc	(nc-nc)
Female	5	4.9	101.3	(32.7-236.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	11.4	52.6	(19.2-114.4)
Male	8	5.4	147.5	(63.5-290.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.7	105.7	(34.0-246.6)	Female	13	14.3	91.1	(48.4-155.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.7	106.3	(34.2-248.0)	Male	176	178.6	98.6	(84.5-114.3)
Female	2	1.9	nc	(nc-nc)	Female	196	214.2	91.5	(79.1-105.2)
<b><u>Lung and Bronchus</u></b>									
Male	29	23.5	123.4	(82.6-177.2)					
Female	35	29.7	117.9	(82.1-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	85.2	(36.7-167.8)	Male	5	6.1	82.3	(26.5-192.2)
Female	5	3.2	155.4	(50.1-362.7)	Female	14	4.3	324.3	(177.1-544.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	111.9	(40.8-243.5)
Female	40	35.0	114.3	(81.7-155.7)	Female	1	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	4.4	114.5	(36.9-267.2)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	12	10.0	120.0	(62.0-209.7)	<b><u>Ovary</u></b>				
Female	5	9.5	52.7	(17.0-123.0)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	26	30.6	85.0	(55.5-124.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	7	5.1	137.7	(55.2-283.7)	Female	0	1.2	nc	(nc-nc)
Female	5	2.8	177.2	(57.1-413.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.0	133.1	(57.3-262.3)
Male	2	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	8	8.0	99.7	(42.9-196.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	107	122.2	87.6	(71.8-105.8)
Female	1	1.0	nc	(nc-nc)	Female	132	118.5	111.4	(93.2-132.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	17.0	58.9	(28.2-108.4)					
Female	10	17.3	57.7	(27.6-106.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	8	8.0	99.8	(43.0-196.6)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	9	8.6	104.1	(47.5-197.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	5	1.9	263.6	(85.0-615.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	29	34.7	83.6	(56.0-120.1)
Female	0	0.2	nc	(nc-nc)	Female	30	26.6	112.8	(76.1-161.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.9	nc	(nc-nc)					
Female	4	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	27.1	103.2	(68.5-149.1)	Male	29	16.6	174.5	(116.9-250.7)
Female	7	9.1	76.6	(30.7-157.8)	Female	18	11.1	161.8	(95.8-255.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.6	107.6	(34.7-251.2)	Male	5	5.4	93.3	(30.1-217.6)
Female	5	3.5	144.5	(46.6-337.1)	Female	4	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	13	14.9	87.4	(46.5-149.5)
Female	114	89.3	127.6	(105.3-153.3)	Female	9	12.0	74.7	(34.1-141.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	10	11.5	86.7	(41.5-159.4)
<b><u>Colon / Rectum</u></b>					Female	5	5.0	99.8	(32.1-232.8)
Male	19	28.5	66.7	(40.1-104.2)	<b><u>Ovary</u></b>				
Female	35	27.6	126.7	(88.2-176.2)	Female	15	8.1	185.1	(103.5-305.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	14	9.3	150.2	(82.0-252.0)
Female	0	1.7	nc	(nc-nc)	Female	8	9.3	85.7	(36.9-168.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	86	84.8	101.4	(81.1-125.2)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.2	nc	(nc-nc)
Male	13	13.8	94.2	(50.1-161.1)	Female	0	3.6	nc	(nc-nc)
Female	7	7.3	96.5	(38.6-198.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.7	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	13.7	87.6	(45.2-153.1)
Male	6	10.3	58.1	(21.2-126.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	7.0	nc	(nc-nc)	Female	25	20.2	124.0	(80.2-183.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.8	68.4	(25.0-149.0)	Male	295	338.6	87.1	(77.5-97.7)
Female	4	2.7	nc	(nc-nc)	Female	334	312.9	106.8	(95.6-118.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	47.3	40.1	(24.1-62.7)					
Female	27	45.6	59.1	(39.0-86.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	11	9.5	116.1	(57.9-207.8)	Female	0	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	65.1	(21.0-151.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	29	28.7	101.0	(67.6-145.1)
Female	0	0.3	nc	(nc-nc)	Female	26	29.9	86.9	(56.7-127.3)
<b><u>Lung and Bronchus</u></b>									
Male	4	3.8	nc	(nc-nc)					
Female	1	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	7	4.5	155.2	(62.2-319.7)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	1.3	389.3	(125.5-908.5)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	18.0	88.9	(50.8-144.4)
Female	1	0.1	nc	(nc-nc)	Female	21	15.3	137.2	(84.9-209.7)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.6	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	10.3	106.5	(53.1-190.5)	Male	8	6.2	128.3	(55.2-252.8)
Female	2	3.2	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	27	33.2	81.4	(53.6-118.4)	Female	2	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	11	10.7	102.8	(51.3-184.0)	<b><u>Ovary</u></b>				
Female	11	9.6	115.0	(57.3-205.8)	Female	3	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	33	29.5	111.8	(77.0-157.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	5.3	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	7	7.7	91.1	(36.5-187.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	102	124.5	81.9	(66.8-99.4)
Female	0	1.0	nc	(nc-nc)	Female	94	114.3	82.2	(66.4-100.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	18.0	72.2	(38.4-123.5)					
Female	19	16.8	113.3	(68.2-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	35.1	105.3	(74.1-145.2)	Male	18	21.6	83.3	(49.3-131.7)
Female	15	12.3	121.6	(68.0-200.5)	Female	14	16.0	87.7	(47.9-147.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	6.1	196.4	(101.4-343.1)	Male	4	6.9	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	14	19.2	72.8	(39.7-122.1)
Female	141	123.9	113.8	(95.8-134.2)	Female	28	16.5	169.6	(112.7-245.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.0	nc	(nc-nc)	Male	14	14.7	95.1	(52.0-159.6)
<b><u>Colon / Rectum</u></b>					Female	7	6.8	103.3	(41.4-212.8)
Male	29	36.5	79.4	(53.2-114.1)	<b><u>Ovary</u></b>				
Female	39	37.1	105.2	(74.8-143.8)	Female	11	11.1	99.0	(49.3-177.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.8	125.2	(62.4-224.0)	Male	12	12.0	99.7	(51.5-174.2)
Female	2	2.3	nc	(nc-nc)	Female	9	12.5	72.2	(33.0-137.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	119	106.6	111.6	(92.5-133.6)
Female	4	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.0	62.2	(20.1-145.3)
Male	25	17.6	141.9	(91.8-209.5)	Female	7	4.8	144.5	(57.9-297.7)
Female	8	10.0	79.6	(34.3-156.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.8	130.3	(42.0-304.0)
Male	3	5.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	11	7.6	144.2	(71.9-258.0)
<b><u>Leukemia</u></b>					Female	23	21.4	107.4	(68.1-161.2)
Male	12	13.5	88.9	(45.9-155.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	9.7	133.9	(71.2-229.0)	Female	38	27.4	138.5	(98.0-190.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	11.2	107.3	(55.4-187.4)	Male	446	434.9	102.5	(93.2-112.5)
Female	6	3.7	161.1	(58.8-350.7)	Female	467	432.2	108.1	(98.5-118.3)
<b><u>Lung and Bronchus</u></b>									
Male	65	61.4	105.8	(81.6-134.9)					
Female	52	62.2	83.7	(62.5-109.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	43.1	132.2	(100.1-171.3)	Male	24	26.6	90.4	(57.9-134.5)
Female	17	15.4	110.1	(64.1-176.3)	Female	18	19.7	91.4	(54.1-144.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.6	92.2	(37.0-190.1)	Male	5	8.3	60.0	(19.3-140.0)
Female	7	6.1	115.5	(46.3-238.0)	Female	5	6.8	73.7	(23.7-171.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	21	24.0	87.6	(54.2-133.9)
Female	126	153.1	82.3	(68.6-98.0)	Female	17	20.6	82.6	(48.1-132.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.8	104.3	(33.6-243.3)	Male	16	18.3	87.3	(49.9-141.7)
<b><u>Colon / Rectum</u></b>					Female	13	8.6	151.7	(80.7-259.5)
Male	42	45.5	92.4	(66.6-124.9)	<b><u>Ovary</u></b>				
Female	44	46.2	95.2	(69.2-127.8)	Female	8	14.0	57.1	(24.6-112.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	10.8	101.7	(50.7-182.0)	Male	14	14.8	94.6	(51.7-158.8)
Female	2	3.0	nc	(nc-nc)	Female	8	15.8	50.7	(21.8-99.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	160	131.6	121.6	(103.5-141.9)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	9.9	121.7	(62.8-212.6)
Male	24	21.7	110.8	(71.0-164.9)	Female	7	6.1	115.5	(46.3-238.0)
Female	15	12.4	120.7	(67.5-199.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.7	105.9	(38.7-230.4)
Male	7	6.1	114.5	(45.9-235.8)	<b><u>Thyroid</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	8	9.7	82.3	(35.5-162.3)
<b><u>Leukemia</u></b>					Female	32	25.7	124.4	(85.1-175.7)
Male	17	16.8	101.4	(59.0-162.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	12.0	66.9	(28.8-131.9)	Female	37	35.0	105.7	(74.4-145.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	13.7	65.7	(30.0-124.8)	Male	544	537.2	101.3	(92.9-110.2)
Female	1	4.7	nc	(nc-nc)	Female	456	537.1	84.9	(77.3-93.1)
<b><u>Lung and Bronchus</u></b>									
Male	69	74.2	93.0	(72.4-117.7)					
Female	44	77.4	56.9	(41.3-76.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	33.0	106.1	(73.9-147.5)	Male	21	20.0	105.0	(65.0-160.5)
Female	11	12.1	91.1	(45.4-163.1)	Female	20	15.2	131.2	(80.1-202.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.6	160.8	(73.4-305.2)	Male	9	6.4	140.3	(64.0-266.4)
Female	4	4.7	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	20	17.9	111.4	(68.0-172.1)
Female	146	117.3	124.4	(105.1-146.3)	Female	15	15.9	94.1	(52.6-155.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.8	133.2	(42.9-310.8)	Male	14	13.2	106.1	(58.0-178.1)
<b><u>Colon / Rectum</u></b>					Female	12	6.5	183.7	(94.8-320.9)
Male	24	34.1	70.4	(45.1-104.8)	<b><u>Ovary</u></b>				
Female	29	36.3	79.8	(53.4-114.6)	Female	11	10.6	103.6	(51.6-185.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.0	74.8	(27.3-162.9)	Male	11	11.0	99.8	(49.7-178.5)
Female	0	2.3	nc	(nc-nc)	Female	17	12.2	139.1	(81.0-222.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	94	93.8	100.2	(81.0-122.6)
Female	3	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.5	120.3	(54.9-228.3)
Male	14	16.1	86.8	(47.4-145.6)	Female	7	4.7	147.6	(59.1-304.1)
Female	12	9.6	124.6	(64.3-217.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.7	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	5	7.0	71.4	(23.0-166.7)
<b><u>Leukemia</u></b>					Female	30	20.0	149.8	(101.1-213.9)
Male	9	12.6	71.5	(32.6-135.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.4	74.7	(29.9-153.9)	Female	25	25.8	96.9	(62.7-143.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	10.0	109.9	(54.8-196.7)	Male	390	398.2	97.9	(88.5-108.2)
Female	6	3.6	167.4	(61.1-364.5)	Female	468	415.0	112.8	(102.8-123.5)
<b><u>Lung and Bronchus</u></b>									
Male	50	56.7	88.2	(65.5-116.3)					
Female	77	60.6	127.1	(100.3-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	5	3.2	155.1	(50.0-361.9)
Female	3	2.1	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	19	24.6	77.4	(46.6-120.8)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	5.3	112.6	(41.1-245.2)	<b><u>Ovary</u></b>				
Female	5	6.3	80.0	(25.8-186.6)	Female	0	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	19	19.4	97.9	(58.9-152.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	5	3.1	162.4	(52.3-379.0)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	54	68.0	79.5	(59.7-103.7)
Female	0	0.7	nc	(nc-nc)	Female	60	80.8	74.3	(56.7-95.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.6	nc	(nc-nc)					
Female	5	11.4	43.7	(14.1-101.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dennis

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	28.9	145.4	(104.8-196.6)	Male	37	16.2	228.2	(160.7-314.6)
Female	15	10.4	144.8	(81.0-238.9)	Female	20	11.7	171.6	(104.8-265.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	10	5.3	187.7	(89.8-345.2)
Female	1	3.6	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	15	14.2	105.5	(59.0-174.1)
Female	114	96.2	118.5	(97.7-142.3)	Female	10	13.3	75.4	(36.1-138.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	16	10.1	159.0	(90.8-258.2)
<b><u>Colon / Rectum</u></b>					Female	3	5.4	nc	(nc-nc)
Male	29	27.4	105.8	(70.9-152.0)	<b><u>Ovary</u></b>				
Female	24	28.5	84.3	(54.0-125.5)	Female	13	8.6	150.4	(80.0-257.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	6.8	146.9	(70.3-270.2)	Male	17	9.5	179.1	(104.3-286.8)
Female	5	2.0	251.6	(81.1-587.2)	Female	11	10.2	107.7	(53.7-192.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	108	81.8	132.0	(108.3-159.4)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	6.3	nc	(nc-nc)
Male	10	12.6	79.6	(38.1-146.4)	Female	2	3.7	nc	(nc-nc)
Female	6	8.2	73.1	(26.7-159.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	17	13.1	129.4	(75.3-207.2)
Male	14	10.1	139.2	(76.0-233.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.3	95.8	(38.4-197.3)	Female	20	22.8	87.6	(53.5-135.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.1	98.7	(42.5-194.6)	Male	401	331.3	121.0	(109.5-133.5)
Female	4	3.1	nc	(nc-nc)	Female	366	342.3	106.9	(96.3-118.5)
<b><u>Lung and Bronchus</u></b>									
Male	44	50.7	86.9	(63.1-116.6)					
Female	54	56.3	95.9	(72.1-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.8	71.6	(28.7-147.4)	Male	5	5.9	84.9	(27.3-198.0)
Female	1	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	94.7	(30.5-220.9)
Female	16	29.6	54.1	(30.9-87.9)	Female	1	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	15	10.2	147.0	(82.2-242.5)	<b><u>Ovary</u></b>				
Female	5	8.2	60.9	(19.6-142.1)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	30	28.7	104.4	(70.4-149.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	6	4.8	126.0	(46.0-274.2)	Female	0	1.1	nc	(nc-nc)
Female	5	2.4	211.3	(68.1-493.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.3	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	7	6.6	106.1	(42.5-218.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	110	119.0	92.5	(76.0-111.4)
Female	1	0.9	nc	(nc-nc)	Female	75	100.3	74.7	(58.8-93.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	16.9	59.2	(28.4-109.0)					
Female	14	14.2	98.6	(53.9-165.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.1	84.4	(30.8-183.8)	Male	6	5.2	116.3	(42.5-253.1)
Female	4	2.0	nc	(nc-nc)	Female	6	3.8	156.5	(57.1-340.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	29	31.4	92.2	(61.7-132.5)	Female	2	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	5	8.4	59.3	(19.1-138.3)	<b><u>Ovary</u></b>				
Female	5	6.5	77.0	(24.8-179.6)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	28.4	84.7	(54.2-126.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	8	4.7	170.2	(73.3-335.4)	Female	0	0.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.3	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.7	134.1	(61.2-254.7)
Male	1	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	9	7.1	126.6	(57.8-240.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	101	105.8	95.5	(77.8-116.0)
Female	1	0.7	nc	(nc-nc)	Female	98	95.5	102.6	(83.3-125.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	13.4	104.5	(57.1-175.3)					
Female	11	11.8	93.3	(46.5-166.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	11	4.7	234.9	(117.1-420.4)
Female	0	2.0	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.2	168.7	(67.6-347.5)
Female	27	25.1	107.4	(70.8-156.3)	Female	3	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	6	7.9	75.7	(27.6-164.7)	<b><u>Ovary</u></b>				
Female	5	6.2	80.2	(25.9-187.2)	Female	0	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	27	23.4	115.4	(76.0-167.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	115.1	(37.1-268.6)
Male	1	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	1	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	92	94.8	97.0	(78.2-119.0)
Female	0	0.7	nc	(nc-nc)	Female	63	81.2	77.6	(59.6-99.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.6	58.8	(25.3-115.8)					
Female	6	11.5	52.2	(19.1-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	29.9	133.9	(95.6-182.3)	Male	10	20.1	49.7	(23.8-91.4)
Female	16	10.4	153.7	(87.8-249.5)	Female	15	15.8	95.0	(53.2-156.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.3	110.7	(44.3-228.0)	Male	7	6.3	111.7	(44.7-230.1)
Female	3	4.9	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	17.9	83.7	(46.8-138.1)
Female	138	123.2	112.0	(94.1-132.3)	Female	10	15.0	66.7	(32.0-122.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.3	115.3	(37.2-269.1)	Male	8	15.2	52.8	(22.7-104.0)
<b><u>Colon / Rectum</u></b>					Female	10	6.4	155.9	(74.6-286.7)
Male	38	33.3	114.2	(80.8-156.8)	<b><u>Ovary</u></b>				
Female	48	31.8	151.0	(111.4-200.3)	Female	12	10.8	110.6	(57.1-193.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.4	155.5	(82.7-266.0)	Male	7	10.8	64.7	(25.9-133.4)
Female	3	2.1	nc	(nc-nc)	Female	12	10.4	115.0	(59.4-200.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	99	108.7	91.1	(74.0-110.9)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.2	83.8	(30.6-182.3)
Male	20	17.5	114.0	(69.6-176.0)	Female	5	4.1	123.3	(39.7-287.7)
Female	7	9.6	73.0	(29.3-150.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.5	nc	(nc-nc)
Male	8	4.9	164.1	(70.6-323.3)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	7	8.3	84.6	(33.9-174.4)
<b><u>Leukemia</u></b>					Female	28	23.7	118.0	(78.4-170.5)
Male	18	12.5	144.2	(85.4-228.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	8.7	114.4	(54.8-210.5)	Female	13	28.2	46.1	(24.5-78.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.3	nc	(nc-nc)	Male	408	412.2	99.0	(89.6-109.1)
Female	5	3.4	145.9	(47.0-340.4)	Female	461	408.6	112.8	(102.8-123.6)
<b><u>Lung and Bronchus</u></b>									
Male	61	54.7	111.6	(85.4-143.4)					
Female	75	55.9	134.1	(105.5-168.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.2	107.1	(55.3-187.0)	Male	5	7.3	68.6	(22.1-160.0)
Female	3	3.1	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	42	39.6	106.0	(76.4-143.3)	Female	5	4.6	108.4	(34.9-252.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	12	12.0	100.1	(51.7-174.9)	<b><u>Ovary</u></b>				
Female	11	9.5	115.4	(57.6-206.6)	Female	8	3.4	233.5	(100.5-460.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	5	3.9	129.8	(41.8-303.0)
Female	2	0.6	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	33	34.5	95.5	(65.8-134.2)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.6	190.4	(61.3-444.2)
Male	8	6.1	132.2	(56.9-260.5)	Female	0	1.2	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.8	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	8.0	138.1	(68.8-247.1)
Male	9	4.6	194.5	(88.8-369.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	2.7	185.0	(59.6-431.7)	Female	17	8.9	190.3	(110.8-304.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.8	nc	(nc-nc)	Male	149	144.7	103.0	(87.1-120.9)
Female	1	1.0	nc	(nc-nc)	Female	158	128.1	123.3	(104.9-144.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	19.9	130.5	(85.2-191.2)					
Female	26	17.0	152.6	(99.6-223.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	18	14.1	127.6	(75.6-201.7)	Female	2	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.7	nc	(nc-nc)
Male	5	3.5	144.6	(46.6-337.5)	<b><u>Ovary</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	12.3	57.1	(22.9-117.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.7	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	39	43.3	90.1	(64.0-123.1)
Female	0	0.4	nc	(nc-nc)	Female	45	45.1	99.8	(72.8-133.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.5	nc	(nc-nc)					
Female	8	5.7	140.2	(60.4-276.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	18.0	138.6	(89.7-204.6)	Male	29	11.3	255.7	(171.2-367.3)
Female	1	6.7	nc	(nc-nc)	Female	15	9.1	164.4	(91.9-271.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	7	3.7	189.8	(76.0-391.0)
Female	1	2.9	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	18	10.2	176.6	(104.6-279.1)
Female	82	74.5	110.0	(87.5-136.5)	Female	4	9.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	6	8.4	71.4	(26.1-155.5)
<b><u>Colon / Rectum</u></b>					Female	4	4.0	nc	(nc-nc)
Male	10	19.3	51.9	(24.8-95.4)	<b><u>Ovary</u></b>				
Female	14	20.4	68.5	(37.4-114.9)	Female	6	6.6	90.7	(33.1-197.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.9	122.9	(44.9-267.5)	Male	5	6.3	78.8	(25.4-183.9)
Female	1	1.3	nc	(nc-nc)	Female	6	6.8	88.4	(32.3-192.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	73	62.9	116.1	(91.0-146.0)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	4.2	nc	(nc-nc)
Male	16	9.9	161.3	(92.2-262.0)	Female	2	2.6	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	12.5	79.8	(38.2-146.7)
Male	7	7.1	99.2	(39.7-204.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.3	nc	(nc-nc)	Female	8	17.0	47.1	(20.3-92.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.3	nc	(nc-nc)	Male	261	237.0	110.1	(97.2-124.4)
Female	0	2.1	nc	(nc-nc)	Female	207	249.3	83.0	(72.1-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	28	32.4	86.4	(57.4-124.8)					
Female	17	34.9	48.6	(28.3-77.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.2	130.9	(74.8-212.6)	Male	10	8.4	119.5	(57.2-219.8)
Female	6	5.8	102.6	(37.5-223.4)	Female	8	8.3	96.2	(41.4-189.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.5	106.3	(45.8-209.5)
Female	47	66.9	70.3	(51.6-93.4)	Female	11	8.3	132.8	(66.2-237.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	8	6.4	124.6	(53.6-245.5)
<b><u>Colon / Rectum</u></b>					Female	1	3.5	nc	(nc-nc)
Male	17	14.1	121.0	(70.4-193.7)	<b><u>Ovary</u></b>				
Female	11	17.7	62.3	(31.0-111.4)	Female	6	5.9	101.5	(37.1-220.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.4	175.2	(64.0-381.3)	Male	2	4.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	5.8	137.2	(59.1-270.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	46	44.7	102.8	(75.3-137.2)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	12	7.5	160.5	(82.8-280.3)	Female	2	2.2	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	5	3.6	138.3	(44.6-322.7)
<b><u>Leukemia</u></b>					Female	11	12.1	91.1	(45.4-163.0)
Male	3	5.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.7	nc	(nc-nc)	Female	11	15.3	71.9	(35.8-128.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.6	109.1	(35.2-254.6)	Male	192	171.0	112.3	(97.0-129.3)
Female	0	1.9	nc	(nc-nc)	Female	183	223.2	82.0	(70.5-94.8)
<b><u>Lung and Bronchus</u></b>									
Male	27	22.4	120.7	(79.6-175.7)					
Female	24	31.6	75.8	(48.6-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	8	10.0	80.0	(34.4-157.6)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.5	84.4	(36.4-166.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	29	35.3	82.1	(55.0-117.9)
Female	0	0.3	nc	(nc-nc)	Female	29	32.8	88.4	(59.2-127.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.7	nc	(nc-nc)					
Female	5	4.6	108.6	(35.0-253.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	20.2	89.2	(52.8-141.0)	Male	19	12.3	154.1	(92.7-240.6)
Female	5	8.6	58.3	(18.8-136.0)	Female	10	10.4	96.2	(46.1-177.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	11.1	125.9	(68.8-211.2)
Female	75	80.7	92.9	(73.1-116.5)	Female	9	11.3	80.0	(36.5-151.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	9	8.7	104.0	(47.5-197.4)
<b><u>Colon / Rectum</u></b>					Female	5	4.6	108.7	(35.0-253.6)
Male	21	21.4	98.2	(60.8-150.1)	<b><u>Ovary</u></b>				
Female	23	25.8	89.0	(56.4-133.5)	Female	12	7.4	163.0	(84.1-284.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	5	6.9	72.1	(23.2-168.4)
Female	2	1.6	nc	(nc-nc)	Female	11	8.8	125.2	(62.4-224.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	53	63.2	83.8	(62.8-109.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.6	107.8	(34.7-251.5)
Male	13	10.3	126.2	(67.1-215.9)	Female	4	3.4	nc	(nc-nc)
Female	8	6.7	119.9	(51.6-236.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.1	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	12.8	62.4	(26.9-123.0)
Male	7	7.7	90.5	(36.3-186.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.6	nc	(nc-nc)	Female	16	18.0	88.8	(50.7-144.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	234	252.4	92.7	(81.2-105.4)
Female	1	2.6	nc	(nc-nc)	Female	273	288.8	94.5	(83.7-106.5)
<b><u>Lung and Bronchus</u></b>									
Male	36	34.9	103.0	(72.1-142.6)					
Female	51	42.7	119.5	(89.0-157.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.1	89.9	(43.0-165.3)	Male	8	6.4	124.7	(53.7-245.8)
Female	4	3.6	nc	(nc-nc)	Female	13	4.2	307.7	(163.7-526.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	45	35.8	125.8	(91.8-168.4)	Female	7	4.7	149.6	(59.9-308.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.0	nc	(nc-nc)
Male	11	10.8	101.6	(50.7-181.9)	<b><u>Ovary</u></b>				
Female	12	9.9	121.5	(62.7-212.2)	Female	4	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	6	3.5	169.5	(61.9-369.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	42	36.6	114.8	(82.7-155.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.9	nc	(nc-nc)
Male	9	3.9	230.0	(104.9-436.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	7	8.7	80.7	(32.3-166.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	141	135.5	104.0	(87.6-122.7)
Female	1	1.1	nc	(nc-nc)	Female	140	123.3	113.5	(95.5-134.0)
<b><u>Lung and Bronchus</u></b>									
Male	25	20.0	124.9	(80.8-184.4)					
Female	14	19.9	70.4	(38.4-118.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	18.4	49.0	(22.3-93.0)	Male	9	12.0	74.9	(34.2-142.1)
Female	2	7.0	nc	(nc-nc)	Female	7	9.7	72.3	(29.0-149.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	10.7	84.5	(38.5-160.3)
Female	66	73.9	89.3	(69.1-113.6)	Female	11	9.6	114.6	(57.1-205.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	10	8.8	113.8	(54.5-209.2)
<b><u>Colon / Rectum</u></b>					Female	7	4.0	174.8	(70.0-360.1)
Male	32	20.1	159.3	(108.9-224.8)	<b><u>Ovary</u></b>				
Female	25	21.0	119.1	(77.0-175.8)	Female	3	6.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	9	6.9	129.7	(59.2-246.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	52	62.2	83.6	(62.4-109.6)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	7	10.1	69.0	(27.6-142.2)	Female	2	2.7	nc	(nc-nc)
Female	8	6.0	134.0	(57.7-264.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.7	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	13.8	58.1	(25.0-114.5)
Male	7	7.3	95.4	(38.2-196.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.5	nc	(nc-nc)	Female	19	16.8	113.3	(68.2-176.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.6	nc	(nc-nc)	Male	206	243.5	84.6	(73.4-97.0)
Female	3	2.2	nc	(nc-nc)	Female	231	254.8	90.7	(79.3-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	29	32.8	88.3	(59.1-126.8)					
Female	34	36.4	93.3	(64.6-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	20.9	115.1	(73.7-171.2)	Male	19	14.2	134.1	(80.7-209.5)
Female	9	7.2	124.2	(56.7-235.8)	Female	18	11.4	157.6	(93.4-249.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.6	131.8	(48.1-286.9)	Male	5	4.4	112.5	(36.3-262.5)
Female	4	3.7	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	8	12.7	62.9	(27.1-123.9)
Female	117	89.0	131.5	(108.8-157.6)	Female	14	10.7	130.8	(71.5-219.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	10	10.8	92.4	(44.2-169.9)
<b><u>Colon / Rectum</u></b>					Female	3	4.6	nc	(nc-nc)
Male	18	23.3	77.3	(45.8-122.2)	<b><u>Ovary</u></b>				
Female	31	22.3	139.0	(94.4-197.3)	Female	9	7.8	115.4	(52.7-219.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.9	101.0	(36.9-219.9)	Male	8	7.6	105.6	(45.5-208.1)
Female	3	1.4	nc	(nc-nc)	Female	8	7.2	111.3	(47.9-219.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	71	78.5	90.4	(70.6-114.1)
Female	2	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.0	99.2	(32.0-231.4)
Male	15	12.6	118.8	(66.4-195.9)	Female	3	2.9	nc	(nc-nc)
Female	6	6.8	87.7	(32.0-191.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	10	6.0	167.1	(80.0-307.4)
<b><u>Leukemia</u></b>					Female	19	17.9	106.2	(63.9-165.8)
Male	13	8.9	146.6	(78.0-250.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.3	111.3	(44.6-229.3)	Female	15	20.1	74.5	(41.7-122.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	8.0	125.5	(60.1-230.8)	Male	312	293.4	106.3	(94.9-118.8)
Female	3	2.4	nc	(nc-nc)	Female	351	292.5	120.0	(107.8-133.2)
<b><u>Lung and Bronchus</u></b>									
Male	47	38.6	121.7	(89.4-161.8)					
Female	47	39.2	119.8	(88.0-159.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.0	99.3	(39.8-204.7)	Male	12	4.5	269.2	(138.9-470.3)
Female	2	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	24	19.0	126.1	(80.8-187.7)	Female	3	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.0	nc	(nc-nc)
Male	9	7.5	120.2	(54.9-228.3)	<b><u>Ovary</u></b>				
Female	3	5.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	30	25.6	117.0	(78.9-167.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.3	180.9	(66.1-393.8)
Male	2	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	87	93.7	92.9	(74.4-114.6)
Female	0	0.5	nc	(nc-nc)	Female	71	62.7	113.3	(88.5-142.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.7	39.5	(12.7-92.1)					
Female	11	8.8	125.5	(62.6-224.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	5	2.2	229.2	(73.9-534.9)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.7	64.5	(20.8-150.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	21	27.7	75.8	(46.9-115.8)
Female	0	0.3	nc	(nc-nc)	Female	16	27.4	58.4	(33.4-94.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.9	nc	(nc-nc)					
Female	3	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	15	23.9	62.7	(35.1-103.4)
Female	0	0.2	nc	(nc-nc)	Female	16	24.7	64.9	(37.1-105.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.2	nc	(nc-nc)					
Female	2	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.9	127.7	(41.1-298.0)	Male	5	2.6	190.7	(61.4-445.0)
Female	1	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	13	16.6	78.5	(41.8-134.2)	Female	2	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	5	2.0	246.1	(79.3-574.3)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.7	nc	(nc-nc)	Female	5	1.4	348.4	(112.3-813.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.0	46.6	(18.7-96.0)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	55	54.7	100.6	(75.7-130.9)
Female	0	0.4	nc	(nc-nc)	Female	54	52.7	102.4	(77.0-133.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	7.2	138.1	(66.1-254.1)					
Female	8	7.3	109.7	(47.2-216.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	37.7	76.9	(51.5-110.5)	Male	19	25.2	75.3	(45.3-117.5)
Female	10	13.6	73.7	(35.3-135.6)	Female	6	20.8	28.9	(10.6-62.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	8.1	nc	(nc-nc)	Male	9	7.7	117.6	(53.7-223.3)
Female	3	6.4	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	15	22.5	66.6	(37.3-109.9)
Female	137	153.3	89.4	(75.0-105.6)	Female	18	19.3	93.3	(55.2-147.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	5.8	258.6	(144.6-426.5)	Male	18	17.7	101.9	(60.4-161.1)
<b><u>Colon / Rectum</u></b>					Female	9	8.0	112.0	(51.1-212.6)
Male	38	41.6	91.4	(64.6-125.4)	<b><u>Ovary</u></b>				
Female	33	42.3	78.0	(53.7-109.6)	Female	10	13.6	73.3	(35.1-134.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	9.8	112.7	(56.2-201.6)	Male	11	13.2	83.5	(41.6-149.5)
Female	2	2.6	nc	(nc-nc)	Female	16	13.6	118.0	(67.4-191.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	104	118.2	88.0	(71.9-106.6)
Female	5	2.9	173.4	(55.9-404.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	8.9	168.3	(94.1-277.6)
Male	25	21.0	119.3	(77.2-176.1)	Female	6	5.4	110.9	(40.5-241.5)
Female	18	12.2	147.5	(87.4-233.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	7.4	95.2	(38.1-196.1)
Male	6	5.6	106.3	(38.8-231.3)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	8	10.5	76.3	(32.9-150.3)
<b><u>Leukemia</u></b>					Female	24	32.3	74.2	(47.6-110.5)
Male	10	16.1	62.3	(29.8-114.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	11.7	110.7	(58.9-189.3)	Female	27	33.3	81.1	(53.5-118.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	12.9	115.9	(64.8-191.1)	Male	454	496.0	91.5	(83.3-100.3)
Female	9	4.3	211.5	(96.5-401.5)	Female	500	521.9	95.8	(87.6-104.6)
<b><u>Lung and Bronchus</u></b>									
Male	79	66.8	118.2	(93.6-147.3)					
Female	98	70.6	138.8	(112.7-169.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	20.0	144.6	(96.9-207.7)	Male	6	12.7	47.4	(17.3-103.1)
Female	16	8.3	193.2	(110.3-313.7)	Female	11	10.6	103.9	(51.8-185.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	5	4.0	123.9	(39.9-289.1)
Female	5	3.2	155.3	(50.0-362.3)	Female	0	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	7	11.3	61.9	(24.8-127.6)
Female	79	81.1	97.4	(77.1-121.4)	Female	15	11.0	136.5	(76.4-225.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	6	9.3	64.6	(23.6-140.6)
<b><u>Colon / Rectum</u></b>					Female	4	4.6	nc	(nc-nc)
Male	13	21.5	60.5	(32.2-103.4)	<b><u>Ovary</u></b>				
Female	21	25.1	83.8	(51.9-128.1)	Female	12	7.5	160.5	(82.9-280.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	10	8.5	118.0	(56.5-217.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	75	70.0	107.2	(84.3-134.4)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.7	128.1	(46.8-278.7)
Male	17	10.9	156.1	(90.9-249.9)	Female	3	3.3	nc	(nc-nc)
Female	10	6.6	151.0	(72.3-277.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	4.7	105.6	(34.0-246.3)
<b><u>Leukemia</u></b>					Female	14	13.8	101.7	(55.6-170.7)
Male	10	7.7	130.3	(62.4-239.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.5	138.8	(63.3-263.5)	Female	17	18.5	92.0	(53.6-147.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.9	nc	(nc-nc)	Male	274	263.0	104.2	(92.2-117.3)
Female	1	2.5	nc	(nc-nc)	Female	300	286.4	104.7	(93.2-117.3)
<b><u>Lung and Bronchus</u></b>									
Male	50	35.8	139.5	(103.5-183.9)					
Female	46	40.9	112.5	(82.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	102	88.3	115.6	(94.2-140.3)	Male	29	57.1	50.8	(34.0-73.0)
Female	37	38.0	97.3	(68.5-134.1)	Female	25	51.6	48.4	(31.3-71.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	17.5	102.9	(60.9-162.6)	Male	13	17.7	73.4	(39.1-125.6)
Female	11	16.1	68.3	(34.1-122.2)	Female	16	16.8	95.0	(54.3-154.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	44	51.1	86.1	(62.6-115.6)
Female	297	390.4	76.1	(67.7-85.2)	Female	54	52.0	103.9	(78.1-135.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	13.3	127.8	(74.4-204.7)	Male	39	40.6	96.0	(68.3-131.3)
<b><u>Colon / Rectum</u></b>					Female	15	21.6	69.5	(38.9-114.6)
Male	115	95.4	120.6	(99.5-144.7)	<b><u>Ovary</u></b>				
Female	119	114.8	103.6	(85.8-124.0)	Female	19	35.5	53.5	(32.2-83.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	23.1	77.8	(46.1-122.9)	Male	33	30.9	106.7	(73.4-149.8)
Female	4	7.3	nc	(nc-nc)	Female	39	38.5	101.2	(72.0-138.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	12	7.2	165.8	(85.5-289.6)	Male	287	292.7	98.1	(87.0-110.1)
Female	6	6.5	92.4	(33.7-201.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	36	20.7	173.7	(121.6-240.5)
Male	47	48.3	97.3	(71.5-129.5)	Female	29	14.9	194.5	(130.8-279.4)
Female	31	31.7	97.7	(66.4-138.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	14	13.6	103.1	(56.3-173.0)
Male	23	13.5	170.8	(108.2-256.3)	<b><u>Thyroid</u></b>				
Female	12	4.8	251.7	(129.9-439.8)	Male	18	22.4	80.3	(47.6-126.9)
<b><u>Leukemia</u></b>					Female	77	72.3	106.5	(84.0-133.1)
Male	34	36.0	94.4	(65.3-131.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	34	30.9	110.0	(76.2-153.8)	Female	99	87.6	113.1	(91.9-137.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	32	30.1	106.5	(72.8-150.3)	Male	1243	1157.9	107.3	(101.5-113.5)
Female	14	11.7	119.7	(65.4-200.9)	Female	1311	1365.9	96.0	(90.9-101.3)
<b><u>Lung and Bronchus</u></b>									
Male	231	157.4	146.8	(128.4-167.0)					
Female	218	195.0	111.8	(97.4-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	58.7	91.9	(69.1-119.9)	Male	35	33.7	103.9	(72.3-144.4)
Female	13	21.0	61.9	(32.9-105.8)	Female	41	24.5	167.1	(119.9-226.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	8.6	162.9	(89.0-273.4)	Male	7	11.0	63.8	(25.6-131.5)
Female	9	7.4	121.4	(55.4-230.5)	Female	7	9.2	76.0	(30.4-156.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	31	29.8	104.1	(70.7-147.8)
Female	216	200.0	108.0	(94.1-123.4)	Female	24	27.2	88.1	(56.4-131.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.6	nc	(nc-nc)	Male	24	22.0	109.1	(69.9-162.3)
<b><u>Colon / Rectum</u></b>					Female	7	11.3	61.9	(24.8-127.6)
Male	53	57.6	92.0	(68.9-120.4)	<b><u>Ovary</u></b>				
Female	52	59.9	86.9	(64.9-113.9)	Female	24	18.2	132.2	(84.7-196.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.3	91.2	(48.5-155.9)	Male	15	19.7	76.1	(42.6-125.5)
Female	6	4.0	149.4	(54.6-325.3)	Female	17	21.0	81.1	(47.2-129.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	195	175.6	111.1	(96.0-127.8)
Female	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	13.0	77.1	(36.9-141.9)
Male	30	26.8	111.8	(75.4-159.6)	Female	5	7.7	64.7	(20.8-151.0)
Female	16	16.8	95.4	(54.5-154.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.6	nc	(nc-nc)
Male	9	8.2	110.1	(50.2-209.0)	<b><u>Thyroid</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.4)
<b><u>Leukemia</u></b>					Female	14	28.8	48.6	(26.5-81.5)
Male	18	20.9	86.0	(50.9-135.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	15.2	59.3	(27.1-112.6)	Female	39	47.2	82.6	(58.7-112.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	17.3	98.5	(57.3-157.6)	Male	667	694.7	96.0	(88.9-103.6)
Female	3	6.3	nc	(nc-nc)	Female	667	706.2	94.4	(87.4-101.9)
<b><u>Lung and Bronchus</u></b>									
Male	65	103.3	62.9	(48.6-80.2)					
Female	109	110.8	98.4	(80.8-118.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	39.6	103.4	(74.2-140.3)	Male	15	25.6	58.5	(32.7-96.5)
Female	14	14.9	93.8	(51.3-157.5)	Female	13	20.7	62.7	(33.4-107.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	8.1	nc	(nc-nc)	Male	12	8.0	150.2	(77.5-262.5)
Female	9	6.5	138.4	(63.1-262.7)	Female	7	6.6	105.9	(42.4-218.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	16	22.9	69.7	(39.8-113.2)
Female	133	155.9	85.3	(71.4-101.1)	Female	15	20.4	73.6	(41.1-121.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.3	169.5	(77.3-321.8)	Male	24	18.0	133.6	(85.5-198.7)
<b><u>Colon / Rectum</u></b>					Female	11	8.5	129.4	(64.5-231.5)
Male	34	42.3	80.3	(55.6-112.2)	<b><u>Ovary</u></b>				
Female	43	44.4	96.9	(70.1-130.5)	Female	16	14.1	113.2	(64.6-183.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	10.4	86.9	(39.7-165.0)	Male	11	13.8	79.6	(39.7-142.5)
Female	2	2.9	nc	(nc-nc)	Female	7	15.0	46.8	(18.7-96.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	3.5	142.1	(45.8-331.6)	Male	101	129.7	77.9	(63.4-94.6)
Female	0	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	9.2	151.8	(82.9-254.8)
Male	19	21.5	88.6	(53.3-138.3)	Female	5	5.7	87.0	(28.0-203.1)
Female	9	12.7	70.7	(32.3-134.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.5	92.9	(33.9-202.2)
Male	1	6.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	4	10.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	27	29.5	91.6	(60.3-133.2)
Male	12	16.5	72.9	(37.6-127.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.2	90.0	(44.8-161.0)	Female	29	35.3	82.1	(55.0-118.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	13.5	96.3	(51.2-164.7)	Male	478	518.8	92.1	(84.1-100.8)
Female	5	4.6	108.3	(34.9-252.7)	Female	492	542.7	90.7	(82.8-99.0)
<b><u>Lung and Bronchus</u></b>									
Male	95	71.2	133.4	(107.9-163.1)					
Female	84	78.1	107.6	(85.8-133.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	9.7	92.6	(42.3-175.8)
Female	0	0.1	nc	(nc-nc)	Female	11	12.1	90.9	(45.3-162.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.3	nc	(nc-nc)					
Female	3	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.5	68.5	(35.4-119.7)	Male	22	11.4	193.6	(121.3-293.2)
Female	4	6.2	nc	(nc-nc)	Female	12	9.2	130.3	(67.2-227.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.5	144.2	(46.5-336.6)	Male	2	3.6	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.2	117.4	(60.6-205.0)
Female	92	73.9	124.5	(100.4-152.7)	Female	7	8.9	78.2	(31.3-161.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	7	8.3	84.8	(34.0-174.8)
<b><u>Colon / Rectum</u></b>					Female	0	3.8	nc	(nc-nc)
Male	20	19.3	103.6	(63.2-160.0)	<b><u>Ovary</u></b>				
Female	20	18.4	108.6	(66.3-167.7)	Female	10	6.4	155.1	(74.2-285.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.6	107.5	(34.7-250.9)	Male	3	6.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	6	6.1	98.9	(36.1-215.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.4	365.9	(117.9-853.9)	Male	66	58.0	113.8	(88.0-144.7)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	4.1	169.6	(68.0-349.5)
Male	9	9.7	92.5	(42.2-175.6)	Female	1	2.3	nc	(nc-nc)
Female	6	5.8	104.2	(38.1-226.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	4.5	177.0	(76.2-348.7)
<b><u>Leukemia</u></b>					Female	19	13.8	137.9	(83.0-215.4)
Male	8	7.1	112.5	(48.4-221.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.1	137.4	(55.1-283.2)	Female	21	17.1	122.6	(75.9-187.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	251	230.5	108.9	(95.8-123.2)
Female	1	2.1	nc	(nc-nc)	Female	276	243.4	113.4	(100.4-127.6)
<b><u>Lung and Bronchus</u></b>									
Male	32	31.1	103.0	(70.4-145.4)					
Female	35	34.3	102.0	(71.0-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	66.5	84.2	(63.6-109.4)	Male	42	43.6	96.3	(69.4-130.1)
Female	29	26.0	111.6	(74.7-160.3)	Female	29	37.5	77.4	(51.8-111.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	13.4	81.9	(40.8-146.5)	Male	17	13.5	126.3	(73.5-202.2)
Female	5	11.7	42.6	(13.7-99.3)	Female	13	11.6	112.1	(59.6-191.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	42	39.0	107.8	(77.7-145.7)
Female	273	282.1	96.8	(85.6-109.0)	Female	31	36.2	85.7	(58.2-121.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	10.1	177.8	(105.3-281.1)	Male	31	30.8	100.6	(68.3-142.8)
<b><u>Colon / Rectum</u></b>					Female	7	15.1	46.3	(18.6-95.4)
Male	74	72.4	102.2	(80.3-128.4)	<b><u>Ovary</u></b>				
Female	85	79.1	107.4	(85.8-132.8)	Female	28	25.3	110.7	(73.5-160.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	17.4	86.3	(48.3-142.4)	Male	29	23.3	124.6	(83.4-178.9)
Female	7	5.0	140.4	(56.3-289.3)	Female	29	26.1	110.9	(74.3-159.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	197	216.7	90.9	(78.7-104.5)
Female	9	5.0	181.6	(82.9-344.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	15.7	140.1	(87.8-212.1)
Male	46	36.7	125.2	(91.6-167.0)	Female	11	10.2	107.4	(53.5-192.1)
Female	15	22.6	66.5	(37.2-109.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	11.0	81.9	(37.4-155.6)
Male	4	10.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	3.3	nc	(nc-nc)	Male	22	17.6	125.2	(78.5-189.6)
<b><u>Leukemia</u></b>					Female	56	55.6	100.7	(76.1-130.8)
Male	29	27.4	105.9	(70.9-152.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	21.8	96.4	(59.6-147.3)	Female	56	62.7	89.3	(67.5-116.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	28	22.8	122.6	(81.4-177.2)	Male	848	873.4	97.1	(90.7-103.8)
Female	8	8.1	98.9	(42.6-194.8)	Female	969	968.3	100.1	(93.9-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	109	117.7	92.6	(76.0-111.7)					
Female	138	133.9	103.1	(86.6-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	27.0	103.7	(68.9-149.9)	Male	16	18.4	86.8	(49.6-141.0)
Female	9	9.9	91.2	(41.6-173.1)	Female	16	15.5	103.0	(58.9-167.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.1	82.1	(26.5-191.7)	Male	9	5.7	158.1	(72.1-300.1)
Female	5	5.0	100.8	(32.5-235.2)	Female	4	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	14	16.6	84.1	(46.0-141.2)
Female	130	121.4	107.1	(89.5-127.2)	Female	14	14.4	97.3	(53.2-163.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.4	136.0	(49.7-296.0)	Male	17	13.7	123.8	(72.1-198.2)
<b><u>Colon / Rectum</u></b>					Female	3	6.2	nc	(nc-nc)
Male	25	30.7	81.4	(52.7-120.2)	<b><u>Ovary</u></b>				
Female	30	30.9	97.2	(65.6-138.7)	Female	10	10.6	94.7	(45.3-174.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	7.4	149.2	(74.4-267.0)	Male	13	9.7	133.7	(71.1-228.7)
Female	3	1.9	nc	(nc-nc)	Female	7	9.8	71.1	(28.5-146.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	92	93.3	98.6	(79.5-120.9)
Female	6	2.0	294.6	(107.6-641.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.5	107.1	(42.9-220.8)
Male	16	16.1	99.1	(56.6-161.0)	Female	3	3.9	nc	(nc-nc)
Female	14	9.3	150.7	(82.3-252.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	4.6	174.8	(75.3-344.5)
Male	10	4.3	230.3	(110.3-423.6)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	13	7.9	164.7	(87.6-281.7)
<b><u>Leukemia</u></b>					Female	31	24.5	126.4	(85.9-179.4)
Male	13	11.8	110.4	(58.7-188.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	8.6	58.1	(18.7-135.6)	Female	32	26.6	120.3	(82.2-169.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.9	101.0	(48.3-185.7)	Male	377	371.3	101.5	(91.5-112.3)
Female	1	3.2	nc	(nc-nc)	Female	392	397.7	98.6	(89.1-108.8)
<b><u>Lung and Bronchus</u></b>									
Male	43	49.0	87.7	(63.4-118.1)					
Female	38	52.9	71.8	(50.8-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.3	85.9	(37.0-169.3)	Male	4	6.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	88.6	(28.5-206.6)
Female	41	34.5	118.8	(85.2-161.2)	Female	7	3.9	180.3	(72.2-371.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	5	4.9	101.5	(32.7-236.9)
<b><u>Colon / Rectum</u></b>					Female	4	1.7	nc	(nc-nc)
Male	10	10.4	95.8	(45.9-176.2)	<b><u>Ovary</u></b>				
Female	6	7.9	75.8	(27.7-164.9)	Female	3	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	45	35.7	126.1	(92.0-168.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	6	5.7	105.7	(38.6-230.0)	Female	1	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	7.0	85.4	(31.2-185.9)
Male	2	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	11	7.9	139.5	(69.5-249.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	130	131.4	98.9	(82.6-117.5)
Female	1	0.9	nc	(nc-nc)	Female	137	109.5	125.1	(105.0-147.9)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.3	110.1	(66.2-171.9)					
Female	25	14.4	174.2	(112.7-257.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	22.1	90.5	(55.3-139.8)	Male	6	14.3	41.9	(15.3-91.1)
Female	9	8.5	105.4	(48.1-200.0)	Female	7	11.3	62.0	(24.8-127.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	6	3.5	171.1	(62.5-372.3)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	12.9	69.9	(31.9-132.8)
Female	72	85.7	84.0	(65.7-105.8)	Female	13	11.5	112.9	(60.1-193.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	12	10.2	117.1	(60.4-204.5)
<b><u>Colon / Rectum</u></b>					Female	4	4.7	nc	(nc-nc)
Male	24	24.2	99.3	(63.6-147.8)	<b><u>Ovary</u></b>				
Female	26	25.7	101.1	(66.0-148.2)	Female	7	7.7	90.4	(36.2-186.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	5.8	172.3	(82.5-316.9)	Male	8	7.7	103.7	(44.7-204.4)
Female	2	1.6	nc	(nc-nc)	Female	8	8.7	92.1	(39.7-181.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	67	71.4	93.8	(72.7-119.1)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.2	nc	(nc-nc)
Male	17	12.1	140.8	(82.0-225.4)	Female	5	3.4	149.1	(48.0-347.9)
Female	8	7.0	114.3	(49.2-225.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	15.3	78.3	(40.4-136.9)
Male	11	8.9	123.2	(61.4-220.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	6.8	160.6	(80.1-287.5)	Female	22	19.3	114.1	(71.5-172.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	7.7	130.6	(62.5-240.2)	Male	285	288.2	98.9	(87.7-111.1)
Female	3	2.6	nc	(nc-nc)	Female	299	301.1	99.3	(88.4-111.2)
<b><u>Lung and Bronchus</u></b>									
Male	53	38.9	136.3	(102.1-178.3)					
Female	49	43.0	113.8	(84.2-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	8.8	nc	(nc-nc)	Male	8	5.8	136.8	(58.9-269.5)
Female	1	2.8	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.2	172.2	(78.6-327.0)
Female	33	35.7	92.5	(63.7-129.9)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.8	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-132.9)	<b><u>Ovary</u></b>				
Female	7	8.4	83.6	(33.5-172.3)	Female	0	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	36	32.1	112.3	(78.6-155.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.1	nc	(nc-nc)
Male	7	5.2	134.0	(53.7-276.2)	Female	1	1.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.1	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.7	74.7	(24.1-174.2)
Male	2	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	12	8.3	144.5	(74.6-252.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.2	nc	(nc-nc)	Male	101	120.6	83.7	(68.2-101.8)
Female	1	0.9	nc	(nc-nc)	Female	114	114.1	99.9	(82.4-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	7	16.3	43.1	(17.3-88.7)					
Female	20	15.6	127.8	(78.0-197.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	7.3	109.9	(47.3-216.6)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	9	7.6	117.8	(53.8-223.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	26	26.3	98.8	(64.5-144.8)
Female	0	0.2	nc	(nc-nc)	Female	28	23.4	119.7	(79.5-173.1)
<b><u>Lung and Bronchus</u></b>									
Male	7	3.4	205.3	(82.2-423.0)					
Female	6	3.2	189.6	(69.2-412.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	39.0	107.8	(77.7-145.7)	Male	29	24.4	118.7	(79.5-170.5)
Female	23	14.7	156.8	(99.3-235.3)	Female	23	19.4	118.8	(75.3-178.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	9	7.8	114.9	(52.4-218.1)
Female	5	5.9	84.2	(27.1-196.4)	Female	2	6.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	24	21.7	110.4	(70.7-164.3)
Female	168	157.5	106.6	(91.1-124.0)	Female	21	20.1	104.7	(64.8-160.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.9	nc	(nc-nc)	Male	21	18.0	116.8	(72.3-178.6)
<b><u>Colon / Rectum</u></b>					Female	11	8.5	129.9	(64.7-232.4)
Male	43	40.7	105.7	(76.5-142.3)	<b><u>Ovary</u></b>				
Female	35	43.1	81.3	(56.6-113.0)	Female	18	14.0	128.9	(76.3-203.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	10.6	141.4	(79.1-233.2)	Male	22	13.8	159.1	(99.7-241.0)
Female	2	2.8	nc	(nc-nc)	Female	12	14.6	82.2	(42.4-143.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	141	140.9	100.1	(84.2-118.0)
Female	4	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.1	110.1	(52.7-202.5)
Male	16	21.3	75.3	(43.0-122.2)	Female	2	5.5	nc	(nc-nc)
Female	17	12.6	134.5	(78.3-215.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.8	nc	(nc-nc)
Male	8	6.3	127.7	(55.0-251.7)	<b><u>Thyroid</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	10	8.9	112.7	(53.9-207.2)
<b><u>Leukemia</u></b>					Female	33	25.9	127.6	(87.8-179.2)
Male	21	14.9	141.3	(87.4-216.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	11.3	79.8	(36.4-151.5)	Female	28	36.9	75.8	(50.4-109.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	13.4	74.4	(35.6-136.8)	Male	565	514.6	109.8	(100.9-119.2)
Female	6	4.7	128.7	(47.0-280.0)	Female	562	533.9	105.3	(96.7-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	87	71.1	122.4	(98.0-151.0)					
Female	100	78.3	127.6	(103.8-155.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	3	5.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	12	16.1	74.5	(38.5-130.2)
Female	0	0.2	nc	(nc-nc)	Female	8	18.3	43.8	(18.8-86.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.2	nc	(nc-nc)					
Female	0	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Grafton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	15.3	117.8	(69.8-186.2)	Male	9	10.6	85.2	(38.9-161.7)
Female	4	5.2	nc	(nc-nc)	Female	10	8.6	116.7	(55.9-214.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	3.5	315.5	(157.3-564.6)	Male	4	3.2	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
Female	80	65.9	121.3	(96.2-151.0)	Female	11	7.7	142.2	(70.9-254.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	17	7.9	214.6	(124.9-343.6)
<b><u>Colon / Rectum</u></b>					Female	3	3.3	nc	(nc-nc)
Male	14	17.6	79.4	(43.3-133.1)	<b><u>Ovary</u></b>				
Female	22	16.2	136.0	(85.2-205.9)	Female	6	5.7	104.4	(38.1-227.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.2	119.6	(38.6-279.2)	Male	4	5.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	59	52.4	112.6	(85.7-145.3)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.7	nc	(nc-nc)
Male	11	9.2	119.9	(59.8-214.5)	Female	1	2.1	nc	(nc-nc)
Female	5	5.1	98.9	(31.9-230.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.8	nc	(nc-nc)
Male	6	2.5	243.6	(89.0-530.3)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	7	4.6	152.6	(61.2-314.5)
<b><u>Leukemia</u></b>					Female	13	13.9	93.4	(49.7-159.7)
Male	12	6.7	179.0	(92.4-312.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	4.6	216.4	(103.6-397.9)	Female	13	14.7	88.7	(47.2-151.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.8	103.5	(37.8-225.3)	Male	235	211.0	111.4	(97.6-126.6)
Female	0	1.7	nc	(nc-nc)	Female	248	215.2	115.2	(101.3-130.5)
<b><u>Lung and Bronchus</u></b>									
Male	34	27.4	123.9	(85.8-173.1)					
Female	35	28.5	122.7	(85.5-170.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	74.6	(24.0-174.0)	Male	1	4.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.9	154.7	(56.5-336.7)
Female	18	32.6	55.3	(32.8-87.4)	Female	3	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	7.2	124.4	(56.8-236.1)	<b><u>Ovary</u></b>				
Female	6	8.7	69.2	(25.3-150.7)	Female	5	2.9	174.8	(56.3-407.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	18	23.0	78.2	(46.3-123.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	11	7.4	149.2	(74.4-267.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	79	89.0	88.7	(70.2-110.6)
Female	1	0.9	nc	(nc-nc)	Female	82	107.5	76.3	(60.7-94.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	11.9	109.2	(58.1-186.8)					
Female	13	14.7	88.5	(47.1-151.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	7	7.7	91.2	(36.5-188.0)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	10	8.4	118.9	(56.9-218.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	32	30.1	106.1	(72.6-149.9)
Female	0	0.2	nc	(nc-nc)	Female	26	24.7	105.1	(68.6-154.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.1	nc	(nc-nc)					
Female	5	3.5	141.4	(45.6-330.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	8.4	142.7	(73.6-249.2)	Male	9	5.2	172.4	(78.7-327.3)
Female	9	3.9	230.8	(105.3-438.1)	Female	3	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	39	36.8	106.1	(75.5-145.1)	Female	5	5.1	98.4	(31.7-229.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.1	nc	(nc-nc)
Male	8	8.9	90.2	(38.8-177.8)	<b><u>Ovary</u></b>				
Female	10	11.5	87.2	(41.7-160.4)	Female	3	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	32	25.3	126.7	(86.6-178.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.9	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.7	158.4	(72.3-300.6)
Male	3	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.9	nc	(nc-nc)	Female	7	8.4	83.1	(33.3-171.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	115	104.7	109.9	(90.7-131.9)
Female	1	1.2	nc	(nc-nc)	Female	131	131.0	100.0	(83.6-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	14	14.3	97.9	(53.5-164.2)					
Female	21	19.7	106.5	(65.9-162.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	20.2	94.0	(56.6-146.8)	Male	13	13.0	100.1	(53.2-171.1)
Female	5	8.0	62.5	(20.1-145.9)	Female	5	10.7	46.6	(15.0-108.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.8	130.4	(42.0-304.4)	Male	4	4.1	nc	(nc-nc)
Female	7	3.3	214.9	(86.1-442.9)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	5	11.5	43.4	(14.0-101.3)
Female	74	82.8	89.4	(70.2-112.2)	Female	13	10.8	119.9	(63.8-205.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	9	9.4	95.5	(43.6-181.3)
<b><u>Colon / Rectum</u></b>					Female	3	4.5	nc	(nc-nc)
Male	28	21.7	129.2	(85.8-186.7)	<b><u>Ovary</u></b>				
Female	26	24.3	107.0	(69.9-156.7)	Female	9	7.4	120.9	(55.2-229.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	7	7.1	97.9	(39.2-201.8)
Female	1	1.5	nc	(nc-nc)	Female	5	8.1	61.5	(19.8-143.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	1.5	412.8	(150.8-898.6)	Male	46	69.1	66.6	(48.7-88.8)
Female	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.8	nc	(nc-nc)
Male	6	11.0	54.6	(20.0-118.9)	Female	3	3.2	nc	(nc-nc)
Female	6	6.7	90.2	(32.9-196.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.7	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	14.7	nc	(nc-nc)
Male	3	8.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.4	94.4	(34.5-205.5)	Female	21	18.7	112.6	(69.6-172.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.2	69.1	(22.3-161.2)	Male	222	266.3	83.4	(72.7-95.1)
Female	5	2.5	203.8	(65.7-475.5)	Female	273	286.4	95.3	(84.4-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	33	36.2	91.1	(62.7-127.9)					
Female	44	40.4	109.0	(79.2-146.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.5	125.8	(64.9-219.8)	Male	3	6.9	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	38	45.1	84.3	(59.6-115.6)	Female	4	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	5	5.6	89.1	(28.7-208.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.2	nc	(nc-nc)
Male	16	11.4	140.8	(80.4-228.7)	<b><u>Ovary</u></b>				
Female	9	9.8	91.5	(41.7-173.6)	Female	2	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	31	38.4	80.6	(54.8-114.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	1.4	486.1	(194.7-1001.6)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	8.8	79.4	(31.8-163.5)
Male	5	4.2	120.0	(38.7-280.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	10	10.3	97.1	(46.5-178.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	128	141.8	90.3	(75.3-107.4)
Female	2	1.1	nc	(nc-nc)	Female	104	138.7	75.0	(61.3-90.9)
<b><u>Lung and Bronchus</u></b>									
Male	11	18.1	60.8	(30.3-108.7)					
Female	10	17.9	56.0	(26.8-103.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	8.0	99.9	(43.0-196.9)	Male	6	5.1	117.1	(42.8-254.9)
Female	2	2.7	nc	(nc-nc)	Female	11	3.9	281.5	(140.3-503.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.6	174.3	(75.1-343.5)
Female	39	32.6	119.5	(85.0-163.4)	Female	6	3.9	155.2	(56.7-337.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	4	8.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	8.0	112.6	(51.4-213.8)	Female	3	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	24	26.9	89.3	(57.2-132.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	4	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.6	179.8	(86.1-330.7)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.2	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	90	104.9	85.8	(69.0-105.4)
Female	1	0.9	nc	(nc-nc)	Female	125	106.1	117.8	(98.1-140.4)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.5	76.1	(37.9-136.1)					
Female	17	15.1	112.8	(65.7-180.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	6.8	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
Female	6	3.2	187.4	(68.4-408.0)	Female	3	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.7	188.3	(75.4-388.0)
Female	28	29.4	95.2	(63.3-137.6)	Female	7	4.1	170.1	(68.1-350.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	7	2.9	240.6	(96.4-495.7)
<b><u>Colon / Rectum</u></b>					Female	0	1.7	nc	(nc-nc)
Male	5	7.0	70.9	(22.9-165.6)	<b><u>Ovary</u></b>				
Female	10	9.2	108.9	(52.1-200.3)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	19	22.1	86.1	(51.8-134.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.4	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	9	6.9	131.3	(59.9-249.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	71	85.9	82.6	(64.5-104.2)
Female	1	0.9	nc	(nc-nc)	Female	92	105.6	87.1	(70.2-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	6	12.1	49.7	(18.1-108.1)					
Female	9	16.2	55.7	(25.4-105.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Halifax

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.1	98.9	(39.6-203.7)	Male	5	5.0	100.8	(32.5-235.2)
Female	2	3.2	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.5	112.3	(36.2-262.0)
Female	38	35.6	106.6	(75.5-146.4)	Female	7	4.4	158.5	(63.5-326.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	13	8.3	156.0	(83.0-266.8)	<b><u>Ovary</u></b>				
Female	12	9.6	124.5	(64.2-217.4)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	8	2.6	308.4	(132.8-607.7)
Female	0	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	36	26.7	134.9	(94.5-186.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	8	4.5	178.4	(76.8-351.5)	Female	1	1.2	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	6	2.2	277.3	(101.3-603.6)
<b><u>Leukemia</u></b>					Female	11	6.2	177.0	(88.2-316.7)
Male	2	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	12	7.9	152.6	(78.8-266.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	2.8	180.6	(58.2-421.5)	Male	143	101.2	141.3	(119.1-166.5)
Female	1	1.0	nc	(nc-nc)	Female	135	119.0	113.5	(95.2-134.3)
<b><u>Lung and Bronchus</u></b>									
Male	22	13.3	165.6	(103.8-250.8)					
Female	20	17.1	116.7	(71.3-180.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.7	77.8	(28.4-169.3)	Male	3	5.1	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	5	4.3	117.0	(37.7-273.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	5	1.6	312.8	(100.8-729.9)
Female	3	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	131.1	(47.9-285.4)
Female	32	33.9	94.4	(64.5-133.2)	Female	8	4.2	191.2	(82.3-376.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	3.7	134.8	(43.4-314.5)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	6	8.5	70.6	(25.8-153.8)	<b><u>Ovary</u></b>				
Female	10	8.9	111.8	(53.5-205.6)	Female	2	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	24	26.3	91.3	(58.5-135.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	7	4.4	158.5	(63.5-326.7)	Female	0	1.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	241.5	(77.8-563.5)
<b><u>Leukemia</u></b>					Female	8	6.2	129.7	(55.8-255.6)
Male	6	3.3	184.3	(67.3-401.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	7	7.7	90.8	(36.4-187.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	107	103.6	103.3	(84.7-124.8)
Female	0	1.0	nc	(nc-nc)	Female	114	113.3	100.6	(83.0-120.9)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.0	93.0	(49.5-159.0)					
Female	11	16.1	68.5	(34.1-122.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.6	70.0	(25.6-152.3)	Male	2	5.2	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.5	(47.7-284.1)
Female	23	26.6	86.4	(54.7-129.6)	Female	1	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	2	8.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	7.1	70.1	(22.6-163.6)	Female	1	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	5	2.9	170.9	(55.1-398.7)
Female	0	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	21	28.2	74.4	(46.1-113.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.9	nc	(nc-nc)
Male	5	4.4	114.3	(36.8-266.8)	Female	2	0.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.4	113.9	(36.7-265.8)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	87	107.5	80.9	(64.8-99.8)
Female	0	0.8	nc	(nc-nc)	Female	67	89.1	75.2	(58.3-95.5)
<b><u>Lung and Bronchus</u></b>									
Male	15	15.5	96.5	(54.0-159.2)					
Female	8	12.9	61.9	(26.6-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	9.2	87.2	(37.5-171.8)
Female	0	0.1	nc	(nc-nc)	Female	8	10.2	78.8	(33.9-155.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.2	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	13.6	88.0	(45.4-153.8)	Male	15	9.1	165.0	(92.3-272.1)
Female	4	4.9	nc	(nc-nc)	Female	5	7.3	68.8	(22.2-160.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.9	173.1	(55.8-404.0)	Male	2	2.9	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	5	2.2	224.2	(72.3-523.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.2	98.0	(42.2-193.0)
Female	78	58.2	134.0	(105.9-167.2)	Female	10	7.0	143.3	(68.6-263.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	6	6.8	88.1	(32.2-191.7)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	15	15.1	99.1	(55.4-163.4)	<b><u>Ovary</u></b>				
Female	17	14.6	116.2	(67.7-186.1)	Female	4	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	69	47.8	144.4	(112.3-182.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.3	nc	(nc-nc)
Male	4	8.0	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	5	4.5	111.0	(35.8-259.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	5	2.2	228.8	(73.7-533.8)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	8	3.7	213.6	(92.0-420.8)
<b><u>Leukemia</u></b>					Female	10	11.0	90.9	(43.5-167.2)
Male	6	5.7	104.4	(38.1-227.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	4.1	nc	(nc-nc)	Female	19	13.3	142.7	(85.8-222.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	198	185.5	106.7	(92.4-122.7)
Female	0	1.6	nc	(nc-nc)	Female	207	191.2	108.3	(94.0-124.1)
<b><u>Lung and Bronchus</u></b>									
Male	21	24.7	85.0	(52.6-130.0)					
Female	27	26.2	102.9	(67.8-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.2	119.5	(59.6-213.8)	Male	4	6.5	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	4.9	102.2	(32.9-238.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	31	40.8	75.9	(51.6-107.8)	Female	5	4.4	114.4	(36.9-267.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	9	5.2	173.7	(79.3-329.7)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	13	10.7	121.9	(64.8-208.4)	<b><u>Ovary</u></b>				
Female	12	8.5	140.7	(72.6-245.9)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.4	145.3	(46.8-339.1)
Female	1	0.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	39	37.7	103.6	(73.6-141.6)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.3	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	5	3.0	167.0	(53.8-389.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.2	121.2	(58.0-223.0)
Male	4	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	15	9.3	161.3	(90.2-266.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.7	135.6	(43.7-316.4)	Male	143	135.5	105.5	(88.9-124.3)
Female	3	1.0	nc	(nc-nc)	Female	127	125.8	100.9	(84.1-120.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	17.3	150.0	(98.0-219.8)					
Female	17	16.5	102.8	(59.8-164.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	12	14.3	83.7	(43.2-146.2)	Female	2	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.7	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.3	45.8	(18.3-94.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	37	59.6	62.0	(43.7-85.5)
Female	0	0.4	nc	(nc-nc)	Female	34	47.4	71.7	(49.6-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	6	8.6	70.0	(25.6-152.5)					
Female	6	6.6	90.3	(33.0-196.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	8.4	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.2	153.6	(66.1-302.7)
Female	20	24.1	83.0	(50.7-128.2)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.2	nc	(nc-nc)
Male	4	9.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	5.6	160.3	(73.1-304.3)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	22	33.3	66.1	(41.4-100.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	115.8	(37.3-270.2)
Male	4	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	6	5.5	108.9	(39.8-237.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	74	121.3	61.0	(47.9-76.6)
Female	0	0.6	nc	(nc-nc)	Female	57	76.4	74.6	(56.5-96.7)
<b><u>Lung and Bronchus</u></b>									
Male	5	15.9	31.5	(10.2-73.6)					
Female	5	10.8	46.3	(14.9-108.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	21.3	121.8	(79.6-178.5)	Male	18	12.4	145.5	(86.2-230.0)
Female	10	8.3	121.0	(57.9-222.6)	Female	19	9.7	196.5	(118.3-306.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	6	4.0	149.7	(54.7-325.8)
Female	2	3.0	nc	(nc-nc)	Female	6	3.6	165.6	(60.5-360.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	15	10.8	138.5	(77.5-228.5)
Female	102	79.1	128.9	(105.1-156.5)	Female	10	10.8	92.9	(44.5-170.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	10	8.0	125.4	(60.0-230.6)
<b><u>Colon / Rectum</u></b>					Female	3	4.4	nc	(nc-nc)
Male	21	20.8	101.1	(62.6-154.6)	<b><u>Ovary</u></b>				
Female	32	23.4	136.5	(93.3-192.7)	Female	7	7.1	98.6	(39.5-203.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.2	115.2	(42.1-250.7)	Male	9	7.2	125.8	(57.4-238.9)
Female	2	1.6	nc	(nc-nc)	Female	10	8.3	120.8	(57.8-222.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.0	496.7	(160.1-1159.2)	Male	100	64.7	154.5	(125.7-187.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	4.7	170.3	(73.3-335.6)
Male	9	9.9	90.9	(41.5-172.5)	Female	2	3.0	nc	(nc-nc)
Female	8	6.6	121.1	(52.1-238.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.5	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	3.7	135.3	(43.6-315.8)
<b><u>Leukemia</u></b>					Female	2	11.3	nc	(nc-nc)
Male	9	7.6	117.7	(53.7-223.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.0	nc	(nc-nc)	Female	18	18.8	95.8	(56.8-151.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.2	nc	(nc-nc)	Male	326	254.2	128.2	(114.7-142.9)
Female	2	2.5	nc	(nc-nc)	Female	311	278.6	111.6	(99.6-124.8)
<b><u>Lung and Bronchus</u></b>									
Male	47	38.2	123.2	(90.5-163.8)					
Female	39	43.5	89.7	(63.8-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	15	18.9	79.2	(44.3-130.6)	Female	1	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	5	5.0	100.8	(32.5-235.1)	<b><u>Ovary</u></b>				
Female	9	4.9	182.2	(83.2-346.0)	Female	4	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	16.4	121.7	(74.3-187.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	5	1.5	338.6	(109.1-790.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.1	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	5	4.4	114.9	(37.0-268.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	60	60.5	99.1	(75.7-127.6)
Female	0	0.5	nc	(nc-nc)	Female	57	62.7	91.0	(68.9-117.9)
<b><u>Lung and Bronchus</u></b>									
Male	7	8.4	83.2	(33.3-171.4)					
Female	4	9.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	59.1	96.4	(73.0-124.9)	Male	24	38.7	62.0	(39.7-92.3)
Female	27	21.7	124.5	(82.0-181.1)	Female	20	32.3	61.9	(37.8-95.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	12.1	115.8	(63.3-194.4)	Male	10	11.9	84.0	(40.2-154.6)
Female	11	10.1	109.0	(54.3-195.0)	Female	8	9.8	81.4	(35.1-160.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	40	34.9	114.8	(82.0-156.3)
Female	255	244.4	104.3	(91.9-117.9)	Female	41	30.7	133.5	(95.8-181.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	8.8	nc	(nc-nc)	Male	39	28.0	139.0	(98.9-190.1)
<b><u>Colon / Rectum</u></b>					Female	16	12.9	123.7	(70.6-200.8)
Male	77	65.7	117.3	(92.5-146.6)	<b><u>Ovary</u></b>				
Female	67	67.7	99.0	(76.7-125.8)	Female	20	21.9	91.3	(55.8-141.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	15.5	77.2	(39.9-134.9)	Male	25	20.9	119.7	(77.5-176.8)
Female	4	4.2	nc	(nc-nc)	Female	28	22.0	127.0	(84.4-183.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	5.0	119.5	(43.6-260.0)	Male	165	194.1	85.0	(72.5-99.0)
Female	3	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	14.0	142.6	(87.1-220.2)
Male	32	32.8	97.6	(66.8-137.8)	Female	6	8.7	68.8	(25.1-149.7)
Female	24	19.2	124.8	(79.9-185.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	9.7	72.5	(29.1-149.4)
Male	9	9.0	100.4	(45.8-190.6)	<b><u>Thyroid</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	16	15.7	101.8	(58.2-165.4)
<b><u>Leukemia</u></b>					Female	56	48.3	115.9	(87.6-150.6)
Male	22	24.6	89.5	(56.1-135.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	18.6	102.0	(61.4-159.4)	Female	58	54.8	105.8	(80.3-136.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	20.6	87.2	(51.7-137.9)	Male	749	780.4	96.0	(89.2-103.1)
Female	4	6.9	nc	(nc-nc)	Female	896	827.6	108.3	(101.3-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	105	103.3	101.7	(83.1-123.1)					
Female	152	110.2	138.0	(116.9-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.2	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	3.8	159.2	(58.1-346.6)
Female	1	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	12.5	112.4	(61.4-188.5)
Female	0	0.1	nc	(nc-nc)	Female	6	10.8	55.5	(20.3-120.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.6	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	30.1	96.3	(64.5-138.3)	Male	37	18.2	203.0	(142.9-279.8)
Female	9	11.5	78.2	(35.7-148.5)	Female	25	14.2	176.6	(114.3-260.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.1	97.2	(31.3-226.9)	Male	6	5.8	103.6	(37.8-225.6)
Female	6	4.5	134.7	(49.2-293.1)	Female	5	5.0	99.5	(32.0-232.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	18	16.2	111.2	(65.9-175.8)
Female	116	111.4	104.2	(86.1-124.9)	Female	30	15.1	198.0	(133.6-282.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	16	12.4	129.4	(73.9-210.1)
<b><u>Colon / Rectum</u></b>					Female	6	6.3	95.6	(34.9-208.1)
Male	28	31.1	90.0	(59.8-130.2)	<b><u>Ovary</u></b>				
Female	40	34.3	116.5	(83.2-158.6)	Female	11	10.1	108.6	(54.1-194.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.5	nc	(nc-nc)	Male	5	10.3	48.4	(15.6-113.0)
Female	5	2.2	228.9	(73.8-534.2)	Female	10	11.7	85.7	(41.0-157.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	111	90.6	122.5	(100.7-147.5)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	6.8	131.7	(60.1-250.1)
Male	13	14.8	88.0	(46.8-150.5)	Female	1	4.5	nc	(nc-nc)
Female	11	9.2	119.8	(59.7-214.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.7	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	5	6.2	81.2	(26.2-189.5)
<b><u>Leukemia</u></b>					Female	29	17.9	162.2	(108.6-232.9)
Male	15	11.5	129.9	(72.6-214.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	8.9	134.6	(69.5-235.1)	Female	21	25.2	83.2	(51.5-127.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.5	nc	(nc-nc)	Male	367	368.7	99.5	(89.6-110.3)
Female	0	3.4	nc	(nc-nc)	Female	417	393.5	106.0	(96.0-116.6)
<b><u>Lung and Bronchus</u></b>									
Male	27	52.6	51.3	(33.8-74.7)					
Female	41	57.9	70.8	(50.8-96.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	16	9.5	169.1	(96.6-274.6)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	9	10.8	83.7	(38.2-158.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.8	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	43	43.8	98.1	(71.0-132.1)
Female	0	0.2	nc	(nc-nc)	Female	40	31.0	128.9	(92.1-175.6)
<b><u>Lung and Bronchus</u></b>									
Male	10	5.9	168.1	(80.5-309.2)					
Female	5	4.2	118.3	(38.1-276.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	13.2	166.5	(104.3-252.1)	Male	3	8.5	nc	(nc-nc)
Female	8	4.1	193.2	(83.2-380.7)	Female	9	6.1	146.6	(66.9-278.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	7	1.9	372.4	(149.2-767.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.6	131.4	(62.9-241.7)
Female	49	49.1	99.9	(73.9-132.1)	Female	8	5.8	136.8	(58.9-269.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
<b><u>Colon / Rectum</u></b>					Female	2	2.5	nc	(nc-nc)
Male	14	14.2	98.3	(53.7-164.9)	<b><u>Ovary</u></b>				
Female	14	12.5	112.2	(61.3-188.3)	Female	9	4.3	210.4	(96.0-399.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.5	201.1	(80.6-414.3)	Male	5	4.6	108.9	(35.1-254.1)
Female	1	0.8	nc	(nc-nc)	Female	5	4.1	123.3	(39.7-287.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	51	42.7	119.5	(89.0-157.2)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.1	nc	(nc-nc)
Male	12	7.2	167.0	(86.2-291.8)	Female	1	1.6	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	9.2	75.7	(30.3-156.0)
Male	6	5.2	115.7	(42.3-251.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.3	210.3	(84.3-433.4)	Female	11	10.9	100.6	(50.2-180.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.6	152.5	(61.1-314.2)	Male	192	171.5	112.0	(96.7-129.0)
Female	1	1.3	nc	(nc-nc)	Female	202	161.4	125.2	(108.5-143.7)
<b><u>Lung and Bronchus</u></b>									
Male	23	23.5	97.7	(61.9-146.7)					
Female	42	22.8	184.0	(132.6-248.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	19.1	89.2	(51.9-142.9)	Male	23	12.4	185.6	(117.6-278.4)
Female	10	6.9	145.5	(69.7-267.6)	Female	8	9.7	82.3	(35.4-162.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	5	3.9	127.4	(41.1-297.3)
Female	4	3.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.1	98.9	(49.3-176.9)
Female	86	76.9	111.8	(89.4-138.1)	Female	9	9.6	93.6	(42.7-177.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	12	9.1	132.2	(68.2-230.9)
<b><u>Colon / Rectum</u></b>					Female	4	4.1	nc	(nc-nc)
Male	14	21.0	66.8	(36.5-112.1)	<b><u>Ovary</u></b>				
Female	25	20.9	119.5	(77.3-176.4)	Female	7	6.8	103.0	(41.3-212.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.1	157.5	(67.8-310.3)	Male	10	6.7	148.5	(71.1-273.2)
Female	1	1.3	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	63	63.8	98.7	(75.8-126.3)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.5	nc	(nc-nc)
Male	7	10.6	65.8	(26.3-135.5)	Female	3	2.7	nc	(nc-nc)
Female	6	6.1	99.0	(36.2-215.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	14.1	49.5	(19.8-102.0)
Male	10	7.7	130.1	(62.3-239.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.6	nc	(nc-nc)	Female	30	17.2	174.5	(117.7-249.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.8	73.9	(23.8-172.4)	Male	252	251.8	100.1	(88.1-113.2)
Female	3	2.2	nc	(nc-nc)	Female	273	258.7	105.5	(93.4-118.8)
<b><u>Lung and Bronchus</u></b>									
Male	33	34.1	96.7	(66.5-135.8)					
Female	29	36.3	80.0	(53.6-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	8	10.0	80.2	(34.5-158.0)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	7	10.4	67.0	(26.8-138.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	28	40.1	69.8	(46.4-100.9)
Female	0	0.2	nc	(nc-nc)	Female	33	30.8	107.1	(73.7-150.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	5.5	nc	(nc-nc)					
Female	5	3.9	127.6	(41.1-297.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	13.8	123.5	(71.9-197.7)	Male	10	9.2	109.0	(52.2-200.4)
Female	2	4.9	nc	(nc-nc)	Female	6	7.4	81.0	(29.6-176.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	2.9	312.7	(142.7-593.6)	Male	4	2.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.3	133.3	(66.5-238.5)
Female	71	60.2	117.9	(92.1-148.7)	Female	4	7.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.0	nc	(nc-nc)	Male	8	7.0	113.9	(49.1-224.5)
<b><u>Colon / Rectum</u></b>					Female	4	3.1	nc	(nc-nc)
Male	16	15.6	102.3	(58.4-166.2)	<b><u>Ovary</u></b>				
Female	14	15.0	93.0	(50.8-156.1)	Female	3	5.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.8	182.9	(73.3-376.8)	Male	4	5.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	68	49.9	136.3	(105.8-172.8)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.3	nc	(nc-nc)
Male	11	8.1	135.4	(67.5-242.2)	Female	1	1.9	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.8	271.4	(87.5-633.4)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	11.1	135.3	(75.7-223.2)
Male	5	5.7	87.8	(28.3-204.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.1	nc	(nc-nc)	Female	21	13.8	152.3	(94.3-232.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	223	189.4	117.7	(102.8-134.2)
Female	1	1.6	nc	(nc-nc)	Female	196	195.7	100.1	(86.6-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	24.9	60.2	(33.7-99.4)					
Female	24	26.6	90.2	(57.8-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	39.9	75.2	(50.8-107.4)	Male	20	24.8	80.8	(49.3-124.8)
Female	13	16.2	80.1	(42.6-136.9)	Female	10	22.1	45.2	(21.6-83.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	7.6	118.9	(54.3-225.8)	Male	4	7.7	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	Female	1	7.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	19	22.3	85.0	(51.2-132.8)
Female	126	166.3	75.7	(63.1-90.2)	Female	17	22.0	77.4	(45.1-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.7	158.3	(72.2-300.4)	Male	26	16.9	153.7	(100.3-225.2)
<b><u>Colon / Rectum</u></b>					Female	4	9.0	nc	(nc-nc)
Male	40	42.2	94.7	(67.6-128.9)	<b><u>Ovary</u></b>				
Female	49	48.9	100.2	(74.1-132.4)	Female	13	15.0	86.5	(46.0-147.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.9	80.9	(34.8-159.3)	Male	15	13.7	109.7	(61.4-181.0)
Female	2	3.1	nc	(nc-nc)	Female	23	16.4	139.9	(88.7-210.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	113	120.9	93.4	(77.0-112.3)
Female	5	2.8	178.1	(57.4-415.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	9.2	54.4	(17.5-127.0)
Male	19	20.2	93.9	(56.5-146.6)	Female	10	6.4	156.6	(75.0-288.1)
Female	6	13.6	44.1	(16.1-96.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	5.7	nc	(nc-nc)
Male	8	5.7	140.3	(60.4-276.6)	<b><u>Thyroid</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	1	9.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	31.1	70.7	(44.3-107.0)
Male	10	16.1	62.2	(29.8-114.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	13.5	66.8	(30.5-126.8)	Female	45	36.8	122.2	(89.1-163.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	25	12.7	196.6	(127.2-290.3)	Male	486	499.5	97.3	(88.8-106.3)
Female	7	4.9	142.4	(57.0-293.4)	Female	493	581.7	84.7	(77.4-92.6)
<b><u>Lung and Bronchus</u></b>									
Male	78	68.8	113.4	(89.6-141.5)					
Female	65	82.5	78.8	(60.8-100.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.5	76.7	(24.7-179.0)	Male	6	4.1	146.0	(53.3-317.8)
Female	2	2.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	26	24.5	106.3	(69.4-155.7)	Female	0	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	4	7.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	7.0	128.1	(58.5-243.2)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	26	19.4	134.0	(87.5-196.3)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.5	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.5	133.6	(48.8-290.9)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	8	5.4	149.3	(64.3-294.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	92	82.5	111.5	(89.9-136.7)
Female	0	0.7	nc	(nc-nc)	Female	80	82.9	96.4	(76.5-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	15	10.7	140.3	(78.5-231.4)					
Female	12	11.3	106.0	(54.7-185.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.7	102.9	(53.1-179.8)	Male	13	8.3	156.4	(83.2-267.4)
Female	5	4.1	120.9	(38.9-282.1)	Female	11	7.0	156.6	(78.1-280.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	2.9	347.9	(166.5-639.8)	Male	2	2.6	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.6	79.4	(29.0-172.9)
Female	54	57.6	93.8	(70.5-122.4)	Female	7	6.3	111.0	(44.5-228.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	7	6.7	105.1	(42.1-216.5)
<b><u>Colon / Rectum</u></b>					Female	1	2.7	nc	(nc-nc)
Male	5	14.0	35.8	(11.5-83.4)	<b><u>Ovary</u></b>				
Female	10	13.2	75.9	(36.3-139.6)	Female	2	4.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	6	4.1	147.5	(53.8-321.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	54	45.1	119.8	(90.0-156.4)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.9	171.3	(55.2-399.9)
Male	5	7.7	65.3	(21.0-152.3)	Female	0	1.7	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.8	130.6	(42.1-304.7)
<b><u>Leukemia</u></b>					Female	16	11.7	137.3	(78.4-223.0)
Male	4	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	3.8	nc	(nc-nc)	Female	11	12.6	87.4	(43.6-156.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.8	nc	(nc-nc)	Male	167	170.7	97.8	(83.5-113.8)
Female	2	1.4	nc	(nc-nc)	Female	163	180.1	90.5	(77.1-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	13	21.4	60.8	(32.3-103.9)					
Female	18	23.2	77.7	(46.0-122.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.8	177.1	(57.1-413.4)
Female	18	18.1	99.6	(59.0-157.4)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	7	0.9	797.4	(319.5-1643.1)
Male	0	5.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	4.3	139.3	(50.9-303.3)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	16.1	68.2	(34.0-122.1)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.6	139.7	(45.0-326.0)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	42	63.4	66.3	(47.7-89.6)
Female	0	0.4	nc	(nc-nc)	Female	63	56.4	111.7	(85.9-143.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.5	nc	(nc-nc)					
Female	9	7.0	127.8	(58.3-242.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	23.1	99.7	(63.2-149.6)	Male	11	14.8	74.1	(36.9-132.6)
Female	8	7.9	101.7	(43.8-200.5)	Female	10	11.1	89.8	(43.0-165.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	4.4	205.5	(93.8-390.1)	Male	3	4.7	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	6	13.2	45.6	(16.6-99.2)
Female	81	89.3	90.7	(72.0-112.7)	Female	7	10.9	64.1	(25.7-132.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	12	10.7	112.5	(58.1-196.6)
<b><u>Colon / Rectum</u></b>					Female	5	4.6	108.1	(34.9-252.4)
Male	31	24.6	126.1	(85.7-179.0)	<b><u>Ovary</u></b>				
Female	28	22.9	122.4	(81.3-176.9)	Female	9	7.8	115.6	(52.8-219.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.2	80.8	(26.0-188.5)	Male	4	8.2	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	5	7.8	64.3	(20.7-150.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	77	80.5	95.6	(75.5-119.5)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.4	92.8	(29.9-216.5)
Male	7	12.8	54.6	(21.9-112.5)	Female	5	2.9	170.8	(55.0-398.5)
Female	9	7.1	126.7	(57.8-240.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.8	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	27	16.1	167.8	(110.5-244.1)
Male	7	9.1	76.5	(30.7-157.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	6.3	nc	(nc-nc)	Female	27	20.5	131.5	(86.6-191.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.9	76.1	(27.8-165.6)	Male	265	305.4	86.8	(76.6-97.9)
Female	2	2.5	nc	(nc-nc)	Female	292	297.9	98.0	(87.1-109.9)
<b><u>Lung and Bronchus</u></b>									
Male	31	42.4	73.2	(49.7-103.9)					
Female	36	43.3	83.1	(58.2-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hull

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.5	128.0	(73.1-207.8)	Male	15	8.1	185.1	(103.5-305.4)
Female	5	5.0	99.6	(32.1-232.3)	Female	11	7.2	153.5	(76.5-274.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	5	7.2	69.8	(22.5-162.9)
Female	56	58.8	95.3	(72.0-123.8)	Female	9	7.1	127.1	(58.0-241.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	3.1	163.8	(52.8-382.3)
Male	13	13.5	96.3	(51.2-164.7)	<b><u>Ovary</u></b>				
Female	9	15.0	60.0	(27.4-113.9)	Female	4	5.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	8	4.9	162.8	(70.1-320.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	45	45.2	99.5	(72.6-133.1)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	9	7.1	127.4	(58.1-241.9)	Female	1	1.9	nc	(nc-nc)
Female	5	4.6	108.5	(35.0-253.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.3	381.2	(122.9-889.7)
Male	5	2.1	238.9	(77.0-557.4)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	10.2	49.1	(15.8-114.5)
Male	2	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.9	nc	(nc-nc)	Female	16	13.7	116.4	(66.5-189.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	4.7	301.0	(164.4-505.0)	Male	194	168.3	115.2	(99.6-132.7)
Female	0	1.7	nc	(nc-nc)	Female	194	193.4	100.3	(86.7-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	24	23.2	103.5	(66.3-154.0)					
Female	30	27.8	107.8	(72.7-153.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	11	9.0	122.8	(61.2-219.8)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	3	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.7	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	34	27.7	122.9	(85.1-171.7)
Female	1	0.2	nc	(nc-nc)	Female	34	29.0	117.4	(81.3-164.1)
<b><u>Lung and Bronchus</u></b>									
Male	8	3.5	231.0	(99.5-455.2)					
Female	6	4.0	148.9	(54.4-324.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	19.1	115.3	(72.2-174.5)	Male	15	12.0	124.9	(69.8-205.9)
Female	10	6.7	149.5	(71.6-274.9)	Female	10	8.5	117.6	(56.3-216.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	8	10.6	75.2	(32.4-148.1)
Female	86	69.7	123.4	(98.7-152.5)	Female	8	9.0	88.6	(38.2-174.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	8	8.7	91.5	(39.4-180.3)
<b><u>Colon / Rectum</u></b>					Female	7	3.8	185.3	(74.2-381.8)
Male	13	20.5	63.6	(33.8-108.7)	<b><u>Ovary</u></b>				
Female	15	19.8	75.8	(42.4-125.0)	Female	8	6.2	129.3	(55.7-254.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.1	177.9	(81.2-337.8)	Male	7	6.7	103.8	(41.6-213.9)
Female	3	1.3	nc	(nc-nc)	Female	6	6.7	89.4	(32.7-194.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	81	65.4	123.9	(98.4-154.0)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.5	nc	(nc-nc)
Male	7	10.2	68.5	(27.4-141.1)	Female	5	2.5	196.4	(63.3-458.3)
Female	6	5.6	106.9	(39.0-232.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	11.0	109.3	(56.4-190.9)
Male	3	7.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.1	117.8	(43.0-256.5)	Female	12	16.1	74.5	(38.5-130.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.6	nc	(nc-nc)	Male	242	248.2	97.5	(85.6-110.6)
Female	5	2.1	240.3	(77.4-560.8)	Female	248	238.0	104.2	(91.6-118.0)
<b><u>Lung and Bronchus</u></b>									
Male	24	34.4	69.8	(44.7-103.9)					
Female	29	35.1	82.6	(55.3-118.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	14.6	89.3	(47.5-152.7)	Male	13	9.3	139.9	(74.4-239.3)
Female	6	5.5	108.8	(39.7-236.8)	Female	10	7.5	133.1	(63.7-244.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	60	60.2	99.8	(76.1-128.4)	Female	8	7.6	104.9	(45.2-206.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	6	6.6	90.9	(33.2-198.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	14	15.5	90.3	(49.3-151.5)	<b><u>Ovary</u></b>				
Female	14	16.9	82.9	(45.3-139.1)	Female	2	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	14	5.1	276.5	(151.1-464.0)
Female	5	1.0	476.5	(153.6-1112.0)	Female	10	5.5	180.7	(86.5-332.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	40	46.8	85.6	(61.1-116.5)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.4	146.7	(47.3-342.2)
Male	9	7.8	116.1	(53.0-220.4)	Female	1	2.2	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	10.6	131.6	(71.9-220.8)
Male	6	5.7	104.7	(38.2-227.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.4	135.9	(49.6-295.9)	Female	17	13.3	127.8	(74.4-204.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	5.1	nc	(nc-nc)	Male	173	187.5	92.3	(79.0-107.1)
Female	1	1.7	nc	(nc-nc)	Female	218	203.4	107.2	(93.4-122.4)
<b><u>Lung and Bronchus</u></b>									
Male	27	26.1	103.6	(68.3-150.8)					
Female	29	28.7	101.2	(67.7-145.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.0	99.8	(51.5-174.3)	Male	8	7.9	101.3	(43.6-199.6)
Female	5	3.7	135.2	(43.6-315.4)	Female	4	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.0	99.9	(40.0-205.9)
Female	55	48.1	114.5	(86.2-149.0)	Female	4	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	6.1	98.8	(36.1-215.2)
<b><u>Colon / Rectum</u></b>					Female	5	2.4	206.5	(66.5-481.8)
Male	13	13.1	99.2	(52.8-169.7)	<b><u>Ovary</u></b>				
Female	10	11.3	88.2	(42.2-162.2)	Female	4	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.4	147.0	(47.4-343.0)	Male	4	4.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.7	135.9	(43.8-317.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	40	45.8	87.4	(62.4-119.0)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.9	nc	(nc-nc)
Male	5	7.0	71.5	(23.0-166.8)	Female	0	1.4	nc	(nc-nc)
Female	5	3.6	138.1	(44.5-322.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	9.0	166.8	(93.3-275.2)
Male	3	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.2	nc	(nc-nc)	Female	14	11.3	124.3	(67.9-208.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	147	165.8	88.7	(74.9-104.2)
Female	2	1.3	nc	(nc-nc)	Female	167	153.5	108.8	(92.9-126.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	22.3	58.3	(31.0-99.8)					
Female	19	20.5	92.8	(55.9-145.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.4	119.4	(57.2-219.6)	Male	7	5.7	122.3	(49.0-252.0)
Female	3	2.4	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.1	117.4	(42.9-255.6)
Female	29	28.2	102.7	(68.8-147.6)	Female	2	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	9.2	65.6	(23.9-142.7)	<b><u>Ovary</u></b>				
Female	2	7.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	39	31.1	125.2	(89.0-171.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.0	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.3	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	118	117.2	100.7	(83.3-120.6)
Female	2	0.8	nc	(nc-nc)	Female	77	93.0	82.8	(65.3-103.4)
<b><u>Lung and Bronchus</u></b>									
Male	9	15.4	58.4	(26.6-110.8)					
Female	9	12.8	70.2	(32.0-133.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	6	2.0	293.2	(107.1-638.2)
Female	0	1.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	7	12.0	58.5	(23.4-120.6)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	8	12.4	64.3	(27.7-126.8)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.7	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	44	43.3	101.5	(73.8-136.3)
Female	0	0.3	nc	(nc-nc)	Female	27	39.2	68.9	(45.4-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	5.5	144.8	(62.3-285.3)					
Female	4	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	52.0	94.3	(69.7-124.6)	Male	13	35.8	36.3	(19.3-62.1)
Female	17	20.7	82.1	(47.8-131.4)	Female	10	34.0	29.4	(14.1-54.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	12.9	69.9	(31.9-132.7)	Male	12	10.8	110.7	(57.2-193.5)
Female	7	11.3	62.1	(24.9-127.9)	Female	18	9.5	189.7	(112.4-299.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	29	32.5	89.1	(59.7-128.0)
Female	176	251.3	70.0	(60.1-81.2)	Female	32	30.6	104.7	(71.6-147.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	9.8	152.9	(85.5-252.2)	Male	31	26.2	118.1	(80.3-167.7)
<b><u>Colon / Rectum</u></b>					Female	12	13.0	92.3	(47.6-161.2)
Male	60	58.8	102.0	(77.8-131.3)	<b><u>Ovary</u></b>				
Female	55	64.3	85.6	(64.4-111.4)	Female	12	22.3	53.7	(27.7-93.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	14.1	63.7	(29.0-120.9)	Male	17	18.6	91.3	(53.1-146.1)
Female	9	4.1	221.6	(101.1-420.7)	Female	13	20.8	62.4	(33.2-106.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	6.0	nc	(nc-nc)	Male	238	179.2	132.8	(116.5-150.8)
Female	3	5.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	12.5	159.8	(97.6-246.8)
Male	22	30.9	71.2	(44.6-107.9)	Female	14	8.3	168.5	(92.0-282.7)
Female	19	19.5	97.3	(58.5-151.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	12.0	108.6	(57.8-185.7)
Male	9	8.2	109.4	(49.9-207.8)	<b><u>Thyroid</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	15	15.9	94.5	(52.8-155.8)
<b><u>Leukemia</u></b>					Female	65	55.4	117.4	(90.6-149.6)
Male	16	24.0	66.8	(38.1-108.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	19.2	109.4	(67.7-167.2)	Female	47	56.0	83.9	(61.7-111.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	34	19.2	177.5	(122.9-248.1)	Male	747	721.9	103.5	(96.2-111.2)
Female	15	6.8	220.6	(123.4-363.8)	Female	715	839.5	85.2	(79.0-91.7)
<b><u>Lung and Bronchus</u></b>									
Male	89	93.1	95.6	(76.8-117.7)					
Female	88	108.6	81.0	(65.0-99.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	8.7	160.8	(87.8-269.8)	Male	7	5.4	130.3	(52.2-268.5)
Female	1	2.5	nc	(nc-nc)	Female	9	3.5	260.0	(118.6-493.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	5	1.1	454.3	(146.4-1060.1)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
Female	21	28.0	75.1	(46.5-114.8)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	5	8.8	56.5	(18.2-131.9)	<b><u>Ovary</u></b>				
Female	6	7.1	84.9	(31.0-184.8)	Female	1	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	29	29.5	98.2	(65.8-141.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	5	4.5	111.4	(35.9-260.0)	Female	3	0.9	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.9	102.6	(33.1-239.4)
Male	2	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	112	111.4	100.5	(82.8-120.9)
Female	3	0.8	nc	(nc-nc)	Female	96	93.5	102.6	(83.1-125.4)
<b><u>Lung and Bronchus</u></b>									
Male	18	15.8	114.0	(67.5-180.1)					
Female	20	13.7	146.4	(89.4-226.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.6	85.1	(38.8-161.6)	Male	12	7.2	166.2	(85.8-290.4)
Female	4	4.6	nc	(nc-nc)	Female	8	6.5	124.0	(53.4-244.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	49	50.1	97.7	(72.3-129.2)	Female	5	6.4	78.5	(25.3-183.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.7	nc	(nc-nc)	Male	7	5.5	128.2	(51.4-264.2)
<b><u>Colon / Rectum</u></b>					Female	4	2.7	nc	(nc-nc)
Male	9	11.9	75.6	(34.5-143.6)	<b><u>Ovary</u></b>				
Female	10	13.5	74.2	(35.5-136.6)	Female	5	4.5	111.4	(35.9-260.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	4.5	155.8	(62.4-320.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	29	38.9	74.5	(49.9-107.0)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.6	nc	(nc-nc)
Male	6	6.3	94.5	(34.5-205.8)	Female	0	1.7	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	9.3	nc	(nc-nc)
Male	10	4.4	229.5	(109.9-422.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.6	nc	(nc-nc)	Female	14	11.8	118.9	(64.9-199.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	141	147.6	95.5	(80.4-112.7)
Female	0	1.5	nc	(nc-nc)	Female	157	170.5	92.1	(78.2-107.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	19.6	117.1	(74.2-175.7)					
Female	21	24.5	85.8	(53.1-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	10.3	165.5	(96.3-264.9)	Male	8	5.6	143.8	(61.9-283.4)
Female	1	3.9	nc	(nc-nc)	Female	5	4.1	121.1	(39.0-282.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
Female	34	32.4	104.9	(72.6-146.6)	Female	4	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	18	9.7	184.9	(109.5-292.2)	<b><u>Ovary</u></b>				
Female	16	11.3	141.1	(80.6-229.2)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	25	27.7	90.4	(58.5-133.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.2	nc	(nc-nc)
Male	5	3.6	140.0	(45.1-326.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	9	7.5	119.3	(54.4-226.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	111	114.1	97.3	(80.0-117.2)
Female	2	1.1	nc	(nc-nc)	Female	117	121.3	96.4	(79.8-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	11	17.0	64.9	(32.3-116.1)					
Female	15	19.1	78.7	(44.0-129.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	48.3	111.7	(83.9-145.8)	Male	23	30.4	75.7	(48.0-113.6)
Female	29	15.6	186.2	(124.7-267.4)	Female	20	22.3	89.8	(54.8-138.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	8.8	68.4	(25.0-148.8)	Male	9	9.6	94.0	(42.9-178.5)
Female	7	6.9	101.0	(40.4-208.0)	Female	4	7.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	29	27.3	106.3	(71.2-152.7)
Female	164	172.0	95.3	(81.3-111.1)	Female	25	21.7	115.3	(74.6-170.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	6.0	133.0	(57.3-262.1)	Male	21	21.1	99.3	(61.5-151.8)
<b><u>Colon / Rectum</u></b>					Female	9	9.2	98.3	(44.9-186.7)
Male	41	51.8	79.1	(56.8-107.4)	<b><u>Ovary</u></b>				
Female	37	47.9	77.2	(54.4-106.5)	Female	28	15.4	182.1	(121.0-263.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	12.3	97.9	(50.5-171.0)	Male	13	16.7	78.0	(41.5-133.5)
Female	2	3.0	nc	(nc-nc)	Female	15	15.6	96.3	(53.9-158.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	149	149.1	99.9	(84.5-117.3)
Female	4	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	11.2	116.1	(61.8-198.6)
Male	25	25.2	99.4	(64.3-146.7)	Female	5	6.1	81.4	(26.2-189.8)
Female	15	13.7	109.8	(61.4-181.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.3	nc	(nc-nc)
Male	8	7.0	113.7	(49.0-224.1)	<b><u>Thyroid</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	9	11.4	78.7	(35.9-149.5)
<b><u>Leukemia</u></b>					Female	19	32.8	57.9	(34.8-90.4)
Male	18	19.0	95.0	(56.3-150.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.9	85.4	(42.6-152.9)	Female	35	38.2	91.6	(63.8-127.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	15.8	44.4	(17.8-91.6)	Male	575	610.1	94.2	(86.7-102.3)
Female	0	4.9	nc	(nc-nc)	Female	563	583.8	96.4	(88.6-104.7)
<b><u>Lung and Bronchus</u></b>									
Male	91	84.0	108.3	(87.2-133.0)					
Female	77	80.6	95.5	(75.4-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	15	10.0	150.1	(83.9-247.5)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	11.0	45.3	(14.6-105.6)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	26	38.3	68.0	(44.4-99.6)
Female	0	0.3	nc	(nc-nc)	Female	36	32.6	110.4	(77.3-152.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	5.3	93.5	(30.1-218.1)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	42.9	58.3	(37.7-86.0)	Male	26	26.1	99.7	(65.1-146.1)
Female	6	15.8	38.1	(13.9-82.9)	Female	25	20.1	124.7	(80.7-184.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.4	81.5	(29.8-177.3)	Male	13	8.4	154.8	(82.3-264.7)
Female	5	6.3	80.0	(25.8-186.6)	Female	6	7.0	85.9	(31.4-187.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	21	23.4	89.8	(55.5-137.2)
Female	164	162.3	101.0	(86.2-117.7)	Female	24	21.2	113.2	(72.5-168.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.0	nc	(nc-nc)	Male	15	18.2	82.3	(46.0-135.8)
<b><u>Colon / Rectum</u></b>					Female	8	8.9	90.2	(38.8-177.7)
Male	35	44.7	78.2	(54.5-108.8)	<b><u>Ovary</u></b>				
Female	31	47.3	65.5	(44.5-93.0)	Female	20	14.5	138.0	(84.3-213.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	10.9	nc	(nc-nc)	Male	12	14.8	81.2	(41.9-141.9)
Female	1	3.0	nc	(nc-nc)	Female	18	15.9	113.5	(67.2-179.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	140	134.3	104.3	(87.7-123.0)
Female	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	9.8	nc	(nc-nc)
Male	21	21.7	96.8	(59.9-148.0)	Female	8	6.1	131.0	(56.4-258.1)
Female	8	13.1	61.2	(26.4-120.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.6	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	10	9.0	110.6	(52.9-203.4)
<b><u>Leukemia</u></b>					Female	36	26.1	137.8	(96.5-190.8)
Male	19	16.4	115.5	(69.5-180.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	12.2	98.6	(50.9-172.3)	Female	30	36.9	81.4	(54.9-116.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	13.8	nc	(nc-nc)	Male	428	533.9	80.2	(72.7-88.1)
Female	4	4.8	nc	(nc-nc)	Female	503	558.0	90.1	(82.4-98.4)
<b><u>Lung and Bronchus</u></b>									
Male	35	74.9	46.7	(32.6-65.0)					
Female	48	81.3	59.1	(43.5-78.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	12.4	88.7	(44.2-158.7)
Female	0	0.1	nc	(nc-nc)	Female	5	11.7	42.9	(13.8-100.1)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	8.9	56.4	(18.2-131.7)	Male	5	5.1	98.4	(31.7-229.6)
Female	7	2.3	305.5	(122.4-629.4)	Female	7	3.3	214.3	(85.9-441.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.6	108.6	(35.0-253.3)
Female	41	25.2	162.9	(116.9-221.0)	Female	5	3.2	154.7	(49.9-361.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	3.3	153.7	(49.5-358.7)
<b><u>Colon / Rectum</u></b>					Female	2	1.4	nc	(nc-nc)
Male	8	9.0	88.9	(38.3-175.3)	<b><u>Ovary</u></b>				
Female	8	7.2	111.2	(47.9-219.1)	Female	5	2.2	222.3	(71.6-518.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	6	2.9	204.0	(74.5-444.1)
Female	0	0.4	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	45	22.7	198.5	(144.8-265.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.0	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.7	nc	(nc-nc)
Male	6	3.4	179.1	(65.4-389.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	2.0	351.8	(141.0-724.9)	Female	9	5.7	158.8	(72.5-301.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	122	101.0	120.8	(100.3-144.3)
Female	1	0.7	nc	(nc-nc)	Female	122	86.0	141.9	(117.8-169.4)
<b><u>Lung and Bronchus</u></b>									
Male	7	14.4	48.8	(19.5-100.5)					
Female	8	11.6	68.7	(29.6-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.8	147.7	(78.6-252.7)	Male	4	6.0	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.4	167.1	(76.3-317.3)
Female	33	42.0	78.6	(54.1-110.4)	Female	6	5.3	113.9	(41.6-248.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.2	nc	(nc-nc)
Male	6	10.0	60.1	(21.9-130.8)	<b><u>Ovary</u></b>				
Female	9	11.6	77.3	(35.3-146.8)	Female	4	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	5	3.2	156.4	(50.4-365.0)
Female	0	0.7	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	35	31.1	112.4	(78.3-156.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.5	107.3	(46.2-211.5)
Male	2	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	11	9.4	117.5	(58.6-210.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	124	121.6	102.0	(84.8-121.6)
Female	2	1.2	nc	(nc-nc)	Female	108	141.3	76.5	(62.7-92.3)
<b><u>Lung and Bronchus</u></b>									
Male	21	16.3	128.8	(79.7-196.9)					
Female	9	19.7	45.6	(20.8-86.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	22.2	53.9	(27.8-94.2)	Male	20	13.2	152.0	(92.8-234.7)
Female	7	7.8	89.3	(35.8-183.9)	Female	13	9.8	132.4	(70.4-226.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	8	11.9	67.4	(29.0-132.8)
Female	78	76.4	102.1	(80.7-127.5)	Female	14	10.3	135.4	(74.0-227.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	4	9.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	4.3	nc	(nc-nc)
Male	13	23.1	56.3	(29.9-96.2)	<b><u>Ovary</u></b>				
Female	13	24.1	54.0	(28.7-92.3)	Female	6	7.0	85.7	(31.3-186.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	3	7.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	4	8.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	66	66.5	99.3	(76.8-126.3)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.0	119.1	(43.5-259.3)
Male	9	10.7	84.2	(38.4-159.8)	Female	2	3.1	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.9	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	12.6	55.5	(22.2-114.3)
Male	12	8.3	144.6	(74.6-252.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.2	nc	(nc-nc)	Female	9	17.0	53.0	(24.2-100.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	6.9	nc	(nc-nc)	Male	215	269.2	79.9	(69.6-91.3)
Female	5	2.3	216.8	(69.9-506.0)	Female	225	269.6	83.4	(72.9-95.1)
<b><u>Lung and Bronchus</u></b>									
Male	19	37.9	50.1	(30.2-78.3)					
Female	22	38.4	57.2	(35.9-86.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	82	81.8	100.3	(79.7-124.5)	Male	34	57.0	59.7	(41.3-83.4)
Female	46	33.0	139.5	(102.1-186.1)	Female	34	51.1	66.6	(46.1-93.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	17	19.3	87.9	(51.2-140.8)	Male	21	17.2	122.3	(75.7-187.0)
Female	16	16.3	98.3	(56.2-159.6)	Female	21	14.9	141.1	(87.3-215.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	53	51.2	103.6	(77.6-135.5)
Female	312	373.9	83.5	(74.4-93.2)	Female	32	47.2	67.7	(46.3-95.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	14.1	127.8	(75.7-202.0)	Male	52	41.9	124.1	(92.7-162.7)
<b><u>Colon / Rectum</u></b>					Female	7	19.8	35.4	(14.2-73.0)
Male	91	92.7	98.2	(79.0-120.5)	<b><u>Ovary</u></b>				
Female	102	101.2	100.8	(82.2-122.4)	Female	28	33.5	83.5	(55.5-120.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	23	22.4	102.5	(64.9-153.8)	Male	25	29.5	84.8	(54.8-125.1)
Female	4	6.4	nc	(nc-nc)	Female	22	33.0	66.7	(41.8-100.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	9.0	122.5	(61.1-219.1)	Male	223	287.8	77.5	(67.6-88.3)
Female	4	7.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	24	19.9	120.7	(77.3-179.6)
Male	46	49.2	93.6	(68.5-124.8)	Female	28	13.0	215.4	(143.1-311.3)
Female	38	29.8	127.3	(90.1-174.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	15	18.1	82.7	(46.2-136.4)
Male	19	13.3	142.5	(85.8-222.6)	<b><u>Thyroid</u></b>				
Female	8	4.3	186.0	(80.1-366.4)	Male	22	25.1	87.6	(54.9-132.6)
<b><u>Leukemia</u></b>					Female	74	79.5	93.1	(73.1-116.8)
Male	32	36.4	87.8	(60.1-124.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	41	29.1	140.8	(101.0-191.0)	Female	80	83.1	96.3	(76.3-119.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	61	30.6	199.3	(152.5-256.1)	Male	1163	1142.6	101.8	(96.0-107.8)
Female	7	10.6	66.2	(26.5-136.5)	Female	1221	1276.9	95.6	(90.3-101.1)
<b><u>Lung and Bronchus</u></b>									
Male	185	148.4	124.7	(107.4-144.0)					
Female	190	173.3	109.6	(94.6-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	26.1	111.3	(74.5-159.8)	Male	15	16.6	90.3	(50.5-148.9)
Female	6	10.2	58.9	(21.5-128.2)	Female	15	13.3	113.0	(63.2-186.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.8	101.1	(56.5-166.7)
Female	79	106.0	74.5	(59.0-92.9)	Female	10	13.8	72.6	(34.7-133.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.3	149.4	(48.1-348.6)	Male	7	12.1	58.1	(23.3-119.6)
<b><u>Colon / Rectum</u></b>					Female	2	5.8	nc	(nc-nc)
Male	34	28.3	119.9	(83.0-167.6)	<b><u>Ovary</u></b>				
Female	25	30.3	82.5	(53.4-121.7)	Female	11	9.5	116.3	(58.0-208.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	4	9.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	12	10.2	117.3	(60.6-205.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	71	86.7	81.9	(63.9-103.3)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.1	114.7	(45.9-236.3)
Male	18	14.0	128.3	(76.0-202.7)	Female	3	3.9	nc	(nc-nc)
Female	6	8.6	70.1	(25.6-152.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	17.8	28.2	(9.1-65.7)
Male	6	10.2	58.7	(21.4-127.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.9	75.7	(27.6-164.8)	Female	21	24.2	86.9	(53.8-132.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	9.0	89.1	(38.4-175.5)	Male	290	338.9	85.6	(76.0-96.0)
Female	3	3.1	nc	(nc-nc)	Female	284	364.2	78.0	(69.2-87.6)
<b><u>Lung and Bronchus</u></b>									
Male	32	45.8	69.8	(47.7-98.6)					
Female	38	53.1	71.5	(50.6-98.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	11.9	58.9	(23.6-121.4)	Male	6	7.7	77.5	(28.3-168.6)
Female	4	3.9	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	6	2.5	242.9	(88.7-528.7)
Female	3	1.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
Female	56	47.6	117.6	(88.9-152.8)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	5	5.8	85.8	(27.7-200.2)
<b><u>Colon / Rectum</u></b>					Female	0	2.5	nc	(nc-nc)
Male	16	13.3	120.2	(68.6-195.1)	<b><u>Ovary</u></b>				
Female	12	12.1	99.0	(51.1-172.9)	Female	3	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	43	41.4	103.8	(75.1-139.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.8	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	8.6	69.5	(25.4-151.2)
Male	8	4.7	168.5	(72.5-331.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	17	11.3	150.6	(87.7-241.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	156	159.4	97.9	(83.1-114.5)
Female	3	1.3	nc	(nc-nc)	Female	148	156.1	94.8	(80.1-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	24	21.3	112.9	(72.3-168.1)					
Female	16	21.1	75.7	(43.2-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	65	71.2	91.2	(70.4-116.3)	Male	43	48.7	88.2	(63.8-118.8)
Female	24	29.4	81.6	(52.3-121.4)	Female	32	44.6	71.8	(49.1-101.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	21	16.4	128.4	(79.5-196.3)	Male	26	14.9	174.7	(114.1-256.0)
Female	15	14.3	105.1	(58.8-173.4)	Female	13	13.3	98.0	(52.1-167.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.5	199.1	(64.2-464.7)	Male	54	44.0	122.8	(92.2-160.2)
Female	319	332.7	95.9	(85.6-107.0)	Female	49	41.9	117.1	(86.6-154.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	12.2	139.8	(81.4-223.9)	Male	50	35.8	139.7	(103.7-184.2)
<b><u>Colon / Rectum</u></b>					Female	20	17.6	113.6	(69.4-175.4)
Male	110	81.0	135.8	(111.6-163.7)	<b><u>Ovary</u></b>				
Female	109	90.1	121.0	(99.4-146.0)	Female	25	29.8	83.8	(54.2-123.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	24	19.3	124.2	(79.5-184.8)	Male	23	25.5	90.2	(57.2-135.4)
Female	6	5.7	105.4	(38.5-229.4)	Female	24	29.4	81.6	(52.3-121.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	7.2	69.2	(22.3-161.5)	Male	305	247.5	123.2	(109.8-137.9)
Female	2	6.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	17.2	92.9	(53.1-150.9)
Male	41	42.3	96.9	(69.5-131.5)	Female	21	11.6	181.8	(112.5-277.9)
Female	23	26.5	86.7	(54.9-130.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	17	14.2	119.6	(69.6-191.5)
Male	17	11.4	148.9	(86.7-238.4)	<b><u>Thyroid</u></b>				
Female	4	3.9	nc	(nc-nc)	Male	17	21.1	80.5	(46.9-129.0)
<b><u>Leukemia</u></b>					Female	53	68.3	77.6	(58.1-101.5)
Male	40	31.3	128.0	(91.4-174.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	32	25.7	124.7	(85.3-176.0)	Female	71	74.1	95.8	(74.8-120.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	56	26.0	215.1	(162.5-279.4)	Male	1231	982.5	125.3	(118.4-132.5)
Female	18	9.4	191.3	(113.3-302.4)	Female	1159	1132.6	102.3	(96.5-108.4)
<b><u>Lung and Bronchus</u></b>									
Male	195	128.1	152.2	(131.6-175.1)					
Female	179	155.2	115.3	(99.1-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.9	94.3	(52.7-155.5)	Male	22	10.0	220.5	(138.1-333.8)
Female	9	5.0	178.5	(81.4-338.9)	Female	12	6.8	175.8	(90.7-307.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.2	155.4	(50.1-362.7)
Female	5	2.1	233.7	(75.3-545.3)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.8	158.8	(86.8-266.5)
Female	50	55.7	89.7	(66.6-118.3)	Female	15	6.9	216.2	(120.9-356.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.9	nc	(nc-nc)
Male	13	16.8	77.5	(41.2-132.5)	<b><u>Ovary</u></b>				
Female	22	15.1	145.8	(91.4-220.8)	Female	7	4.9	143.5	(57.5-295.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	6	5.5	108.9	(39.8-237.1)
Female	0	1.0	nc	(nc-nc)	Female	6	5.0	119.6	(43.7-260.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	46	51.6	89.1	(65.2-118.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.7	nc	(nc-nc)
Male	11	8.3	131.9	(65.8-236.1)	Female	2	1.9	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.6	320.6	(103.3-748.2)
Male	3	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.6	167.7	(61.2-365.1)
<b><u>Leukemia</u></b>					Female	15	9.6	156.5	(87.5-258.2)
Male	10	6.1	165.0	(79.0-303.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.0	125.9	(40.6-293.9)	Female	16	12.5	127.6	(72.9-207.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	200	203.0	98.5	(85.4-113.2)
Female	1	1.6	nc	(nc-nc)	Female	221	186.8	118.3	(103.2-135.0)
<b><u>Lung and Bronchus</u></b>									
Male	20	28.7	69.6	(42.5-107.5)					
Female	28	26.8	104.3	(69.3-150.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	48.6	55.5	(36.6-80.8)	Male	8	33.6	23.8	(10.3-46.9)
Female	26	19.3	134.8	(88.0-197.5)	Female	20	30.2	66.2	(40.4-102.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	10.9	nc	(nc-nc)	Male	7	10.1	69.0	(27.6-142.1)
Female	8	9.4	85.5	(36.8-168.4)	Female	7	8.7	80.1	(32.1-165.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	40	30.0	133.2	(95.1-181.3)
Female	193	221.6	87.1	(75.2-100.3)	Female	23	27.8	82.7	(52.4-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	13	8.5	153.4	(81.6-262.3)	Male	23	24.3	94.7	(60.0-142.2)
<b><u>Colon / Rectum</u></b>					Female	9	11.7	77.0	(35.1-146.2)
Male	71	54.6	130.0	(101.5-163.9)	<b><u>Ovary</u></b>				
Female	79	59.9	131.8	(104.3-164.2)	Female	16	19.9	80.5	(46.0-130.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	13.1	114.2	(63.9-188.4)	Male	21	17.3	121.2	(75.0-185.3)
Female	8	3.7	216.4	(93.2-426.4)	Female	15	19.3	77.7	(43.5-128.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	129	165.3	78.0	(65.1-92.7)
Female	5	4.4	113.1	(36.4-263.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	11.7	127.8	(71.5-210.8)
Male	34	28.6	119.0	(82.4-166.3)	Female	6	7.7	78.1	(28.5-170.0)
Female	18	17.4	103.2	(61.2-163.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	10.8	73.8	(31.8-145.4)
Male	11	7.7	142.3	(70.9-254.6)	<b><u>Thyroid</u></b>				
Female	5	2.5	196.7	(63.4-458.9)	Male	15	14.8	101.4	(56.7-167.2)
<b><u>Leukemia</u></b>					Female	62	47.7	129.9	(99.6-166.5)
Male	24	20.9	114.7	(73.5-170.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	16.7	95.7	(54.7-155.5)	Female	51	48.8	104.4	(77.7-137.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	17.7	135.5	(86.8-201.7)	Male	639	666.6	95.9	(88.6-103.6)
Female	13	6.2	211.0	(112.2-360.8)	Female	772	752.3	102.6	(95.5-110.1)
<b><u>Lung and Bronchus</u></b>									
Male	117	86.9	134.6	(111.3-161.3)					
Female	111	100.7	110.3	(90.7-132.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	8.1	nc	(nc-nc)	Male	14	4.7	295.1	(161.2-495.2)
Female	1	2.6	nc	(nc-nc)	Female	5	3.3	150.1	(48.4-350.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	32	27.7	115.6	(79.0-163.2)	Female	3	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	5	8.3	59.9	(19.3-139.8)	<b><u>Ovary</u></b>				
Female	5	7.5	66.8	(21.5-155.8)	Female	2	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	28	22.9	122.5	(81.4-177.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.8	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	4.4	203.1	(92.7-385.7)
Male	1	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	8	6.3	126.8	(54.6-249.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	89	96.1	92.6	(74.4-114.0)
Female	0	0.8	nc	(nc-nc)	Female	95	93.3	101.8	(82.4-124.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	13.7	43.9	(16.0-95.5)					
Female	10	14.1	71.0	(34.0-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	15.6	128.2	(78.3-197.9)	Male	26	11.6	223.6	(146.0-327.6)
Female	0	5.6	nc	(nc-nc)	Female	20	10.3	193.6	(118.2-299.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.1	193.7	(83.4-381.6)	Male	3	3.5	nc	(nc-nc)
Female	7	3.3	214.9	(86.1-442.8)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	14	10.6	132.6	(72.5-222.6)
Female	89	80.2	110.9	(89.1-136.5)	Female	4	8.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	11	9.2	119.5	(59.6-213.9)
<b><u>Colon / Rectum</u></b>					Female	1	3.8	nc	(nc-nc)
Male	27	19.3	140.0	(92.2-203.7)	<b><u>Ovary</u></b>				
Female	28	18.5	151.6	(100.7-219.2)	Female	7	6.9	102.0	(40.8-210.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	9	5.5	162.6	(74.2-308.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	57	58.5	97.4	(73.7-126.1)
Female	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.0	150.6	(55.0-327.8)
Male	14	10.5	132.9	(72.6-222.9)	Female	3	2.3	nc	(nc-nc)
Female	9	5.9	153.6	(70.1-291.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.5	170.0	(62.1-370.1)
Male	0	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	16	5.6	284.1	(162.3-461.4)
<b><u>Leukemia</u></b>					Female	19	17.9	106.3	(64.0-166.0)
Male	9	7.4	121.6	(55.5-230.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	5.3	188.5	(90.2-346.7)	Female	14	17.4	80.3	(43.9-134.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.5	92.4	(33.7-201.2)	Male	279	231.9	120.3	(106.6-135.3)
Female	3	1.9	nc	(nc-nc)	Female	290	251.3	115.4	(102.5-129.5)
<b><u>Lung and Bronchus</u></b>									
Male	32	28.6	112.1	(76.6-158.2)					
Female	38	30.2	125.8	(89.0-172.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	24.9	96.5	(61.8-143.5)	Male	38	15.5	244.7	(173.1-335.8)
Female	13	8.8	147.7	(78.6-252.7)	Female	22	12.1	181.3	(113.6-274.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	4.4	nc	(nc-nc)	Male	8	5.0	160.9	(69.3-317.1)
Female	3	3.8	nc	(nc-nc)	Female	8	4.0	200.1	(86.2-394.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	13	13.9	93.9	(49.9-160.5)
Female	122	99.4	122.7	(101.9-146.6)	Female	11	12.3	89.8	(44.7-160.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	11	11.0	99.6	(49.7-178.3)
<b><u>Colon / Rectum</u></b>					Female	6	5.3	114.1	(41.7-248.5)
Male	32	26.2	122.0	(83.4-172.2)	<b><u>Ovary</u></b>				
Female	17	26.4	64.3	(37.5-103.0)	Female	6	8.8	68.5	(25.0-149.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.5	92.7	(33.8-201.7)	Male	13	8.6	150.4	(80.0-257.1)
Female	3	1.7	nc	(nc-nc)	Female	14	8.8	159.2	(86.9-267.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	96	81.0	118.5	(96.0-144.8)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.8	121.3	(48.6-250.0)
Male	11	13.2	83.6	(41.7-149.5)	Female	1	3.4	nc	(nc-nc)
Female	5	7.8	63.9	(20.6-149.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.3	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	9	5.6	160.0	(73.0-303.8)
<b><u>Leukemia</u></b>					Female	17	17.1	99.6	(58.0-159.5)
Male	11	9.7	113.9	(56.8-203.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.1	141.6	(67.8-260.4)	Female	20	22.9	87.3	(53.3-134.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	8.3	nc	(nc-nc)	Male	338	317.6	106.4	(95.4-118.4)
Female	2	2.8	nc	(nc-nc)	Female	360	331.2	108.7	(97.8-120.5)
<b><u>Lung and Bronchus</u></b>									
Male	25	44.4	56.3	(36.4-83.1)					
Female	38	47.0	80.9	(57.3-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.2	nc	(nc-nc)	Male	8	4.5	179.7	(77.4-354.0)
Female	4	2.9	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.0	201.9	(86.9-397.9)
Female	33	26.2	126.1	(86.8-177.0)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	8	7.5	107.3	(46.2-211.5)	<b><u>Ovary</u></b>				
Female	10	8.6	115.8	(55.4-213.0)	Female	0	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	23	27.0	85.1	(54.0-127.8)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.9	nc	(nc-nc)
Male	10	2.7	368.9	(176.6-678.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	6	6.1	98.5	(36.0-214.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	86	95.3	90.2	(72.2-111.4)
Female	1	0.8	nc	(nc-nc)	Female	101	94.2	107.2	(87.3-130.2)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.0	61.3	(26.4-120.9)					
Female	18	13.4	134.3	(79.6-212.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	38.1	104.9	(74.9-142.8)	Male	25	25.6	97.7	(63.2-144.3)
Female	9	13.3	67.9	(31.0-128.9)	Female	15	20.1	74.7	(41.8-123.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	8.0	74.7	(27.3-162.6)	Male	5	7.9	63.1	(20.3-147.2)
Female	8	6.2	128.5	(55.3-253.3)	Female	5	6.0	82.8	(26.7-193.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	19	22.8	83.3	(50.1-130.1)
Female	140	154.0	90.9	(76.5-107.3)	Female	17	19.0	89.3	(52.0-143.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.6	159.9	(73.0-303.6)	Male	18	18.5	97.2	(57.6-153.6)
<b><u>Colon / Rectum</u></b>					Female	18	8.0	224.3	(132.9-354.5)
Male	46	42.4	108.5	(79.4-144.7)	<b><u>Ovary</u></b>				
Female	61	40.9	149.1	(114.0-191.5)	Female	16	13.5	118.3	(67.6-192.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.2	117.5	(60.6-205.2)	Male	9	13.5	66.8	(30.5-126.8)
Female	5	2.6	194.6	(62.7-454.0)	Female	14	13.3	105.5	(57.6-177.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.3	181.9	(66.4-396.0)	Male	128	126.9	100.9	(84.1-119.9)
Female	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	9.1	76.9	(30.8-158.5)
Male	25	21.8	114.5	(74.0-169.0)	Female	6	5.2	115.1	(42.0-250.6)
Female	10	12.1	82.8	(39.6-152.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	6.4	nc	(nc-nc)
Male	6	6.0	100.5	(36.7-218.8)	<b><u>Thyroid</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	10	10.6	94.8	(45.4-174.3)
<b><u>Leukemia</u></b>					Female	38	30.8	123.5	(87.4-169.6)
Male	17	16.1	105.9	(61.6-169.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	11.3	106.6	(55.0-186.3)	Female	37	34.5	107.4	(75.6-148.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	13.7	80.1	(40.0-143.4)	Male	478	511.1	93.5	(85.3-102.3)
Female	7	4.3	163.3	(65.4-336.4)	Female	551	515.7	106.8	(98.1-116.2)
<b><u>Lung and Bronchus</u></b>									
Male	48	68.4	70.1	(51.7-93.0)					
Female	71	70.0	101.4	(79.2-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	26.4	83.2	(52.1-126.0)	Male	32	17.7	180.8	(123.6-255.2)
Female	11	9.2	119.8	(59.7-214.3)	Female	27	14.2	190.1	(125.3-276.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.5	164.1	(74.9-311.4)	Male	10	5.6	179.5	(85.9-330.0)
Female	6	4.4	135.7	(49.6-295.4)	Female	3	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	11	15.9	69.1	(34.4-123.6)
Female	139	116.3	119.5	(100.5-141.1)	Female	9	13.6	66.1	(30.2-125.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.9	127.1	(41.0-296.7)	Male	10	14.0	71.4	(34.2-131.4)
<b><u>Colon / Rectum</u></b>					Female	5	5.9	84.5	(27.2-197.2)
Male	25	29.9	83.5	(54.0-123.2)	<b><u>Ovary</u></b>				
Female	29	27.7	104.6	(70.0-150.2)	Female	12	10.1	119.2	(61.5-208.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.6	65.8	(21.2-153.5)	Male	13	9.8	132.9	(70.7-227.2)
Female	0	1.9	nc	(nc-nc)	Female	13	9.2	142.0	(75.5-242.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	119	102.3	116.4	(96.4-139.3)
Female	4	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.4	93.3	(34.1-203.1)
Male	23	16.0	143.6	(91.0-215.5)	Female	3	3.5	nc	(nc-nc)
Female	6	8.9	67.7	(24.7-147.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.4	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	7	7.3	95.7	(38.3-197.1)
<b><u>Leukemia</u></b>					Female	25	21.4	116.6	(75.5-172.2)
Male	12	10.9	109.7	(56.6-191.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	7.6	nc	(nc-nc)	Female	21	27.4	76.7	(47.5-117.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	10.2	117.4	(60.6-205.0)	Male	389	372.1	104.5	(94.4-115.5)
Female	1	3.2	nc	(nc-nc)	Female	407	374.9	108.6	(98.3-119.6)
<b><u>Lung and Bronchus</u></b>									
Male	45	48.4	93.0	(67.8-124.5)					
Female	59	51.7	114.1	(86.9-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	22.7	118.9	(78.3-173.0)	Male	16	13.4	119.4	(68.2-193.8)
Female	8	8.7	91.8	(39.5-181.0)	Female	20	10.3	193.4	(118.1-298.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	5	4.4	114.0	(36.8-266.1)
Female	3	3.2	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	17	11.8	144.2	(83.9-230.8)
Female	80	84.0	95.2	(75.5-118.5)	Female	16	11.3	141.7	(80.9-230.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	12	8.8	135.7	(70.0-237.1)
<b><u>Colon / Rectum</u></b>					Female	4	4.7	nc	(nc-nc)
Male	18	22.5	80.0	(47.4-126.4)	<b><u>Ovary</u></b>				
Female	25	24.6	101.8	(65.9-150.3)	Female	7	7.6	92.1	(36.9-189.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.6	88.5	(28.5-206.6)	Male	9	7.6	117.7	(53.7-223.4)
Female	0	1.7	nc	(nc-nc)	Female	8	8.6	93.1	(40.1-183.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	79	69.3	114.0	(90.3-142.1)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.0	nc	(nc-nc)
Male	13	10.8	120.3	(64.0-205.7)	Female	2	3.2	nc	(nc-nc)
Female	8	7.1	112.6	(48.5-221.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	12.4	72.6	(33.1-137.8)
Male	5	8.2	60.7	(19.5-141.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.4	156.5	(74.9-287.7)	Female	16	19.8	80.8	(46.1-131.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.9	86.6	(31.6-188.6)	Male	285	274.1	104.0	(92.2-116.8)
Female	1	2.6	nc	(nc-nc)	Female	299	295.9	101.1	(89.9-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	34	40.4	84.1	(58.2-117.5)					
Female	50	47.0	106.3	(78.9-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.8	128.2	(61.4-235.9)	Male	7	4.9	142.7	(57.2-294.1)
Female	3	2.7	nc	(nc-nc)	Female	6	3.6	167.2	(61.1-364.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	45	29.9	150.5	(109.8-201.4)	Female	5	3.7	136.2	(43.9-317.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	11	3.4	323.9	(161.4-579.5)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	10	8.0	125.0	(59.8-229.8)	<b><u>Ovary</u></b>				
Female	11	7.7	143.1	(71.3-256.1)	Female	6	2.6	231.2	(84.4-503.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	44	26.1	168.8	(122.6-226.6)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	12	6.9	173.7	(89.7-303.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	129	100.3	128.6	(107.3-152.8)
Female	1	0.8	nc	(nc-nc)	Female	122	99.2	122.9	(102.1-146.8)
<b><u>Lung and Bronchus</u></b>									
Male	16	14.5	110.4	(63.1-179.4)					
Female	12	14.6	82.0	(42.3-143.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	11.5	112.8	(60.0-192.9)	Male	7	7.4	94.7	(37.9-195.1)
Female	2	3.6	nc	(nc-nc)	Female	6	5.5	108.4	(39.6-236.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.6	120.6	(51.9-237.6)
Female	49	42.4	115.6	(85.5-152.8)	Female	4	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	5	5.3	93.7	(30.2-218.6)
<b><u>Colon / Rectum</u></b>					Female	2	2.2	nc	(nc-nc)
Male	18	12.5	144.5	(85.6-228.4)	<b><u>Ovary</u></b>				
Female	19	11.1	171.6	(103.3-268.0)	Female	2	3.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	5	3.6	138.8	(44.7-323.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	29	38.0	76.2	(51.1-109.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.7	nc	(nc-nc)
Male	3	6.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	5	3.3	151.3	(48.8-353.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.5	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.5	117.3	(56.2-215.7)
Male	3	4.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.1	162.7	(52.4-379.6)	Female	5	9.7	51.7	(16.7-120.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	126	150.4	83.8	(69.8-99.7)
Female	2	1.2	nc	(nc-nc)	Female	154	141.1	109.2	(92.6-127.8)
<b><u>Lung and Bronchus</u></b>									
Male	9	20.4	44.1	(20.1-83.7)					
Female	19	18.8	101.2	(60.9-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	13.2	60.7	(26.1-119.5)	Male	10	8.7	115.6	(55.3-212.5)
Female	4	3.9	nc	(nc-nc)	Female	9	6.2	146.0	(66.6-277.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	54	49.8	108.4	(81.4-141.4)	Female	5	5.7	87.4	(28.2-203.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	7	6.6	106.3	(42.6-219.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.5	nc	(nc-nc)
Male	14	14.7	95.0	(51.9-159.5)	<b><u>Ovary</u></b>				
Female	13	12.5	104.2	(55.4-178.2)	Female	4	4.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	59	46.2	127.8	(97.3-164.9)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.2	nc	(nc-nc)
Male	6	7.5	79.7	(29.1-173.4)	Female	2	1.6	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.5	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.5	94.4	(43.1-179.1)
Male	6	5.4	111.4	(40.7-242.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	3.3	240.4	(103.5-473.7)	Female	9	11.3	79.9	(36.5-151.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.9	nc	(nc-nc)	Male	151	177.7	85.0	(72.0-99.7)
Female	1	1.3	nc	(nc-nc)	Female	152	159.5	95.3	(80.7-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	11	23.4	47.1	(23.5-84.2)					
Female	14	20.3	69.0	(37.7-115.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	63	57.2	110.1	(84.6-140.8)	Male	25	36.5	68.4	(44.3-101.0)
Female	21	22.5	93.2	(57.7-142.5)	Female	25	32.1	77.9	(50.4-115.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.0	109.6	(56.6-191.4)	Male	10	11.3	88.8	(42.5-163.3)
Female	11	9.7	112.9	(56.3-202.0)	Female	11	10.0	109.5	(54.6-196.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	29	32.6	88.8	(59.5-127.6)
Female	243	237.4	102.4	(89.9-116.1)	Female	22	31.3	70.4	(44.1-106.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	8.4	82.9	(33.2-170.9)	Male	33	24.7	133.8	(92.1-187.9)
<b><u>Colon / Rectum</u></b>					Female	14	12.9	108.2	(59.1-181.6)
Male	72	60.9	118.2	(92.5-148.8)	<b><u>Ovary</u></b>				
Female	81	67.4	120.2	(95.5-149.4)	Female	25	21.5	116.3	(75.3-171.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.3	90.7	(48.2-155.1)	Male	18	19.6	91.8	(54.4-145.1)
Female	7	4.3	161.8	(64.8-333.3)	Female	13	22.6	57.6	(30.7-98.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.0	99.5	(32.1-232.3)	Male	155	174.1	89.0	(75.6-104.2)
Female	5	4.4	112.9	(36.4-263.5)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	13.2	120.9	(69.0-196.3)
Male	27	29.6	91.2	(60.1-132.6)	Female	9	8.7	103.6	(47.3-196.6)
Female	24	19.2	124.7	(79.9-185.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	10.0	130.2	(69.3-222.7)
Male	10	8.3	120.5	(57.7-221.7)	<b><u>Thyroid</u></b>				
Female	2	2.8	nc	(nc-nc)	Male	12	14.1	85.1	(43.9-148.6)
<b><u>Leukemia</u></b>					Female	46	46.7	98.5	(72.1-131.3)
Male	27	23.0	117.6	(77.5-171.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	25	18.3	137.0	(88.6-202.2)	Female	56	53.8	104.2	(78.7-135.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	19	18.5	102.7	(61.8-160.3)	Male	717	725.2	98.9	(91.8-106.4)
Female	8	7.1	113.2	(48.8-223.1)	Female	867	826.2	104.9	(98.1-112.2)
<b><u>Lung and Bronchus</u></b>									
Male	101	99.8	101.2	(82.4-122.9)					
Female	135	117.6	114.8	(96.2-135.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	11.9	117.4	(64.2-197.1)	Male	7	8.1	86.7	(34.7-178.6)
Female	2	4.4	nc	(nc-nc)	Female	5	6.8	73.5	(23.7-171.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	7.3	164.0	(84.7-286.6)
Female	54	53.4	101.1	(75.9-131.9)	Female	6	6.4	94.5	(34.5-205.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.7	nc	(nc-nc)
Male	17	13.7	124.1	(72.3-198.8)	<b><u>Ovary</u></b>				
Female	16	14.2	112.8	(64.4-183.1)	Female	6	4.7	127.0	(46.4-276.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.4	206.1	(82.6-424.6)	Male	2	4.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	43	44.7	96.2	(69.6-129.6)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.9	nc	(nc-nc)
Male	5	7.3	68.7	(22.1-160.2)	Female	0	1.8	nc	(nc-nc)
Female	0	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	10.5	114.6	(59.1-200.1)
Male	3	5.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	10	11.8	84.4	(40.4-155.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	153	167.7	91.2	(77.4-106.9)
Female	1	1.4	nc	(nc-nc)	Female	161	174.9	92.0	(78.4-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	14	21.7	64.6	(35.3-108.5)					
Female	25	22.3	112.3	(72.6-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	28.4	81.1	(51.4-121.7)	Male	22	18.6	118.4	(74.2-179.3)
Female	13	11.2	116.0	(61.7-198.3)	Female	21	15.8	133.1	(82.4-203.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.6	88.5	(28.5-206.6)	Male	5	5.8	86.2	(27.8-201.2)
Female	7	4.8	144.6	(57.9-298.0)	Female	4	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	16.6	120.4	(73.5-186.0)
Female	124	120.5	102.9	(85.6-122.7)	Female	16	15.6	102.7	(58.6-166.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	13	13.3	97.9	(52.1-167.4)
<b><u>Colon / Rectum</u></b>					Female	5	6.5	76.5	(24.7-178.6)
Male	46	31.0	148.2	(108.5-197.6)	<b><u>Ovary</u></b>				
Female	35	34.6	101.3	(70.5-140.8)	Female	10	10.8	92.4	(44.2-169.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	7.5	160.0	(82.6-279.5)	Male	12	10.0	120.3	(62.1-210.1)
Female	1	2.2	nc	(nc-nc)	Female	16	11.5	139.6	(79.8-226.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	91	94.7	96.1	(77.3-118.0)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.7	74.8	(24.1-174.5)
Male	14	16.0	87.5	(47.8-146.7)	Female	5	4.5	111.8	(36.0-260.9)
Female	10	9.6	104.6	(50.1-192.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.2	nc	(nc-nc)
Male	9	4.3	207.0	(94.4-392.9)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	9	7.6	119.2	(54.4-226.2)
<b><u>Leukemia</u></b>					Female	25	22.6	110.6	(71.6-163.3)
Male	19	11.6	164.2	(98.8-256.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	9.2	97.9	(44.7-185.9)	Female	31	27.1	114.4	(77.7-162.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.7	nc	(nc-nc)	Male	397	374.8	105.9	(95.8-116.9)
Female	4	3.5	nc	(nc-nc)	Female	419	413.3	101.4	(91.9-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	50	50.7	98.6	(73.2-130.0)					
Female	46	56.7	81.1	(59.4-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	6.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	21	22.9	91.7	(56.7-140.2)	Female	7	2.5	281.8	(112.9-580.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	2	7.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	5.0	99.2	(32.0-231.6)	Female	2	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	24	22.4	107.2	(68.7-159.6)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.6	nc	(nc-nc)
Male	6	2.7	219.8	(80.2-478.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	7	5.1	137.0	(54.9-282.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	58	88.6	65.4	(49.7-84.6)
Female	1	0.6	nc	(nc-nc)	Female	77	70.5	109.2	(86.2-136.5)
<b><u>Lung and Bronchus</u></b>									
Male	4	11.5	nc	(nc-nc)					
Female	7	8.8	79.1	(31.7-163.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	75.0	(24.2-175.1)	Male	5	4.5	112.2	(36.2-261.9)
Female	5	2.3	220.3	(71.0-514.2)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	20	29.2	68.5	(41.8-105.8)	Female	3	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	9	7.4	121.1	(55.2-229.8)	<b><u>Ovary</u></b>				
Female	8	7.1	113.3	(48.8-223.3)	Female	5	2.5	197.2	(63.5-460.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	21	24.4	86.0	(53.2-131.5)
Female	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	5	2.2	226.6	(73.0-528.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.9	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	87	91.7	94.9	(76.0-117.0)
Female	2	0.8	nc	(nc-nc)	Female	98	93.6	104.7	(85.0-127.6)
<b><u>Lung and Bronchus</u></b>									
Male	10	12.3	81.6	(39.1-150.0)					
Female	20	12.7	157.4	(96.1-243.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	45.9	104.6	(77.1-138.6)	Male	24	30.6	78.5	(50.3-116.9)
Female	25	18.8	132.9	(86.0-196.1)	Female	25	26.4	94.7	(61.3-139.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	9.6	125.1	(64.5-218.5)	Male	10	9.5	104.8	(50.2-192.8)
Female	13	8.2	157.9	(84.0-270.0)	Female	8	8.4	95.0	(40.9-187.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	29	27.4	105.8	(70.8-151.9)
Female	188	205.9	91.3	(78.7-105.3)	Female	25	26.1	95.6	(61.9-141.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	7.1	113.4	(48.8-223.4)	Male	18	22.7	79.2	(46.9-125.1)
<b><u>Colon / Rectum</u></b>					Female	6	11.0	54.8	(20.0-119.3)
Male	48	51.0	94.1	(69.4-124.8)	<b><u>Ovary</u></b>				
Female	55	57.1	96.4	(72.6-125.4)	Female	11	18.2	60.3	(30.1-107.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	12.6	55.7	(22.3-114.8)	Male	17	16.5	103.1	(60.0-165.1)
Female	1	3.6	nc	(nc-nc)	Female	18	18.9	95.4	(56.5-150.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.8	158.2	(57.8-344.2)	Male	171	162.5	105.2	(90.0-122.2)
Female	2	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	11.0	127.2	(69.5-213.4)
Male	22	26.6	82.6	(51.8-125.1)	Female	5	7.3	68.2	(22.0-159.2)
Female	19	16.4	115.9	(69.7-180.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	6.9	158.8	(79.2-284.2)
Male	7	7.4	94.5	(37.9-194.8)	<b><u>Thyroid</u></b>				
Female	4	2.4	nc	(nc-nc)	Male	17	12.5	135.5	(78.9-217.0)
<b><u>Leukemia</u></b>					Female	37	38.2	96.9	(68.2-133.6)
Male	24	19.2	125.3	(80.2-186.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	15.3	123.8	(74.5-193.4)	Female	47	46.0	102.3	(75.1-136.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	16.8	89.1	(49.8-147.0)	Male	643	625.4	102.8	(95.0-111.1)
Female	5	5.9	84.8	(27.3-198.0)	Female	708	699.9	101.2	(93.8-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	99	83.0	119.3	(97.0-145.3)					
Female	121	98.8	122.5	(101.6-146.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	24.0	120.9	(80.9-173.6)	Male	21	16.0	131.3	(81.2-200.7)
Female	13	8.1	159.8	(85.0-273.2)	Female	13	12.5	104.4	(55.5-178.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.0	100.6	(32.4-234.8)	Male	5	5.0	99.5	(32.1-232.3)
Female	5	3.9	129.7	(41.8-302.7)	Female	7	3.8	185.8	(74.4-382.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	14	14.3	98.0	(53.5-164.5)
Female	115	99.2	116.0	(95.8-139.2)	Female	9	11.8	76.5	(34.9-145.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.4	146.8	(47.3-342.6)	Male	10	12.1	82.6	(39.6-152.0)
<b><u>Colon / Rectum</u></b>					Female	9	5.1	177.3	(80.9-336.6)
Male	39	26.6	146.4	(104.1-200.2)	<b><u>Ovary</u></b>				
Female	29	24.7	117.4	(78.6-168.6)	Female	10	8.7	115.0	(55.1-211.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.8	88.7	(32.4-193.0)	Male	13	8.7	149.5	(79.5-255.6)
Female	3	1.6	nc	(nc-nc)	Female	6	8.1	73.7	(26.9-160.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	99	91.7	107.9	(87.7-131.4)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.8	104.2	(38.1-226.9)
Male	17	14.4	118.3	(68.9-189.4)	Female	0	3.2	nc	(nc-nc)
Female	3	7.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.3	150.7	(48.6-351.8)
Male	3	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	5	1.2	422.8	(136.3-986.7)	Male	8	6.5	122.4	(52.7-241.2)
<b><u>Leukemia</u></b>					Female	26	18.8	138.0	(90.1-202.2)
Male	12	9.9	121.4	(62.6-212.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	6.8	249.8	(145.4-399.9)	Female	30	22.8	131.6	(88.8-187.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	8.8	158.6	(86.6-266.2)	Male	378	334.6	113.0	(101.9-125.0)
Female	7	2.7	261.3	(104.7-538.4)	Female	408	324.4	125.8	(113.9-138.6)
<b><u>Lung and Bronchus</u></b>									
Male	47	44.6	105.4	(77.5-140.2)					
Female	69	44.4	155.5	(121.0-196.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.2	65.4	(28.1-128.8)
Female	0	0.1	nc	(nc-nc)	Female	7	8.4	83.2	(33.4-171.5)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.8	nc	(nc-nc)					
Female	2	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	10.2	147.1	(82.3-242.7)	Male	8	7.2	110.9	(47.8-218.6)
Female	3	2.5	nc	(nc-nc)	Female	5	3.8	130.7	(42.1-304.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.4	155.2	(74.3-285.4)
Female	36	31.4	114.5	(80.2-158.6)	Female	7	3.7	188.9	(75.7-389.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	5	5.6	88.5	(28.5-206.6)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	11	11.8	93.3	(46.5-167.0)	<b><u>Ovary</u></b>				
Female	13	7.6	171.0	(91.0-292.5)	Female	0	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	42	40.5	103.6	(74.7-140.1)
Female	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.5	197.6	(63.7-461.2)
Male	3	6.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	5	2.4	207.2	(66.8-483.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.8	103.6	(37.8-225.5)
Male	5	4.4	114.8	(37.0-267.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	8	7.3	109.3	(47.0-215.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	159	148.6	107.0	(91.0-125.0)
Female	0	0.9	nc	(nc-nc)	Female	126	101.9	123.7	(103.0-147.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	18.9	95.0	(56.3-150.2)					
Female	19	14.2	134.1	(80.7-209.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	26.1	183.8	(135.5-243.7)	Male	10	17.5	57.2	(27.4-105.3)
Female	13	9.3	139.1	(74.0-237.9)	Female	16	14.2	113.0	(64.5-183.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.6	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	7	4.3	164.7	(66.0-339.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	19	15.7	120.7	(72.6-188.5)
Female	99	108.7	91.1	(74.1-110.9)	Female	22	13.5	163.5	(102.5-247.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.9	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.9)
<b><u>Colon / Rectum</u></b>					Female	6	5.7	105.8	(38.6-230.4)
Male	29	29.5	98.3	(65.8-141.2)	<b><u>Ovary</u></b>				
Female	35	28.9	120.9	(84.2-168.2)	Female	10	9.6	104.4	(50.0-192.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.0	128.6	(58.7-244.2)	Male	7	9.3	74.9	(30.0-154.3)
Female	1	1.8	nc	(nc-nc)	Female	6	9.4	63.7	(23.3-138.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	115	89.0	129.3	(106.7-155.2)
Female	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	6.3	223.1	(121.9-374.4)
Male	14	15.1	92.6	(50.6-155.4)	Female	1	3.7	nc	(nc-nc)
Female	10	8.5	117.9	(56.4-216.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.4	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	21.6	88.0	(52.9-137.4)
Male	11	11.1	99.4	(49.6-177.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	8.0	149.5	(77.2-261.2)	Female	26	24.2	107.5	(70.2-157.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	9.3	nc	(nc-nc)	Male	379	352.9	107.4	(96.9-118.8)
Female	1	3.0	nc	(nc-nc)	Female	388	363.9	106.6	(96.3-117.8)
<b><u>Lung and Bronchus</u></b>									
Male	42	46.5	90.4	(65.1-122.2)					
Female	65	49.2	132.1	(101.9-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	14.7	95.1	(52.0-159.6)	Male	4	9.7	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	5	7.6	65.5	(21.1-152.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	5	3.0	164.9	(53.1-384.8)
Female	0	2.4	nc	(nc-nc)	Female	6	2.4	248.7	(90.8-541.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.6	161.9	(88.5-271.7)
Female	59	60.3	97.8	(74.5-126.2)	Female	3	7.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	10	7.2	138.7	(66.4-255.0)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	8	16.1	49.8	(21.5-98.2)	<b><u>Ovary</u></b>				
Female	13	15.9	81.8	(43.5-139.9)	Female	6	5.3	112.9	(41.2-245.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.1	147.5	(53.9-321.1)	Male	6	5.3	113.0	(41.3-245.9)
Female	3	1.0	nc	(nc-nc)	Female	11	5.2	210.1	(104.7-375.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	61	54.1	112.8	(86.3-144.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.5	nc	(nc-nc)
Male	13	8.6	150.9	(80.3-258.1)	Female	3	2.0	nc	(nc-nc)
Female	7	4.8	146.8	(58.8-302.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.9	179.5	(71.9-369.8)
<b><u>Leukemia</u></b>					Female	8	11.3	70.7	(30.4-139.2)
Male	6	5.9	101.0	(36.9-219.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.3	139.3	(50.9-303.3)	Female	10	13.8	72.4	(34.6-133.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.2	135.8	(54.4-279.8)	Male	234	200.5	116.7	(102.2-132.6)
Female	1	1.7	nc	(nc-nc)	Female	201	201.8	99.6	(86.3-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	45	27.1	165.9	(121.0-222.0)					
Female	32	28.3	113.2	(77.4-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	6.7	164.9	(82.2-295.0)	Male	4	4.9	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	5	4.3	116.5	(37.5-271.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.4	114.7	(37.0-267.7)
Female	33	34.1	96.7	(66.6-135.8)	Female	3	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	6	4.0	150.3	(54.9-327.1)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	8.3	108.4	(49.5-205.8)	<b><u>Ovary</u></b>				
Female	12	8.6	140.2	(72.3-244.9)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	35	26.8	130.4	(90.8-181.3)
Female	3	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	7	4.5	155.1	(62.1-319.5)	Female	0	1.1	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	6.5	245.2	(140.1-398.2)
Male	4	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.4	nc	(nc-nc)	Female	6	7.8	77.1	(28.2-167.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	119	100.2	118.8	(98.4-142.1)
Female	1	0.9	nc	(nc-nc)	Female	120	111.8	107.4	(89.0-128.4)
<b><u>Lung and Bronchus</u></b>									
Male	12	12.8	93.8	(48.4-163.9)					
Female	15	15.4	97.7	(54.6-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	10	11.1	90.4	(43.3-166.2)	Female	2	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	11	7.7	142.8	(71.2-255.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	35	29.3	119.5	(83.2-166.1)
Female	1	0.3	nc	(nc-nc)	Female	33	34.9	94.6	(65.1-132.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.4	nc	(nc-nc)					
Female	9	4.4	205.1	(93.6-389.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	26.1	76.7	(46.9-118.5)	Male	30	16.8	179.0	(120.8-255.6)
Female	7	10.8	64.6	(25.9-133.1)	Female	26	14.7	176.5	(115.3-258.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	6	5.2	115.0	(42.0-250.2)
Female	8	4.7	169.8	(73.1-334.6)	Female	13	4.8	270.8	(144.1-463.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	13	15.2	85.6	(45.5-146.4)
Female	115	114.6	100.4	(82.9-120.5)	Female	11	14.9	74.0	(36.9-132.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.8	nc	(nc-nc)	Male	9	12.1	74.1	(33.8-140.7)
<b><u>Colon / Rectum</u></b>					Female	4	6.2	nc	(nc-nc)
Male	25	28.7	87.0	(56.3-128.4)	<b><u>Ovary</u></b>				
Female	39	32.8	118.9	(84.5-162.5)	Female	17	10.3	165.7	(96.4-265.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.8	88.3	(32.3-192.3)	Male	11	9.2	119.1	(59.4-213.1)
Female	3	2.1	nc	(nc-nc)	Female	10	10.9	91.9	(44.0-169.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	117	85.8	136.4	(112.8-163.5)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.1	nc	(nc-nc)
Male	9	14.3	63.0	(28.8-119.7)	Female	6	4.2	141.7	(51.7-308.4)
Female	14	9.2	152.0	(83.0-255.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.7	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	6	6.6	90.6	(33.1-197.2)
<b><u>Leukemia</u></b>					Female	33	20.8	158.4	(109.0-222.5)
Male	12	10.8	111.1	(57.3-194.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.8	102.0	(46.5-193.6)	Female	39	25.5	152.8	(108.6-208.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.0	nc	(nc-nc)	Male	350	341.7	102.4	(92.0-113.8)
Female	2	3.4	nc	(nc-nc)	Female	435	394.5	110.3	(100.1-121.1)
<b><u>Lung and Bronchus</u></b>									
Male	33	45.7	72.2	(49.7-101.3)					
Female	48	56.1	85.5	(63.1-113.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.1	88.8	(40.5-168.6)	Male	8	6.7	118.7	(51.1-233.9)
Female	2	2.9	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
Female	43	38.1	112.8	(81.6-152.0)	Female	6	4.4	137.2	(50.1-298.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	1	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.9	nc	(nc-nc)
Male	9	11.3	79.9	(36.5-151.7)	<b><u>Ovary</u></b>				
Female	3	8.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	33	39.3	84.0	(57.8-117.9)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	7	6.1	114.9	(46.0-236.7)	Female	1	1.1	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.3	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.4	nc	(nc-nc)	Female	8	9.2	86.6	(37.3-170.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.9	128.5	(41.4-300.0)	Male	119	141.8	83.9	(69.5-100.4)
Female	0	1.0	nc	(nc-nc)	Female	103	121.4	84.8	(69.2-102.9)
<b><u>Lung and Bronchus</u></b>									
Male	14	18.8	74.3	(40.6-124.6)					
Female	12	16.4	73.1	(37.7-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.8	81.8	(35.2-161.1)	Male	8	6.2	128.9	(55.5-254.0)
Female	6	3.7	162.0	(59.1-352.6)	Female	1	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.8	278.3	(89.7-649.6)	Male	2	2.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.6	89.8	(28.9-209.5)
Female	35	40.8	85.8	(59.7-119.3)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.2	nc	(nc-nc)
Male	10	10.5	95.1	(45.5-174.9)	<b><u>Ovary</u></b>				
Female	14	11.1	126.5	(69.1-212.3)	Female	6	3.7	163.4	(59.7-355.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	33.0	75.8	(49.1-111.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	5	5.3	94.6	(30.5-220.8)	Female	1	1.4	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	7.2	nc	(nc-nc)
Male	6	3.9	155.8	(56.9-339.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.0	nc	(nc-nc)	Female	11	9.7	113.2	(56.4-202.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	116	127.3	91.1	(75.3-109.3)
Female	0	1.2	nc	(nc-nc)	Female	120	138.2	86.8	(72.0-103.8)
<b><u>Lung and Bronchus</u></b>									
Male	20	17.2	116.1	(70.9-179.3)					
Female	15	19.5	77.1	(43.1-127.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	18.3	60.3	(30.0-107.8)
Female	0	0.1	nc	(nc-nc)	Female	11	12.8	86.0	(42.9-153.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.6	nc	(nc-nc)					
Female	1	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.2	165.1	(66.1-340.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	15.4	91.1	(49.8-152.8)
Female	0	0.1	nc	(nc-nc)	Female	6	13.3	45.0	(16.4-97.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.5	154.8	(62.0-318.9)	Male	11	2.9	385.5	(192.2-689.9)
Female	3	2.2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	16	20.3	78.9	(45.1-128.2)	Female	2	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	4	4.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	6.6	75.9	(24.5-177.1)	Female	1	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	15.8	126.8	(77.4-195.9)
Female	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.2	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	6	4.7	128.9	(47.1-280.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	73	59.3	123.1	(96.5-154.8)
Female	1	0.7	nc	(nc-nc)	Female	59	72.8	81.0	(61.7-104.5)
<b><u>Lung and Bronchus</u></b>									
Male	9	8.1	110.9	(50.6-210.5)					
Female	6	10.7	55.9	(20.4-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.6	75.3	(32.4-148.4)	Male	20	7.2	278.8	(170.2-430.6)
Female	2	3.3	nc	(nc-nc)	Female	21	5.2	407.0	(251.8-622.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	6	2.2	268.6	(98.1-584.7)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	58	39.5	146.9	(111.5-189.9)	Female	5	4.8	103.4	(33.3-241.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	10	5.2	190.6	(91.3-350.6)
<b><u>Colon / Rectum</u></b>					Female	4	2.1	nc	(nc-nc)
Male	8	11.7	68.1	(29.3-134.2)	<b><u>Ovary</u></b>				
Female	11	10.1	108.7	(54.2-194.4)	Female	3	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	5	3.8	132.0	(42.6-308.1)
Female	4	0.7	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	29	36.9	78.5	(52.6-112.7)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.0	124.6	(59.7-229.2)
Male	8	4.4	182.3	(78.5-359.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	11	9.0	122.0	(60.8-218.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	136	144.3	94.3	(79.1-111.5)
Female	0	1.1	nc	(nc-nc)	Female	162	131.8	123.0	(104.8-143.4)
<b><u>Lung and Bronchus</u></b>									
Male	13	19.2	67.6	(35.9-115.6)					
Female	16	18.0	89.1	(50.9-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	35.1	94.0	(64.7-132.1)	Male	21	22.8	92.1	(57.0-140.8)
Female	10	13.0	76.9	(36.8-141.4)	Female	21	18.9	111.0	(68.7-169.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	7.0	143.1	(68.5-263.2)	Male	5	7.1	70.4	(22.7-164.3)
Female	8	5.8	137.3	(59.1-270.6)	Female	4	5.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	14	20.4	68.6	(37.5-115.1)
Female	154	151.5	101.6	(86.2-119.0)	Female	17	18.4	92.2	(53.7-147.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.2	nc	(nc-nc)	Male	16	16.3	98.1	(56.0-159.3)
<b><u>Colon / Rectum</u></b>					Female	11	7.8	140.3	(70.0-251.1)
Male	46	38.1	120.8	(88.4-161.1)	<b><u>Ovary</u></b>				
Female	36	39.6	91.0	(63.7-126.0)	Female	21	13.2	159.1	(98.4-243.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.2	130.2	(67.2-227.4)	Male	10	12.3	81.1	(38.8-149.2)
Female	4	2.5	nc	(nc-nc)	Female	9	12.9	69.7	(31.8-132.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	110	114.8	95.8	(78.7-115.5)
Female	2	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	8.3	157.2	(83.6-268.8)
Male	17	19.3	88.2	(51.3-141.2)	Female	2	5.0	nc	(nc-nc)
Female	12	11.8	101.3	(52.3-177.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	5.0	139.0	(55.7-286.3)
Male	4	5.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.8	nc	(nc-nc)	Male	16	9.0	178.2	(101.8-289.3)
<b><u>Leukemia</u></b>					Female	25	28.1	89.0	(57.6-131.4)
Male	11	14.4	76.6	(38.2-137.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	10.6	65.9	(26.4-135.7)	Female	38	34.0	111.6	(79.0-153.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	12.1	49.7	(18.2-108.2)	Male	445	459.4	96.9	(88.1-106.3)
Female	3	4.2	nc	(nc-nc)	Female	493	501.7	98.3	(89.8-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	51	62.2	82.0	(61.0-107.8)					
Female	63	70.0	89.9	(69.1-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	37.6	95.8	(67.1-132.7)	Male	35	22.7	154.5	(107.6-214.8)
Female	12	13.3	89.9	(46.4-157.1)	Female	15	17.2	87.2	(48.8-143.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.5	138.6	(63.2-263.1)	Male	8	7.2	111.8	(48.2-220.4)
Female	11	5.4	202.0	(100.7-361.4)	Female	4	5.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	22	20.4	107.7	(67.5-163.0)
Female	157	135.6	115.8	(98.4-135.4)	Female	15	17.9	83.6	(46.8-137.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.4	nc	(nc-nc)	Male	13	15.7	82.8	(44.0-141.6)
<b><u>Colon / Rectum</u></b>					Female	7	7.5	93.3	(37.4-192.2)
Male	29	39.5	73.4	(49.1-105.4)	<b><u>Ovary</u></b>				
Female	35	40.6	86.2	(60.1-119.9)	Female	12	12.3	97.9	(50.5-171.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	9.3	64.3	(23.5-140.1)	Male	9	12.9	69.6	(31.8-132.2)
Female	2	2.6	nc	(nc-nc)	Female	19	13.7	138.8	(83.5-216.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	134	114.2	117.4	(98.3-139.0)
Female	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.6	58.2	(18.8-135.9)
Male	14	18.6	75.4	(41.2-126.5)	Female	2	5.3	nc	(nc-nc)
Female	11	10.8	101.4	(50.6-181.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.5	142.6	(46.0-332.9)
Male	2	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	9	7.9	114.2	(52.1-216.8)
<b><u>Leukemia</u></b>					Female	36	22.9	157.4	(110.2-217.9)
Male	11	14.5	75.6	(37.7-135.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.6	141.1	(78.9-232.7)	Female	28	30.6	91.7	(60.9-132.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.8	nc	(nc-nc)	Male	425	462.0	92.0	(83.4-101.2)
Female	1	4.0	nc	(nc-nc)	Female	464	470.3	98.7	(89.9-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	41	63.9	64.2	(46.1-87.1)					
Female	39	65.9	59.2	(42.1-80.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	111	98.2	113.0	(93.0-136.1)	Male	30	62.0	48.4	(32.6-69.1)
Female	37	39.4	93.9	(66.1-129.4)	Female	18	53.1	33.9	(20.1-53.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	18.7	96.0	(56.9-151.8)	Male	21	19.4	108.3	(67.0-165.5)
Female	14	16.8	83.2	(45.4-139.6)	Female	13	17.3	75.0	(39.9-128.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	48	55.4	86.7	(63.9-115.0)
Female	345	397.0	86.9	(78.0-96.6)	Female	43	53.3	80.7	(58.4-108.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	22	13.6	161.8	(101.4-245.0)	Male	54	42.8	126.1	(94.7-164.5)
<b><u>Colon / Rectum</u></b>					Female	28	22.0	127.1	(84.5-183.8)
Male	118	103.5	114.0	(94.4-136.5)	<b><u>Ovary</u></b>				
Female	111	118.9	93.4	(76.8-112.5)	Female	32	36.3	88.2	(60.3-124.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	25.2	123.1	(83.6-174.7)	Male	37	33.9	109.1	(76.8-150.3)
Female	11	7.5	147.2	(73.4-263.5)	Female	58	39.8	145.6	(110.6-188.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	10	7.6	131.7	(63.0-242.2)	Male	334	314.4	106.2	(95.1-118.3)
Female	3	6.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	40	22.7	176.5	(126.1-240.4)
Male	60	51.4	116.6	(89.0-150.1)	Female	25	15.5	161.6	(104.5-238.5)
Female	40	32.5	122.9	(87.8-167.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	14.1	64.0	(29.2-121.5)
Male	27	14.6	185.4	(122.1-269.7)	<b><u>Thyroid</u></b>				
Female	12	4.8	250.9	(129.5-438.3)	Male	18	23.2	77.5	(45.9-122.5)
<b><u>Leukemia</u></b>					Female	79	74.2	106.5	(84.3-132.7)
Male	32	39.4	81.3	(55.6-114.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	32.2	65.1	(40.3-99.6)	Female	89	88.8	100.3	(80.5-123.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	65	32.2	201.6	(155.6-256.9)	Male	1418	1256.5	112.9	(107.1-118.9)
Female	10	11.9	83.7	(40.1-153.9)	Female	1349	1399.5	96.4	(91.3-101.7)
<b><u>Lung and Bronchus</u></b>									
Male	251	173.8	144.4	(127.1-163.4)					
Female	207	198.7	104.2	(90.5-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	15.7	89.4	(48.9-150.1)
Female	0	0.1	nc	(nc-nc)	Female	13	14.1	92.4	(49.1-158.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	8.7	115.6	(55.3-212.6)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	9.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	35.8	42.0	(23.5-69.2)
Female	0	0.2	nc	(nc-nc)	Female	22	28.8	76.5	(47.9-115.8)
<b><u>Lung and Bronchus</u></b>									
Male	0	5.0	nc	(nc-nc)					
Female	2	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	15.8	76.1	(39.3-133.0)
Female	0	0.1	nc	(nc-nc)	Female	11	16.1	68.3	(34.1-122.3)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.1	nc	(nc-nc)					
Female	0	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.7	80.6	(32.3-166.1)	Male	14	5.7	246.5	(134.7-413.7)
Female	3	2.6	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.4	(32.0-231.9)
Female	36	31.8	113.3	(79.4-156.9)	Female	4	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	8	9.5	84.5	(36.4-166.6)	<b><u>Ovary</u></b>				
Female	6	7.8	77.2	(28.2-168.1)	Female	3	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	33	32.9	100.4	(69.1-140.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.1	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.6	125.5	(50.3-258.7)
Male	0	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.1	nc	(nc-nc)	Female	9	7.5	120.5	(55.0-228.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	109	119.2	91.5	(75.1-110.4)
Female	1	0.9	nc	(nc-nc)	Female	95	103.7	91.7	(74.1-112.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	16.1	68.2	(34.0-122.1)					
Female	9	15.0	60.2	(27.5-114.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	20.6	92.0	(55.4-143.7)	Male	29	13.4	216.3	(144.8-310.7)
Female	7	8.4	83.1	(33.3-171.3)	Female	18	11.6	155.7	(92.3-246.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	6	3.8	156.2	(57.0-340.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	18	11.9	151.6	(89.8-239.7)
Female	95	93.4	101.7	(82.3-124.4)	Female	8	11.7	68.3	(29.4-134.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	12	10.1	118.5	(61.2-207.0)
<b><u>Colon / Rectum</u></b>					Female	4	5.0	nc	(nc-nc)
Male	24	22.5	106.7	(68.4-158.8)	<b><u>Ovary</u></b>				
Female	27	24.7	109.4	(72.1-159.2)	Female	5	8.3	60.2	(19.4-140.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.7	104.4	(38.1-227.3)	Male	9	7.4	121.0	(55.2-229.7)
Female	1	1.7	nc	(nc-nc)	Female	9	8.4	107.0	(48.8-203.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	85	76.2	111.6	(89.1-138.0)
Female	2	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.9	122.4	(44.7-266.3)
Male	9	11.8	76.5	(34.9-145.2)	Female	4	3.2	nc	(nc-nc)
Female	3	7.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.3	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	11	5.2	212.4	(105.9-380.1)
<b><u>Leukemia</u></b>					Female	21	15.7	133.6	(82.7-204.2)
Male	5	8.1	61.6	(19.9-143.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	6.6	nc	(nc-nc)	Female	22	22.3	98.5	(61.7-149.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	7.6	nc	(nc-nc)	Male	287	280.1	102.5	(91.0-115.0)
Female	4	2.7	nc	(nc-nc)	Female	307	313.9	97.8	(87.2-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	22	37.9	58.1	(36.4-87.9)					
Female	40	45.5	87.9	(62.8-119.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	88	102.1	86.2	(69.1-106.2)	Male	69	62.6	110.3	(85.8-139.6)
Female	46	35.1	130.9	(95.8-174.6)	Female	62	48.3	128.4	(98.4-164.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	24	18.0	133.2	(85.3-198.2)	Male	26	19.9	130.6	(85.3-191.3)
Female	16	15.4	104.0	(59.4-168.9)	Female	18	15.7	114.5	(67.8-180.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	61	56.2	108.6	(83.1-139.5)
Female	437	375.2	116.5	(105.8-127.9)	Female	53	48.5	109.2	(81.8-142.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	12.5	79.7	(38.2-146.6)	Male	30	43.2	69.5	(46.9-99.2)
<b><u>Colon / Rectum</u></b>					Female	28	20.4	137.2	(91.2-198.3)
Male	92	107.0	86.0	(69.3-105.5)	<b><u>Ovary</u></b>				
Female	82	105.9	77.4	(61.6-96.1)	Female	38	33.7	112.6	(79.7-154.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	25.8	42.6	(21.2-76.3)	Male	34	35.0	97.0	(67.2-135.6)
Female	9	6.8	132.7	(60.6-251.9)	Female	51	35.4	143.9	(107.1-189.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	341	320.1	106.5	(95.5-118.4)
Female	3	6.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	23.3	85.7	(52.3-132.3)
Male	56	51.6	108.5	(81.9-140.9)	Female	14	13.7	102.3	(55.9-171.7)
Female	21	30.1	69.7	(43.2-106.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	11.7	93.8	(46.8-167.9)
Male	10	14.8	67.6	(32.4-124.4)	<b><u>Thyroid</u></b>				
Female	1	4.5	nc	(nc-nc)	Male	34	22.4	152.1	(105.3-212.5)
<b><u>Leukemia</u></b>					Female	81	68.0	119.1	(94.6-148.0)
Male	41	39.5	103.8	(74.5-140.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	22	28.7	76.6	(48.0-115.9)	Female	91	85.7	106.2	(85.5-130.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	31	32.8	94.4	(64.1-134.0)	Male	1189	1278.0	93.0	(87.8-98.5)
Female	9	11.0	81.5	(37.2-154.7)	Female	1370	1288.7	106.3	(100.8-112.1)
<b><u>Lung and Bronchus</u></b>									
Male	130	177.9	73.1	(61.0-86.8)					
Female	158	182.0	86.8	(73.8-101.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	11.2	62.3	(24.9-128.3)	Male	12	8.5	140.6	(72.6-245.7)
Female	2	2.5	nc	(nc-nc)	Female	7	4.3	161.5	(64.7-332.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.7	104.5	(45.0-205.9)
Female	46	36.0	127.9	(93.6-170.6)	Female	0	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	11	13.9	79.2	(39.5-141.7)	<b><u>Ovary</u></b>				
Female	8	7.8	103.1	(44.4-203.2)	Female	1	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	44	49.3	89.3	(64.9-119.9)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	2.9	205.2	(74.9-446.6)
Male	6	8.1	74.1	(27.1-161.4)	Female	1	1.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.3	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.1	112.7	(48.5-222.0)
Male	6	5.1	118.1	(43.1-257.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.2	nc	(nc-nc)	Female	7	8.5	82.6	(33.1-170.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	149	176.5	84.4	(71.4-99.1)
Female	0	0.9	nc	(nc-nc)	Female	113	111.4	101.4	(83.6-121.9)
<b><u>Lung and Bronchus</u></b>									
Male	19	21.5	88.5	(53.2-138.2)					
Female	12	14.2	84.3	(43.5-147.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	17.1	105.4	(62.4-166.5)	Male	6	10.4	57.6	(21.0-125.4)
Female	12	5.9	202.8	(104.6-354.2)	Female	8	7.8	102.5	(44.1-201.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	12	9.3	129.1	(66.6-225.5)
Female	52	60.6	85.8	(64.1-112.5)	Female	7	8.0	88.0	(35.3-181.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	5	6.9	72.8	(23.5-169.9)
<b><u>Colon / Rectum</u></b>					Female	3	3.3	nc	(nc-nc)
Male	27	17.6	153.3	(101.0-223.0)	<b><u>Ovary</u></b>				
Female	22	17.3	127.1	(79.7-192.5)	Female	6	5.4	110.4	(40.3-240.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.2	191.5	(82.5-377.3)	Male	0	5.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	10	5.9	169.6	(81.2-311.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	51	49.7	102.6	(76.4-134.9)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.9	155.8	(56.9-339.1)
Male	14	8.3	167.7	(91.6-281.5)	Female	1	2.2	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	0.7	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	10.7	84.4	(38.5-160.1)
Male	6	6.6	90.9	(33.2-197.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.7	107.0	(34.5-249.7)	Female	12	13.7	87.9	(45.4-153.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	5.2	209.6	(104.5-375.1)	Male	230	208.2	110.5	(96.7-125.7)
Female	3	1.8	nc	(nc-nc)	Female	223	210.8	105.8	(92.4-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	34	29.7	114.5	(79.3-160.0)					
Female	47	31.4	149.8	(110.0-199.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	28.9	121.1	(84.3-168.4)	Male	18	18.8	95.5	(56.6-151.0)
Female	13	11.5	112.7	(59.9-192.7)	Female	12	15.7	76.3	(39.4-133.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.8	102.9	(37.6-224.1)	Male	5	5.8	85.5	(27.5-199.5)
Female	7	4.9	142.4	(57.1-293.4)	Female	5	5.1	97.9	(31.6-228.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	19	17.0	111.8	(67.3-174.7)
Female	117	123.4	94.8	(78.4-113.6)	Female	17	15.8	107.8	(62.8-172.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.2	119.9	(38.6-279.7)	Male	11	13.7	80.4	(40.1-143.8)
<b><u>Colon / Rectum</u></b>					Female	5	6.6	75.8	(24.4-176.9)
Male	29	32.0	90.6	(60.6-130.1)	<b><u>Ovary</u></b>				
Female	45	35.2	128.0	(93.3-171.2)	Female	9	10.9	82.4	(37.6-156.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.6	91.9	(36.8-189.4)	Male	13	10.2	127.5	(67.8-218.0)
Female	1	2.2	nc	(nc-nc)	Female	9	11.6	77.4	(35.3-147.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	102	94.6	107.8	(87.9-130.9)
Female	3	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	6.8	117.1	(50.4-230.8)
Male	19	16.0	118.7	(71.4-185.4)	Female	6	4.6	131.4	(48.0-286.1)
Female	7	9.8	71.2	(28.5-146.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.1	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	10	7.5	133.0	(63.7-244.6)
<b><u>Leukemia</u></b>					Female	27	22.4	120.7	(79.5-175.6)
Male	10	11.9	83.7	(40.1-154.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.3	107.0	(51.2-196.8)	Female	22	27.1	81.2	(50.9-123.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	10.0	nc	(nc-nc)	Male	375	380.0	98.7	(89.0-109.2)
Female	3	3.5	nc	(nc-nc)	Female	407	421.2	96.6	(87.5-106.5)
<b><u>Lung and Bronchus</u></b>									
Male	36	50.8	70.8	(49.6-98.1)					
Female	52	59.2	87.8	(65.6-115.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	23.1	90.7	(56.1-138.7)	Male	17	16.3	104.1	(60.6-166.7)
Female	7	8.2	85.1	(34.1-175.4)	Female	22	13.4	164.2	(102.9-248.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.5	108.8	(39.7-236.8)	Male	4	5.0	nc	(nc-nc)
Female	8	4.3	185.5	(79.9-365.6)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	17	14.7	115.6	(67.3-185.1)
Female	103	104.5	98.5	(80.4-119.5)	Female	14	12.2	114.4	(62.5-191.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.0	nc	(nc-nc)	Male	11	12.7	86.9	(43.3-155.5)
<b><u>Colon / Rectum</u></b>					Female	8	5.3	151.7	(65.3-298.9)
Male	33	26.9	122.8	(84.5-172.5)	<b><u>Ovary</u></b>				
Female	26	26.2	99.4	(64.9-145.6)	Female	5	9.1	55.2	(17.8-128.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	119.8	(51.6-236.1)	Male	6	8.6	70.1	(25.6-152.5)
Female	1	1.6	nc	(nc-nc)	Female	10	8.3	120.6	(57.7-221.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	96	88.7	108.3	(87.7-132.2)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.7	nc	(nc-nc)
Male	14	14.8	94.7	(51.7-159.0)	Female	2	3.3	nc	(nc-nc)
Female	6	7.9	75.7	(27.6-164.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.3	nc	(nc-nc)
Male	8	4.0	201.9	(86.9-397.8)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	6	7.3	81.7	(29.8-177.7)
<b><u>Leukemia</u></b>					Female	27	21.8	123.9	(81.6-180.2)
Male	6	10.3	58.0	(21.2-126.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.4	67.2	(21.7-156.8)	Female	21	22.9	91.7	(56.8-140.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.1	110.0	(52.7-202.4)	Male	347	334.5	103.7	(93.1-115.2)
Female	1	2.7	nc	(nc-nc)	Female	342	339.8	100.7	(90.3-111.9)
<b><u>Lung and Bronchus</u></b>									
Male	45	42.9	105.0	(76.6-140.5)					
Female	47	43.8	107.4	(78.9-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.3	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	15	20.7	72.5	(40.6-119.6)	Female	4	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	5.5	91.1	(29.4-212.6)	Female	4	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	18	15.6	115.5	(68.4-182.6)
Female	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	64	60.9	105.2	(81.0-134.3)
Female	1	0.6	nc	(nc-nc)	Female	57	68.6	83.1	(63.0-107.7)
<b><u>Lung and Bronchus</u></b>									
Male	8	8.2	97.7	(42.1-192.5)					
Female	5	9.6	52.0	(16.8-121.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	14.4	76.5	(38.1-136.9)	Male	16	9.8	163.0	(93.1-264.8)
Female	8	5.2	153.9	(66.3-303.4)	Female	13	8.1	160.7	(85.5-274.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.1	160.3	(51.6-374.0)	Male	4	3.1	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.8	90.6	(39.0-178.4)
Female	76	65.9	115.4	(90.9-144.4)	Female	5	7.6	65.6	(21.1-153.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	5	7.6	66.0	(21.3-154.0)
<b><u>Colon / Rectum</u></b>					Female	1	3.3	nc	(nc-nc)
Male	14	16.3	85.6	(46.8-143.7)	<b><u>Ovary</u></b>				
Female	15	16.1	93.4	(52.2-154.1)	Female	3	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	4.1	217.7	(99.4-413.3)	Male	3	5.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	50	54.8	91.2	(67.7-120.2)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.5	nc	(nc-nc)
Male	9	8.9	101.4	(46.2-192.4)	Female	0	2.0	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.3	nc	(nc-nc)
Male	5	2.4	205.4	(66.2-479.3)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	12.5	128.1	(73.2-208.0)
Male	12	6.0	198.5	(102.4-346.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	4.3	162.0	(64.9-333.7)	Female	18	14.7	122.4	(72.5-193.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.5	nc	(nc-nc)	Male	201	203.6	98.7	(85.5-113.4)
Female	3	1.7	nc	(nc-nc)	Female	214	211.9	101.0	(87.9-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	19	26.5	71.7	(43.1-112.0)					
Female	23	29.0	79.3	(50.2-118.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	29.4	108.7	(74.3-153.5)	Male	12	18.8	63.7	(32.9-111.3)
Female	10	11.1	90.1	(43.1-165.7)	Female	12	16.1	74.4	(38.4-130.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.5	108.4	(39.6-235.9)	Male	1	6.0	nc	(nc-nc)
Female	6	5.1	118.8	(43.4-258.6)	Female	9	5.0	180.4	(82.3-342.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	16.9	89.0	(49.8-146.8)
Female	153	119.9	127.6	(108.2-149.5)	Female	18	15.6	115.6	(68.5-182.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.1	nc	(nc-nc)	Male	15	13.6	110.3	(61.7-182.0)
<b><u>Colon / Rectum</u></b>					Female	8	6.5	122.2	(52.6-240.8)
Male	31	31.5	98.5	(66.9-139.8)	<b><u>Ovary</u></b>				
Female	35	33.6	104.1	(72.5-144.7)	Female	15	11.0	136.4	(76.3-225.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.9	63.0	(20.3-147.1)	Male	9	10.4	86.9	(39.7-165.0)
Female	5	2.2	232.3	(74.8-542.0)	Female	14	11.2	124.6	(68.0-209.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	68	103.0	66.0	(51.3-83.7)
Female	2	2.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.9	72.8	(23.5-169.8)
Male	9	16.2	55.4	(25.3-105.2)	Female	4	4.4	nc	(nc-nc)
Female	9	9.5	94.4	(43.1-179.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.0	151.6	(55.3-329.9)
Male	3	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	5	7.3	68.4	(22.0-159.7)
<b><u>Leukemia</u></b>					Female	11	23.5	46.7	(23.3-83.6)
Male	13	11.6	112.5	(59.8-192.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.2	108.7	(52.0-199.9)	Female	33	27.6	119.5	(82.2-167.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	10.1	69.4	(27.8-143.0)	Male	313	389.3	80.4	(71.7-89.8)
Female	1	3.5	nc	(nc-nc)	Female	451	413.8	109.0	(99.2-119.5)
<b><u>Lung and Bronchus</u></b>									
Male	47	52.8	89.1	(65.5-118.5)					
Female	56	56.9	98.4	(74.3-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	15.2	132.0	(80.6-203.9)	Male	9	9.9	91.0	(41.5-172.7)
Female	9	5.4	166.5	(76.0-316.1)	Female	6	7.7	78.1	(28.5-170.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.0	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	8.9	56.0	(18.1-130.7)
Female	71	59.7	118.9	(92.9-150.0)	Female	3	7.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	3	7.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	3.2	nc	(nc-nc)
Male	12	17.0	70.8	(36.5-123.7)	<b><u>Ovary</u></b>				
Female	15	17.0	88.1	(49.3-145.3)	Female	3	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.0	148.7	(54.3-323.6)	Male	5	5.4	92.6	(29.8-216.0)
Female	0	1.0	nc	(nc-nc)	Female	7	5.5	127.3	(51.0-262.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	48	51.3	93.6	(69.0-124.1)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.6	nc	(nc-nc)
Male	6	8.5	70.6	(25.8-153.7)	Female	3	2.2	nc	(nc-nc)
Female	5	4.7	106.0	(34.1-247.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	11.0	72.4	(31.2-142.7)
Male	12	6.2	193.7	(100.0-338.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.5	nc	(nc-nc)	Female	21	13.3	157.7	(97.6-241.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	172	201.7	85.3	(73.0-99.0)
Female	1	1.7	nc	(nc-nc)	Female	196	202.5	96.8	(83.7-111.3)
<b><u>Lung and Bronchus</u></b>									
Male	16	26.8	59.8	(34.1-97.1)					
Female	18	27.5	65.6	(38.8-103.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	15.8	138.8	(87.0-210.2)	Male	8	10.4	77.2	(33.2-152.0)
Female	8	5.3	150.8	(64.9-297.1)	Female	9	8.1	111.5	(50.9-211.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	8	3.3	245.6	(105.8-484.0)
Female	1	2.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	5	9.3	53.7	(17.3-125.4)
Female	52	62.0	83.9	(62.6-110.0)	Female	7	7.6	91.9	(36.8-189.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	10	7.5	133.4	(63.9-245.3)
<b><u>Colon / Rectum</u></b>					Female	4	3.2	nc	(nc-nc)
Male	12	17.4	69.0	(35.6-120.5)	<b><u>Ovary</u></b>				
Female	27	16.4	164.5	(108.4-239.3)	Female	6	5.5	109.3	(39.9-237.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.2	118.9	(38.3-277.4)	Male	3	5.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	9	5.3	168.9	(77.1-320.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	60	53.1	113.0	(86.2-145.5)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.8	nc	(nc-nc)
Male	20	8.9	224.8	(137.2-347.2)	Female	3	2.1	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	12.4	104.8	(55.7-179.2)
Male	6	6.5	92.2	(33.7-200.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.6	nc	(nc-nc)	Female	20	13.9	143.9	(87.9-222.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.6	nc	(nc-nc)	Male	223	210.0	106.2	(92.7-121.1)
Female	4	1.7	nc	(nc-nc)	Female	220	207.2	106.2	(92.6-121.2)
<b><u>Lung and Bronchus</u></b>									
Male	32	28.3	113.2	(77.4-159.8)					
Female	26	27.7	93.8	(61.2-137.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	13	14.2	91.7	(48.8-156.8)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	5	4.6	108.8	(35.1-253.9)	<b><u>Ovary</u></b>				
Female	1	3.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	15.4	45.4	(18.2-93.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	33	56.4	58.5	(40.2-82.1)
Female	1	0.4	nc	(nc-nc)	Female	38	46.1	82.5	(58.4-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	3	7.6	nc	(nc-nc)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	16.8	59.4	(28.5-109.3)	Male	14	11.5	121.3	(66.3-203.6)
Female	8	6.3	127.4	(54.9-251.1)	Female	15	9.7	155.2	(86.8-255.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.7	135.3	(43.6-315.6)	Male	1	3.6	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	7	10.4	67.5	(27.0-139.0)
Female	68	75.9	89.6	(69.5-113.5)	Female	13	9.1	142.5	(75.8-243.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	8	8.9	89.7	(38.6-176.7)
<b><u>Colon / Rectum</u></b>					Female	3	4.0	nc	(nc-nc)
Male	27	19.1	141.3	(93.1-205.6)	<b><u>Ovary</u></b>				
Female	28	19.5	143.7	(95.5-207.7)	Female	7	6.8	103.6	(41.5-213.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.8	103.8	(33.4-242.2)	Male	9	6.2	146.3	(66.8-277.7)
Female	1	1.2	nc	(nc-nc)	Female	11	6.4	173.1	(86.3-309.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	60	63.0	95.3	(72.7-122.6)
Female	0	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.1	nc	(nc-nc)
Male	13	10.3	126.7	(67.4-216.6)	Female	2	2.5	nc	(nc-nc)
Female	10	5.8	172.8	(82.7-317.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	8	5.0	160.2	(69.0-315.6)
<b><u>Leukemia</u></b>					Female	15	14.7	101.8	(57.0-168.0)
Male	6	7.2	83.3	(30.4-181.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.3	112.4	(41.0-244.6)	Female	25	17.4	143.5	(92.8-211.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	6.5	153.5	(73.5-282.3)	Male	239	237.7	100.6	(88.2-114.1)
Female	0	2.1	nc	(nc-nc)	Female	271	249.8	108.5	(96.0-122.2)
<b><u>Lung and Bronchus</u></b>									
Male	27	31.0	87.0	(57.3-126.6)					
Female	27	33.0	81.9	(54.0-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	12.9	85.6	(42.7-153.1)	Male	5	8.1	61.7	(19.9-144.1)
Female	2	4.6	nc	(nc-nc)	Female	14	6.1	229.3	(125.3-384.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.4	250.3	(91.4-544.8)	Male	1	2.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	5	2.1	240.9	(77.6-562.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.3	82.7	(30.2-180.1)
Female	45	50.0	90.1	(65.7-120.5)	Female	11	6.3	173.3	(86.4-310.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.9	85.2	(27.4-198.7)
<b><u>Colon / Rectum</u></b>					Female	9	2.7	336.2	(153.4-638.3)
Male	10	13.9	72.1	(34.5-132.6)	<b><u>Ovary</u></b>				
Female	8	13.8	57.9	(24.9-114.1)	Female	7	4.4	158.4	(63.5-326.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	6	4.7	127.7	(46.6-278.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	40	43.3	92.3	(65.9-125.7)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	6	6.9	86.7	(31.7-188.8)	Female	1	1.8	nc	(nc-nc)
Female	5	4.0	126.2	(40.7-294.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	8.1	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.6	nc	(nc-nc)	Female	15	11.5	130.3	(72.9-214.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.4	114.1	(36.8-266.2)	Male	137	167.1	82.0	(68.8-96.9)
Female	1	1.5	nc	(nc-nc)	Female	172	168.9	101.8	(87.2-118.2)
<b><u>Lung and Bronchus</u></b>									
Male	13	23.0	56.5	(30.1-96.6)					
Female	15	24.5	61.3	(34.3-101.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	34.0	41.1	(22.5-69.0)	Male	33	21.5	153.5	(105.7-215.6)
Female	13	12.3	105.4	(56.0-180.2)	Female	25	16.4	152.4	(98.6-225.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.3	159.6	(76.4-293.5)	Male	8	6.8	117.2	(50.5-231.0)
Female	7	5.1	137.8	(55.2-283.9)	Female	5	5.4	92.1	(29.7-215.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	22	19.1	115.5	(72.3-174.8)
Female	133	125.9	105.6	(88.4-125.2)	Female	17	16.7	102.1	(59.4-163.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.2	nc	(nc-nc)	Male	12	14.6	82.1	(42.4-143.4)
<b><u>Colon / Rectum</u></b>					Female	6	6.9	87.1	(31.8-189.7)
Male	48	35.7	134.3	(99.0-178.1)	<b><u>Ovary</u></b>				
Female	49	37.4	131.2	(97.0-173.4)	Female	15	11.3	132.2	(73.9-218.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	8.6	115.6	(55.4-212.6)	Male	18	11.6	154.9	(91.8-244.8)
Female	3	2.4	nc	(nc-nc)	Female	21	12.5	168.1	(104.0-257.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	93	104.5	89.0	(71.8-109.0)
Female	3	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.8	114.9	(52.4-218.1)
Male	15	17.6	85.0	(47.5-140.2)	Female	7	4.8	144.5	(57.9-297.7)
Female	15	10.2	146.4	(81.9-241.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.5	134.8	(49.2-293.3)
Male	8	5.0	159.3	(68.6-313.9)	<b><u>Thyroid</u></b>				
Female	4	1.5	nc	(nc-nc)	Male	14	7.9	177.4	(96.9-297.6)
<b><u>Leukemia</u></b>					Female	29	22.5	128.9	(86.3-185.2)
Male	13	13.4	97.2	(51.7-166.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	9.9	111.1	(55.4-198.8)	Female	32	27.8	115.1	(78.7-162.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	11.1	134.8	(75.4-222.4)	Male	460	429.0	107.2	(97.7-117.5)
Female	4	3.7	nc	(nc-nc)	Female	517	439.1	117.7	(107.8-128.3)
<b><u>Lung and Bronchus</u></b>									
Male	62	60.5	102.4	(78.5-131.3)					
Female	83	63.3	131.2	(104.5-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	6.9	115.8	(49.9-228.3)	Male	10	4.3	233.9	(112.0-430.2)
Female	0	2.4	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	26	21.8	119.5	(78.0-175.1)	Female	2	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.3	nc	(nc-nc)
Male	8	6.9	115.3	(49.6-227.2)	<b><u>Ovary</u></b>				
Female	6	7.1	84.1	(30.7-183.0)	Female	3	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	6	2.3	256.9	(93.8-559.3)
Female	0	0.5	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	16	20.7	77.4	(44.2-125.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.4	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.8	nc	(nc-nc)	Female	8	4.9	163.5	(70.4-322.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	80	84.8	94.3	(74.8-117.4)
Female	0	0.7	nc	(nc-nc)	Female	84	78.5	107.1	(85.4-132.6)
<b><u>Lung and Bronchus</u></b>									
Male	8	12.5	64.1	(27.6-126.4)					
Female	15	11.4	131.4	(73.5-216.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	6	8.0	75.2	(27.5-163.7)	Female	2	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	8.1	135.1	(67.3-241.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	26	30.0	86.5	(56.5-126.8)
Female	0	0.2	nc	(nc-nc)	Female	23	25.2	91.1	(57.8-136.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.1	nc	(nc-nc)					
Female	1	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	9.3	53.6	(17.3-125.0)	Male	2	6.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.3	150.6	(64.8-296.8)
Female	33	33.9	97.5	(67.1-136.9)	Female	3	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	5	9.8	51.0	(16.4-118.9)	<b><u>Ovary</u></b>				
Female	4	9.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	29	31.1	93.3	(62.5-134.1)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	5	5.1	99.0	(31.9-231.0)	Female	0	1.2	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	6.1	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.4	nc	(nc-nc)	Female	12	7.7	154.9	(80.0-270.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	105	121.9	86.1	(70.5-104.3)
Female	0	1.0	nc	(nc-nc)	Female	100	114.3	87.5	(71.2-106.4)
<b><u>Lung and Bronchus</u></b>									
Male	17	17.1	99.4	(57.9-159.2)					
Female	13	16.4	79.3	(42.2-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	15.7	89.0	(48.6-149.3)	Male	19	8.7	218.4	(131.4-341.1)
Female	7	5.2	133.5	(53.5-275.1)	Female	10	5.6	178.9	(85.6-329.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.5	132.7	(63.5-244.1)
Female	67	46.6	143.8	(111.5-182.7)	Female	6	6.6	91.1	(33.3-198.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.7	nc	(nc-nc)
Male	13	14.4	90.0	(47.9-153.9)	<b><u>Ovary</u></b>				
Female	15	14.4	104.4	(58.4-172.2)	Female	3	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.8	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	7	5.2	135.2	(54.2-278.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	29	47.3	61.3	(41.1-88.1)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.4	nc	(nc-nc)
Male	2	6.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.7	nc	(nc-nc)
Male	7	5.2	133.5	(53.5-275.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.6	nc	(nc-nc)	Female	13	11.3	114.9	(61.1-196.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	144	181.2	79.5	(67.0-93.6)
Female	1	1.6	nc	(nc-nc)	Female	183	168.0	108.9	(93.7-125.9)
<b><u>Lung and Bronchus</u></b>									
Male	12	28.3	42.5	(21.9-74.2)					
Female	18	28.0	64.4	(38.1-101.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	7.4	176.5	(93.9-301.9)	Female	3	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	9	9.6	94.1	(42.9-178.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	30	35.8	83.9	(56.6-119.8)
Female	0	0.2	nc	(nc-nc)	Female	30	24.3	123.6	(83.4-176.4)
<b><u>Lung and Bronchus</u></b>									
Male	8	5.2	154.2	(66.4-303.9)					
Female	4	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oxford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	11.0	181.7	(111.0-280.7)	Male	12	7.9	151.7	(78.3-265.0)
Female	7	4.5	156.1	(62.5-321.7)	Female	6	7.0	85.3	(31.2-185.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	5	2.4	207.4	(66.8-484.0)
Female	0	2.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.1	112.4	(48.4-221.5)
Female	60	54.9	109.3	(83.4-140.7)	Female	9	6.6	137.2	(62.6-260.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	9	6.2	145.5	(66.4-276.2)
<b><u>Colon / Rectum</u></b>					Female	4	2.8	nc	(nc-nc)
Male	8	13.2	60.8	(26.2-119.9)	<b><u>Ovary</u></b>				
Female	17	14.2	119.3	(69.5-191.1)	Female	6	4.8	124.4	(45.4-270.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	47	42.1	111.7	(82.1-148.6)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.8	nc	(nc-nc)
Male	6	7.2	83.3	(30.4-181.2)	Female	4	1.8	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.1	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	6	3.6	165.1	(60.3-359.4)
<b><u>Leukemia</u></b>					Female	16	10.9	146.5	(83.7-237.9)
Male	10	5.0	201.3	(96.4-370.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.9	181.6	(72.8-374.3)	Female	19	12.2	155.9	(93.8-243.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.4	159.0	(63.7-327.6)	Male	200	160.6	124.6	(107.9-143.1)
Female	1	1.5	nc	(nc-nc)	Female	222	180.0	123.3	(107.6-140.6)
<b><u>Lung and Bronchus</u></b>									
Male	37	20.4	181.8	(128.0-250.6)					
Female	34	23.7	143.3	(99.2-200.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	11.9	150.6	(89.2-238.1)	Male	11	8.2	134.0	(66.8-239.7)
Female	9	5.6	161.8	(73.8-307.1)	Female	8	7.3	110.3	(47.5-217.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.5	237.3	(86.6-516.4)	Male	0	2.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	7.3	nc	(nc-nc)
Female	58	56.4	102.8	(78.0-132.9)	Female	6	7.4	80.9	(29.6-176.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	7	6.3	111.3	(44.6-229.3)
<b><u>Colon / Rectum</u></b>					Female	1	3.1	nc	(nc-nc)
Male	12	13.6	88.5	(45.7-154.7)	<b><u>Ovary</u></b>				
Female	14	16.6	84.4	(46.1-141.6)	Female	5	5.1	98.0	(31.6-228.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	5	4.4	114.7	(37.0-267.6)
Female	0	1.1	nc	(nc-nc)	Female	7	5.6	124.8	(50.0-257.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	37	43.8	84.4	(59.4-116.4)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	2.9	205.9	(75.2-448.3)
Male	10	7.2	139.2	(66.6-256.0)	Female	2	2.2	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	5	2.0	248.4	(80.0-579.6)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.8	91.5	(41.8-173.7)
Male	5	5.0	100.7	(32.5-235.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.4	136.7	(49.9-297.6)	Female	12	12.6	95.2	(49.1-166.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.7	106.2	(34.2-247.7)	Male	179	167.1	107.1	(92.0-124.0)
Female	2	1.7	nc	(nc-nc)	Female	173	196.1	88.2	(75.6-102.4)
<b><u>Lung and Bronchus</u></b>									
Male	33	22.1	149.0	(102.6-209.3)					
Female	16	28.1	56.9	(32.5-92.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	6	3.7	162.4	(59.3-353.4)
Female	1	1.8	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	20	19.9	100.6	(61.4-155.3)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	6.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	5.2	135.1	(54.1-278.3)	Female	1	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	26	19.1	136.1	(88.9-199.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.4	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.5	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	75	75.5	99.3	(78.1-124.5)
Female	1	0.6	nc	(nc-nc)	Female	61	66.8	91.4	(69.9-117.4)
<b><u>Lung and Bronchus</u></b>									
Male	7	10.7	65.7	(26.3-135.3)					
Female	6	9.4	63.6	(23.2-138.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	87	72.3	120.4	(96.4-148.5)	Male	38	43.0	88.4	(62.6-121.4)
Female	36	27.9	129.1	(90.4-178.8)	Female	33	34.4	96.1	(66.1-134.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	11.7	85.2	(40.8-156.6)	Male	21	13.7	152.8	(94.6-233.6)
Female	14	10.3	135.3	(73.9-227.0)	Female	20	12.0	166.0	(101.4-256.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	43	38.4	112.1	(81.1-151.0)
Female	276	262.2	105.3	(93.2-118.5)	Female	56	36.5	153.6	(116.0-199.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	8.3	145.4	(75.0-254.0)	Male	35	28.4	123.0	(85.7-171.1)
<b><u>Colon / Rectum</u></b>					Female	13	14.9	87.4	(46.5-149.4)
Male	58	73.5	78.9	(59.9-102.0)	<b><u>Ovary</u></b>				
Female	90	84.5	106.5	(85.6-130.9)	Female	20	24.0	83.2	(50.8-128.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	17.6	73.7	(39.2-126.1)	Male	22	24.3	90.4	(56.7-136.9)
Female	3	5.3	nc	(nc-nc)	Female	33	28.6	115.5	(79.5-162.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	4.3	116.6	(37.6-272.0)	Male	252	211.4	119.2	(104.9-134.9)
Female	8	3.7	215.3	(92.7-424.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	16.2	92.6	(51.8-152.7)
Male	28	34.4	81.5	(54.1-117.7)	Female	8	11.1	72.2	(31.1-142.2)
Female	19	21.6	87.9	(52.9-137.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	7.1	168.9	(87.2-295.1)
Male	16	10.0	160.7	(91.8-260.9)	<b><u>Thyroid</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	15	14.3	105.0	(58.7-173.1)
<b><u>Leukemia</u></b>					Female	43	43.5	98.9	(71.6-133.2)
Male	32	27.1	118.1	(80.8-166.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	21.4	131.0	(87.0-189.3)	Female	55	57.9	95.0	(71.6-123.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	23	21.8	105.4	(66.8-158.2)	Male	945	868.6	108.8	(102.0-116.0)
Female	9	8.2	110.3	(50.3-209.5)	Female	1031	938.7	109.8	(103.2-116.8)
<b><u>Lung and Bronchus</u></b>									
Male	122	124.3	98.1	(81.5-117.2)					
Female	161	136.5	117.9	(100.4-137.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	12	25.8	46.4	(24.0-81.1)
Female	0	0.2	nc	(nc-nc)	Female	10	25.3	39.6	(18.9-72.8)
<b><u>Lung and Bronchus</u></b>									
Male	0	3.5	nc	(nc-nc)					
Female	0	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	16.2	129.5	(80.1-197.9)	Male	12	11.1	108.1	(55.8-188.8)
Female	8	5.4	148.6	(64.0-292.8)	Female	13	9.0	143.7	(76.5-245.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	13	9.9	130.7	(69.5-223.6)
Female	89	72.8	122.2	(98.1-150.3)	Female	8	8.3	96.9	(41.7-190.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	11	8.5	129.6	(64.6-232.0)
<b><u>Colon / Rectum</u></b>					Female	2	3.6	nc	(nc-nc)
Male	26	18.6	140.1	(91.5-205.3)	<b><u>Ovary</u></b>				
Female	24	16.9	141.9	(90.9-211.1)	Female	4	6.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.6	109.7	(35.4-256.1)	Male	4	5.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	68	59.4	114.6	(89.0-145.2)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.0	126.5	(40.8-295.1)
Male	13	9.9	131.8	(70.1-225.3)	Female	1	2.1	nc	(nc-nc)
Female	7	5.4	129.4	(51.9-266.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	6	4.7	126.8	(46.3-276.0)
<b><u>Leukemia</u></b>					Female	20	14.7	136.1	(83.1-210.2)
Male	9	6.9	130.0	(59.3-246.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.8	125.7	(45.9-273.7)	Female	17	16.6	102.4	(59.6-163.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	260	226.8	114.6	(101.1-129.4)
Female	1	1.9	nc	(nc-nc)	Female	276	231.1	119.4	(105.7-134.4)
<b><u>Lung and Bronchus</u></b>									
Male	36	29.7	121.2	(84.9-167.9)					
Female	47	29.9	157.1	(115.4-208.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	10.5	47.4	(15.3-110.7)	Male	8	7.5	107.1	(46.1-211.0)
Female	3	3.4	nc	(nc-nc)	Female	3	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.7	103.7	(41.5-213.7)
Female	52	47.6	109.2	(81.5-143.2)	Female	5	5.2	95.5	(30.8-222.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.3	nc	(nc-nc)
Male	11	12.5	87.9	(43.8-157.4)	<b><u>Ovary</u></b>				
Female	16	10.5	152.7	(87.2-248.0)	Female	2	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	5	4.0	125.1	(40.3-291.9)
Female	0	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	31	43.6	71.1	(48.3-100.9)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.6	nc	(nc-nc)
Male	5	6.9	72.1	(23.2-168.1)	Female	0	1.3	nc	(nc-nc)
Female	5	3.5	142.6	(45.9-332.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	7	3.4	208.3	(83.4-429.1)
<b><u>Leukemia</u></b>					Female	7	9.4	74.7	(29.9-153.9)
Male	5	4.6	109.8	(35.4-256.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.9	nc	(nc-nc)	Female	15	11.1	135.2	(75.6-223.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	141	156.8	89.9	(75.7-106.1)
Female	0	1.2	nc	(nc-nc)	Female	156	148.6	105.0	(89.1-122.8)
<b><u>Lung and Bronchus</u></b>									
Male	22	19.7	111.5	(69.8-168.8)					
Female	19	19.5	97.5	(58.7-152.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	11	10.2	108.2	(53.9-193.6)
Female	0	0.1	nc	(nc-nc)	Female	3	9.7	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.2	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	6	7.1	84.3	(30.8-183.6)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	13	21.0	61.9	(32.9-105.9)
Female	1	0.2	nc	(nc-nc)	Female	14	25.2	55.5	(30.3-93.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	2.8	nc	(nc-nc)					
Female	0	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	6.8	73.3	(23.6-171.0)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	6.3	95.9	(35.0-208.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	17	23.3	73.0	(42.5-116.9)
Female	0	0.2	nc	(nc-nc)	Female	19	21.0	90.6	(54.5-141.5)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.9	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	54.6	113.5	(87.0-145.5)	Male	31	33.8	91.8	(62.3-130.3)
Female	26	22.3	116.8	(76.3-171.1)	Female	28	28.6	97.9	(65.0-141.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	9.6	145.4	(79.4-244.0)	Male	9	10.7	83.8	(38.2-159.0)
Female	7	8.8	79.5	(31.9-163.8)	Female	3	9.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	34	30.1	112.8	(78.1-157.6)
Female	201	222.6	90.3	(78.2-103.7)	Female	31	29.8	104.1	(70.7-147.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	7.0	128.1	(58.5-243.2)	Male	33	23.7	139.1	(95.7-195.3)
<b><u>Colon / Rectum</u></b>					Female	10	12.4	80.9	(38.7-148.7)
Male	55	57.3	96.1	(72.4-125.0)	<b><u>Ovary</u></b>				
Female	79	66.0	119.8	(94.8-149.3)	Female	13	20.2	64.3	(34.2-110.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	26	14.1	184.2	(120.3-270.0)	Male	20	19.0	105.5	(64.4-162.9)
Female	5	4.3	117.5	(37.9-274.2)	Female	13	22.4	58.0	(30.8-99.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	163	178.6	91.3	(77.8-106.4)
Female	2	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	12.6	63.6	(27.4-125.4)
Male	29	28.1	103.0	(69.0-148.0)	Female	9	8.6	105.2	(48.0-199.7)
Female	19	18.2	104.1	(62.7-162.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	6.2	128.1	(55.2-252.4)
Male	8	8.2	98.2	(42.3-193.4)	<b><u>Thyroid</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	15	12.1	123.5	(69.1-203.8)
<b><u>Leukemia</u></b>					Female	32	37.6	85.2	(58.3-120.3)
Male	18	21.0	85.7	(50.7-135.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	17.3	46.1	(19.9-90.9)	Female	52	51.0	101.9	(76.1-133.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	18.1	94.0	(54.7-150.5)	Male	723	694.8	104.1	(96.6-111.9)
Female	6	6.8	88.0	(32.1-191.6)	Female	757	779.5	97.1	(90.3-104.3)
<b><u>Lung and Bronchus</u></b>									
Male	112	96.3	116.3	(95.8-139.9)					
Female	143	114.3	125.1	(105.4-147.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	14.8	81.2	(41.9-141.9)
Female	0	0.1	nc	(nc-nc)	Female	10	12.1	82.4	(39.4-151.5)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.1	nc	(nc-nc)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.1	182.4	(97.0-311.9)	Male	5	5.0	100.2	(32.3-233.7)
Female	2	3.0	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	8	4.5	178.2	(76.7-351.1)
Female	39	34.8	112.0	(79.7-153.2)	Female	3	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.8	nc	(nc-nc)
Male	7	8.3	83.9	(33.6-172.8)	<b><u>Ovary</u></b>				
Female	12	9.4	127.5	(65.8-222.8)	Female	6	3.1	194.0	(70.9-422.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	7	2.6	265.7	(106.4-547.5)
Female	0	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	31	27.3	113.6	(77.2-161.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.8	nc	(nc-nc)
Male	10	4.5	222.5	(106.5-409.1)	Female	1	1.2	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.9	116.3	(50.1-229.1)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	2.5	276.8	(110.9-570.3)	Female	6	7.8	76.9	(28.1-167.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	130	102.5	126.9	(106.0-150.7)
Female	0	1.0	nc	(nc-nc)	Female	134	116.5	115.0	(96.4-136.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	13.0	115.4	(64.5-190.3)					
Female	22	15.6	140.8	(88.2-213.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	71	65.2	108.9	(85.0-137.3)	Male	65	42.6	152.5	(117.7-194.4)
Female	19	22.9	82.8	(49.8-129.3)	Female	61	32.3	188.6	(144.2-242.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	12.7	86.7	(43.2-155.1)	Male	9	13.4	67.1	(30.6-127.3)
Female	10	10.1	98.9	(47.3-181.8)	Female	9	10.5	86.0	(39.2-163.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	49	37.9	129.2	(95.6-170.9)
Female	300	259.9	115.4	(102.7-129.3)	Female	35	32.2	108.8	(75.8-151.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	8.6	57.9	(18.7-135.2)	Male	37	31.5	117.4	(82.6-161.8)
<b><u>Colon / Rectum</u></b>					Female	14	13.8	101.7	(55.6-170.6)
Male	79	70.5	112.0	(88.7-139.6)	<b><u>Ovary</u></b>				
Female	74	68.7	107.6	(84.5-135.1)	Female	31	23.0	134.6	(91.4-191.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	21	18.0	116.8	(72.2-178.5)	Male	26	23.4	111.1	(72.6-162.8)
Female	1	4.5	nc	(nc-nc)	Female	21	23.0	91.2	(56.4-139.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	248	238.6	103.9	(91.4-117.7)
Female	2	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	15.4	64.9	(31.1-119.3)
Male	33	37.3	88.5	(60.9-124.3)	Female	9	8.8	102.0	(46.5-193.6)
Female	19	20.4	93.0	(55.9-145.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	8.8	57.1	(18.4-133.2)
Male	13	10.6	123.1	(65.5-210.5)	<b><u>Thyroid</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	19	16.9	112.6	(67.8-175.8)
<b><u>Leukemia</u></b>					Female	70	46.2	151.6	(118.2-191.5)
Male	37	26.1	141.9	(99.9-195.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	18.5	91.8	(53.4-146.9)	Female	70	60.3	116.0	(90.4-146.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	23.3	115.8	(76.3-168.5)	Male	975	884.6	110.2	(103.4-117.4)
Female	5	7.4	67.9	(21.9-158.4)	Female	978	868.4	112.6	(105.7-119.9)
<b><u>Lung and Bronchus</u></b>									
Male	130	119.5	108.8	(90.9-129.2)					
Female	135	121.9	110.7	(92.8-131.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	11	12.2	90.0	(44.9-161.0)	Female	0	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.6	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.9	100.4	(53.4-171.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.4	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	38	46.1	82.4	(58.3-113.2)
Female	0	0.3	nc	(nc-nc)	Female	43	39.0	110.2	(79.8-148.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	6.2	nc	(nc-nc)					
Female	6	5.4	111.8	(40.8-243.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.3	150.3	(48.4-350.8)	Male	4	2.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	16	14.6	109.9	(62.8-178.5)	Female	2	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	6	2.0	300.5	(109.7-654.1)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	5	4.0	125.2	(40.3-292.1)	<b><u>Ovary</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	5	1.2	403.5	(130.0-941.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	14.4	138.9	(84.8-214.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	5	2.2	224.6	(72.4-524.2)	Female	0	0.4	nc	(nc-nc)
Female	5	1.1	473.1	(152.5-1104.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	2.7	183.3	(59.1-427.7)
Male	2	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	67	50.3	133.3	(103.3-169.3)
Female	0	0.4	nc	(nc-nc)	Female	51	44.7	114.0	(84.9-149.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	6.2	nc	(nc-nc)					
Female	3	5.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	4.9	nc	(nc-nc)	Male	7	3.3	214.1	(85.8-441.1)
Female	4	1.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	19	16.3	116.4	(70.1-181.8)	Female	1	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	6	2.7	223.7	(81.7-486.9)
<b><u>Colon / Rectum</u></b>					Female	2	0.9	nc	(nc-nc)
Male	7	5.7	123.2	(49.3-253.8)	<b><u>Ovary</u></b>				
Female	8	4.7	169.0	(72.7-332.9)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	19.6	71.5	(39.0-119.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.4	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.2	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	79	69.3	113.9	(90.2-142.0)
Female	1	0.5	nc	(nc-nc)	Female	72	56.5	127.4	(99.7-160.5)
<b><u>Lung and Bronchus</u></b>									
Male	12	9.1	132.0	(68.1-230.7)					
Female	14	8.3	168.7	(92.2-283.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	91	97.3	93.5	(75.3-114.8)	Male	51	62.8	81.2	(60.4-106.7)
Female	31	36.7	84.6	(57.5-120.0)	Female	56	52.6	106.5	(80.4-138.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	18	18.8	95.6	(56.6-151.1)	Male	18	19.4	92.6	(54.8-146.3)
Female	14	15.9	88.0	(48.1-147.7)	Female	11	16.4	67.0	(33.4-120.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	49	56.0	87.5	(64.7-115.7)
Female	379	394.1	96.2	(86.7-106.4)	Female	60	50.9	117.9	(89.9-151.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	19	13.9	136.8	(82.3-213.6)	Male	66	43.4	152.1	(117.6-193.5)
<b><u>Colon / Rectum</u></b>					Female	22	21.3	103.4	(64.8-156.6)
Male	145	103.9	139.6	(117.8-164.2)	<b><u>Ovary</u></b>				
Female	108	110.9	97.4	(79.9-117.6)	Female	32	35.6	89.8	(61.4-126.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	28	25.0	112.0	(74.4-161.9)	Male	30	33.7	88.9	(60.0-127.0)
Female	11	7.0	156.1	(77.8-279.3)	Female	36	36.8	97.9	(68.5-135.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	8.2	97.6	(42.0-192.3)	Male	265	309.3	85.7	(75.7-96.7)
Female	8	6.7	118.8	(51.2-234.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	25	22.7	110.0	(71.2-162.5)
Male	47	52.0	90.4	(66.4-120.2)	Female	11	14.3	77.1	(38.4-138.0)
Female	36	31.7	113.6	(79.5-157.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	15	16.5	90.7	(50.7-149.6)
Male	19	14.6	130.1	(78.3-203.2)	<b><u>Thyroid</u></b>				
Female	6	4.8	125.5	(45.8-273.2)	Male	18	24.6	73.0	(43.3-115.4)
<b><u>Leukemia</u></b>					Female	69	76.8	89.9	(69.9-113.8)
Male	23	39.1	58.8	(37.3-88.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	27	29.9	90.4	(59.5-131.5)	Female	89	88.7	100.4	(80.6-123.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	63	32.3	195.0	(149.8-249.4)	Male	1318	1255.8	105.0	(99.4-110.8)
Female	14	11.4	122.5	(66.9-205.6)	Female	1374	1358.0	101.2	(95.9-106.7)
<b><u>Lung and Bronchus</u></b>									
Male	233	171.8	135.6	(118.8-154.2)					
Female	230	191.4	120.2	(105.1-136.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	34.2	102.2	(71.2-142.2)	Male	17	21.9	77.6	(45.2-124.2)
Female	7	12.7	55.1	(22.1-113.5)	Female	16	18.6	86.3	(49.3-140.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	6.5	92.8	(33.9-201.9)	Male	7	6.9	101.3	(40.6-208.7)
Female	4	5.8	nc	(nc-nc)	Female	10	5.8	173.1	(82.9-318.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	15	19.6	76.7	(42.9-126.5)
Female	123	144.6	85.0	(70.7-101.5)	Female	16	18.1	88.4	(50.5-143.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	5.0	138.8	(55.6-285.9)	Male	6	15.3	39.1	(14.3-85.1)
<b><u>Colon / Rectum</u></b>					Female	8	7.7	104.4	(44.9-205.7)
Male	39	36.7	106.3	(75.6-145.4)	<b><u>Ovary</u></b>				
Female	42	39.0	107.6	(77.5-145.4)	Female	11	12.8	86.0	(42.9-153.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.9	67.7	(24.7-147.4)	Male	11	11.8	93.1	(46.4-166.6)
Female	4	2.5	nc	(nc-nc)	Female	8	12.8	62.5	(26.9-123.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	118	109.5	107.8	(89.2-129.1)
Female	0	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	8.0	100.0	(43.1-197.0)
Male	21	18.3	114.6	(70.9-175.2)	Female	7	5.0	139.8	(56.0-288.1)
Female	11	11.3	97.1	(48.4-173.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	4.8	nc	(nc-nc)
Male	6	5.2	115.5	(42.2-251.4)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	9	8.4	107.3	(49.0-203.8)
<b><u>Leukemia</u></b>					Female	33	27.4	120.5	(82.9-169.2)
Male	10	13.6	73.7	(35.3-135.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	10.6	nc	(nc-nc)	Female	29	32.6	88.8	(59.5-127.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	11.6	138.3	(79.0-224.6)	Male	401	441.0	90.9	(82.2-100.3)
Female	3	4.1	nc	(nc-nc)	Female	428	486.2	88.0	(79.9-96.8)
<b><u>Lung and Bronchus</u></b>									
Male	46	60.7	75.8	(55.5-101.1)					
Female	56	66.9	83.7	(63.2-108.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	13.7	116.6	(66.6-189.4)	Male	4	9.1	nc	(nc-nc)
Female	7	5.1	137.7	(55.2-283.8)	Female	9	7.2	124.4	(56.7-236.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.1	111.2	(50.7-211.1)
Female	58	57.0	101.7	(77.2-131.4)	Female	8	7.2	111.6	(48.1-220.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.0	nc	(nc-nc)	Male	5	6.8	73.9	(23.8-172.4)
<b><u>Colon / Rectum</u></b>					Female	2	3.0	nc	(nc-nc)
Male	24	15.3	156.4	(100.2-232.7)	<b><u>Ovary</u></b>				
Female	20	15.3	130.3	(79.6-201.3)	Female	5	5.0	99.2	(32.0-231.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	7	4.9	142.2	(57.0-292.9)
Female	4	1.0	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	49	47.6	103.0	(76.2-136.2)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.3	nc	(nc-nc)
Male	13	7.9	165.5	(88.0-283.0)	Female	4	2.0	nc	(nc-nc)
Female	10	4.5	222.4	(106.5-409.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	1.9	317.1	(115.8-690.3)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.6	165.0	(60.2-359.1)
<b><u>Leukemia</u></b>					Female	24	10.6	226.1	(144.8-336.4)
Male	3	5.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.1	120.6	(38.9-281.4)	Female	14	12.9	108.8	(59.4-182.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	214	185.1	115.6	(100.6-132.2)
Female	1	1.6	nc	(nc-nc)	Female	235	192.1	122.3	(107.2-139.0)
<b><u>Lung and Bronchus</u></b>									
Male	34	24.8	136.9	(94.8-191.3)					
Female	30	27.0	111.1	(74.9-158.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	26.0	138.4	(96.9-191.7)	Male	18	16.9	106.3	(62.9-168.0)
Female	6	10.5	57.3	(20.9-124.7)	Female	13	14.2	91.3	(48.5-156.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.2	96.7	(31.1-225.6)	Male	5	5.3	93.9	(30.3-219.1)
Female	6	4.5	133.7	(48.8-291.0)	Female	4	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	18	15.1	119.2	(70.6-188.4)
Female	135	111.9	120.7	(101.2-142.9)	Female	8	14.3	55.8	(24.0-109.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.7	nc	(nc-nc)	Male	7	12.3	57.1	(22.9-117.6)
<b><u>Colon / Rectum</u></b>					Female	5	6.0	83.0	(26.8-193.8)
Male	28	28.1	99.7	(66.2-144.1)	<b><u>Ovary</u></b>				
Female	22	31.5	69.8	(43.7-105.7)	Female	10	10.0	100.3	(48.0-184.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	7.0	143.4	(68.7-263.8)	Male	7	9.2	75.9	(30.4-156.5)
Female	2	2.0	nc	(nc-nc)	Female	9	10.6	85.1	(38.8-161.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	56	88.3	63.4	(47.9-82.4)
Female	4	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.1	98.0	(35.8-213.3)
Male	13	14.5	89.7	(47.7-153.4)	Female	1	4.1	nc	(nc-nc)
Female	6	8.9	67.5	(24.6-146.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.4	174.6	(63.8-380.0)
Male	4	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	8	6.6	120.7	(52.0-237.8)
<b><u>Leukemia</u></b>					Female	28	20.0	140.2	(93.2-202.7)
Male	11	10.6	103.8	(51.8-185.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.4	130.5	(65.0-233.4)	Female	28	25.1	111.4	(74.0-161.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	9.1	98.8	(45.1-187.5)	Male	311	344.4	90.3	(80.6-100.9)
Female	5	3.3	153.8	(49.6-358.9)	Female	395	382.0	103.4	(93.4-114.1)
<b><u>Lung and Bronchus</u></b>									
Male	42	46.9	89.5	(64.5-121.0)					
Female	47	54.0	87.1	(64.0-115.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.5	80.0	(38.3-147.1)	Male	10	8.4	118.8	(56.9-218.5)
Female	3	3.6	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.6	92.1	(36.9-189.7)
Female	57	47.0	121.3	(91.9-157.2)	Female	7	5.4	130.0	(52.1-267.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	1	6.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	13	14.2	91.4	(48.6-156.3)	<b><u>Ovary</u></b>				
Female	12	10.9	109.7	(56.6-191.6)	Female	2	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	39	49.2	79.3	(56.4-108.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.0	nc	(nc-nc)
Male	8	7.7	104.2	(44.9-205.4)	Female	0	1.4	nc	(nc-nc)
Female	6	3.5	172.0	(62.8-374.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.5	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	9.1	87.8	(37.8-173.0)
Male	4	5.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.0	nc	(nc-nc)	Female	16	11.0	146.0	(83.4-237.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.8	nc	(nc-nc)	Male	139	177.6	78.3	(65.8-92.4)
Female	2	1.2	nc	(nc-nc)	Female	161	149.5	107.7	(91.7-125.7)
<b><u>Lung and Bronchus</u></b>									
Male	26	22.8	114.0	(74.4-167.0)					
Female	19	19.6	96.9	(58.3-151.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	50	47.8	104.6	(77.7-138.0)	Male	23	32.5	70.8	(44.8-106.2)
Female	16	19.7	81.2	(46.4-131.8)	Female	27	28.3	95.5	(62.9-139.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	10.3	106.7	(53.2-190.9)	Male	6	9.8	61.2	(22.3-133.2)
Female	11	8.6	127.9	(63.8-228.8)	Female	11	8.8	125.0	(62.3-223.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	31	29.0	106.9	(72.7-151.8)
Female	208	213.8	97.3	(84.5-111.4)	Female	27	27.5	98.3	(64.7-143.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	7.5	nc	(nc-nc)	Male	22	23.1	95.3	(59.7-144.2)
<b><u>Colon / Rectum</u></b>					Female	16	11.4	139.8	(79.9-227.1)
Male	67	53.3	125.7	(97.4-159.6)	<b><u>Ovary</u></b>				
Female	45	59.8	75.3	(54.9-100.8)	Female	17	19.1	89.0	(51.8-142.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	12.6	87.1	(43.4-155.9)	Male	23	16.9	135.8	(86.1-203.8)
Female	5	3.8	130.9	(42.2-305.6)	Female	17	19.9	85.6	(49.8-137.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	4.7	107.2	(34.5-250.2)	Male	116	158.0	73.4	(60.6-88.0)
Female	4	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	11.5	174.5	(106.6-269.5)
Male	35	27.4	127.6	(88.8-177.4)	Female	8	7.7	103.9	(44.7-204.7)
Female	32	17.1	187.2	(128.0-264.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	9.5	73.9	(29.6-152.3)
Male	10	7.4	134.8	(64.5-247.9)	<b><u>Thyroid</u></b>				
Female	9	2.5	353.9	(161.5-671.9)	Male	11	13.9	79.4	(39.6-142.1)
<b><u>Leukemia</u></b>					Female	44	41.2	106.9	(77.7-143.5)
Male	31	20.3	152.7	(103.7-216.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	16.2	68.0	(33.9-121.7)	Female	35	47.7	73.3	(51.1-102.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	16.9	160.0	(105.4-232.8)	Male	683	642.7	106.3	(98.5-114.6)
Female	6	6.2	96.9	(35.4-210.9)	Female	742	733.0	101.2	(94.1-108.8)
<b><u>Lung and Bronchus</u></b>									
Male	127	85.0	149.4	(124.6-177.8)					
Female	139	103.2	134.7	(113.2-159.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	3.0	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	5	9.4	53.3	(17.2-124.5)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	13	9.6	135.6	(72.1-231.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	27	36.0	75.1	(49.4-109.2)
Female	0	0.3	nc	(nc-nc)	Female	17	32.1	52.9	(30.8-84.7)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.3	nc	(nc-nc)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	6.0	nc	(nc-nc)	Male	5	3.9	127.6	(41.1-297.8)
Female	4	2.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	24	24.0	100.1	(64.1-148.9)	Female	3	3.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	7	6.5	107.9	(43.2-222.4)	<b><u>Ovary</u></b>				
Female	8	6.4	124.5	(53.6-245.4)	Female	2	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	23	22.6	101.9	(64.6-152.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.3	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	78	82.4	94.7	(74.8-118.2)
Female	0	0.7	nc	(nc-nc)	Female	65	80.2	81.1	(62.6-103.3)
<b><u>Lung and Bronchus</u></b>									
Male	13	11.0	117.7	(62.6-201.3)					
Female	3	10.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	17.6	119.0	(73.6-181.9)	Male	15	11.8	127.1	(71.1-209.7)
Female	11	7.2	152.7	(76.1-273.2)	Female	17	10.0	169.3	(98.5-271.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.6	164.9	(60.2-359.0)	Male	3	3.6	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	0	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.5	114.4	(59.1-199.9)
Female	81	79.5	101.9	(81.0-126.7)	Female	16	10.1	158.6	(90.6-257.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	12	8.8	136.1	(70.3-237.8)
<b><u>Colon / Rectum</u></b>					Female	4	4.2	nc	(nc-nc)
Male	25	19.5	128.2	(82.9-189.2)	<b><u>Ovary</u></b>				
Female	25	21.5	116.4	(75.3-171.9)	Female	4	7.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.9	122.6	(44.8-266.9)	Male	8	6.4	125.2	(53.9-246.7)
Female	1	1.4	nc	(nc-nc)	Female	7	7.2	96.8	(38.8-199.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	71	65.3	108.7	(84.9-137.1)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	13	10.3	126.0	(67.0-215.5)	Female	7	2.7	255.3	(102.3-526.1)
Female	16	6.3	252.1	(144.0-409.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.8	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	14.3	154.0	(96.5-233.2)
Male	14	7.2	194.3	(106.1-326.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	5.8	206.5	(106.6-360.7)	Female	24	18.4	130.8	(83.8-194.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.5	76.6	(24.7-178.8)	Male	282	243.6	115.8	(102.6-130.1)
Female	3	2.3	nc	(nc-nc)	Female	328	269.1	121.9	(109.1-135.8)
<b><u>Lung and Bronchus</u></b>									
Male	34	32.4	104.9	(72.6-146.6)					
Female	48	38.5	124.8	(92.0-165.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.4	97.1	(50.1-169.6)	Male	10	7.3	136.7	(65.4-251.4)
Female	2	4.7	nc	(nc-nc)	Female	7	5.5	127.6	(51.1-262.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	45	44.1	102.1	(74.5-136.6)	Female	5	6.1	82.5	(26.6-192.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	6	5.0	120.6	(44.0-262.5)
<b><u>Colon / Rectum</u></b>					Female	6	2.5	240.5	(87.8-523.5)
Male	10	12.3	81.2	(38.9-149.3)	<b><u>Ovary</u></b>				
Female	8	13.8	58.1	(25.0-114.4)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	5	4.8	104.9	(33.8-244.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	40	39.8	100.5	(71.8-136.9)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.8	nc	(nc-nc)
Male	8	6.0	134.4	(57.9-264.9)	Female	2	1.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.4	78.5	(25.3-183.2)
Male	2	4.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.4	nc	(nc-nc)	Female	7	10.2	68.9	(27.6-142.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	139	151.8	91.6	(77.0-108.1)
Female	1	1.4	nc	(nc-nc)	Female	128	156.2	82.0	(68.4-97.5)
<b><u>Lung and Bronchus</u></b>									
Male	17	22.1	77.0	(44.8-123.2)					
Female	7	23.7	29.5	(11.8-60.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	10.7	65.2	(26.1-134.4)
Female	0	0.1	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.5	128.4	(51.4-264.6)	Male	4	3.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	6	3.4	178.9	(65.3-389.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	27	27.2	99.4	(65.5-144.6)	Female	3	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.4	nc	(nc-nc)
Male	6	6.4	93.9	(34.3-204.4)	<b><u>Ovary</u></b>				
Female	6	6.8	88.8	(32.4-193.2)	Female	4	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.7	nc	(nc-nc)	Male	5	2.1	235.2	(75.8-549.0)
Female	0	0.4	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	26	24.4	106.7	(69.7-156.4)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.2	134.9	(54.1-278.0)
Male	3	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.8	nc	(nc-nc)	Female	5	6.2	80.7	(26.0-188.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	78	83.2	93.8	(74.1-117.1)
Female	0	0.7	nc	(nc-nc)	Female	87	86.9	100.1	(80.2-123.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	10.5	66.7	(26.7-137.4)					
Female	5	11.2	44.7	(14.4-104.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	8	5.0	160.7	(69.2-316.7)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	5.1	138.6	(55.5-285.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	18	18.5	97.3	(57.6-153.7)
Female	0	0.1	nc	(nc-nc)	Female	19	15.9	119.5	(71.9-186.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.4	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	9	6.6	136.6	(62.3-259.3)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	1.5	390.9	(142.7-850.8)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	21.0	76.2	(43.5-123.7)
Female	1	0.2	nc	(nc-nc)	Female	28	21.1	132.8	(88.2-192.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.7	nc	(nc-nc)					
Female	3	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.7	104.5	(45.0-205.9)	Male	5	5.3	94.9	(30.6-221.3)
Female	2	2.1	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.7	126.4	(46.1-275.0)
Female	37	28.8	128.4	(90.4-177.0)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	10	8.7	114.4	(54.8-210.4)	<b><u>Ovary</u></b>				
Female	5	6.7	75.0	(24.2-175.1)	Female	1	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	23	28.9	79.5	(50.4-119.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.9	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	6.0	nc	(nc-nc)
Male	6	3.3	180.7	(66.0-393.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	9	6.4	139.7	(63.7-265.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	93	108.3	85.8	(69.3-105.2)
Female	0	0.7	nc	(nc-nc)	Female	82	90.9	90.2	(71.8-112.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.1	78.2	(39.0-139.9)					
Female	10	11.6	86.5	(41.4-159.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salem

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	34.8	112.0	(79.6-153.1)	Male	25	23.4	106.6	(69.0-157.4)
Female	10	15.9	62.9	(30.1-115.7)	Female	26	23.5	110.7	(72.3-162.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	7.5	159.8	(82.5-279.1)	Male	4	7.2	nc	(nc-nc)
Female	5	7.2	69.2	(22.3-161.4)	Female	12	7.2	166.6	(86.0-291.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	36	21.2	170.2	(119.2-235.6)
Female	188	177.2	106.1	(91.4-122.4)	Female	25	22.5	111.2	(71.9-164.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	6.2	nc	(nc-nc)	Male	17	17.2	98.6	(57.4-157.9)
<b><u>Colon / Rectum</u></b>					Female	12	9.5	125.9	(65.0-220.0)
Male	42	39.3	106.8	(77.0-144.4)	<b><u>Ovary</u></b>				
Female	40	48.4	82.7	(59.0-112.6)	Female	10	16.0	62.3	(29.8-114.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	9.4	191.8	(113.6-303.2)	Male	11	12.5	88.2	(44.0-157.8)
Female	4	3.1	nc	(nc-nc)	Female	17	16.0	106.2	(61.8-170.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	151	120.4	125.4	(106.2-147.1)
Female	7	3.2	215.6	(86.4-444.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	8.4	155.4	(82.7-265.7)
Male	23	20.2	114.1	(72.3-171.3)	Female	3	6.2	nc	(nc-nc)
Female	17	14.0	121.5	(70.7-194.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.8	88.5	(32.3-192.7)
Male	5	5.5	90.8	(29.3-212.0)	<b><u>Thyroid</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	11	10.0	110.2	(54.9-197.1)
<b><u>Leukemia</u></b>					Female	37	34.7	106.5	(75.0-146.8)
Male	16	14.8	108.2	(61.8-175.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	13.2	121.0	(69.1-196.5)	Female	45	40.8	110.4	(80.5-147.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	12.6	126.5	(72.3-205.5)	Male	571	475.0	120.2	(110.6-130.5)
Female	5	5.1	97.8	(31.5-228.2)	Female	624	603.2	103.5	(95.5-111.9)
<b><u>Lung and Bronchus</u></b>									
Male	73	62.1	117.6	(92.2-147.8)					
Female	90	82.5	109.0	(87.7-134.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.5	85.4	(39.0-162.1)	Male	10	6.9	145.2	(69.5-267.0)
Female	4	3.4	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.1	81.6	(26.3-190.4)
Female	42	41.0	102.5	(73.9-138.6)	Female	9	4.8	186.6	(85.1-354.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	12	5.3	227.7	(117.5-397.8)
<b><u>Colon / Rectum</u></b>					Female	2	2.1	nc	(nc-nc)
Male	14	11.5	121.9	(66.6-204.5)	<b><u>Ovary</u></b>				
Female	14	10.0	139.8	(76.4-234.6)	Female	9	3.6	252.5	(115.2-479.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	5	3.4	148.0	(47.7-345.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	33	40.5	81.5	(56.1-114.5)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.5	nc	(nc-nc)
Male	8	6.1	130.7	(56.3-257.5)	Female	0	1.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.2	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.7	nc	(nc-nc)	Female	8	9.7	82.8	(35.7-163.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	130	145.3	89.5	(74.7-106.2)
Female	1	1.1	nc	(nc-nc)	Female	151	133.1	113.4	(96.0-133.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	19.6	86.7	(50.5-138.9)					
Female	27	18.7	144.1	(95.0-209.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	13	22.2	58.5	(31.1-100.1)
Female	1	0.1	nc	(nc-nc)	Female	10	13.6	73.8	(35.3-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.3	nc	(nc-nc)					
Female	3	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	22.9	153.0	(106.5-212.7)	Male	23	14.9	154.4	(97.8-231.6)
Female	6	7.6	79.3	(29.0-172.6)	Female	17	11.3	150.3	(87.5-240.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	4.5	201.4	(91.9-382.4)	Male	4	4.7	nc	(nc-nc)
Female	4	3.6	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	18	13.4	134.7	(79.8-213.0)
Female	111	91.9	120.8	(99.4-145.5)	Female	18	11.0	163.3	(96.8-258.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.1	nc	(nc-nc)	Male	11	11.3	97.4	(48.5-174.2)
<b><u>Colon / Rectum</u></b>					Female	8	4.8	167.8	(72.2-330.6)
Male	17	25.2	67.6	(39.3-108.2)	<b><u>Ovary</u></b>				
Female	25	23.0	108.6	(70.3-160.4)	Female	8	8.1	98.9	(42.6-195.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.3	94.9	(34.7-206.5)	Male	12	8.2	145.7	(75.2-254.5)
Female	2	1.5	nc	(nc-nc)	Female	9	7.5	119.5	(54.5-226.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	107	81.8	130.8	(107.2-158.1)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.4	nc	(nc-nc)
Male	11	13.1	84.2	(42.0-150.6)	Female	4	2.9	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	16.8	59.5	(28.5-109.5)
Male	16	9.2	173.2	(98.9-281.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.3	79.4	(25.6-185.3)	Female	26	21.4	121.3	(79.2-177.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.4	95.3	(41.1-187.9)	Male	354	308.9	114.6	(103.0-127.2)
Female	1	2.5	nc	(nc-nc)	Female	331	300.5	110.1	(98.6-122.7)
<b><u>Lung and Bronchus</u></b>									
Male	26	41.5	62.7	(40.9-91.8)					
Female	49	41.3	118.8	(87.9-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	34.1	137.9	(101.3-183.4)	Male	14	21.6	64.8	(35.4-108.8)
Female	23	13.2	174.0	(110.3-261.1)	Female	22	17.7	124.3	(77.9-188.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	6.0	nc	(nc-nc)	Male	6	6.9	87.5	(32.0-190.5)
Female	9	5.5	164.8	(75.2-312.8)	Female	3	6.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	24	19.0	126.2	(80.8-187.8)
Female	144	141.3	101.9	(86.0-120.0)	Female	24	18.1	132.3	(84.7-196.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.5	nc	(nc-nc)	Male	20	15.0	133.0	(81.2-205.4)
<b><u>Colon / Rectum</u></b>					Female	4	7.7	nc	(nc-nc)
Male	48	35.6	135.0	(99.5-178.9)	<b><u>Ovary</u></b>				
Female	33	38.9	84.7	(58.3-119.0)	Female	7	12.7	55.3	(22.1-113.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	8.8	147.1	(78.2-251.6)	Male	15	11.8	127.4	(71.3-210.2)
Female	4	2.6	nc	(nc-nc)	Female	14	13.2	105.8	(57.8-177.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	86	109.3	78.7	(63.0-97.2)
Female	4	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.9	101.1	(43.5-199.1)
Male	25	17.9	139.4	(90.2-205.7)	Female	2	5.0	nc	(nc-nc)
Female	8	11.4	70.1	(30.2-138.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	3.9	253.7	(121.5-466.7)
Male	7	5.2	134.0	(53.7-276.1)	<b><u>Thyroid</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	9	7.9	114.1	(52.1-216.6)
<b><u>Leukemia</u></b>					Female	19	23.9	79.6	(47.9-124.3)
Male	20	13.0	153.9	(94.0-237.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	10.3	nc	(nc-nc)	Female	26	33.3	78.1	(51.0-114.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	11.4	139.9	(79.9-227.2)	Male	478	434.6	110.0	(100.4-120.3)
Female	4	4.2	nc	(nc-nc)	Female	494	482.4	102.4	(93.6-111.8)
<b><u>Lung and Bronchus</u></b>									
Male	70	61.4	114.0	(88.8-144.0)					
Female	90	70.7	127.2	(102.3-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	13.9	50.2	(20.1-103.5)
Female	0	0.1	nc	(nc-nc)	Female	7	9.8	71.7	(28.7-147.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	22.9	96.1	(60.2-145.5)	Male	36	14.4	250.7	(175.5-347.1)
Female	12	8.4	143.3	(73.9-250.3)	Female	29	11.1	261.2	(174.9-375.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.1	145.9	(53.3-317.6)	Male	5	4.6	109.0	(35.1-254.4)
Female	2	3.5	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	10	12.8	78.2	(37.4-143.8)
Female	99	90.8	109.0	(88.6-132.7)	Female	10	11.5	86.8	(41.5-159.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	13	10.4	125.4	(66.7-214.5)
<b><u>Colon / Rectum</u></b>					Female	7	4.9	142.8	(57.2-294.3)
Male	24	24.4	98.5	(63.1-146.5)	<b><u>Ovary</u></b>				
Female	19	25.2	75.5	(45.4-117.8)	Female	7	8.1	86.9	(34.8-179.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.0	83.1	(26.8-193.9)	Male	8	8.0	100.1	(43.1-197.2)
Female	0	1.6	nc	(nc-nc)	Female	7	8.4	83.6	(33.5-172.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	67	74.9	89.5	(69.3-113.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.3	94.0	(30.3-219.5)
Male	4	12.1	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	6	7.2	83.5	(30.5-181.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	1	5.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	18	15.0	120.2	(71.2-190.0)
Male	10	8.9	112.4	(53.8-206.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.6	106.1	(42.5-218.6)	Female	20	20.9	95.5	(58.3-147.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	288	293.6	98.1	(87.1-110.1)
Female	2	2.7	nc	(nc-nc)	Female	318	306.6	103.7	(92.6-115.8)
<b><u>Lung and Bronchus</u></b>									
Male	36	40.7	88.5	(62.0-122.6)					
Female	42	43.8	95.9	(69.1-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	17.2	81.2	(44.4-136.3)	Male	6	11.1	53.9	(19.7-117.3)
Female	2	5.4	nc	(nc-nc)	Female	8	7.9	101.5	(43.7-200.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.8	142.8	(78.0-239.6)
Female	48	63.3	75.8	(55.9-100.5)	Female	5	7.7	64.5	(20.8-150.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	5	8.0	62.3	(20.1-145.4)
<b><u>Colon / Rectum</u></b>					Female	5	3.3	150.0	(48.3-350.0)
Male	13	18.2	71.6	(38.1-122.4)	<b><u>Ovary</u></b>				
Female	10	16.0	62.3	(29.8-114.6)	Female	7	5.6	125.9	(50.4-259.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	4.7	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	9	5.4	166.2	(75.9-315.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	40	60.0	66.7	(47.6-90.8)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.0	nc	(nc-nc)
Male	6	9.6	62.7	(22.9-136.5)	Female	1	2.0	nc	(nc-nc)
Female	0	4.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.9	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.4	96.5	(48.1-172.7)
Male	6	6.7	89.2	(32.6-194.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	4.4	nc	(nc-nc)	Female	11	14.8	74.3	(37.0-133.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	156	228.1	68.4	(58.1-80.0)
Female	0	1.8	nc	(nc-nc)	Female	158	210.1	75.2	(63.9-87.9)
<b><u>Lung and Bronchus</u></b>									
Male	20	32.1	62.2	(38.0-96.1)					
Female	25	30.1	83.1	(53.8-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.9	66.9	(34.5-116.8)	Male	11	12.1	90.7	(45.2-162.4)
Female	7	6.0	116.3	(46.6-239.6)	Female	18	9.5	189.3	(112.1-299.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	7	3.9	181.5	(72.7-373.9)
Female	1	3.0	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	15	10.8	138.4	(77.4-228.3)
Female	86	77.3	111.2	(88.9-137.3)	Female	8	8.9	89.5	(38.6-176.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	6	9.6	62.2	(22.7-135.5)
<b><u>Colon / Rectum</u></b>					Female	1	3.9	nc	(nc-nc)
Male	13	20.5	63.6	(33.8-108.7)	<b><u>Ovary</u></b>				
Female	9	18.8	47.8	(21.8-90.8)	Female	8	6.7	119.6	(51.5-235.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	9	6.7	134.7	(61.5-255.7)
Female	2	1.2	nc	(nc-nc)	Female	8	6.1	132.0	(56.8-260.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	68	71.0	95.7	(74.3-121.3)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	6	11.1	54.2	(19.8-117.9)	Female	2	2.4	nc	(nc-nc)
Female	8	5.8	137.2	(59.1-270.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.0	246.9	(79.6-576.3)
Male	1	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	5.0	159.9	(68.8-315.0)
<b><u>Leukemia</u></b>					Female	26	14.7	177.0	(115.6-259.4)
Male	7	7.3	95.3	(38.2-196.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.2	96.2	(31.0-224.5)	Female	16	17.7	90.2	(51.5-146.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	7.1	nc	(nc-nc)	Male	220	255.4	86.1	(75.1-98.3)
Female	1	2.0	nc	(nc-nc)	Female	261	248.3	105.1	(92.8-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	18	33.5	53.7	(31.8-84.8)					
Female	35	32.7	107.0	(74.5-148.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.8	125.0	(45.7-272.2)	Male	3	3.0	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	16	16.4	97.6	(55.7-158.5)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.8	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	20	16.5	121.2	(74.0-187.2)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	5	4.0	125.4	(40.4-292.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	56	62.2	90.0	(68.0-116.9)
Female	1	0.5	nc	(nc-nc)	Female	59	53.4	110.5	(84.2-142.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	8.5	58.5	(18.9-136.6)					
Female	15	7.7	195.2	(109.2-322.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	9	11.0	82.1	(37.5-155.9)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	14	10.2	137.6	(75.2-230.9)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	6	2.6	229.3	(83.7-499.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	40	36.6	109.2	(78.0-148.7)
Female	0	0.3	nc	(nc-nc)	Female	44	37.3	118.1	(85.8-158.6)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.0	nc	(nc-nc)					
Female	5	5.5	91.6	(29.5-213.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.1	156.7	(67.5-308.8)	Male	5	3.2	156.0	(50.3-364.2)
Female	1	1.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	24	19.4	123.6	(79.1-183.8)	Female	4	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	8	5.5	144.7	(62.3-285.1)	<b><u>Ovary</u></b>				
Female	3	4.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	19	16.7	113.8	(68.5-177.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.4	147.1	(47.4-343.3)
Male	4	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	66	65.7	100.4	(77.7-127.7)
Female	0	0.5	nc	(nc-nc)	Female	63	62.4	100.9	(77.6-129.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	9.0	55.5	(17.9-129.6)					
Female	6	8.7	69.0	(25.2-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	6.0	201.4	(103.9-351.8)	Male	3	4.8	nc	(nc-nc)
Female	6	1.9	314.3	(114.8-684.0)	Female	1	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.3	186.7	(80.4-367.9)
Female	28	23.3	119.9	(79.7-173.3)	Female	2	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.2	nc	(nc-nc)
Male	10	7.7	129.3	(61.9-237.8)	<b><u>Ovary</u></b>				
Female	8	5.8	136.9	(58.9-269.7)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	27	24.0	112.3	(74.0-163.4)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	6	4.4	136.6	(49.9-297.3)	Female	1	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.6	109.4	(35.2-255.3)
Male	2	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	12	5.3	227.4	(117.4-397.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	2.7	300.5	(129.4-592.1)	Male	120	93.8	127.9	(106.0-152.9)
Female	0	0.6	nc	(nc-nc)	Female	94	76.5	122.9	(99.3-150.5)
<b><u>Lung and Bronchus</u></b>									
Male	22	11.2	196.9	(123.4-298.2)					
Female	11	10.3	106.4	(53.0-190.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	34.5	112.9	(80.3-154.4)	Male	17	22.6	75.2	(43.8-120.5)
Female	14	12.5	111.7	(61.0-187.5)	Female	20	18.4	108.9	(66.5-168.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.0	99.4	(39.8-204.8)	Male	11	7.0	157.2	(78.4-281.3)
Female	2	5.8	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	29	20.5	141.5	(94.8-203.2)
Female	151	142.0	106.3	(90.0-124.7)	Female	15	17.7	84.6	(47.3-139.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.0	nc	(nc-nc)	Male	12	16.4	73.1	(37.7-127.6)
<b><u>Colon / Rectum</u></b>					Female	5	7.5	67.1	(21.6-156.5)
Male	35	38.3	91.3	(63.6-126.9)	<b><u>Ovary</u></b>				
Female	27	38.7	69.9	(46.0-101.6)	Female	13	12.5	104.0	(55.3-177.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	9.1	131.6	(67.9-229.9)	Male	9	12.2	73.7	(33.6-140.0)
Female	5	2.4	206.1	(66.4-481.0)	Female	11	12.6	87.2	(43.5-156.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	124	115.1	107.7	(89.6-128.4)
Female	4	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	8.2	nc	(nc-nc)
Male	28	19.5	143.9	(95.6-208.0)	Female	2	5.0	nc	(nc-nc)
Female	11	11.2	98.6	(49.2-176.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.3	113.7	(41.5-247.5)
Male	0	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	15	9.2	162.6	(90.9-268.2)
<b><u>Leukemia</u></b>					Female	14	27.6	50.8	(27.7-85.2)
Male	11	14.4	76.6	(38.2-137.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	10.6	142.0	(79.4-234.2)	Female	27	31.1	86.8	(57.2-126.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	11.8	92.8	(46.3-166.1)	Male	483	457.9	105.5	(96.3-115.3)
Female	3	4.0	nc	(nc-nc)	Female	445	478.4	93.0	(84.6-102.1)
<b><u>Lung and Bronchus</u></b>									
Male	59	60.7	97.2	(74.0-125.4)					
Female	64	66.0	97.0	(74.7-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	8.9	90.0	(38.7-177.3)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	12	25.2	47.7	(24.6-83.3)
Female	0	0.2	nc	(nc-nc)	Female	18	28.0	64.4	(38.1-101.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.1	nc	(nc-nc)					
Female	1	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	24.4	102.4	(66.2-151.1)	Male	11	15.1	72.9	(36.4-130.5)
Female	13	10.1	128.7	(68.5-220.2)	Female	8	12.1	66.1	(28.4-130.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	118.3	(38.1-276.0)	Male	1	4.7	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	5	4.4	114.6	(36.9-267.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	13	13.4	97.1	(51.7-166.1)
Female	88	95.8	91.8	(73.7-113.2)	Female	14	13.1	107.0	(58.5-179.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	6	10.5	57.4	(21.0-125.0)
<b><u>Colon / Rectum</u></b>					Female	7	5.3	131.0	(52.5-270.0)
Male	23	25.5	90.1	(57.1-135.2)	<b><u>Ovary</u></b>				
Female	30	29.6	101.3	(68.3-144.6)	Female	8	8.6	92.8	(39.9-182.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	6.2	112.6	(45.1-231.9)	Male	10	8.4	118.4	(56.7-217.8)
Female	0	1.9	nc	(nc-nc)	Female	15	10.2	147.1	(82.3-242.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	81	77.8	104.1	(82.7-129.4)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	5.6	196.7	(98.1-352.0)
Male	16	12.5	128.2	(73.2-208.2)	Female	4	3.9	nc	(nc-nc)
Female	7	8.0	87.7	(35.1-180.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.6	229.3	(83.7-499.2)
Male	4	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	15.0	126.6	(76.2-197.7)
Male	12	9.3	128.5	(66.3-224.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.6	131.5	(62.9-241.8)	Female	19	21.4	88.9	(53.5-138.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.8	76.8	(28.0-167.1)	Male	325	307.0	105.8	(94.7-118.0)
Female	0	3.0	nc	(nc-nc)	Female	320	339.8	94.2	(84.1-105.1)
<b><u>Lung and Bronchus</u></b>									
Male	54	43.3	124.7	(93.6-162.7)					
Female	40	51.6	77.6	(55.4-105.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	49.9	76.2	(53.9-104.6)	Male	30	35.8	83.9	(56.6-119.8)
Female	19	19.7	96.3	(58.0-150.5)	Female	20	34.6	57.8	(35.3-89.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	12.5	64.1	(27.6-126.3)	Male	11	10.2	107.7	(53.7-192.7)
Female	13	10.5	124.4	(66.2-212.7)	Female	11	8.9	123.0	(61.3-220.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	40	31.9	125.2	(89.5-170.5)
Female	176	227.3	77.4	(66.4-89.8)	Female	21	29.4	71.5	(44.2-109.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	10.1	99.3	(47.5-182.7)	Male	25	24.0	104.3	(67.5-154.0)
<b><u>Colon / Rectum</u></b>					Female	11	12.0	91.7	(45.7-164.0)
Male	52	56.1	92.6	(69.2-121.5)	<b><u>Ovary</u></b>				
Female	48	61.4	78.2	(57.7-103.7)	Female	23	20.7	110.9	(70.3-166.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	12.9	85.6	(42.6-153.1)	Male	19	17.3	109.7	(66.0-171.3)
Female	5	3.8	130.7	(42.1-304.9)	Female	21	19.8	106.1	(65.6-162.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	7.5	146.9	(73.3-262.9)	Male	144	157.2	91.6	(77.2-107.8)
Female	4	6.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	12.0	125.1	(70.0-206.3)
Male	36	29.1	123.8	(86.7-171.3)	Female	14	7.9	178.0	(97.3-298.7)
Female	24	18.3	131.5	(84.2-195.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	17.5	40.1	(16.1-82.6)
Male	11	7.6	145.6	(72.6-260.5)	<b><u>Thyroid</u></b>				
Female	2	2.5	nc	(nc-nc)	Male	14	17.0	82.2	(44.9-137.9)
<b><u>Leukemia</u></b>					Female	50	58.7	85.1	(63.2-112.3)
Male	16	22.7	70.5	(40.3-114.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	18.1	110.2	(67.3-170.2)	Female	48	49.4	97.2	(71.7-128.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	26	17.1	152.4	(99.5-223.3)	Male	669	683.0	97.9	(90.7-105.7)
Female	16	6.3	252.3	(144.1-409.8)	Female	723	792.0	91.3	(84.8-98.2)
<b><u>Lung and Bronchus</u></b>									
Male	105	87.5	120.0	(98.1-145.2)					
Female	100	103.8	96.3	(78.4-117.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	21.0	90.6	(54.5-141.4)	Male	18	12.8	140.6	(83.3-222.2)
Female	11	8.2	134.0	(66.8-239.7)	Female	10	11.1	90.4	(43.3-166.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.4	78.8	(36.0-149.6)
Female	96	85.3	112.5	(91.1-137.4)	Female	11	11.1	98.9	(49.3-177.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.7	183.7	(59.2-428.7)	Male	6	8.9	67.7	(24.7-147.4)
<b><u>Colon / Rectum</u></b>					Female	6	4.6	129.6	(47.3-282.2)
Male	21	22.0	95.6	(59.2-146.2)	<b><u>Ovary</u></b>				
Female	32	24.0	133.1	(91.0-187.9)	Female	3	7.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.3	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	8	8.2	97.9	(42.2-192.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	62	64.7	95.8	(73.4-122.8)
Female	0	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.8	104.0	(33.5-242.8)
Male	7	10.5	66.5	(26.6-137.0)	Female	2	3.1	nc	(nc-nc)
Female	8	7.0	114.8	(49.4-226.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	6	3.0	197.2	(72.0-429.2)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	15.4	71.4	(35.6-127.7)
Male	5	7.9	63.7	(20.5-148.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.6	121.7	(52.4-239.8)	Female	26	19.5	133.2	(87.0-195.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.7	nc	(nc-nc)	Male	239	259.9	92.0	(80.7-104.4)
Female	0	2.5	nc	(nc-nc)	Female	304	295.9	102.7	(91.5-114.9)
<b><u>Lung and Bronchus</u></b>									
Male	37	36.6	101.2	(71.3-139.5)					
Female	40	43.2	92.5	(66.1-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.7	74.2	(23.9-173.0)	Male	1	4.4	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	20	26.1	76.6	(46.8-118.4)	Female	2	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	7	7.2	97.7	(39.1-201.3)	<b><u>Ovary</u></b>				
Female	9	6.2	145.2	(66.3-275.6)	Female	2	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	25	23.7	105.6	(68.3-155.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.9	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	6	6.1	98.6	(36.0-214.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	74	90.3	81.9	(64.3-102.8)
Female	0	0.7	nc	(nc-nc)	Female	72	84.6	85.1	(66.6-107.2)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.2	41.0	(13.2-95.8)					
Female	13	11.9	109.5	(58.2-187.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.3	78.0	(33.6-153.8)	Male	8	6.8	118.4	(51.0-233.3)
Female	2	3.2	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	45	40.3	111.7	(81.5-149.5)	Female	4	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	6	5.1	116.6	(42.6-253.7)
<b><u>Colon / Rectum</u></b>					Female	2	2.0	nc	(nc-nc)
Male	6	11.6	51.8	(18.9-112.8)	<b><u>Ovary</u></b>				
Female	12	10.0	120.2	(62.0-209.9)	Female	1	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	3.1	159.3	(51.3-371.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	37	35.7	103.7	(73.0-142.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	8	5.9	135.5	(58.3-267.0)	Female	1	1.3	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.7	181.9	(58.6-424.6)
<b><u>Leukemia</u></b>					Female	6	7.8	77.0	(28.1-167.5)
Male	5	4.2	119.1	(38.4-278.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.8	nc	(nc-nc)	Female	5	8.9	55.9	(18.0-130.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	129	138.3	93.3	(77.9-110.8)
Female	0	1.0	nc	(nc-nc)	Female	117	129.7	90.2	(74.6-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	13	18.2	71.5	(38.1-122.3)					
Female	18	17.1	105.2	(62.3-166.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	16.1	111.9	(66.3-176.9)	Male	6	10.4	57.4	(21.0-125.0)
Female	10	6.6	152.3	(72.9-280.0)	Female	4	9.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.4	106.9	(51.2-196.6)
Female	59	69.7	84.7	(64.5-109.2)	Female	13	9.1	143.5	(76.3-245.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	10	7.5	134.2	(64.3-246.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.8	nc	(nc-nc)
Male	16	17.5	91.7	(52.4-148.9)	<b><u>Ovary</u></b>				
Female	21	20.0	104.9	(64.9-160.4)	Female	7	6.3	111.5	(44.7-229.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.2	nc	(nc-nc)	Male	7	5.6	124.1	(49.7-255.7)
Female	1	1.3	nc	(nc-nc)	Female	2	6.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	50	52.1	95.9	(71.2-126.5)
Female	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	3.8	158.2	(57.8-344.4)
Male	7	8.8	79.9	(32.0-164.7)	Female	5	2.6	191.1	(61.6-446.0)
Female	10	5.6	180.0	(86.2-331.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	8	2.5	326.3	(140.5-642.9)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	13.1	76.2	(36.5-140.1)
Male	8	6.7	120.1	(51.7-236.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	5.5	201.1	(100.3-359.9)	Female	20	15.7	127.6	(77.9-197.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.6	125.4	(50.2-258.4)	Male	233	210.3	110.8	(97.0-126.0)
Female	0	2.0	nc	(nc-nc)	Female	233	240.4	96.9	(84.9-110.2)
<b><u>Lung and Bronchus</u></b>									
Male	43	28.5	150.8	(109.1-203.1)					
Female	28	33.0	84.8	(56.3-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.0	99.8	(49.7-178.5)	Male	5	7.0	71.2	(22.9-166.2)
Female	2	4.1	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	40	42.5	94.0	(67.2-128.0)	Female	6	5.6	107.8	(39.4-234.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.3	nc	(nc-nc)
Male	8	11.9	67.4	(29.0-132.8)	<b><u>Ovary</u></b>				
Female	11	12.4	88.8	(44.3-158.9)	Female	4	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	32	35.2	91.0	(62.2-128.4)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	7	5.9	118.5	(47.5-244.2)	Female	2	1.6	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.6	65.7	(21.2-153.3)
Male	2	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.2	186.2	(68.0-405.3)	Female	8	9.4	85.4	(36.8-168.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	117	141.7	82.6	(68.3-99.0)
Female	1	1.3	nc	(nc-nc)	Female	121	146.4	82.6	(68.6-98.7)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.3	98.4	(59.2-153.6)					
Female	16	20.7	77.1	(44.0-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	11.2	178.3	(108.9-275.4)	Male	10	7.7	129.8	(62.1-238.7)
Female	11	4.2	263.0	(131.1-470.5)	Female	4	6.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	46	47.5	96.9	(71.0-129.3)	Female	6	5.9	101.6	(37.1-221.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	10	5.8	171.5	(82.1-315.5)
<b><u>Colon / Rectum</u></b>					Female	3	2.5	nc	(nc-nc)
Male	10	12.4	80.8	(38.7-148.6)	<b><u>Ovary</u></b>				
Female	11	12.5	87.9	(43.8-157.2)	Female	1	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.2	155.4	(50.1-362.7)	Male	5	4.1	122.6	(39.5-286.0)
Female	1	0.8	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	32	42.4	75.5	(51.6-106.6)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	10	6.9	145.9	(69.8-268.3)	Female	2	1.6	nc	(nc-nc)
Female	8	3.7	215.4	(92.8-424.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	9.0	66.7	(24.4-145.2)
Male	15	4.7	316.8	(177.2-522.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.5	141.4	(45.6-330.0)	Female	18	10.8	167.2	(99.0-264.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.3	140.7	(51.4-306.2)	Male	168	158.1	106.2	(90.8-123.6)
Female	1	1.4	nc	(nc-nc)	Female	170	159.5	106.6	(91.2-123.9)
<b><u>Lung and Bronchus</u></b>									
Male	27	20.9	129.0	(85.0-187.7)					
Female	24	22.1	108.7	(69.6-161.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	94	122.5	76.7	(62.0-93.9)	Male	36	81.2	44.3	(31.0-61.4)
Female	40	47.7	83.9	(59.9-114.3)	Female	33	72.8	45.3	(31.2-63.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	27	27.2	99.3	(65.4-144.5)	Male	25	25.1	99.8	(64.6-147.3)
Female	22	24.0	91.7	(57.5-138.9)	Female	26	21.7	120.0	(78.4-175.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	7	4.2	166.1	(66.6-342.3)	Male	77	73.5	104.8	(82.7-131.0)
Female	512	546.6	93.7	(85.7-102.1)	Female	67	68.6	97.6	(75.6-124.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	35	19.9	175.5	(122.2-244.1)	Male	67	58.5	114.5	(88.7-145.4)
<b><u>Colon / Rectum</u></b>					Female	20	29.0	68.9	(42.1-106.4)
Male	150	134.8	111.3	(94.2-130.6)	<b><u>Ovary</u></b>				
Female	158	145.3	108.7	(92.4-127.1)	Female	32	49.0	65.3	(44.7-92.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	37	32.7	113.2	(79.7-156.1)	Male	48	43.3	110.7	(81.6-146.8)
Female	12	9.3	129.0	(66.6-225.3)	Female	43	47.8	89.9	(65.1-121.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	16	12.1	132.6	(75.8-215.4)	Male	388	414.2	93.7	(84.6-103.5)
Female	16	10.8	148.2	(84.7-240.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	34	29.0	117.3	(81.2-163.9)
Male	85	69.2	122.8	(98.1-151.8)	Female	25	18.7	133.7	(86.5-197.3)
Female	51	43.3	117.8	(87.7-154.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	22.6	53.1	(27.4-92.8)
Male	17	19.0	89.5	(52.1-143.4)	<b><u>Thyroid</u></b>				
Female	7	6.4	109.8	(44.0-226.1)	Male	12	33.6	35.7	(18.4-62.4)
<b><u>Leukemia</u></b>					Female	81	111.9	72.4	(57.5-90.0)
Male	52	53.1	98.0	(73.2-128.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	41	42.0	97.5	(70.0-132.3)	Female	120	124.0	96.8	(80.2-115.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	58	43.3	134.0	(101.8-173.3)	Male	1620	1648.6	98.3	(93.5-103.2)
Female	16	15.5	103.0	(58.9-167.3)	Female	1758	1853.7	94.8	(90.5-99.4)
<b><u>Lung and Bronchus</u></b>									
Male	253	218.7	115.7	(101.8-130.8)					
Female	254	251.7	100.9	(88.9-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	7.9	139.0	(69.3-248.7)	Male	5	5.3	94.1	(30.3-219.7)
Female	4	2.7	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.8	145.1	(58.1-299.0)
Female	42	33.8	124.2	(89.5-167.9)	Female	2	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	6	9.1	65.8	(24.0-143.2)	<b><u>Ovary</u></b>				
Female	4	8.5	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	6	2.9	207.2	(75.7-451.0)
Female	0	0.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	49	30.3	161.6	(119.6-213.7)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	7	4.9	143.3	(57.4-295.3)	Female	1	1.1	nc	(nc-nc)
Female	5	2.5	197.8	(63.7-461.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.5	92.3	(33.7-200.8)
Male	6	3.3	182.7	(66.7-397.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	9	7.5	120.1	(54.8-227.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	134	111.5	120.2	(100.7-142.3)
Female	0	0.9	nc	(nc-nc)	Female	111	109.1	101.7	(83.7-122.5)
<b><u>Lung and Bronchus</u></b>									
Male	11	14.5	76.1	(37.9-136.1)					
Female	18	14.1	127.8	(75.7-202.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	7	1.9	362.5	(145.2-747.0)
Female	2	1.3	nc	(nc-nc)	Female	6	1.5	406.8	(148.6-885.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	11	11.8	93.4	(46.6-167.1)	Female	3	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	3.8	212.0	(91.3-417.7)	Female	3	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	15	10.5	143.2	(80.1-236.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.7	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	45	40.1	112.2	(81.8-150.1)
Female	0	0.4	nc	(nc-nc)	Female	48	43.0	111.7	(82.4-148.2)
<b><u>Lung and Bronchus</u></b>									
Male	1	5.8	nc	(nc-nc)					
Female	1	6.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	30.5	65.5	(40.0-101.2)	Male	11	18.5	59.6	(29.7-106.6)
Female	13	10.0	129.8	(69.1-222.0)	Female	14	13.4	104.7	(57.2-175.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.1	138.0	(55.3-284.3)	Male	7	5.9	119.3	(47.8-245.8)
Female	4	4.1	nc	(nc-nc)	Female	5	4.5	112.1	(36.1-261.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	16	16.4	97.4	(55.7-158.2)
Female	133	104.9	126.7	(106.1-150.2)	Female	10	13.6	73.5	(35.2-135.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	3.4	175.7	(64.1-382.4)	Male	15	12.8	117.6	(65.8-193.9)
<b><u>Colon / Rectum</u></b>					Female	8	5.7	140.1	(60.3-276.1)
Male	36	31.6	113.9	(79.8-157.7)	<b><u>Ovary</u></b>				
Female	33	30.1	109.7	(75.5-154.1)	Female	13	9.4	138.3	(73.6-236.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.7	90.3	(36.2-186.2)	Male	6	10.5	57.1	(20.9-124.3)
Female	1	1.9	nc	(nc-nc)	Female	11	10.1	108.9	(54.3-194.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	65	96.6	67.3	(51.9-85.8)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	6.9	159.3	(79.4-285.1)
Male	14	15.1	92.6	(50.6-155.3)	Female	5	3.9	128.0	(41.2-298.6)
Female	9	8.4	107.1	(48.9-203.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.0	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	10	6.3	157.6	(75.5-289.9)
<b><u>Leukemia</u></b>					Female	21	18.2	115.2	(71.3-176.0)
Male	16	11.5	139.4	(79.6-226.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.9	126.5	(60.6-232.7)	Female	35	23.9	146.2	(101.8-203.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	9.7	62.0	(22.6-135.0)	Male	351	378.8	92.7	(83.2-102.9)
Female	4	3.1	nc	(nc-nc)	Female	420	360.5	116.5	(105.6-128.2)
<b><u>Lung and Bronchus</u></b>									
Male	46	53.2	86.5	(63.3-115.4)					
Female	52	51.2	101.5	(75.8-133.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	31.6	91.8	(61.5-131.9)	Male	17	20.1	84.4	(49.1-135.1)
Female	13	12.6	102.9	(54.7-175.9)	Female	22	17.1	128.3	(80.4-194.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.9	102.1	(37.3-222.2)	Male	8	6.4	125.7	(54.1-247.8)
Female	8	5.2	152.4	(65.6-300.3)	Female	7	5.7	123.4	(49.4-254.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	15	18.0	83.6	(46.7-137.8)
Female	139	136.1	102.1	(85.9-120.6)	Female	20	17.4	115.0	(70.2-177.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.5	134.4	(49.1-292.5)	Male	14	14.3	97.7	(53.4-163.9)
<b><u>Colon / Rectum</u></b>					Female	5	7.3	68.3	(22.0-159.4)
Male	34	33.7	100.9	(69.8-140.9)	<b><u>Ovary</u></b>				
Female	36	38.0	94.7	(66.3-131.1)	Female	12	12.1	99.2	(51.2-173.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.3	132.0	(65.8-236.2)	Male	13	11.1	117.6	(62.5-201.1)
Female	5	2.5	202.8	(65.4-473.4)	Female	18	12.8	140.3	(83.1-221.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	98	106.7	91.9	(74.6-112.0)
Female	5	1.9	269.6	(86.9-629.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.4	67.9	(21.9-158.4)
Male	27	17.1	158.0	(104.1-229.8)	Female	8	4.9	163.2	(70.3-321.5)
Female	15	10.8	138.4	(77.4-228.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.1	nc	(nc-nc)
Male	9	4.9	184.8	(84.3-350.9)	<b><u>Thyroid</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	9	7.6	117.8	(53.7-223.6)
<b><u>Leukemia</u></b>					Female	33	23.7	139.3	(95.9-195.7)
Male	13	12.4	104.8	(55.7-179.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	10.0	89.7	(40.9-170.3)	Female	20	31.1	64.2	(39.2-99.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	10.7	102.5	(51.1-183.4)	Male	431	412.2	104.6	(94.9-114.9)
Female	1	4.0	nc	(nc-nc)	Female	485	463.1	104.7	(95.6-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	65	56.6	114.8	(88.6-146.3)					
Female	56	66.0	84.8	(64.1-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	7.3	192.1	(104.9-322.3)	Male	4	4.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	34	29.2	116.4	(80.6-162.7)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	7	8.0	87.2	(34.9-179.6)	<b><u>Ovary</u></b>				
Female	9	6.7	133.8	(61.1-254.1)	Female	6	2.5	239.5	(87.5-521.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	35	24.5	142.6	(99.3-198.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.6	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.9	nc	(nc-nc)	Female	10	6.9	144.6	(69.2-266.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	90	95.9	93.8	(75.4-115.3)
Female	1	0.8	nc	(nc-nc)	Female	103	92.7	111.1	(90.7-134.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	12.9	nc	(nc-nc)					
Female	10	12.3	81.1	(38.8-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	10.5	180.4	(108.6-281.7)	Male	9	6.9	130.8	(59.7-248.4)
Female	4	4.0	nc	(nc-nc)	Female	8	5.5	144.5	(62.2-284.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.1	82.3	(26.5-192.0)
Female	42	44.9	93.6	(67.5-126.5)	Female	5	5.6	89.7	(28.9-209.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	5	5.1	97.7	(31.5-228.1)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	11	11.3	97.0	(48.3-173.5)	<b><u>Ovary</u></b>				
Female	8	11.8	68.1	(29.3-134.1)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.9	127.0	(40.9-296.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	40	38.2	104.8	(74.9-142.7)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.5	nc	(nc-nc)
Male	7	6.0	117.0	(46.9-241.0)	Female	1	1.5	nc	(nc-nc)
Female	7	3.6	196.2	(78.6-404.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.9	63.4	(20.4-148.0)
Male	5	4.2	118.2	(38.1-275.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.2	nc	(nc-nc)	Female	18	10.4	173.5	(102.8-274.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.9	nc	(nc-nc)	Male	150	142.4	105.4	(89.2-123.6)
Female	2	1.3	nc	(nc-nc)	Female	135	150.4	89.8	(75.3-106.3)
<b><u>Lung and Bronchus</u></b>									
Male	19	19.4	98.2	(59.1-153.3)					
Female	15	21.7	69.0	(38.6-113.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	19.9	80.4	(45.9-130.6)	Male	19	13.0	145.7	(87.7-227.6)
Female	0	6.1	nc	(nc-nc)	Female	8	9.2	87.1	(37.5-171.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.0	150.4	(54.9-327.3)	Male	5	4.2	120.5	(38.8-281.1)
Female	5	3.0	169.3	(54.6-395.1)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	11.6	86.0	(41.2-158.3)
Female	122	75.8	161.0	(133.7-192.2)	Female	11	8.9	123.9	(61.8-221.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	5	9.8	51.1	(16.5-119.1)
<b><u>Colon / Rectum</u></b>					Female	4	3.8	nc	(nc-nc)
Male	25	21.8	114.5	(74.1-169.1)	<b><u>Ovary</u></b>				
Female	14	19.0	73.8	(40.3-123.9)	Female	6	6.5	91.9	(33.6-200.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	9	7.2	125.5	(57.3-238.2)
Female	1	1.2	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	72	71.6	100.6	(78.7-126.7)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.7	nc	(nc-nc)
Male	14	11.5	121.7	(66.5-204.2)	Female	1	2.4	nc	(nc-nc)
Female	6	5.8	103.6	(37.8-225.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	6	5.1	118.3	(43.2-257.5)
<b><u>Leukemia</u></b>					Female	17	13.8	122.8	(71.5-196.6)
Male	5	8.1	61.8	(19.9-144.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.2	154.7	(66.6-304.7)	Female	16	17.1	93.6	(53.5-152.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	228	269.5	84.6	(74.0-96.3)
Female	3	2.0	nc	(nc-nc)	Female	286	245.0	116.8	(103.6-131.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	36.8	27.2	(13.0-50.0)					
Female	31	33.2	93.4	(63.4-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	18	10.9	164.9	(97.7-260.6)	Female	0	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	10	11.5	86.8	(41.5-159.6)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.4	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	33	46.1	71.6	(49.3-100.6)
Female	0	0.3	nc	(nc-nc)	Female	31	38.7	80.1	(54.4-113.8)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.9	nc	(nc-nc)					
Female	3	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.3	118.7	(59.2-212.4)	Male	9	6.4	141.2	(64.4-268.1)
Female	6	2.3	264.1	(96.4-574.8)	Female	4	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.7	140.1	(60.3-276.1)
Female	39	33.9	115.1	(81.8-157.3)	Female	4	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.6	nc	(nc-nc)
Male	7	10.6	66.1	(26.5-136.2)	<b><u>Ovary</u></b>				
Female	8	7.0	113.6	(48.9-223.9)	Female	1	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	27	37.9	71.3	(47.0-103.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	6	5.9	100.9	(36.9-219.7)	Female	2	0.9	nc	(nc-nc)
Female	6	2.5	244.4	(89.3-532.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.1	99.1	(39.7-204.3)
Male	7	3.9	180.3	(72.2-371.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	14	7.9	177.4	(96.9-297.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	127	134.6	94.3	(78.6-112.2)
Female	1	0.8	nc	(nc-nc)	Female	125	104.3	119.8	(99.7-142.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.5	108.5	(65.3-169.4)					
Female	14	13.0	107.7	(58.8-180.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	16.2	160.8	(105.0-235.6)	Male	14	10.1	138.7	(75.8-232.8)
Female	13	6.2	211.2	(112.3-361.2)	Female	16	8.6	187.1	(106.9-303.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	16	9.0	177.2	(101.2-287.7)
Female	83	67.3	123.4	(98.3-153.0)	Female	12	8.5	141.2	(72.9-246.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	6	7.3	82.6	(30.2-179.8)
<b><u>Colon / Rectum</u></b>					Female	4	3.6	nc	(nc-nc)
Male	16	17.3	92.3	(52.7-149.9)	<b><u>Ovary</u></b>				
Female	19	18.7	101.7	(61.2-158.8)	Female	3	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	6	5.6	106.3	(38.8-231.5)
Female	2	1.2	nc	(nc-nc)	Female	6	6.2	97.5	(35.6-212.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	50	52.3	95.6	(70.9-126.0)
Female	3	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.7	nc	(nc-nc)
Male	11	8.5	129.8	(64.7-232.3)	Female	1	2.4	nc	(nc-nc)
Female	6	5.3	112.3	(41.0-244.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	8	3.7	216.6	(93.3-426.8)
<b><u>Leukemia</u></b>					Female	21	12.1	173.2	(107.2-264.8)
Male	5	6.4	78.2	(25.2-182.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.9	162.1	(69.8-319.5)	Female	22	15.2	144.7	(90.6-219.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.5	nc	(nc-nc)	Male	221	206.6	107.0	(93.3-122.1)
Female	2	1.9	nc	(nc-nc)	Female	286	227.7	125.6	(111.4-141.0)
<b><u>Lung and Bronchus</u></b>									
Male	27	28.2	95.7	(63.1-139.3)					
Female	37	31.9	115.9	(81.6-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	18.4	113.9	(70.5-174.1)	Male	10	12.1	82.4	(39.4-151.5)
Female	14	7.2	193.3	(105.6-324.4)	Female	4	10.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	10.7	130.3	(71.2-218.7)
Female	73	81.6	89.5	(70.1-112.5)	Female	10	10.0	99.8	(47.8-183.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	9	9.1	99.2	(45.2-188.2)
<b><u>Colon / Rectum</u></b>					Female	3	4.2	nc	(nc-nc)
Male	19	19.9	95.3	(57.3-148.8)	<b><u>Ovary</u></b>				
Female	17	21.7	78.5	(45.7-125.7)	Female	5	7.1	70.0	(22.6-163.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.1	136.4	(54.7-281.1)	Male	7	6.7	105.2	(42.2-216.8)
Female	0	1.4	nc	(nc-nc)	Female	7	7.2	96.9	(38.8-199.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	85	68.3	124.4	(99.4-153.8)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.4	113.5	(36.6-264.9)
Male	18	10.7	168.3	(99.7-266.0)	Female	4	2.8	nc	(nc-nc)
Female	5	6.4	78.1	(25.2-182.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.2	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	14.2	70.2	(33.6-129.1)
Male	2	7.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.7	nc	(nc-nc)	Female	14	18.6	75.5	(41.2-126.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.7	74.5	(24.0-173.9)	Male	269	251.6	106.9	(94.5-120.5)
Female	2	2.3	nc	(nc-nc)	Female	238	271.5	87.7	(76.9-99.5)
<b><u>Lung and Bronchus</u></b>									
Male	26	34.2	75.9	(49.6-111.3)					
Female	34	38.6	88.2	(61.0-123.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	57	56.3	101.3	(76.7-131.2)	Male	25	37.4	66.9	(43.3-98.7)
Female	22	21.1	104.3	(65.4-158.0)	Female	28	30.9	90.7	(60.3-131.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	11.5	104.3	(53.9-182.3)	Male	10	11.6	86.0	(41.2-158.1)
Female	9	9.5	94.5	(43.1-179.5)	Female	14	9.6	146.4	(80.0-245.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.0	254.0	(81.9-592.7)	Male	38	33.4	113.7	(80.5-156.1)
Female	232	239.2	97.0	(84.9-110.3)	Female	42	29.8	141.2	(101.7-190.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	8.4	119.1	(57.0-219.1)	Male	37	27.5	134.6	(94.7-185.5)
<b><u>Colon / Rectum</u></b>					Female	9	12.6	71.5	(32.6-135.7)
Male	69	61.9	111.5	(86.8-141.1)	<b><u>Ovary</u></b>				
Female	83	64.6	128.5	(102.3-159.3)	Female	16	21.2	75.5	(43.1-122.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	15.3	104.4	(59.7-169.6)	Male	27	20.0	134.7	(88.7-196.0)
Female	3	4.1	nc	(nc-nc)	Female	24	21.2	113.0	(72.4-168.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	9	4.7	191.7	(87.5-363.9)	Male	165	196.4	84.0	(71.7-97.8)
Female	5	3.8	133.2	(42.9-310.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	13.4	96.9	(51.6-165.8)
Male	37	32.4	114.2	(80.4-157.5)	Female	7	8.3	84.2	(33.7-173.4)
Female	24	18.8	127.8	(81.9-190.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	8.6	116.1	(55.6-213.6)
Male	14	9.0	155.3	(84.8-260.6)	<b><u>Thyroid</u></b>				
Female	5	2.8	180.0	(58.0-420.1)	Male	21	15.2	138.4	(85.6-211.5)
<b><u>Leukemia</u></b>					Female	65	45.7	142.2	(109.7-181.2)
Male	19	23.2	81.8	(49.2-127.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	17.5	74.4	(39.6-127.2)	Female	42	53.9	77.9	(56.1-105.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	21	20.2	104.1	(64.4-159.1)	Male	806	760.7	106.0	(98.8-113.5)
Female	6	6.7	89.6	(32.7-195.0)	Female	848	803.7	105.5	(98.5-112.9)
<b><u>Lung and Bronchus</u></b>									
Male	134	102.2	131.1	(109.9-155.3)					
Female	126	110.0	114.5	(95.4-136.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.6	114.1	(56.9-204.1)	Male	4	6.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	0	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	27	36.4	74.2	(48.9-108.0)	Female	5	4.3	117.3	(37.8-273.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	9	10.5	85.5	(39.0-162.3)	<b><u>Ovary</u></b>				
Female	12	8.9	135.3	(69.8-236.4)	Female	6	3.2	189.8	(69.3-413.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	28	37.5	74.7	(49.6-107.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	9	5.7	159.1	(72.6-302.1)	Female	1	1.1	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.0	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.8	73.1	(23.6-170.5)
Male	4	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	11	8.4	131.1	(65.4-234.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.6	139.8	(45.0-326.2)	Male	115	133.4	86.2	(71.2-103.5)
Female	0	1.0	nc	(nc-nc)	Female	118	118.5	99.5	(82.4-119.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.9	106.3	(64.0-166.0)					
Female	25	16.6	150.8	(97.6-222.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	29.3	133.1	(94.6-182.0)	Male	16	19.8	80.9	(46.2-131.4)
Female	12	13.0	92.6	(47.8-161.8)	Female	16	17.6	90.7	(51.8-147.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.0	115.9	(46.4-238.8)	Male	4	6.1	nc	(nc-nc)
Female	6	5.4	110.8	(40.5-241.3)	Female	6	5.8	104.3	(38.1-227.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	21	17.6	119.6	(74.0-182.8)
Female	131	138.6	94.5	(79.0-112.2)	Female	21	17.7	118.3	(73.2-180.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	4.5	175.9	(75.7-346.6)	Male	17	14.8	114.6	(66.7-183.6)
<b><u>Colon / Rectum</u></b>					Female	8	7.4	107.6	(46.3-212.1)
Male	34	32.8	103.8	(71.9-145.0)	<b><u>Ovary</u></b>				
Female	31	39.0	79.4	(54.0-112.7)	Female	16	12.3	130.1	(74.3-211.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.1	135.5	(67.5-242.4)	Male	14	10.6	132.1	(72.2-221.7)
Female	4	2.5	nc	(nc-nc)	Female	8	13.1	61.0	(26.3-120.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	116	105.8	109.7	(90.6-131.6)
Female	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.1	84.8	(31.0-184.6)
Male	28	17.2	162.6	(108.0-235.0)	Female	6	5.1	118.6	(43.3-258.2)
Female	11	11.0	99.6	(49.6-178.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	4.4	nc	(nc-nc)
Male	6	4.8	124.1	(45.3-270.0)	<b><u>Thyroid</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	6	8.1	73.9	(27.0-161.0)
<b><u>Leukemia</u></b>					Female	30	24.5	122.7	(82.7-175.1)
Male	26	12.0	216.3	(141.3-316.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	10.4	135.0	(73.8-226.6)	Female	29	31.1	93.2	(62.4-133.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	11.0	63.8	(25.5-131.4)	Male	464	403.2	115.1	(104.8-126.0)
Female	1	4.0	nc	(nc-nc)	Female	488	473.0	103.2	(94.2-112.7)
<b><u>Lung and Bronchus</u></b>									
Male	64	53.8	118.9	(91.6-151.8)					
Female	79	67.6	116.9	(92.6-145.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.8	156.4	(57.1-340.3)	Male	8	2.7	301.8	(129.9-594.7)
Female	0	1.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	32	18.1	176.7	(120.8-249.4)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.9	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	4.3	115.8	(37.3-270.1)	Female	3	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	14.0	142.8	(87.2-220.5)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	0.9	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.3	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	5	4.4	113.7	(36.7-265.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	70	53.8	130.2	(101.5-164.5)
Female	0	0.5	nc	(nc-nc)	Female	78	59.3	131.5	(103.9-164.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	7.2	nc	(nc-nc)					
Female	10	8.4	118.6	(56.8-218.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	11.2	80.7	(36.8-153.1)
Female	0	0.1	nc	(nc-nc)	Female	3	7.7	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.5	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	8.0	nc	(nc-nc)	Male	6	5.0	119.9	(43.8-261.1)
Female	4	2.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.5	133.6	(48.8-290.8)
Female	27	29.1	92.8	(61.2-135.1)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	4	8.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	8.3	72.2	(26.4-157.1)	Female	4	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	29	27.2	106.5	(71.3-152.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.0	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	6	6.5	92.8	(33.9-201.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	97	103.9	93.3	(75.7-113.9)
Female	1	0.8	nc	(nc-nc)	Female	96	98.2	97.7	(79.2-119.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	14.3	126.0	(74.6-199.1)					
Female	17	13.5	125.7	(73.2-201.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	6.9	145.5	(69.7-267.7)	Male	3	5.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	6	4.4	137.4	(50.2-299.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	4.7	212.0	(101.5-390.0)
Female	35	35.0	99.9	(69.6-138.9)	Female	3	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.7	nc	(nc-nc)
Male	14	8.5	165.6	(90.4-277.8)	<b><u>Ovary</u></b>				
Female	11	8.1	136.4	(68.0-244.0)	Female	4	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	2.3	308.8	(123.7-636.2)	Male	2	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	22	32.2	68.4	(42.8-103.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	5	5.1	97.8	(31.5-228.3)	Female	0	1.0	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.3	123.0	(56.1-233.5)
Male	1	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	117	110.7	105.7	(87.4-126.7)
Female	1	0.9	nc	(nc-nc)	Female	114	109.6	104.0	(85.8-125.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	13.4	104.4	(57.0-175.1)					
Female	15	13.6	110.4	(61.8-182.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	19	11.5	164.9	(99.2-257.4)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	5	3.4	145.1	(46.8-338.6)	<b><u>Ovary</u></b>				
Female	3	2.8	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	11.5	52.1	(19.0-113.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	37	42.7	86.6	(60.9-119.3)
Female	0	0.3	nc	(nc-nc)	Female	49	37.1	132.2	(97.8-174.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	6.0	nc	(nc-nc)					
Female	2	5.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	9.5	157.8	(88.2-260.3)	Male	5	7.0	71.0	(22.9-165.7)
Female	7	3.7	191.6	(76.8-394.9)	Female	7	5.9	117.9	(47.2-243.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	37	47.6	77.7	(54.7-107.0)	Female	3	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.4	nc	(nc-nc)
Male	12	11.9	101.2	(52.2-176.7)	<b><u>Ovary</u></b>				
Female	7	11.6	60.5	(24.2-124.6)	Female	4	4.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	32	41.9	76.3	(52.2-107.8)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	8	6.7	119.2	(51.3-234.8)	Female	1	1.5	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	9.4	85.3	(36.7-168.0)
Male	7	4.2	166.8	(66.8-343.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	11	10.8	101.6	(50.7-181.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.3	164.3	(65.8-338.5)	Male	141	148.2	95.2	(80.1-112.2)
Female	1	1.2	nc	(nc-nc)	Female	131	152.3	86.0	(71.9-102.0)
<b><u>Lung and Bronchus</u></b>									
Male	23	18.1	127.3	(80.7-191.0)					
Female	21	19.7	106.6	(66.0-163.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	10.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	6	12.2	49.4	(18.0-107.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.6	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.0	99.7	(36.4-217.1)	Male	5	4.4	113.2	(36.5-264.2)
Female	2	2.3	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.0	177.0	(70.9-364.6)
Female	38	31.1	122.1	(86.4-167.6)	Female	3	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.5	nc	(nc-nc)
Male	7	7.1	98.0	(39.3-202.0)	<b><u>Ovary</u></b>				
Female	4	7.1	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	20	26.1	76.7	(46.8-118.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.5	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.2	81.1	(26.1-189.3)
Male	4	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	14	7.0	199.4	(108.9-334.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	2.6	228.5	(83.4-497.4)	Male	86	92.4	93.1	(74.5-115.0)
Female	1	0.8	nc	(nc-nc)	Female	108	97.9	110.4	(90.5-133.3)
<b><u>Lung and Bronchus</u></b>									
Male	12	11.6	103.1	(53.2-180.1)					
Female	12	12.9	93.1	(48.1-162.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	12.5	128.0	(73.1-207.9)	Male	13	8.6	150.7	(80.1-257.6)
Female	3	4.9	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.7	90.5	(36.3-186.5)
Female	61	58.4	104.4	(79.9-134.1)	Female	5	7.1	70.5	(22.7-164.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.6	165.8	(82.7-296.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	16	14.3	111.7	(63.8-181.3)	<b><u>Ovary</u></b>				
Female	15	15.3	98.2	(54.9-162.0)	Female	4	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	5.0	100.4	(32.4-234.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	58	46.3	125.3	(95.1-162.0)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.1	163.3	(52.6-381.1)
Male	11	7.6	144.0	(71.8-257.6)	Female	0	1.9	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.2	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	10.7	84.4	(38.5-160.3)
Male	7	5.3	132.4	(53.0-272.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.1	145.8	(53.2-317.3)	Female	13	13.3	98.1	(52.2-167.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	219	176.3	124.2	(108.3-141.8)
Female	1	1.6	nc	(nc-nc)	Female	176	192.6	91.4	(78.4-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	29	22.9	126.8	(84.9-182.1)					
Female	23	26.3	87.4	(55.4-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	29.0	110.3	(75.4-155.7)	Male	27	19.0	142.2	(93.7-206.9)
Female	8	9.0	88.9	(38.3-175.1)	Female	26	13.8	188.4	(123.0-276.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.6	142.8	(61.5-281.3)	Male	3	6.0	nc	(nc-nc)
Female	8	4.3	187.1	(80.6-368.8)	Female	4	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.8	59.6	(28.5-109.7)
Female	125	109.1	114.6	(95.4-136.5)	Female	18	13.0	138.3	(81.9-218.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.8	nc	(nc-nc)	Male	13	13.7	94.8	(50.5-162.2)
<b><u>Colon / Rectum</u></b>					Female	4	5.6	nc	(nc-nc)
Male	33	31.0	106.4	(73.2-149.4)	<b><u>Ovary</u></b>				
Female	34	27.3	124.7	(86.4-174.3)	Female	6	9.6	62.6	(22.9-136.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	7	10.3	68.0	(27.2-140.1)
Female	1	1.8	nc	(nc-nc)	Female	11	9.0	122.6	(61.1-219.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	76	100.2	75.8	(59.8-94.9)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.8	73.1	(23.6-170.6)
Male	8	16.2	49.4	(21.3-97.4)	Female	2	3.5	nc	(nc-nc)
Female	9	8.4	107.0	(48.8-203.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.8	nc	(nc-nc)
Male	5	4.6	108.2	(34.9-252.5)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	5	7.4	67.7	(21.8-158.0)
<b><u>Leukemia</u></b>					Female	22	21.0	104.7	(65.6-158.6)
Male	10	11.6	86.2	(41.3-158.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.6	79.4	(29.0-172.8)	Female	17	25.1	67.6	(39.4-108.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	10.4	57.8	(21.1-125.9)	Male	323	386.0	83.7	(74.8-93.3)
Female	4	3.0	nc	(nc-nc)	Female	396	358.0	110.6	(100.0-122.1)
<b><u>Lung and Bronchus</u></b>									
Male	39	52.9	73.7	(52.4-100.7)					
Female	58	48.7	119.1	(90.4-154.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	8.2	85.1	(34.1-175.3)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	2.1	292.0	(106.6-635.7)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	10.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	6	2.0	298.9	(109.1-650.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	26	35.0	74.3	(48.5-108.9)
Female	0	0.2	nc	(nc-nc)	Female	30	26.9	111.3	(75.1-158.9)
<b><u>Lung and Bronchus</u></b>									
Male	6	4.7	127.0	(46.4-276.4)					
Female	4	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	27.4	76.7	(47.4-117.2)	Male	24	17.8	134.5	(86.1-200.1)
Female	12	10.0	120.4	(62.1-210.3)	Female	13	13.7	95.0	(50.5-162.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.3	113.5	(41.4-247.0)	Male	6	5.6	106.6	(38.9-232.0)
Female	5	4.3	115.1	(37.1-268.5)	Female	5	4.5	111.5	(35.9-260.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	12	15.9	75.3	(38.8-131.5)
Female	137	107.7	127.2	(106.8-150.3)	Female	11	13.8	79.5	(39.6-142.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.6	nc	(nc-nc)	Male	9	13.2	67.9	(31.0-129.0)
<b><u>Colon / Rectum</u></b>					Female	5	5.8	86.5	(27.9-201.8)
Male	35	30.1	116.3	(81.0-161.7)	<b><u>Ovary</u></b>				
Female	32	30.4	105.2	(71.9-148.5)	Female	12	9.6	125.6	(64.8-219.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.4	67.1	(21.6-156.7)	Male	11	9.8	112.2	(55.9-200.8)
Female	2	1.9	nc	(nc-nc)	Female	8	10.1	79.6	(34.3-156.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	117	96.0	121.8	(100.8-146.0)
Female	1	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.5	92.4	(33.7-201.1)
Male	17	15.5	109.9	(64.0-176.0)	Female	3	3.9	nc	(nc-nc)
Female	6	8.6	69.8	(25.5-151.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.5	nc	(nc-nc)
Male	7	4.3	161.7	(64.8-333.2)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	6	7.1	85.0	(31.1-185.1)
<b><u>Leukemia</u></b>					Female	19	19.2	99.2	(59.7-154.9)
Male	7	11.0	63.9	(25.6-131.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.1	135.8	(67.7-243.0)	Female	22	24.4	90.2	(56.5-136.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	9.8	71.2	(28.5-146.7)	Male	376	366.6	102.6	(92.5-113.5)
Female	3	3.1	nc	(nc-nc)	Female	384	367.0	104.6	(94.4-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	40	49.2	81.2	(58.0-110.6)					
Female	47	51.5	91.2	(67.0-121.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	61	52.5	116.2	(88.9-149.3)	Male	25	35.8	69.9	(45.2-103.2)
Female	21	20.2	104.0	(64.3-158.9)	Female	14	30.7	45.6	(24.9-76.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	11.4	132.0	(73.8-217.8)	Male	9	10.7	83.8	(38.3-159.1)
Female	13	9.5	136.8	(72.8-233.9)	Female	4	9.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	26	31.7	82.0	(53.5-120.1)
Female	234	221.2	105.8	(92.7-120.2)	Female	32	28.6	111.8	(76.4-157.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	8.2	109.7	(50.1-208.3)	Male	16	25.4	63.1	(36.0-102.4)
<b><u>Colon / Rectum</u></b>					Female	8	11.9	67.0	(28.9-132.1)
Male	60	57.2	104.8	(80.0-134.9)	<b><u>Ovary</u></b>				
Female	56	60.8	92.1	(69.6-119.6)	Female	18	20.1	89.4	(52.9-141.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.1	92.1	(49.0-157.4)	Male	21	18.7	112.5	(69.6-171.9)
Female	3	3.9	nc	(nc-nc)	Female	25	20.4	122.8	(79.4-181.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	146	181.6	80.4	(67.9-94.5)
Female	5	4.8	104.2	(33.6-243.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	18	12.5	144.2	(85.4-227.9)
Male	36	30.1	119.6	(83.7-165.5)	Female	9	7.9	114.2	(52.1-216.9)
Female	16	17.8	89.9	(51.4-146.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	11.3	105.8	(54.6-184.8)
Male	5	8.3	60.1	(19.4-140.2)	<b><u>Thyroid</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	17	15.2	112.1	(65.3-179.5)
<b><u>Leukemia</u></b>					Female	53	46.6	113.7	(85.1-148.7)
Male	19	22.2	85.5	(51.4-133.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	17.3	75.3	(40.1-128.8)	Female	41	50.5	81.2	(58.3-110.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	19	18.6	102.0	(61.4-159.3)	Male	667	715.5	93.2	(86.3-100.6)
Female	5	6.4	77.6	(25.0-181.2)	Female	750	765.7	98.0	(91.1-105.2)
<b><u>Lung and Bronchus</u></b>									
Male	93	95.6	97.3	(78.5-119.2)					
Female	109	105.4	103.4	(84.9-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.5	66.4	(26.6-136.8)	Male	4	7.0	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	6.3	111.6	(44.7-230.0)
Female	34	47.4	71.8	(49.7-100.3)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.5	nc	(nc-nc)
Male	15	11.8	127.5	(71.3-210.3)	<b><u>Ovary</u></b>				
Female	16	12.2	131.1	(74.9-212.9)	Female	5	4.2	118.7	(38.2-277.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	8	3.8	208.1	(89.6-410.0)
Female	2	0.8	nc	(nc-nc)	Female	6	4.0	149.9	(54.7-326.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	29	39.4	73.7	(49.3-105.8)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	8	3.7	216.5	(93.2-426.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	8.6	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.2	nc	(nc-nc)	Female	9	10.9	82.8	(37.8-157.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.0	125.2	(40.3-292.1)	Male	134	145.8	91.9	(77.0-108.9)
Female	1	1.3	nc	(nc-nc)	Female	134	156.2	85.8	(71.9-101.6)
<b><u>Lung and Bronchus</u></b>									
Male	21	19.3	109.0	(67.4-166.6)					
Female	16	21.8	73.3	(41.8-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	29.7	128.0	(90.6-175.7)	Male	17	18.2	93.2	(54.3-149.3)
Female	15	10.1	148.3	(82.9-244.6)	Female	14	13.8	101.6	(55.5-170.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.0	158.4	(68.2-312.2)	Male	10	5.9	170.7	(81.7-314.0)
Female	3	4.2	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	17	16.2	104.9	(61.1-167.9)
Female	94	109.9	85.5	(69.1-104.6)	Female	8	13.9	57.4	(24.7-113.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.5	nc	(nc-nc)	Male	15	12.5	119.6	(66.9-197.3)
<b><u>Colon / Rectum</u></b>					Female	6	5.9	101.9	(37.2-221.8)
Male	33	30.8	107.2	(73.8-150.5)	<b><u>Ovary</u></b>				
Female	39	30.3	128.7	(91.5-175.9)	Female	9	9.8	92.0	(42.0-174.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.5	93.1	(37.3-191.8)	Male	10	10.2	98.2	(47.0-180.6)
Female	2	2.0	nc	(nc-nc)	Female	12	10.1	118.5	(61.2-207.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	87	92.4	94.1	(75.4-116.1)
Female	3	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.8	88.3	(32.3-192.3)
Male	16	14.9	107.3	(61.3-174.2)	Female	2	3.9	nc	(nc-nc)
Female	15	8.8	171.2	(95.7-282.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.1	nc	(nc-nc)
Male	5	4.4	114.1	(36.8-266.2)	<b><u>Thyroid</u></b>				
Female	4	1.3	nc	(nc-nc)	Male	7	6.3	110.5	(44.3-227.8)
<b><u>Leukemia</u></b>					Female	18	18.9	95.0	(56.3-150.2)
Male	9	11.2	80.3	(36.7-152.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	8.0	226.0	(133.9-357.3)	Female	20	25.3	79.2	(48.3-122.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	9.7	144.5	(78.9-242.5)	Male	412	370.2	111.3	(100.8-122.6)
Female	5	3.2	155.9	(50.2-363.7)	Female	401	372.6	107.6	(97.4-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	79	52.7	150.0	(118.7-186.9)					
Female	82	53.7	152.6	(121.4-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.2	116.5	(42.5-253.6)	Male	2	3.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	15	22.0	68.1	(38.1-112.3)	Female	1	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	5.7	123.5	(49.5-254.4)	Female	1	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	7	1.8	380.8	(152.6-784.7)
Female	1	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	15	18.7	80.3	(44.9-132.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.5	nc	(nc-nc)	Female	6	5.0	120.1	(43.8-261.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	61	69.8	87.4	(66.8-112.2)
Female	0	0.6	nc	(nc-nc)	Female	51	72.4	70.5	(52.5-92.7)
<b><u>Lung and Bronchus</u></b>									
Male	9	9.3	96.4	(44.0-183.0)					
Female	8	9.9	81.1	(34.9-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.1	148.0	(54.1-322.2)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	14	14.6	95.7	(52.3-160.6)
Female	0	0.1	nc	(nc-nc)	Female	14	14.2	98.3	(53.7-164.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.1	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	11.8	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	8	9.0	88.7	(38.2-174.7)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.6	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	33.3	105.2	(73.2-146.3)	Male	14	21.7	64.6	(35.3-108.5)
Female	9	13.1	68.7	(31.4-130.4)	Female	21	19.0	110.8	(68.5-169.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.5	153.1	(73.3-281.7)	Male	5	6.7	74.3	(23.9-173.4)
Female	9	5.6	161.1	(73.5-305.7)	Female	5	5.9	85.2	(27.4-198.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	20	19.3	103.7	(63.3-160.1)
Female	149	141.2	105.5	(89.2-123.9)	Female	21	18.4	114.4	(70.8-174.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.1	155.8	(67.1-307.0)	Male	15	14.8	101.5	(56.8-167.4)
<b><u>Colon / Rectum</u></b>					Female	3	7.6	nc	(nc-nc)
Male	45	36.2	124.3	(90.6-166.3)	<b><u>Ovary</u></b>				
Female	38	39.0	97.5	(69.0-133.8)	Female	15	12.7	118.3	(66.2-195.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	8.4	106.9	(48.8-202.9)	Male	12	11.4	105.4	(54.4-184.1)
Female	1	2.5	nc	(nc-nc)	Female	18	13.1	137.1	(81.2-216.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	92	102.0	90.2	(72.7-110.7)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.8	102.4	(44.1-201.8)
Male	23	17.9	128.2	(81.2-192.3)	Female	11	5.0	220.3	(109.8-394.3)
Female	4	11.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.8	86.4	(27.9-201.7)
Male	5	5.0	100.8	(32.5-235.2)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	12	8.6	139.2	(71.9-243.2)
<b><u>Leukemia</u></b>					Female	24	28.1	85.5	(54.8-127.2)
Male	12	13.4	89.3	(46.1-156.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	10.4	95.8	(45.8-176.1)	Female	26	31.9	81.5	(53.2-119.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	11.0	90.8	(43.5-167.1)	Male	417	427.2	97.6	(88.5-107.4)
Female	6	4.1	146.0	(53.3-317.7)	Female	470	487.1	96.5	(88.0-105.6)
<b><u>Lung and Bronchus</u></b>									
Male	52	58.7	88.7	(66.2-116.3)					
Female	61	70.1	87.1	(66.6-111.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	17.7	45.1	(19.4-88.9)	Male	15	10.9	137.6	(76.9-226.9)
Female	5	6.2	80.2	(25.8-187.2)	Female	16	8.3	192.8	(110.1-313.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	5	3.5	141.1	(45.5-329.2)
Female	4	2.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.8	102.3	(49.0-188.1)
Female	83	69.3	119.7	(95.3-148.4)	Female	11	8.6	127.2	(63.4-227.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	2	7.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	3.7	nc	(nc-nc)
Male	12	18.7	64.1	(33.1-112.0)	<b><u>Ovary</u></b>				
Female	9	18.5	48.6	(22.2-92.2)	Female	4	6.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.6	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	5	6.3	80.0	(25.8-186.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	67	56.6	118.3	(91.7-150.3)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.1	nc	(nc-nc)
Male	8	9.2	87.3	(37.6-172.0)	Female	0	2.4	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.5	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.9	181.6	(72.8-374.3)
<b><u>Leukemia</u></b>					Female	11	11.1	99.3	(49.5-177.7)
Male	8	6.7	118.5	(51.0-233.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	4.9	nc	(nc-nc)	Female	12	16.1	74.4	(38.4-130.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	197	223.5	88.2	(76.3-101.4)
Female	1	2.0	nc	(nc-nc)	Female	205	231.5	88.6	(76.8-101.5)
<b><u>Lung and Bronchus</u></b>									
Male	20	31.3	63.9	(39.0-98.6)					
Female	21	33.9	61.9	(38.3-94.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	19.7	157.6	(107.1-223.7)	Male	10	12.3	81.5	(39.0-149.9)
Female	7	7.6	92.4	(37.0-190.4)	Female	6	10.1	59.4	(21.7-129.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	Female	7	3.3	210.8	(84.5-434.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	0.7	nc	(nc-nc)	Male	12	11.0	109.2	(56.3-190.7)
Female	78	76.6	101.8	(80.5-127.1)	Female	9	10.2	87.9	(40.1-166.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	4	8.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	4.2	118.9	(38.3-277.4)
Male	28	21.0	133.3	(88.6-192.7)	<b><u>Ovary</u></b>				
Female	27	23.0	117.2	(77.2-170.5)	Female	9	6.9	130.4	(59.5-247.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.0	139.1	(55.7-286.6)	Male	7	6.8	103.2	(41.4-212.7)
Female	1	1.4	nc	(nc-nc)	Female	9	7.7	116.2	(53.0-220.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	56	62.5	89.6	(67.7-116.4)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.5	nc	(nc-nc)
Male	10	10.2	97.6	(46.7-179.6)	Female	1	3.0	nc	(nc-nc)
Female	7	6.2	113.1	(45.3-233.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.5	nc	(nc-nc)
Male	5	2.9	172.4	(55.5-402.2)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	6	4.6	131.7	(48.1-286.7)
<b><u>Leukemia</u></b>					Female	12	14.0	85.7	(44.2-149.8)
Male	11	7.6	144.8	(72.2-259.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.1	115.6	(46.3-238.2)	Female	18	16.8	107.1	(63.4-169.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	6.5	154.5	(74.0-284.1)	Male	282	249.6	113.0	(100.2-127.0)
Female	6	2.3	264.1	(96.4-574.9)	Female	284	268.1	105.9	(94.0-119.0)
<b><u>Lung and Bronchus</u></b>									
Male	42	34.6	121.3	(87.4-164.0)					
Female	48	37.9	126.5	(93.3-167.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	29.7	70.8	(43.8-108.2)	Male	30	18.5	162.2	(109.4-231.6)
Female	5	9.9	50.5	(16.3-118.0)	Female	31	14.0	221.7	(150.6-314.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.5	nc	(nc-nc)	Male	5	5.9	84.9	(27.4-198.2)
Female	4	4.8	nc	(nc-nc)	Female	7	4.4	159.3	(63.8-328.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	16	16.7	96.1	(54.9-156.1)
Female	134	108.5	123.5	(103.5-146.3)	Female	12	13.8	86.8	(44.8-151.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.6	nc	(nc-nc)	Male	8	13.3	60.2	(25.9-118.6)
<b><u>Colon / Rectum</u></b>					Female	5	5.8	85.9	(27.7-200.4)
Male	20	31.5	63.4	(38.7-98.0)	<b><u>Ovary</u></b>				
Female	25	29.8	83.8	(54.2-123.8)	Female	10	9.7	102.9	(49.3-189.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	7.8	nc	(nc-nc)	Male	10	10.4	96.5	(46.2-177.6)
Female	2	1.9	nc	(nc-nc)	Female	11	9.9	111.5	(55.6-199.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	122	97.8	124.7	(103.6-148.9)
Female	3	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.9	nc	(nc-nc)
Male	8	15.8	50.8	(21.9-100.1)	Female	1	3.9	nc	(nc-nc)
Female	8	8.6	92.8	(40.0-182.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.0	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	10	6.8	147.7	(70.7-271.6)
<b><u>Leukemia</u></b>					Female	17	20.6	82.4	(48.0-132.0)
Male	12	11.8	101.4	(52.3-177.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	8.4	142.7	(73.6-249.2)	Female	17	24.1	70.6	(41.1-113.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	9.9	60.7	(22.2-132.2)	Male	327	381.3	85.8	(76.7-95.6)
Female	1	3.1	nc	(nc-nc)	Female	367	370.5	99.1	(89.2-109.7)
<b><u>Lung and Bronchus</u></b>									
Male	17	52.5	32.4	(18.8-51.8)					
Female	33	52.0	63.4	(43.6-89.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.2	97.8	(39.2-201.4)	Male	4	4.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	3.0	164.3	(52.9-383.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	22	25.2	87.4	(54.7-132.3)	Female	2	3.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	11	6.7	165.4	(82.4-295.9)	<b><u>Ovary</u></b>				
Female	6	7.7	78.4	(28.6-170.6)	Female	2	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.8	177.5	(57.2-414.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	21	24.7	85.1	(52.7-130.1)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.1	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	71	88.2	80.5	(62.9-101.6)
Female	1	0.8	nc	(nc-nc)	Female	71	90.4	78.6	(61.3-99.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	13.5	36.9	(11.9-86.2)					
Female	12	14.7	81.4	(42.0-142.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	5.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	11	21.0	52.4	(26.1-93.9)
Female	1	0.1	nc	(nc-nc)	Female	10	15.9	63.0	(30.2-115.9)
<b><u>Lung and Bronchus</u></b>									
Male	4	2.8	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	5.1	156.4	(67.3-308.1)	Male	6	3.1	191.3	(69.8-416.3)
Female	0	1.6	nc	(nc-nc)	Female	6	2.3	264.3	(96.5-575.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	22	17.3	127.1	(79.6-192.5)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	4.8	145.1	(58.2-299.1)	Female	0	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	24	14.8	162.1	(103.8-241.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.4	148.8	(48.0-347.3)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.3	nc	(nc-nc)	Female	8	3.9	207.3	(89.3-408.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	67	62.8	106.6	(82.6-135.4)
Female	0	0.5	nc	(nc-nc)	Female	73	59.0	123.6	(96.9-155.4)
<b><u>Lung and Bronchus</u></b>									
Male	4	9.0	nc	(nc-nc)					
Female	10	8.1	123.7	(59.2-227.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	9.0	210.3	(126.6-328.4)	Male	5	6.1	82.3	(26.5-192.1)
Female	3	3.2	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.4	92.6	(29.8-216.0)
Female	31	30.3	102.3	(69.5-145.1)	Female	4	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	3	9.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	9.4	63.9	(23.3-139.1)	Female	5	2.8	181.0	(58.3-422.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	20	30.9	64.7	(39.5-100.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.1	nc	(nc-nc)
Male	7	5.1	137.1	(54.9-282.6)	Female	2	1.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	4.8	229.1	(114.2-409.9)
Male	3	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.4	nc	(nc-nc)	Female	5	7.0	71.6	(23.1-167.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	114	121.7	93.7	(77.3-112.5)
Female	2	1.0	nc	(nc-nc)	Female	109	107.8	101.1	(83.0-121.9)
<b><u>Lung and Bronchus</u></b>									
Male	20	16.1	123.9	(75.6-191.3)					
Female	12	16.2	74.3	(38.3-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.9	78.9	(31.6-162.6)	Male	10	5.5	183.4	(87.8-337.3)
Female	3	2.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.6	317.9	(102.4-741.8)	Male	0	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.9	102.5	(33.0-239.2)
Female	34	31.5	108.1	(74.8-151.0)	Female	8	4.0	200.4	(86.3-394.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	3.8	131.6	(42.4-307.1)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	7	9.2	75.8	(30.4-156.1)	<b><u>Ovary</u></b>				
Female	16	8.6	186.7	(106.7-303.2)	Female	1	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.3	263.3	(96.2-573.2)	Male	1	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	27	28.4	95.0	(62.6-138.2)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	5.6	196.9	(98.2-352.3)
Male	0	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.3	nc	(nc-nc)	Female	3	7.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	111	111.8	99.3	(81.7-119.6)
Female	0	0.9	nc	(nc-nc)	Female	121	106.5	113.6	(94.2-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	15	15.6	96.4	(53.9-159.0)					
Female	18	15.1	119.5	(70.8-188.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	5.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
Female	13	16.7	77.7	(41.4-132.9)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.0	nc	(nc-nc)
Male	6	5.6	108.1	(39.5-235.3)	<b><u>Ovary</u></b>				
Female	3	5.1	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	11	16.9	65.0	(32.4-116.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.2	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.0	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	6	3.9	154.5	(56.4-336.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	50	67.3	74.3	(55.2-98.0)
Female	0	0.5	nc	(nc-nc)	Female	61	59.4	102.6	(78.5-131.8)
<b><u>Lung and Bronchus</u></b>									
Male	9	9.5	94.5	(43.1-179.3)					
Female	15	8.5	177.3	(99.2-292.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	22	17.4	126.5	(79.3-191.6)	Female	0	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	4.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	17	18.0	94.4	(55.0-151.2)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	5	2.8	180.8	(58.3-422.0)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	55	65.0	84.6	(63.7-110.1)
Female	0	0.5	nc	(nc-nc)	Female	50	55.1	90.7	(67.3-119.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.3	nc	(nc-nc)					
Female	5	7.2	69.6	(22.4-162.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	30.4	111.8	(77.4-156.3)	Male	14	19.6	71.5	(39.0-119.9)
Female	6	11.7	51.5	(18.8-112.0)	Female	12	16.0	75.2	(38.8-131.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.0	116.7	(46.7-240.4)	Male	3	6.1	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	15	17.5	85.9	(48.1-141.7)
Female	102	122.7	83.1	(67.8-100.9)	Female	8	15.9	50.3	(21.7-99.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	4.1	242.2	(116.0-445.5)	Male	18	14.1	127.7	(75.6-201.8)
<b><u>Colon / Rectum</u></b>					Female	9	6.6	136.2	(62.2-258.6)
Male	41	32.4	126.5	(90.8-171.7)	<b><u>Ovary</u></b>				
Female	41	35.0	117.3	(84.1-159.1)	Female	9	11.0	81.8	(37.3-155.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.1	135.5	(67.5-242.5)	Male	12	10.7	112.2	(57.9-196.0)
Female	1	2.2	nc	(nc-nc)	Female	9	11.6	77.4	(35.3-146.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	82	103.8	79.0	(62.9-98.1)
Female	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	7.1	nc	(nc-nc)
Male	14	16.6	84.2	(46.0-141.2)	Female	4	4.5	nc	(nc-nc)
Female	9	10.0	90.4	(41.3-171.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.4	113.4	(36.6-264.7)
Male	4	4.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	9	7.6	118.9	(54.2-225.7)
<b><u>Leukemia</u></b>					Female	21	22.6	93.1	(57.6-142.3)
Male	8	12.3	64.9	(28.0-128.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.4	106.8	(51.1-196.4)	Female	27	27.6	98.0	(64.6-142.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	10.6	122.5	(65.1-209.4)	Male	371	401.6	92.4	(83.2-102.3)
Female	3	3.6	nc	(nc-nc)	Female	411	423.2	97.1	(88.0-107.0)
<b><u>Lung and Bronchus</u></b>									
Male	48	54.8	87.7	(64.6-116.2)					
Female	85	60.6	140.3	(112.1-173.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.7	91.3	(36.6-188.0)	Female	3	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	11	7.1	155.4	(77.5-278.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	30	25.6	117.2	(79.1-167.3)
Female	0	0.2	nc	(nc-nc)	Female	24	25.9	92.7	(59.4-138.0)
<b><u>Lung and Bronchus</u></b>									
Male	6	3.6	169.0	(61.7-367.9)					
Female	3	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.4	254.5	(92.9-554.0)	Male	3	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	20	14.5	137.7	(84.0-212.6)	Female	2	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.8	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	10.7	103.1	(51.4-184.5)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	6	1.5	403.5	(147.4-878.4)	Female	0	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	48	34.9	137.7	(101.5-182.5)
Female	0	0.4	nc	(nc-nc)	Female	51	48.2	105.8	(78.8-139.1)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.6	nc	(nc-nc)					
Female	7	6.5	107.2	(42.9-220.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	17.4	68.9	(35.6-120.4)	Male	13	11.7	111.3	(59.2-190.3)
Female	7	6.6	105.3	(42.2-217.0)	Female	5	9.6	52.0	(16.8-121.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.6	137.6	(44.4-321.2)	Male	7	3.6	192.2	(77.0-396.1)
Female	3	3.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	10.5	95.3	(45.6-175.2)
Female	84	73.8	113.8	(90.8-140.9)	Female	7	9.3	75.3	(30.2-155.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	7	8.5	82.3	(33.0-169.6)
<b><u>Colon / Rectum</u></b>					Female	1	3.9	nc	(nc-nc)
Male	17	19.8	85.8	(50.0-137.4)	<b><u>Ovary</u></b>				
Female	25	20.8	120.2	(77.7-177.4)	Female	5	6.6	75.9	(24.5-177.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	5	6.1	81.3	(26.2-189.8)
Female	2	1.3	nc	(nc-nc)	Female	6	6.8	88.0	(32.1-191.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	54	56.6	95.4	(71.7-124.5)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	8	10.0	79.9	(34.4-157.5)	Female	1	2.7	nc	(nc-nc)
Female	2	5.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.8	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	8	4.9	163.6	(70.4-322.3)
<b><u>Leukemia</u></b>					Female	12	14.2	84.3	(43.5-147.3)
Male	9	7.3	123.9	(56.6-235.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	5.6	159.7	(72.9-303.2)	Female	19	16.2	117.4	(70.7-183.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.2	80.5	(25.9-187.8)	Male	215	232.1	92.6	(80.7-105.9)
Female	0	2.1	nc	(nc-nc)	Female	241	249.4	96.6	(84.8-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	30.8	74.6	(47.3-112.0)					
Female	33	32.7	100.9	(69.5-141.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	41.8	105.2	(76.5-141.3)	Male	24	26.9	89.1	(57.1-132.6)
Female	14	15.0	93.1	(50.8-156.2)	Female	20	21.4	93.3	(57.0-144.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.3	60.5	(19.5-141.3)	Male	9	8.4	107.1	(48.9-203.3)
Female	7	6.8	102.6	(41.1-211.4)	Female	0	6.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	21	24.2	86.7	(53.6-132.5)
Female	183	165.1	110.8	(95.3-128.1)	Female	19	21.0	90.3	(54.4-141.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	5.5	146.1	(62.9-287.9)	Male	13	19.4	66.9	(35.6-114.4)
<b><u>Colon / Rectum</u></b>					Female	9	8.9	101.7	(46.4-193.0)
Male	47	45.3	103.9	(76.3-138.1)	<b><u>Ovary</u></b>				
Female	52	45.3	114.7	(85.7-150.4)	Female	19	14.8	128.1	(77.1-200.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	11.1	135.6	(75.9-223.7)	Male	9	14.7	61.1	(27.9-115.9)
Female	3	2.9	nc	(nc-nc)	Female	13	15.2	85.8	(45.6-146.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.5	173.7	(63.4-378.0)	Male	124	140.7	88.2	(73.3-105.1)
Female	1	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	9.8	152.9	(85.5-252.1)
Male	17	22.8	74.5	(43.4-119.2)	Female	6	5.9	102.4	(37.4-223.0)
Female	10	13.1	76.1	(36.4-139.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.3	80.0	(25.8-186.6)
Male	3	6.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	2.0	nc	(nc-nc)	Male	6	10.5	56.9	(20.8-124.0)
<b><u>Leukemia</u></b>					Female	19	30.7	61.8	(37.2-96.6)
Male	22	17.1	128.9	(80.8-195.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.5	88.3	(44.0-158.1)	Female	33	38.0	86.9	(59.8-122.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	14.5	82.6	(42.6-144.3)	Male	529	550.9	96.0	(88.0-104.6)
Female	2	4.8	nc	(nc-nc)	Female	547	562.9	97.2	(89.2-105.7)
<b><u>Lung and Bronchus</u></b>									
Male	79	74.3	106.3	(84.2-132.5)					
Female	81	78.8	102.8	(81.6-127.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	19.3	62.3	(32.1-108.8)	Male	19	13.8	137.6	(82.8-214.9)
Female	4	6.4	nc	(nc-nc)	Female	12	10.9	109.9	(56.7-191.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	7	4.4	160.7	(64.4-331.2)
Female	6	3.5	171.2	(62.5-372.6)	Female	3	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	13	12.4	104.5	(55.6-178.7)
Female	88	89.9	97.9	(78.5-120.6)	Female	8	9.9	80.7	(34.8-159.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.2	nc	(nc-nc)	Male	10	11.4	87.8	(42.0-161.5)
<b><u>Colon / Rectum</u></b>					Female	5	4.4	113.4	(36.5-264.6)
Male	21	22.9	91.5	(56.6-139.9)	<b><u>Ovary</u></b>				
Female	21	20.2	104.1	(64.4-159.2)	Female	6	7.7	78.1	(28.5-170.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	8	7.4	108.8	(46.8-214.4)
Female	1	1.3	nc	(nc-nc)	Female	7	6.4	110.2	(44.1-227.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	76	81.8	92.9	(73.2-116.3)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.9	123.2	(45.0-268.2)
Male	11	13.1	84.2	(42.0-150.7)	Female	1	2.5	nc	(nc-nc)
Female	3	6.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.8	nc	(nc-nc)
Male	6	3.6	166.9	(61.0-363.4)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	9	6.2	144.6	(66.0-274.5)
<b><u>Leukemia</u></b>					Female	15	17.7	84.8	(47.4-139.9)
Male	13	8.4	154.9	(82.4-264.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	5.7	193.1	(96.3-345.6)	Female	35	20.8	168.4	(117.3-234.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.2	61.3	(19.8-143.1)	Male	283	290.7	97.4	(86.3-109.4)
Female	0	2.3	nc	(nc-nc)	Female	275	280.7	98.0	(86.7-110.3)
<b><u>Lung and Bronchus</u></b>									
Male	36	37.1	97.0	(68.0-134.3)					
Female	28	35.9	78.0	(51.8-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	6	1.2	503.9	(184.0-1096.8)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	11	7.6	145.5	(72.5-260.4)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.0	114.3	(49.2-225.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	25.1	99.6	(64.4-147.0)
Female	0	0.2	nc	(nc-nc)	Female	17	23.9	71.2	(41.4-114.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.3	nc	(nc-nc)					
Female	0	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.5	93.7	(37.5-193.1)	Male	6	5.1	118.0	(43.1-256.9)
Female	1	2.1	nc	(nc-nc)	Female	6	3.6	166.9	(61.0-363.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.3	(47.6-283.7)
Female	43	29.2	147.3	(106.6-198.4)	Female	2	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	1.4	347.4	(111.9-810.7)
Male	8	8.7	91.9	(39.6-181.1)	<b><u>Ovary</u></b>				
Female	7	6.5	106.9	(42.8-220.3)	Female	4	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	26	26.8	97.1	(63.4-142.3)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.9	118.9	(47.6-244.9)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	8	6.9	116.3	(50.1-229.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	100	103.5	96.6	(78.6-117.5)
Female	0	0.7	nc	(nc-nc)	Female	111	90.9	122.1	(100.4-147.0)
<b><u>Lung and Bronchus</u></b>									
Male	9	13.2	68.0	(31.0-129.1)					
Female	14	11.2	125.4	(68.5-210.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	15.3	98.2	(54.9-161.9)	Male	11	9.3	118.1	(58.9-211.3)
Female	2	4.8	nc	(nc-nc)	Female	10	6.5	154.4	(73.9-284.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.3	108.4	(49.5-205.8)
Female	50	52.1	95.9	(71.2-126.4)	Female	4	6.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	6	6.6	91.4	(33.4-198.8)
<b><u>Colon / Rectum</u></b>					Female	0	2.8	nc	(nc-nc)
Male	12	15.9	75.5	(39.0-132.0)	<b><u>Ovary</u></b>				
Female	13	14.4	90.4	(48.1-154.6)	Female	2	4.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	8	4.8	166.8	(71.8-328.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	55	48.9	112.5	(84.7-146.4)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.5	nc	(nc-nc)
Male	4	7.7	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.2	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.2	189.1	(69.1-411.6)
<b><u>Leukemia</u></b>					Female	6	8.9	67.7	(24.7-147.3)
Male	9	5.9	153.2	(69.9-290.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	3.9	258.2	(123.6-474.8)	Female	7	12.0	58.2	(23.3-119.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	195	191.8	101.7	(87.9-117.0)
Female	1	1.5	nc	(nc-nc)	Female	153	176.6	86.6	(73.5-101.5)
<b><u>Lung and Bronchus</u></b>									
Male	22	27.2	80.9	(50.7-122.5)					
Female	20	25.0	79.9	(48.8-123.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	23.4	128.2	(86.4-183.0)	Male	16	14.2	112.4	(64.2-182.5)
Female	10	7.5	132.9	(63.6-244.4)	Female	9	9.9	90.5	(41.3-171.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	5	4.6	108.6	(35.0-253.3)
Female	2	3.1	nc	(nc-nc)	Female	6	3.4	175.6	(64.1-382.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	15	12.6	119.2	(66.6-196.6)
Female	74	80.9	91.5	(71.8-114.8)	Female	16	10.4	154.3	(88.1-250.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	7	9.9	70.8	(28.4-145.9)
<b><u>Colon / Rectum</u></b>					Female	6	4.4	135.9	(49.6-295.9)
Male	20	23.7	84.3	(51.5-130.3)	<b><u>Ovary</u></b>				
Female	17	22.0	77.2	(45.0-123.7)	Female	4	7.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	6.1	148.1	(67.6-281.2)	Male	11	8.1	135.7	(67.6-242.8)
Female	1	1.5	nc	(nc-nc)	Female	8	7.5	106.6	(45.9-210.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	91	77.8	116.9	(94.2-143.6)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.3	112.5	(41.1-245.0)
Male	10	11.9	84.0	(40.2-154.5)	Female	4	2.8	nc	(nc-nc)
Female	5	6.5	77.1	(24.8-179.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.0	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	7	4.9	143.5	(57.5-295.7)
<b><u>Leukemia</u></b>					Female	15	13.4	112.1	(62.7-184.9)
Male	8	8.7	92.0	(39.6-181.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.8	nc	(nc-nc)	Female	11	19.2	57.2	(28.5-102.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.6	65.8	(21.2-153.6)	Male	299	295.2	101.3	(90.1-113.5)
Female	1	2.4	nc	(nc-nc)	Female	249	274.8	90.6	(79.7-102.6)
<b><u>Lung and Bronchus</u></b>									
Male	34	41.9	81.2	(56.2-113.5)					
Female	38	40.4	94.2	(66.6-129.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	20.0	99.8	(60.9-154.1)	Male	24	12.0	200.6	(128.5-298.4)
Female	5	7.5	66.7	(21.5-155.6)	Female	22	9.1	242.8	(152.1-367.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	5	3.8	131.0	(42.2-305.8)
Female	4	2.9	nc	(nc-nc)	Female	5	3.2	154.5	(49.8-360.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	9	10.8	83.0	(37.9-157.6)
Female	95	71.4	133.0	(107.6-162.6)	Female	4	9.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	7	8.3	84.6	(33.9-174.3)
<b><u>Colon / Rectum</u></b>					Female	6	4.0	148.8	(54.3-323.9)
Male	28	21.3	131.7	(87.5-190.4)	<b><u>Ovary</u></b>				
Female	27	22.9	117.7	(77.6-171.3)	Female	9	6.5	139.2	(63.5-264.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	11	6.9	160.5	(80.0-287.3)
Female	1	1.4	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.1	nc	(nc-nc)	Male	64	58.4	109.5	(84.4-139.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.6	nc	(nc-nc)
Male	10	9.7	102.7	(49.2-188.9)	Female	1	3.0	nc	(nc-nc)
Female	6	5.8	103.5	(37.8-225.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.1	121.8	(39.3-284.2)
<b><u>Leukemia</u></b>					Female	19	11.3	167.7	(100.9-261.9)
Male	9	7.7	117.3	(53.5-222.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	5.8	171.9	(82.3-316.2)	Female	19	15.6	121.5	(73.1-189.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.3	nc	(nc-nc)	Male	260	242.7	107.1	(94.5-121.0)
Female	4	2.2	nc	(nc-nc)	Female	296	252.9	117.0	(104.1-131.1)
<b><u>Lung and Bronchus</u></b>									
Male	25	33.7	74.2	(48.0-109.5)					
Female	37	36.2	102.1	(71.9-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	57.7	91.8	(68.7-120.1)	Male	40	37.5	106.7	(76.2-145.3)
Female	39	24.3	160.6	(114.2-219.6)	Female	45	33.5	134.5	(98.1-180.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	11.2	89.1	(42.6-163.8)	Male	16	11.8	135.7	(77.5-220.4)
Female	10	10.3	96.9	(46.4-178.3)	Female	7	11.0	63.9	(25.6-131.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	45	33.4	134.6	(98.2-180.1)
Female	275	264.7	103.9	(92.0-116.9)	Female	27	33.8	79.9	(52.6-116.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	8.8	56.8	(18.3-132.6)	Male	33	27.1	121.7	(83.7-170.9)
<b><u>Colon / Rectum</u></b>					Female	20	14.2	140.5	(85.8-217.0)
Male	66	62.9	104.9	(81.1-133.4)	<b><u>Ovary</u></b>				
Female	77	73.2	105.2	(83.1-131.5)	Female	26	23.5	110.4	(72.1-161.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	15.4	91.1	(49.8-152.9)	Male	22	20.3	108.2	(67.8-163.8)
Female	4	4.7	nc	(nc-nc)	Female	21	24.3	86.5	(53.5-132.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	4.4	137.6	(50.2-299.5)	Male	179	194.0	92.3	(79.3-106.8)
Female	1	3.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	13.6	95.4	(50.8-163.2)
Male	35	31.9	109.7	(76.4-152.6)	Female	5	9.4	53.4	(17.2-124.7)
Female	27	21.0	128.4	(84.6-186.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	7.9	100.6	(43.3-198.3)
Male	17	9.0	189.4	(110.3-303.2)	<b><u>Thyroid</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	15	14.6	102.5	(57.3-169.0)
<b><u>Leukemia</u></b>					Female	54	47.1	114.7	(86.1-149.6)
Male	19	23.2	81.8	(49.2-127.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	19.3	67.4	(35.9-115.3)	Female	64	60.5	105.8	(81.4-135.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	19	20.4	93.3	(56.2-145.7)	Male	796	761.6	104.5	(97.4-112.0)
Female	9	7.7	116.4	(53.1-221.0)	Female	955	898.6	106.3	(99.6-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	112	103.5	108.2	(89.1-130.3)					
Female	155	128.0	121.1	(102.8-141.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	6.8	73.7	(23.8-172.0)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.2	83.1	(30.4-180.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.2	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	25.6	97.6	(63.1-144.0)
Female	0	0.2	nc	(nc-nc)	Female	15	22.0	68.1	(38.1-112.3)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.3	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	14.4	208.6	(140.7-297.9)	Male	7	9.6	73.1	(29.3-150.6)
Female	5	4.6	107.9	(34.8-251.8)	Female	12	7.3	163.9	(84.6-286.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
Female	54	57.3	94.3	(70.8-123.1)	Female	5	6.9	73.0	(23.5-170.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.1	243.4	(78.5-568.1)	Male	5	7.1	70.0	(22.6-163.3)
<b><u>Colon / Rectum</u></b>					Female	7	2.9	238.3	(95.5-491.1)
Male	16	16.0	99.8	(57.0-162.1)	<b><u>Ovary</u></b>				
Female	20	14.4	139.3	(85.1-215.2)	Female	2	5.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.0	151.6	(55.3-329.9)	Male	3	5.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	4.6	107.8	(34.7-251.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	51	51.4	99.2	(73.9-130.5)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.4	nc	(nc-nc)
Male	19	8.4	225.7	(135.8-352.5)	Female	1	1.8	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.2	nc	(nc-nc)
Male	5	2.3	217.1	(70.0-506.7)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	11.4	87.9	(42.1-161.6)
Male	8	6.0	132.8	(57.2-261.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.0	nc	(nc-nc)	Female	12	13.2	91.2	(47.1-159.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	213	196.5	108.4	(94.3-124.0)
Female	0	1.6	nc	(nc-nc)	Female	196	187.9	104.3	(90.2-120.0)
<b><u>Lung and Bronchus</u></b>									
Male	35	26.0	134.8	(93.9-187.5)					
Female	37	25.2	147.0	(103.5-202.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	21.6	69.3	(38.8-114.3)	Male	22	13.0	168.8	(105.7-255.6)
Female	9	7.3	123.5	(56.4-234.5)	Female	9	9.3	97.2	(44.3-184.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	7	2.8	246.2	(98.6-507.2)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.6	69.0	(29.7-136.0)
Female	83	74.9	110.8	(88.2-137.3)	Female	11	9.7	113.4	(56.5-202.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.2	nc	(nc-nc)	Male	6	9.1	66.2	(24.2-144.1)
<b><u>Colon / Rectum</u></b>					Female	1	4.1	nc	(nc-nc)
Male	18	22.2	80.9	(47.9-127.9)	<b><u>Ovary</u></b>				
Female	15	21.9	68.5	(38.3-113.0)	Female	4	6.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	13	7.4	175.5	(93.4-300.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	50	68.7	72.8	(54.0-95.9)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.9	101.5	(32.7-236.9)
Male	10	10.7	93.2	(44.6-171.4)	Female	3	2.9	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.3	115.1	(37.1-268.6)
<b><u>Leukemia</u></b>					Female	10	11.8	84.4	(40.4-155.2)
Male	2	8.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.6	142.7	(61.4-281.2)	Female	12	17.2	70.0	(36.1-122.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.0	114.9	(49.5-226.4)	Male	211	268.4	78.6	(68.4-90.0)
Female	2	2.2	nc	(nc-nc)	Female	240	257.1	93.3	(81.9-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	26	38.2	68.0	(44.4-99.7)					
Female	24	37.1	64.7	(41.5-96.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	18	14.0	128.5	(76.1-203.1)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	3.8	133.2	(42.9-310.9)	Female	5	1.3	398.3	(128.4-929.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	12.8	62.6	(26.9-123.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	32	45.7	70.0	(47.9-98.8)
Female	0	0.4	nc	(nc-nc)	Female	45	46.5	96.7	(70.5-129.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	6.1	nc	(nc-nc)					
Female	2	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.9	67.3	(29.0-132.7)	Male	4	6.6	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.0	100.7	(36.8-219.2)
Female	26	35.0	74.3	(48.5-108.8)	Female	5	5.2	96.2	(31.0-224.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.1	nc	(nc-nc)
Male	7	11.6	60.5	(24.2-124.7)	<b><u>Ovary</u></b>				
Female	8	12.0	66.7	(28.7-131.5)	Female	4	3.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	1	3.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	36	33.1	108.9	(76.3-150.8)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.5	91.7	(29.6-214.1)
Male	4	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	3	8.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.3	nc	(nc-nc)	Male	99	136.0	72.8	(59.2-88.6)
Female	3	1.2	nc	(nc-nc)	Female	93	131.1	71.0	(57.3-86.9)
<b><u>Lung and Bronchus</u></b>									
Male	9	19.9	45.3	(20.7-86.0)					
Female	15	19.9	75.4	(42.2-124.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	21.8	123.9	(81.7-180.3)	Male	11	14.4	76.3	(38.1-136.6)
Female	8	8.1	98.4	(42.4-193.9)	Female	15	12.1	124.3	(69.5-205.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	8	3.7	215.3	(92.7-424.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	8	13.1	61.3	(26.4-120.7)
Female	110	96.5	114.0	(93.7-137.4)	Female	16	11.6	138.1	(78.9-224.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	9	10.8	83.5	(38.1-158.4)
<b><u>Colon / Rectum</u></b>					Female	6	5.0	121.1	(44.2-263.5)
Male	24	24.5	98.0	(62.8-145.9)	<b><u>Ovary</u></b>				
Female	27	24.8	108.7	(71.6-158.1)	Female	8	8.4	95.0	(40.9-187.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.9	84.9	(27.4-198.2)	Male	6	7.8	77.0	(28.1-167.7)
Female	0	1.6	nc	(nc-nc)	Female	9	8.1	111.3	(50.8-211.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	62	74.4	83.3	(63.9-106.8)
Female	3	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.2	95.7	(30.8-223.3)
Male	18	12.6	142.5	(84.4-225.2)	Female	5	3.2	157.4	(50.7-367.3)
Female	8	7.5	106.8	(46.0-210.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	3.0	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	8	5.9	135.0	(58.1-266.0)
<b><u>Leukemia</u></b>					Female	14	18.1	77.4	(42.3-129.9)
Male	13	9.2	141.1	(75.0-241.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.8	73.5	(23.7-171.5)	Female	23	21.7	106.1	(67.2-159.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	291	293.3	99.2	(88.1-111.3)
Female	2	2.6	nc	(nc-nc)	Female	347	317.8	109.2	(98.0-121.3)
<b><u>Lung and Bronchus</u></b>									
Male	51	38.7	131.6	(98.0-173.1)					
Female	48	43.7	109.8	(80.9-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.6	103.4	(53.4-180.6)	Male	1	7.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	6.9	nc	(nc-nc)
Female	32	45.3	70.7	(48.3-99.8)	Female	3	5.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.5	nc	(nc-nc)	Male	6	5.9	101.3	(37.0-220.4)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	8	13.0	61.5	(26.5-121.3)	<b><u>Ovary</u></b>				
Female	15	11.0	136.3	(76.2-224.8)	Female	6	3.9	153.2	(55.9-333.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	8	4.2	190.1	(81.9-374.6)
Female	2	0.7	nc	(nc-nc)	Female	5	3.5	142.5	(45.9-332.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	32	42.1	76.1	(52.0-107.4)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.8	nc	(nc-nc)
Male	5	6.8	73.6	(23.7-171.7)	Female	1	1.4	nc	(nc-nc)
Female	5	3.5	144.1	(46.4-336.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.3	95.9	(41.3-188.9)
Male	7	4.8	146.6	(58.7-302.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.9	nc	(nc-nc)	Female	10	10.3	97.3	(46.6-179.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	118	159.7	73.9	(61.1-88.5)
Female	0	1.2	nc	(nc-nc)	Female	139	145.8	95.3	(80.1-112.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	21.4	60.7	(32.3-103.9)					
Female	23	20.4	112.6	(71.3-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	23.6	101.5	(65.0-151.0)	Male	19	15.0	126.4	(76.1-197.4)
Female	5	9.2	54.1	(17.4-126.2)	Female	15	12.3	121.9	(68.2-201.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.4	nc	(nc-nc)	Male	5	4.8	104.2	(33.6-243.2)
Female	11	4.0	276.8	(138.0-495.4)	Female	6	4.1	146.8	(53.6-319.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	19	13.5	140.7	(84.7-219.8)
Female	115	98.8	116.4	(96.1-139.7)	Female	13	12.6	103.4	(55.0-176.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	4	10.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	5.2	nc	(nc-nc)
Male	24	25.7	93.3	(59.7-138.8)	<b><u>Ovary</u></b>				
Female	27	28.2	95.6	(63.0-139.1)	Female	9	8.7	103.6	(47.3-196.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.1	nc	(nc-nc)	Male	5	8.2	61.0	(19.7-142.4)
Female	0	1.8	nc	(nc-nc)	Female	8	9.3	85.6	(36.9-168.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	81	74.6	108.5	(86.2-134.9)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.5	nc	(nc-nc)
Male	8	12.8	62.6	(27.0-123.4)	Female	5	3.7	136.5	(44.0-318.5)
Female	9	7.9	114.3	(52.2-217.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.6	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	17.2	127.6	(79.9-193.2)
Male	16	9.4	170.4	(97.3-276.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	7.5	66.4	(21.4-154.9)	Female	24	21.5	111.8	(71.6-166.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.9	nc	(nc-nc)	Male	285	302.8	94.1	(83.5-105.7)
Female	2	2.8	nc	(nc-nc)	Female	351	336.0	104.5	(93.8-116.0)
<b><u>Lung and Bronchus</u></b>									
Male	29	41.9	69.2	(46.3-99.4)					
Female	41	47.5	86.4	(62.0-117.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	18.5	59.6	(29.7-106.6)
Female	0	0.1	nc	(nc-nc)	Female	16	14.3	111.8	(63.9-181.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.4	nc	(nc-nc)					
Female	3	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	22.7	101.2	(64.1-151.8)	Male	28	14.7	190.2	(126.3-274.8)
Female	7	7.0	99.4	(39.8-204.9)	Female	18	10.2	176.3	(104.4-278.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	8	3.2	250.7	(107.9-494.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	4	12.9	nc	(nc-nc)
Female	88	79.2	111.0	(89.1-136.8)	Female	11	9.9	110.8	(55.2-198.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	10	10.7	93.0	(44.5-171.1)
<b><u>Colon / Rectum</u></b>					Female	1	4.2	nc	(nc-nc)
Male	27	24.1	111.9	(73.7-162.8)	<b><u>Ovary</u></b>				
Female	28	20.9	133.8	(88.9-193.4)	Female	12	7.0	170.7	(88.1-298.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.2	96.6	(35.3-210.2)	Male	14	8.1	173.0	(94.5-290.3)
Female	1	1.4	nc	(nc-nc)	Female	7	7.0	100.5	(40.2-207.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	74	81.5	90.8	(71.3-114.0)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.4	93.4	(30.1-218.0)
Male	25	12.7	196.7	(127.2-290.3)	Female	3	2.7	nc	(nc-nc)
Female	13	6.3	206.2	(109.7-352.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.7	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	9	5.6	161.3	(73.6-306.2)
<b><u>Leukemia</u></b>					Female	15	14.9	100.8	(56.4-166.2)
Male	6	8.9	67.7	(24.7-147.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.7	105.7	(38.6-230.1)	Female	19	18.2	104.2	(62.7-162.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.1	98.7	(42.5-194.4)	Male	331	304.0	108.9	(97.5-121.3)
Female	3	2.3	nc	(nc-nc)	Female	321	267.4	120.0	(107.3-133.9)
<b><u>Lung and Bronchus</u></b>									
Male	55	42.0	130.9	(98.6-170.4)					
Female	49	38.3	127.8	(94.5-169.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	40.7	120.3	(89.0-159.1)	Male	31	26.6	116.7	(79.2-165.6)
Female	23	15.8	145.2	(92.0-217.8)	Female	21	22.0	95.5	(59.1-145.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	8.0	nc	(nc-nc)	Male	9	8.2	109.5	(50.0-208.0)
Female	11	6.7	163.7	(81.6-292.9)	Female	7	7.1	99.0	(39.7-203.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	32	23.7	135.1	(92.4-190.7)
Female	208	167.5	124.2	(107.9-142.3)	Female	28	21.8	128.3	(85.3-185.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.7	156.7	(71.5-297.6)	Male	19	18.8	100.8	(60.7-157.4)
<b><u>Colon / Rectum</u></b>					Female	10	9.1	109.9	(52.6-202.0)
Male	60	44.4	135.1	(103.1-173.9)	<b><u>Ovary</u></b>				
Female	51	48.1	106.1	(79.0-139.4)	Female	16	15.1	105.9	(60.5-172.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.6	112.8	(58.2-197.0)	Male	15	14.3	105.0	(58.7-173.2)
Female	1	3.0	nc	(nc-nc)	Female	21	16.0	131.2	(81.2-200.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	125	133.4	93.7	(78.0-111.6)
Female	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	9.6	114.4	(57.1-204.8)
Male	27	22.3	120.9	(79.7-175.9)	Female	6	6.2	96.7	(35.3-210.4)
Female	15	13.5	111.3	(62.3-183.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	6.5	137.8	(62.9-261.6)
Male	3	6.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	5	2.0	250.3	(80.7-584.2)	Male	12	10.6	113.4	(58.5-198.0)
<b><u>Leukemia</u></b>					Female	33	31.1	106.2	(73.1-149.2)
Male	20	16.5	121.5	(74.2-187.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	12.8	117.0	(65.4-192.9)	Female	40	37.9	105.7	(75.5-143.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	14.0	121.5	(70.7-194.5)	Male	621	533.7	116.3	(107.4-125.9)
Female	1	4.9	nc	(nc-nc)	Female	675	578.1	116.8	(108.1-125.9)
<b><u>Lung and Bronchus</u></b>									
Male	98	72.1	136.0	(110.4-165.7)					
Female	81	81.4	99.5	(79.0-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	181	152.2	118.9	(102.2-137.6)	Male	65	100.7	64.6	(49.8-82.3)
Female	62	61.8	100.4	(77.0-128.7)	Female	56	90.8	61.7	(46.6-80.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	30	32.7	91.6	(61.8-130.8)	Male	25	30.8	81.3	(52.6-120.0)
Female	24	28.9	82.9	(53.1-123.4)	Female	25	27.6	90.7	(58.7-133.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	103	91.1	113.1	(92.3-137.1)
Female	590	667.2	88.4	(81.4-95.9)	Female	80	86.5	92.4	(73.3-115.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	32	24.2	132.5	(90.6-187.0)	Male	67	72.3	92.7	(71.8-117.7)
<b><u>Colon / Rectum</u></b>					Female	40	36.2	110.6	(79.0-150.6)
Male	138	168.5	81.9	(68.8-96.8)	<b><u>Ovary</u></b>				
Female	190	189.6	100.2	(86.5-115.5)	Female	60	60.8	98.8	(75.4-127.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	54	40.1	134.7	(101.2-175.8)	Male	56	53.7	104.3	(78.7-135.4)
Female	11	11.8	93.1	(46.4-166.6)	Female	62	62.3	99.5	(76.3-127.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	16	14.9	107.4	(61.3-174.4)	Male	495	503.8	98.3	(89.8-107.3)
Female	19	13.5	140.5	(84.6-219.5)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	36	36.1	99.8	(69.9-138.1)
Male	85	85.0	100.0	(79.8-123.6)	Female	24	24.5	97.8	(62.7-145.6)
Female	61	53.6	113.8	(87.0-146.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	21	29.2	72.0	(44.5-110.0)
Male	22	23.2	94.9	(59.4-143.7)	<b><u>Thyroid</u></b>				
Female	9	7.9	113.9	(52.0-216.2)	Male	41	41.9	97.7	(70.1-132.6)
<b><u>Leukemia</u></b>					Female	119	136.3	87.3	(72.3-104.5)
Male	70	65.0	107.6	(83.9-136.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	54	53.0	101.9	(76.6-133.0)	Female	156	148.2	105.3	(89.4-123.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	86	53.2	161.5	(129.2-199.5)	Male	2085	2029.7	102.7	(98.4-107.2)
Female	21	19.3	109.1	(67.5-166.8)	Female	2222	2311.3	96.1	(92.2-100.2)
<b><u>Lung and Bronchus</u></b>									
Male	330	266.6	123.8	(110.8-137.9)					
Female	354	317.2	111.6	(100.3-123.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	24	23.1	103.7	(66.4-154.3)
Female	0	0.2	nc	(nc-nc)	Female	18	20.9	86.1	(51.0-136.1)
<b><u>Lung and Bronchus</u></b>									
Male	6	3.2	190.2	(69.4-413.9)					
Female	0	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.9	100.9	(48.3-185.5)	Male	6	7.0	85.7	(31.3-186.6)
Female	2	4.1	nc	(nc-nc)	Female	11	6.1	179.0	(89.2-320.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.4	141.6	(64.6-268.8)
Female	59	49.4	119.5	(90.9-154.1)	Female	4	6.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	2.5	196.2	(63.2-457.9)
Male	22	12.1	181.9	(113.9-275.4)	<b><u>Ovary</u></b>				
Female	11	13.2	83.2	(41.5-148.9)	Female	3	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.9	208.7	(76.2-454.2)	Male	4	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	45	37.3	120.6	(88.0-161.4)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	9.0	55.7	(18.0-130.0)
Male	3	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	3.4	nc	(nc-nc)	Female	6	11.1	54.2	(19.8-117.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	158	143.2	110.3	(93.8-128.9)
Female	2	1.4	nc	(nc-nc)	Female	149	162.1	91.9	(77.8-107.9)
<b><u>Lung and Bronchus</u></b>									
Male	17	17.9	94.7	(55.1-151.7)					
Female	15	21.7	69.2	(38.7-114.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	49.4	99.1	(73.3-131.1)	Male	41	27.3	150.2	(107.7-203.7)
Female	25	17.7	140.9	(91.1-208.0)	Female	50	19.4	257.9	(191.4-340.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.6	75.8	(24.4-176.9)	Male	8	9.0	89.3	(38.4-175.9)
Female	9	5.8	154.0	(70.3-292.3)	Female	7	7.6	92.6	(37.1-190.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	23	24.3	94.8	(60.1-142.2)
Female	178	154.6	115.1	(98.8-133.3)	Female	23	22.3	103.1	(65.4-154.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	21	16.6	126.4	(78.2-193.2)
<b><u>Colon / Rectum</u></b>					Female	8	9.0	89.1	(38.4-175.6)
Male	42	47.6	88.3	(63.6-119.4)	<b><u>Ovary</u></b>				
Female	45	51.1	88.1	(64.3-117.9)	Female	11	14.1	77.9	(38.8-139.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	19	11.2	168.9	(101.7-263.8)	Male	18	16.0	112.4	(66.6-177.7)
Female	6	3.3	181.2	(66.2-394.4)	Female	14	17.8	78.6	(42.9-131.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	147	127.9	114.9	(97.1-135.1)
Female	3	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	10.7	74.9	(32.2-147.5)
Male	14	20.5	68.2	(37.2-114.4)	Female	7	6.7	105.0	(42.1-216.4)
Female	10	13.3	75.1	(35.9-138.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.9	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	11	7.5	146.7	(73.1-262.4)
<b><u>Leukemia</u></b>					Female	11	21.4	51.3	(25.6-91.9)
Male	31	17.1	181.0	(123.0-256.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	12.7	142.1	(84.2-224.6)	Female	32	34.8	92.0	(62.9-129.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	13.4	134.7	(79.8-212.9)	Male	592	548.8	107.9	(99.4-116.9)
Female	8	5.1	156.8	(67.5-308.9)	Female	610	565.4	107.9	(99.5-116.8)
<b><u>Lung and Bronchus</u></b>									
Male	86	82.6	104.1	(83.3-128.6)					
Female	93	90.5	102.8	(82.9-125.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;